*

fimmtudagur, 18. október 2018

júní, 2007

 

BRUSSELS, Belgium - June 29, 2007 - Delhaize Group (Euronext Brussels: DELB, NYSE: DEG), the Belgian international food retailer, has filed today with the Securities and exchange Commission (SEC) its annual report on Form 20-F for the year ended December 31, 2006. The 2006 Form 20-F can be downloaded from the website of the SEC (www.sec.gov) directly or through the Delhaize Group website (www.delhaizegroup.com). Printed copies can be requested free of charge from: Delhaize Group Delhaize Group Investor Relations Department Investor Relations Department Square Marie Curie 40 P.O. Box 1330 B-1070 Brussels Salisbury, NC 28145-1330 Belgium United States Tel.: + 32 2 412 21 51 Tel.: + 1 704 633 82 50 (ext.2529) Email: investor@delhaizegroup.com Delhaize Group Delhaize Group is a Belgian food retailer present in seven countries on three continents. Its sales network consists of approximately 2,500 stores. In 2006, Delhaize Group posted EUR 19.2 billion (USD 24.1 billion) in net sales and other revenues and EUR 351.9 million (USD 441.8 million) in net profit. Delhaize Group employs approximately 138,000 people. Delhaize Group is listed on Euronext Brussels (DELB) and the New York Stock Exchange (DEG). This press release is available in English, French and Dutch. You can also find it on the website http://www.delhaizegroup.com. Questions may be sent to investor@delhaizegroup.com. Contacts Guy Elewaut: +32 2 412 29 48 Katrien Verbeke: +32 412 82 39


 

(Lysaker, 29 June 2007) An investor group led by Ferd Private Equity Fund II has signed an agreement to acquire oil service company Aibel Limited for USD 900 million in the largest ever buy-out by a Norwegian-based private equity fund. Aibel has a leading market position within services related to maintenance, modification and operations on the Norwegian continental shelf (NCS). The company is headquartered in Norway and has operations in 16 countries. The company is represented on all continents with over 7 000 employees and a total turnover of approximately USD 1.5 billion. Maintenance, Modification and Operations account for approximately 60 per cent of the company's revenues, with the main part of these revenues being generated on the NCS. Aibel's other businesses comprise Process and Facilities, Technology and Products and Drilling Control Systems. Aibel is well positioned in a global, growing market and has performed strongly with solid growth in revenues and EBITDA over the last few years and currently enjoys a record-high order backlog. "This represents a good solution for us," says Mr. R. Rasmus Sunde, president and CEO of Aibel. "We regard our new owners as long-term, and they share our views about the company's long term strategy. They also have the necessary understanding of the market, and the financial capacity needed to put the strategy into effect. Our objective is to maintain the leading position on the NCS combined with selective international expansion", Mr. Sunde concludes. Ferd Private Equity Fund II will become the largest shareholder with controlling interest in Aibel. Ferd AS is the largest investor in the Fund and will in addition become the second largest shareholder in Aibel. "Aibel is an exciting company with a solid platform for further domestic and international development. They have a strong market position, a high level of expertise and a strong management team with a proven track record. The company has significant potential, and as owners, we want to make an active contribution to continued development of their market position and profitability," says managing partner Gert W. Munthe at Ferd Equity Partners AS, which advises the private equity fund. Ferd Private Equity Fund consists of two investment funds with a total of NOK 6.25 billion in committed capital. This base allows the Fund to take dominant positions in established companies with potential for further growth development. Ferd Private Equity Fund II has previously acquired European Furniture Group AB, Festival Group AS, Hatteland Display AS, Nille AS and MicroMatic Norge AS. Ferd Private Equity Fund I, the predecessor fund to Ferd Private Equity Fund II, which was established in 2004, has previously acquired Pronova Biocare AS, Collett Pharma AS, Noratel AS, Handicare AS, Wonderland AS, Carpe Diem Beds of Sweden AB and D&F Group AS. The sellers are the Candover, 3i and J P Morgan Partners LLC private equity funds. Completion of the deal is expected following approvals by the Norwegian competition authorities. Advisors were ABN Amro (M&A), Hogan & Hartson and Wiersholm (legal), PWC (financial) and Arkwright (commercial) . Further information from: Ferd Equity Partners ASGert W. Munthe, managing partner, tel: +47 67 10 80 50, mobile: +47 92 02 23 63 Dag W.R. Strømme, partner, tel: +47 67 10 80 56, mobile: +47 93 02 36 22 Web site: www.ferdpe.com Aibel Group Limited R Rasmus Sunde, president and CEO, tel: +47 85 27 00 00, mobile: +47 91 53 55 86 Web site: www.aibel.com About Aibel Aibel (www.aibel.com) is a leading provider of products and services to the upstream oil and gas industry. We provide production facilities, process systems, technology and products and, on behalf of our oil company, shipowner and field operator customers, we maintain, operate and modify on- and offshore facilities around the world. Our involvement in a project from day one ensures maximum optimization right along the value chain. A multicultural company with over 100 years of industry experience and more than 7,000 professionals, our dedication to meeting our customers' needs is matched only by our equal commitment to innovation, integrity, safety and environmental sustainability.


 

Q-Cells AG: Total voting rights announcement Q-Cells AG herby announces that at the end of the month June 2007 the number of voting rights amounts to a total of 79,201,475 voting rights. The change of total voting rights is effective as of June 19, 2007. Q-Cells AG Guardianstraße 16 06766 Thalheim Germany www.q-cells.com investor@q-cells.com --- End of Message --- Q-Cells AG Guardianstr. 16 Thalheim Germany WKN: 555866; ISIN: DE0005558662; Index: CDAX, GEX, Prime All Share, TecDAX; Listed: Amtlicher Markt in Frankfurter Wertpapierbörse, Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Stuttgart;


 

On 29 June 2007 Mr. Wen Jia Bao, Premier of the State Council of the Peoples Republic of China visited DSM Citric Acid (Wuxi) Limited in recognition of its outstanding safety, health and environmental (SHE) performance. Mr. Wen Jia Bao was accompanied by Mr. Li Yuan Chao, Party Secretary of Jiangsu Province and Mr. Lian Bao Hua, Governor of Jiangsu Province. The officials were deeply impressed by DSM's sustainable way of development. Premier Wen Jia Bao expressed his thanks to DSM for its contribution to the local society and environment and recognized the company as a 'Good Citizen'. Jiang Wei Ming, President of DSM China and Ms. Zhu Lin Ying, General Manager of DSM Citrix Acid (Wuxi) Limited, guided the commission on a tour of the plant and in particular the company's environmental facilities. They saw the online emission monitoring system set up jointly with the local Wuxi government. This system is an example of good co-operation in environmental protection between the government and the company. Since 1998, a total amount of RMB 47.4 million has been invested in the company's environmental protection projects. "DSM regards sustainable development as our responsibility. With the commitment of all our staff and close co-operation with the local Wuxi government, we strictly comply with local law and regulations and are confident in maintaining and improving our outstanding SHE performance. Working in accordance with local and DSM standards enables us to manufacture high quality products in a safe, traceable and reliable manner", said Ms. Zhu Lin Ying. At the Wuxi site DSM produces citric acid, an ingredient widely used in the food and beverage industry. DSM places high priority on providing its customers with first quality ingredients, with guaranteed traceability and reliability about the sourcing and manufacturing, specifications which are of increasing importance in today's markets for nutritional ingredients. The environmental facilities at this site encompass amongst other: a waste water treatment plant, a recycling system for cooling water and state of the art boiler flue gas treatment facilities. DSM DSM is active worldwide in nutritional and pharma ingredients, performance materials and industrial chemicals. The company develops, produces and sells innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM's strategy, named Vision 2010 - Building on Strengths, focuses on accelerating profitable and innovative growth of the company's specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over ¤8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with locations in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at www.dsm.com. For more information: DSM Corporate Communications DSM Investor Relations Nelleke Barning Dries Ausems tel. +31 (0) 45 tel. +31 (0) 45 5782864 5782017 fax +31 (0) 45 5782595 fax +31 (0) 45 e-mail 5740680 investor.relations@dsm.com e-mail media.relations@dsm.com


 

Awilco Offshore ASA (AWO) has today signed a contract for a drilling package for a semi-submersible drilling rig with National Oilwell Norway AS. This is the fourth drilling package AWO has ordered. AWO has three semi-submersible drilling rigs under construction at Yantai Raffles Shipyard in China, and an option for a fourth rig. The option for the fourth rig can be exercised until November 2008. This fourth drilling package is an upgraded version compared to the three drilling packages the company already has ordered. The total contract value for this drilling package is MUSD 197. Oslo, 29 June 2007 For further information, please contact: Henrik Fougner, Managing Director Telephone +47 22 01 43 00 Awilco Offshore has invested in eight jack-up drilling rigs (of which six are under construction), three semi submersible drilling rigs under construction and two accommodation units in operation. The company also holds one option for the construction of one further semi submersible drilling rig.


 

29.06.2007: With today's acquisition of Te Strake Surface Technology the Impreglon group has substantially broadened its range of coatings for mass parts, especially for the automotive industry. The Te Strake locations in Obrigheim and Deurne, Holland, complement the Impreglon coating range while the existing Impreglon locations in Germany, France and Hungary offer additional production capacity for Te Strake. The acquisition will increase sales of the Impreglon group in 2007 to approx. 40 Million Euro. The parties agreed not to disclose the purchase price. IMPREGLON AG Hohenhorststraße 1 21337 Lüneburg Tel. 04131 / 2260091 Fax 04131 / 882-250 investorrelations@impreglon.de www.impreglon.de --- End of Message --- Impreglon AG Hohenhorststraße 1 Lüneburg Germany WKN: A0BLCV; ISIN: DE000A0BLCV5; Listed: Entry Standard in Frankfurter Wertpapierbörse;


 

Elderstreet VCT plc 29 June 2007 Elderstreet VCT plc announces that on 29 June 2007 the Company purchased a total of 24,730 Ordinary shares of 5p each for cancellation representing 0.29% of the total issued share capital at a price of 71.5p per share. Following the above transaction the Company's capital consists of 20,683,791Ordinary shares of 5 pence each, comprising Ordinary shares in issue and to be issued shortly in connection with the merger for Elderstreet Millennium Venture Capital Trust plc, and 1,542,202 'C' Ordinary shares of 5 pence each. The Company does not hold any shares in treasury. Therefore the total number of voting rights in Elderstreet VCT plc is 22,225,993. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Elderstreet VCT plc under the FSA's Disclosure and Transparency Rules. ---END OF MESSAGE---


 

Today Parex banka has successfully closed the Syndicated Term Loan Facility of EUR 500 million, at a margin of 0.45% over EURIBOR, with a maturity date after two years. This facility sets a new record for syndicated loans in the Baltic States, reaching the amount of EUR 500 mln. Commerzbank AG, HSBC Bank plc., Intesa SanPaolo S.p.A., Lloyds TSB Bank plc., Mizuho Corporate Bank, Ltd. and Raiffeisen Zentralbank Österreich AG were the initial mandated lead arrangers of the transaction. The first syndicated loan of Parex banka to be closed with a two-year maturity, the transaction has attracted great interest from 36 financial institutions from 16 countries and was substantially oversubscribed. 84% or EUR 422 million of the funds raised came from European and North American investors, while 16% or EUR 78 million have been generated from the Asian investors. Five investors participated in the syndicated loan for the very first time, contributing EUR 58.5 million. Mr. Gene Zolotarev, Board Member, Senior Vice President, Global Head of Capital Markets and Investment Banking, commented: "Parex banka has a long standing and successful track record in raising capital through syndicated lending. We are proud to be the first Latvian private bank to enter this market and are delighted to once again set the market benchmark with this record-breaking amount of EUR 500 million as the largest debt capital markets transaction for any Baltic borrower." Mr. Simon Penniston, Managing Director, Debt Capital Markets, Lloyds TSB, said: "The success of this syndication is a testament to the strength, performance and popularity of Parex banka amongst the international bank investor community. With this EUR 500 million syndicated term loan Parex banka has once again raised the bar for Latvian and Baltic borrowers". This transaction serves to refinance the syndicated loan of EUR 310 million, which matures in July 2007. The remaining funds will be used for general business purposes. Parex banka entered the international syndicated lending market in 1998, raising USD 20 million. Since 1999 the Bank has been continuing to extend the range of its successful syndicated lending transactions, with the volume of funds attracted steadily increasing and margin rates falling, thus reflecting the confidence of the international financial community in Parex banka. List of the participating banks: Initial Mandated Lead Arrangers COMMERZBANK Aktiengesellschaft HSBC Bank plc Intesa Sanpaolo SpA Lloyds TSB Bank plc MIZUHO CORPORATE BANK, LTD. Raiffeisen Zentralbank Österreich Aktiengesellschaft Mandated Lead Arrangers DZ BANK AG Deutsche Zentral-Genossenschaftsbank, Frankfurt am Main Bayerische Landesbank Deutsche Bank AG, London Branch ICICI Bank Limited Hong Kong Branch Landesbank Baden-Württemberg Landesbank Berlin AG LRP Landesbank Rheinland-Pfalz Natixis Sumitomo Mitsui Banking Corporation Europe Limited Lead Arrangers BAWAG P.S.K. Bank für Arbeit und Wirtschaft und Österreichische Postsparkasse Aktiengesellschaft JPMorgan Arrangers Alpha Bank A.E. Dresdner Bank AG, Niederlassung Luxemburg MKB Bank Zrt. Caja de Ahorres y Monte de Piedad de Madrid Lead Managers AKA Ausfuhrkredit-Gesellschaft mbH, Frankfurt (Main) Landsbanki Islands WGZ BANK AG Westdeutsche Genossenschafts-Zentralbank Managers BRED Banque Populaire Erste Bank der oesterreichischen Sparkassen AG First Commercial Bank Ltd., London Branch Landesbank Saar Oberbank AG Raiffeisenlandesbank Niederoesterreich-Wien AG Sparebanken Ost UniCredito Italiano Caixa Geral de Depòsitos, SA Magyar Takarékszövetkezeti Bank Zrt. The Export-Import Bank of the Republic of China Hua Nan Commercial Bank Ltd., London Branch About the Bank: With EUR 3.6 billion in assets, Parex banka is one of the leading banks in the Baltic States, offering integrated client services, including lending, payment card services, leasing, asset management and securities brokerage. The Bank is represented in 15 countries through its wide network of representative offices, branches and subsidiaries, including a subsidiary in Switzerland, AP Anlage und Privatbank AG. Parex banka is rated Baa3 by Moody's Investors Service, BB+ by Fitch Ratings and BBB by Capital Intelligence. Additional information: Julia Kondratovich Deputy Head of International Communications Department Phone: +371 777 8572 E-mail: jk@parex.lv


 

The interim report for January-June will be released on 19 July at 11:00 a.m. CET, followed by a telephone conference at 1:00 p.m., which will be webcasted on Nobia's website, www.nobia.com. Participants in the phone conference are CEO Fredrik Cappelen and CFO Jan Johansson. Dial-in numbers: Sweden: +46 (0)8 505 202 70 UK: +44 (0)208 817 9301 For more information contact: Ingrid Yllmark, Director Communications and IR Phone: +46 (0)8 440 16 00 Nobia AB 29 June 2007 As the leading kitchen company in Europe, Nobia is championing the consolidation of the European kitchen industry. Nobia creates profitable growth by enhancing efficiency and making acquisitions. The Nobia Group works with 20 strong brands in many European countries. Sales are mainly generated through specialised kitchen studios, both wholly owned and franchised. The Group has about 8,000 employees and net sales of approximately SEK 16 billion. Nobia is listed on the OMX Nordic Exchange in Stockholm. More information is available at www.nobia.com.


 

NEWS RELEASE DATE: June 29, 2007 FOR IMMEDIATE RELEASE TRADING SYMBOLS: TSX-V (Canada): WGP.V FRANKFURT: WE6.F WESTERN GEOPOWER ANNOUNCES WARRANT INCENTIVE PROGRAM VANCOUVER, Canada, June 29, 2007, TSX Venture Exchange Trading Symbol: WGP - Western GeoPower Corp., (the "Company"), today announced a warrant incentive program (the "Program") to encourage the early exercise of 66,031,801 warrants relating to share purchase warrants issued on December 30, 2005 and December 15, 2006. Exchanging the warrants early will provide the capital to execute the Company's current business plan while reducing the overall dilution to shareholders versus a new financing. The gross proceeds to the Company if all the $0.25 warrants are exercised would be $16.5 Million. The proceeds of the early exercise will be applied to the development of the Company's wholly-owned Unit 1 project at the Geysers Geothermal field, in Northern California. The Company is currently awaiting approval of the permits to drill the initial 6 production wells and anticipates commencement of drilling in fall 2007. In order to encourage the early exercise of the warrants, Western GeoPower is amending the December 2005 and the December 2006 warrant so that upon payment of the applicable exercise price of $0.25, the holder will receive one unit instead of one common share. The new units will consist of a common share and an additional warrant. Each warrant will allow the holder to acquire one common share at a price of $0.35 per share until December 30, 2008. The warrants are transferable. The warrants will also be subject to an acceleration provision, which would provide that if the Company's shares traded at $0.50 for ten consecutive trading days, it would trigger a 30 day timeframe within which to exercise the warrants or they would expire. The new units will be subject to a four-month hold period. Under the terms of the Program, holders of 66,031,801 warrants expiring on December 30, 2008 (the "Warrants") with an exercise price of $0.25 per share will, for a period of 20 days, from June 29, 2007 to July 19, 2007 (the "Incentive Period"), be entitled to receive an additional warrant. The program will only apply to those warrant holders who exercise their warrants. Any Warrants not exercised during the Incentive Period will remain unchanged. The Company will issue the Units to any warrant holder that exercises their warrants or which has exercised its warrants prior to this incentive program being put in place on the basis that all warrant holders should be treated equally. The warrant incentive program is subject to approval from the TSX Venture Exchange and the Units issued upon the exercise of the warrants are subject to a 4-month hold period. Corporate Overview Western GeoPower Corp. is a renewable energy company dedicated to the development of geothermal energy projects for the delivery of clean, baseload electricity generation. The Company is developing the 25.5 Megawatt (net) geothermal power plant at The Geysers Geothermal Field in Sonoma County, California, United States. The Company is also developing the South Meager Geothermal Project in British Columbia, Canada. On behalf of Western GeoPower Corp. "Kenneth MacLeod" Kenneth MacLeod, President & CEO Cautionary Note Regarding Forward-Looking Statements Statements in this release that are forward-looking are subject to various risks and uncertainties concerning the specific factors identified above that reflect the Company's expectations and projections about its future results. The Company has tried whenever possible to identify these forward-looking statements which include but are not limited to, words such as "anticipates," believes," "estimates," "expects," "plans," "intends," "potential," and similar expressions. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in the forward-looking statements. The Company disclaims any obligation or intention to update or to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Such information contained herein represents management's best judgment as of the date hereof based on information currently available. This news release is not for dissemination in the United States of America or to United States of America news services. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. For more information or to be put on our email list, please contact our office: (604) 662-3338 or US/Canada Toll Free: 1-866-662-3322, email: info@geopower.ca Investor Relations: IR@geopower.ca --- End of Message --- Western GeoPower Corp. 837 West Hastings Street Suite 411 Vancouver, BC<br>V6C 3N6 Canada WKN: 254049; ISIN: CA95827Q1037; ;


 

Fortis - together with Royal Bank of Scotland and Banco Santander - intends to launch a public offer for 100% of the issued and outstanding share capital of ABN AMRO Holding N.V. As of Monday 2 July, Fortis will invite its shareholders to Extraordinary General Meetings of Shareholders (EGMs) to be held on 6 August 2007 in order to allow them to vote on the proposed offer for ABN AMRO and on the capital increase. Agenda Fortis intends to partly finance its participation in the offer consideration by raising up to EUR 15 billion of new equity via a rights issue. By means of this rights issue Fortis will offer its shareholders the opportunity to buy new Fortis shares in proportion to their existing holdings. Since these new shares will be offered at a discount to the market price, the subscription rights have a value in themselves and can be traded separately. Moreover, the holdings of those shareholders who take up their rights will not be diluted. The Extraordinary General Meetings of Shareholders will therefore vote on the following items: * the participation of Fortis in the proposed offer for ABN AMRO * an amendment to the articles of association in order to grant the Board of Directors authorisation to increase the share capital of both Fortis SA/NV and Fortis N.V. in order to finance the offer Fortis will hold the Extraordinary General Meetings of Shareholders in Brussels at 9.15am CET (Fortis SA/NV) and in Utrecht at 3pm CET (Fortis N.V.). A detailed agenda and relevant documents will be published on 2 and 13 July at www.fortis.com. Calendar Since experience in recent years indicates that the quorum of 50% of the issued and outstanding capital - which is required to amend the articles of association in order to allow an increase in the authorised capital - will not be reached at the first EGM of 26 July (EGM I), Fortis is convening a second meeting (EGM II) at which this 50% quorum will no longer be required, but at which a resolution in this respect will need to be passed with a 75% majority. EGM I 26 July 2007 02/07/2007 Notice of EGM (concerning the increase in authorised capital) 19/07/2007 Deadline for registration of shareholders 20/07/2007 Probable announcement that, based on registrations, the quorum has not been attained 26/07/2007 First EGM cannot pass the proposed resolution because of lack of quorum EGM II 6 August 2007 13/07/2007 First notice of EGM (concerning approval of the bid for ABN AMRO shares) 20/07/2007 Second notice of EGM (concerning approval of the increase in authorised capital - in the event that EGM I fails to reach a quorum) 30/07/2007 Deadline for registration of shareholders 06/08/2007 Second EGM: resolutions to approve the bid for ABN AMRO and to increase the authorised capital, the latter with a 75% majority Fortis is an international financial services provider engaged in banking and insurance. We offer our personal, business and institutional customers a comprehensive package of products and services through our own channels, in collaboration with intermediaries and through other distribution partners. With a market capitalisation of EUR 40.3 billion (31/05/2007), Fortis ranks among the 20 largest financial institutions in Europe. Our sound solvency position, our presence in 50 countries and our dedicated, professional workforce of 60,000 enable us to combine global strength with local flexibility and provide our clients with optimum support. More information is available at www.fortis.com. Press Offices Brussels +32 (0)2 565 35 84 Utrecht +31 (0)30 226 32 19 Investor Relations Brussels +32 (0)2 565 53 78 Utrecht +31 (0)30 226 32 20


 

Stockholm - KPN Broadcast Services has placed orders to upgrade its Dutch media network KPN's multi-service media network is based on Net Insight's Nimbra platform and has been operational since the beginning of 2006. The core network, which is currently based on the Nimbra One multiservice switch, is now being upgraded to the high-capacity Nimbra 680 switch and new sites are added. The upgrade of KPN's core network extends the capacity of existing real-time critical DVB-T distribution as well as real-time contribution services and is the foundation for KPN's new services. The orders exceed 10 MSEK, and the equipment will be delivered during the third quarter. The order from KPN Broadcast Services was placed through Net Insight's Dutch partner Alphatron. "We are pleased to be selected to be part of KPN's rapid business expansion and the associated need for upgrade of this network", says Fredrik Trägårdh, CEO of Net Insight. "Net Insight's numerous successes in the market for digital terrestrial TV networks continue. We are now also well placed to pursue the growing market for Mobile TV networks". For more information, please contact: Fredrik Trägårdh, CEO of Net Insight AB, +46 8 685 04 00, fredrik.tragardh@netinsight.net About Net Insight Net Insight delivers the world's most efficient and scaleable optical transport solution for Broadcast and Media, Digital Terrestrial TV, Mobile TV and IPTV/CATV networks. Net Insight products truly deliver 100 percent Quality of Service with three times improvement in utilization of bandwidth for a converged transport infrastructure. Net Insight's Nimbra(TM) platform is the industry solution for video, voice and data, reducing operational costs by 50 percent and enhancing competitiveness in delivery of existing and new media services. World class customers run mission critical video services over Net Insight products for more than 100 million people in more than 20 countries. Net Insight is quoted on the Stockholm Stock Exchange. For more information, visit www.netinsight.net


 

The results for the 2nd quarter results will be presented by Asbjørn Reinkind (CEO) and Tor Lund (CFO) on Monday, 13 August 2007. The presentation will take place in the following premises: 09:00 at DnB NOR, Aker Brygge, Stranden 21, Oslo 15:15 at Rieber & Søn's Board room, 6th floor, Nøstegaten 58, Bergen Enrolment by: Wednesday, 7th August 2007. If you intend to participate, please notify Eli Øvrebø Olsen at the Group Secretariat on +47 55 96 75 65 or by e-mail to: companyadm@rieberson.no The complete material can be accessed at: http://www.rieberson.no at 08.15 am. Facts about Rieber & Søn ASA: Rieber & Søn is one of Norway's leading food conglomerates. The main markets are Western Europe and Central and Eastern Europe where the company has considerable market shares in the retail grocery sector. Rieber & Søn's aim is to be the Local Taste Champion in its main markets. Attractive and sought-after food products based on consumer requirements are developed through Rieber & Søn's competence in established eating habits. Rieber & Søn also introduces ethnic dishes in national and local markets and makes them easier for the consumers to prepare. Through systematic product maintenance and product development, as well as aggressive launches, Rieber & Søn has helped to bring about continuous consumer growth in its main groups. Rieber & Søn had leading brands such as TORO, Denja, MrLee, King Oscar, Vossafår, Vestlandslefsa, Sopps, Black Boy, Geisha, Ming, Trondhjems canned dinner, Mrs Cheng's and Frödinge (Sweden), K-Salat and Bähncke (Denmark), Delecta (Poland), Vitana (Czech Republic and Slovakia) Chaka (Russia), Cronions and Rijnhout (the Netherlands). The company has a workforce of 4 000 (of whom 1 050 are in Norway), production plant in 7 countries and is represented through sales and market offices in a further 6 countries.


 

Nera Networks, 100% owned by Eltek ASA, has won major new orders in Brazil and Pakistan for delivery in the second half of 2007. The contract values are USD 6.7 million in Brazil and USD 10 million in Pakistan. In Brazil the company has signed a turn-key contract with one of the major mobile operators, comprising both InterLink and Evolution products. The products will be used in both the backbone and access parts of the operator's network. -This contract is evidence that Nera's Evolution family is future-proof and top-of-the-line product family. Brazil is one of the major telecom markets in the Americas and this can pave the way for further expansions in the region, says CEO Lars Jervan in Nera Networks. The contract with an operator in Pakistan covers the building of a network in the mountains in the northern parts of Pakistan, which will also link Pakistan with China. Nera will deliver both InterLink and Evolution products under the full turn-key solution, which also comprises civil works and mounting of masts in addition to the telecom equipment. -The environment is extreme, and Nera staff will be working on peaks of up to 3,500 metres in rough weather conditions. The equipment requirements are equally tough, and the order shows that Nera's products and solutions are world class, says Jervan. Deliveries on both contracts will start in the third quarter and be finalised during the fourth quarter of the year. In Pakistan the contract also covers after sales support in order to secure long-term optimal performance. For further information, please contact: CEO Nera Networks, Lars Jervan, tel: +47 905 24 504 CFO Eltek ASA, Jørgen Larsen, tel: +47 32 20 33 41 --- End of Message --- Eltek ASA PO Box 2340 Strømsø Drammen Norway ISIN: NO0003109407; ;


 

Pursuant to the new chapter 4 section 9 of the Swedish Financial Instruments Trading Act (1991:980 and 2007:365) and article 15 of the Transparency Directive (Directive 2004/109/EC) Nordea has to disclose the total number of voting rights and capital at the end of the calendar month during which a change has occurred. During June 2007 the following changes have occurred. On 8 June 2007 the share capital of Nordea Bank AB (publ) was increased by 3,120,000 euro by a new issue of 3,120,000 C-shares. After the increase the total share capital of Nordea Bank AB (publ) is 2,597,228,227 euro. On 15 June 2007 Nordea acquired all the C-shares, which subsequently were converted into ordinary shares on 18 June 2007. After the conversion the total amount of outstanding shares in the company is 2,597,228,227 ordinary shares. For further information: Torben Laustsen, Group Identity and Communications, +46 8 614 79 16


 

ANNOUNCEMENT DATED 29 JUNE 2007 The Bear Stearns Companies Inc. Issue of up to EUR60,000,000 Notes Linked to a Basket of Shares due 2015 (the "Notes") ISIN Code: XS0285953526 under the U.S.$30,000,000,000 Euro Medium Term Note Programme NOTICE OF ISSUE AMOUNT The offer period for the Notes (described above) will end at 5:00pm (Central European Time) on 3 July 2007. Pursuant to the Prospectus for the issue of the Notes dated 25 June 2007, the Aggregate Nominal Amount of the Notes to be issued on 3 July 2007 will be EUR40,000,000. Enquiries: Transaction Management Group Bear, Stearns International Limited One Canada Square London E14 5AD Tel: +44 20 7516 6817 Fax: +44 20 7516 5001 ---END OF MESSAGE---


 

Allied Irish Banks, p.l.c. ("AIB") [NYSE: AIB] has entered into an agreement to acquire AmCredit, the mortgage finance business of the Baltic-American Enterprise Fund ("BalAEF"). The business, which has a strong track record in mortgage lending, operates in Latvia, Lithuania, and Estonia. It was established in 1997. BalAEF is a Delaware corporation chartered in 1994, pursuant to legislation enacted by the U.S. Congress to promote private sector development in the Baltic States. The International Finance Corporation (the private sector arm of the World Bank Group) has played an important role in its development over the years. AmCredit, which has 13 outlets and 145 staff, will give AIB entry to three high growth markets underpinned by an experienced workforce, robust systems and processes and an established brand. The consideration for the transaction, which will comprise both up-front and earn-out components, is expected to be in the order of ¤40m. AmCredit currently operates as a single product mortgage business. AIB will seek regulatory approval to operate through a branch in each country and in time expand the range of banking products sold. The transaction is subject to the completion of the requisite regulatory approvals. Eugene Sheehy, CEO of AIB said: "We look forward to working with AmCredit's management and staff in the development of the business in the years ahead. AmCredit gives us an established foothold in the high-growth Baltic market and an opportunity to develop our business in a market contiguous to our Polish operations. We plan to grow its business and to expand the range of banking products sold into these new markets." - ENDS- For further information, please contact: Alan Kelly Ronan Sheridan General Manager, Group Finance Group Press Officer AIB Group AIB Group Bankcentre Bankcentre Dublin 4 Dublin 4 Tel: +353-1-6412162 Tel: +353-1-6414651


 

FL Group today announced it has signed a EUR 330 million equity finance facility for its shareholding in Glitnir bank. The financing was provided by Morgan Stanley and has a 3 year maturity. This finance facility demonstrates FL Group's long term commitment to its investment in Glitnir bank and with it FL Group has secured long term financing for its entire stake in the bank, which is FL Group's largest shareholding The facility also confirms the strong relationship that FL Group has established with a large number of influential institutions in the international financial markets. Hannes Smárason, CEO of FL Group: "This transaction is an important addition to our capital structure and increases both the liquidity of FL Group and the geographical diversification in our debt portfolio. FL Group has taken great pleasure in working with Morgan Stanley on the transaction and is very pleased with the result. This transaction also further underpins FL Group's long term belief in Glitnir Bank as a quality investment." For further information, please contact: Sveinbjörn Indriðason Kristján Kristjánsson CFO of FL Group Director Corporate Communication Tel.: +354 591 4400 Tel.: +354 591 4427 Notes to Editors About FL Group FL Group is an international investment company, focusing its activities on two areas of investments. The company's Private Equity and strategic investments focus on investments in public and private companies and has a long term view. The company's Capital Markets unit oversees the company's short term trading as well as derivative and security trading related to the company's asset portfolio. With its head office in Reykjavik and offices in Copenhagen and London, FL Group invests in companies in Northern Europe, focusing primarily on the Nordics and the UK but also has investments elsewhere. FL Group is listed on the OMX Nordic Exchange in Reykjavik (OMX: FL). At the end of first quarter 2007 FL Group's total assets amounted to ISK 303 billion (EUR 3.4 billion). Its market capitalisation at the end of March 2007 was ISK 236 billion (EUR 2.7 billion). The largest shareholders of FL Group are Gnúpur fjárfestingafélag hf. (20.2%), Oddaflug BV (19.8%), owned by Hannes Smárason, CEO; Baugur Group (19.4%) and Icon and Materia Invest (10.7%). The shareholding can in some cases be in the name of Icelandic financial institutions because of forward contracts. More information on www.flgroup.is


 

Chromex Mining plc / Epic: CHX / Market: AIM / Sector: Mining & Exploration 29 June 2007 Chromex Mining plc ('Chromex' or 'the Company') Interim Statement Chromex Mining plc, the AIM listed dedicated chrome mining company focused in Southern Africa, is pleased to announce its results for the six months ended 31 March 2007. Overview * Application accepted by Department of Minerals and Energy for a mining right to mine chromite on the farm Mecklenburg 112 KT on Eastern limb of the Bushveld Complex in South Africa * Raised £1.75 million through a placing with institutional investors * Received a number of enquiries from potential end users of the chrome ore including major steel producers * Discussions underway to expand resources by acquiring interests in other properties Chairman's statement It is less than three months since my report to you on the accounts for the year ended 30 September 2006, but they have been important months in the development of Chromex. Our application for a mining right to enable us to mine chrome ore on the farm Mecklenburg 112 KT ('Mecklenburg') on the chromite rich Eastern Limb of the Bushveld Complex in the Limpopo Province of South Africa ("Eastern Limb") has been formally accepted by the Department of Minerals and Energy ("DME"). The further information required in connection with the application has been supplied well in advance of the time limits laid down by the DME, so that the ball is now firmly in their court. The legislation does not lay down a time frame for the issue of a mining right, so that all Chromex can do at this stage is to position itself to progress rapidly when the right is issued, and this is being done. The DME has informed the Company that another application for a mining right at Mecklenburg has been submitted. As part of its due diligence procedures, Chromex investigated the possibility of such an application and commissioned a report on its rights and title from Harrison Attorneys, a Johannesburg law firm specialising in this area of law. The opinion of Harrison Attorneys was that Chromex held the Old Order Right as well as the New Order Right to the area where mining will take place, and that such rights were not open to challenge. This opinion was subsequently borne out by a further opinion from Senior Counsel. Under the circumstances, and following further discussions with Harrison Attorneys and with leading counsel, Chromex has commenced administrative proceedings, which permit the Minister to cancel a prospecting right under certain circumstances. Chromex, on legal advice, remains confident that it will be successful in doing so. The proceedings will run in parallel with the consideration of the application for a mining right. Following the grant of the mining right we need to secure the necessary mining finance, which we initially envisage to be by a combination of debt and equity. As a first step towards this, Chromex announced on 14 June 2007 that it had placed 7 million new ordinary shares at 25p per share with institutional investors to raise £1.75 million before costs. The placees were also issued with warrants entitling them to subscribe for further shares at 35p each, exercisable up to 30 June 2009, on the basis of one warrant for every two shares subscribed for in the placing. The Directors are particularly pleased to bring three substantial institutional shareholders onto the share register. Since the publication of the Bankable Feasibility Study, Chromex has been encouraged to receive a number of enquiries from potential end users of the chromite ore. These include major steel producers, and several potential buyers of the ore have also offered to assist in funding the mine and plant. In addition, Chromex is evaluating a proposal to use production for conversion to foundry sand, which could prolong mine life as well as improve margins. As well as developing the Mecklenburg mine, Chromex intends to expand the resources under its control by acquiring interests in other properties. Discussions to acquire nearby chrome deposits on the Eastern Limb are ongoing but have proved more protracted than the Directors had hoped. For that reason we are also discussing the possible acquisition of chrome deposits on the Western Limb and in other parts of Southern Africa. The results for the six months ended 31 March 2007 represent overhead costs with no income other than interest. The loss reported is £183,000. The Company has now registered for VAT and this should result in a small reduction in costs as VAT is repaid. Brian Moritz Chairman Unaudited consolidated income statement For the six months ended 31 March 2007 6 Months ended 31 Year ended 30 March 2007 Sept 2006 £'000 £'000 Revenue - Administrative expenses (193) (55) ________ ________ Loss from operations (193) (55) Income from investments 10 1 ________ ________ Loss for the period (183) (54) ________ ________ Loss per share Basic and diluted 0.32p 0.35p The operating loss for the period arises from the Group's continuing operations. Unaudited consolidated balance sheets As at 31 March 2007 31 March 2007 30 Sept £'000 2006 £'000 Assets Non-current assets Intangible assets 570 400 Investments - - ________ ________ 570 400 ________ ________ Current assets Cash and cash equivalents 612 779 Trade and other receivables 29 300 ________ ________ 641 1,079 ________ ________ Total assets 1,211 1,479 ________ ________ Equity and liabilities Equity attributable to equity holders of the company Share capital 564 564 Share premium 794 794 Exchange reserves (14) (13) Accumulated losses (237) (54) ________ ________ Total equity 1,107 1,291 ________ ________ Current liabilities Trade and other payables 104 188 ________ ________ Total liabilities 104 188 ________ ________ Total equity and liabilities 1,211 1,479 ________ ________ Unaudited consolidated cash flow statement For the six months ended 31 March 2007 6 months ended 31 Period ended 30 March 2007 September 2006 £'000 £'000 Net cash from operating activities (7) (181) ________ ________ Cash flows from investing activities Purchase of intangible assets (170) (400) Purchase of investments - Interest received 10 1 ________ ________ Net cash from investing activities (160) (399) ________ ________ Cash flows from financing activities Proceeds of issues of share capital - 1,359 ________ ________ Net cash from financing activities - 1,359 ________ ________ Net increase in cash and cash (167) 779 equivalents Cash and cash equivalents at the beginning of the period 779 - ________ ________ Cash and cash equivalents at the 612 779 end of the period ________ ________ Notes 1. The financial information set out above does not comprise full accounts as defined in the Companies Act 1985. 2. Losses per share are calculated on the basis of losses of £183,000 (2006 - £54,000) and a weighted average of 56,440,000 ordinary shares in issue (2006 - 15,486,684 shares). 3. No dividend is proposed in respect of the period. 4. No comparative figures are available for the 6 months ended 31 March 2006. The group was established on 7 September 2006 so that the comparative figures for the year ended 30 September 2006 do not include a full year. **ENDS** For further information please visit www.chromexmining.co.uk or contact: +-------------------------------------------------------------------+ | Nigel Wyatt | Chromex Mining plc | Tel: +27 82 900 | | | | 6827 | |-------------------+---------------------------+-------------------| | Brian Moritz | Chromex Mining plc | Tel: 07976 994300 | |-------------------+---------------------------+-------------------| | Romil Patel | Blue Oar Securities plc | Tel: 020 7448 | | | | 4400 | |-------------------+---------------------------+-------------------| | Hugo de Salis | St Brides Media & Finance | Tel: 020 7242 | | | Ltd | 4477 | +-------------------------------------------------------------------+ ---END OF MESSAGE---


 

The Dutch-based Sanoma Uitgevers, part of Sanoma Magazines, the magazine division of SanomaWSOY Group, has sold its puzzle magazines in the Netherlands to Keesing Media Group B.V. (Keesing), part of Telegraaf Media Group N.V., a Dutch stock listed company. After the due diligence process and positive advice of the works councils of Sanoma Uitgevers and Keesing Media Group, and the Supervisory Board of Keesing Media Group, the sale is now completed. The sale follows the redefinition of Sanoma Uitgevers' position in the puzzle market in the Netherlands. In 2006, the puzzle cluster's consolidated net sales amounted to EUR 12.8 million. The acquisition involves all activities of the puzzle cluster, and 23 employees. Sanoma Uitgevers' puzzle portfolio consists of brands such as Puzzelsport and Bingo!. All activities will be transferred to Keesing's premises in Amsterdam. SANOMAWSOY CORPORATION Matti Salmi Senior Vice President Finance and Administration Additional information: Corporate Communications Sanoma Magazines, Trudy de Jong, tel. +31 (0) 6 274 028 80 Sanoma Uitgevers, with more than 80 consumer magazines and well over 125 websites, is the largest multimedia publisher in the Netherlands. Sanoma Uitgevers is a business of Sanoma Magazines, one of the largest consumer magazine publishers in Europe. The company publishes more than 300 magazines in thirteen different countries. Apart from developing its strong portfolio of magazine brands for various reader communities, Sanoma Magazines is expanding its business to other media platforms, with a clear focus on interactivity. Sanoma Magazines is part of the SanomaWSOY Group, which operates in versatile fields of media in over 20 European countries.


 
Hitt og þetta
29. júní 2007

Acquisition

Kitron ASA ("Kitron") and EDC i Munkfors AB ("EDC"), headquartered in Sweden, have entered into an agreement whereby Kitron will acquire certain assets from EDC, among these EDC's subsidiary EDC Elsis UAB in Kaunas, Lithuania. EDC Elsis UAB currently employs about 40 people and operates a manufacturing facility of about 2,000 sqm. The agreement is subject to customary closing conditions, which are expected to be completed by August. The investment will amount to about SEK 14 million. Furthermore, EDC and Kitron may enter into further agreements at a later stage. By this acquisition, Kitron expands its customer portfolio and also obtains additional capacity to serve current customers' growth requirements. 28 June 2007 Kitron ASA Contact persons Kitron ASA: CEO Jørgen Bredesen, tel +47 48 25 25 84 and CFO Erling Svela, tel +47 40 62 10 40 Kitron is one of Scandinavia`s leading companies within development, industrialisation and production for the data/telecom, defence/marine, medical and other industries. The company is located in Norway, Sweden and Lithuania. Kitron had a turnover of about NOK 1,7 billion in 2006 and has 1,300 employees. See also www.kitron.com.


 

KONE Corporation, Press Release, 29 June, 2007 KONE has won four major orders in Saudi Arabia, United Arab Emirates and Qatar. One of the developments is the world's largest mosque, the Holy Harram (Holy Mosque), located in Mecca, Saudi Arabia. The other three projects represent new architectural landmarks in the Middle East. The combined value of the orders exceeds EUR 40 million. In Saudi Arabia, KONE will supply 128 heavy-duty escalators and 14 elevators for the Holy Harram located in the city of Mecca. The mosque, also known as Al Harram Al Sherriff, is currently being further expanded to handle the growth of religious tourism in Saudi Arabia. The installation of the equipment will start in September 2007 and is estimated to be completed in March 2008. In the United Arab Emirates (UAE), KONE has signed a contract with Bando Engineering and Construction Co. of South Korea to supply 36 customized elevators in the new U-Bora Tower development located in the heart of Dubai's Business Bay. The highest tower of the three-building complex will reach up to 263 meters. When installed, the elevators will travel up to speeds of 8 m/s. The installation of the elevators will start in February 2008 and is estimated to be completed in January 2009. In Qatar, KONE has won a contract to supply all elevators and escalators for two new office, residential and retail centers in Doha; The Twin Palm Towers and the West Bay Lagoon Plaza. The Twin Palm development consists of two office towers reaching up to 246 meters. Both towers will be equipped with 52 high-rise elevators travelling at maximum speeds of 8 m/s. The installation of the elevators will start in March 2008 and is estimated to be finished in April 2009. The West Bay Lagoon Plaza forms a modern residential and commercial area combining two architecturally impressive high-rise towers. KONE will supply a total of 26 elevators and 8 escalators for the 143-meter building complex. The installation of the equioment will start in November 2007 and is estimated to be finished in June 2008. Earlier this year, KONE won an order of 36 units for the five-tower multi-purpose office center Capital Plaza in Abu Dhabi, UAE with the first double-deck elevators in the Middle East. Sender: KONE Corporation Eric Maziol Executive Vice President, Area Director, West and South Europe Minna Mars Senior Vice President, Corporate Communications & IR For further information, please contact: Minna Mars, SVP, Corporate Communications & IR, tel. +358 (0)204 75 4501 KONE is one of the world's leading elevator and escalator companies. It provides its customers with industry-leading elevators and escalators, with innovative solutions for their maintenance and modernization. KONE also provides maintenance of automatic building doors. In 2006, KONE had annual net sales of EUR 3.6 billion and approximately 29,000 employees. Its class B shares are listed on the Helsinki Stock Exchange in Finland. www.kone.com


 

29 June 2007 LSE ANNOUNCEMENT Monto Minerals Limited (the "Company") ENTERING THE PRODUCTION PHASE... - Plant commissioning under way at Goondicum industrial minerals project - First production mid-July - Sales to commence second half calendar 2007 Monto Minerals' Goondicum industrial minerals project has entered the production phase with commissioning of the processing plant. The Company is planning to produce feldspar, ilmenite, apatite and titanomagnetite for domestic and export markets from its multi-product mining project in central Queensland. Dry commissioning of mechanical equipment commenced on Friday 22nd June and will be staged as various parts of the plant are commissioned. Stockpiled ore will start to be processed through the plant from mid July with commercial production achieved during August. Mining began in February, the soft ore being easily accessed from the surface by excavator and truck. Announcing the commissioning today, Monto Managing Director Mr Geoff Moore said: "Queensland will have an important new industry next month. The Goondicum project will commence production from the processing plant in mid-July and will be generating its first sales revenue during the second half of this year." The 35 km water pipeline has been completed and water is being pumped to the site as the facility is commissioned over the next two weeks. Water is being pumped from the company's licensed bore in the Mulgildie Basin west of Monto. Clearing for the power line has commenced and construction is expected to be completed in the September quarter to be followed by completion of the sub-station in October. Diesel generators are powering initial operations until power is available from the network provider. Also under construction is the feldspar washing plant at Dakiel, 25 km from the mine. The plant is on track for completion in September. Feldspar will be upgraded at Dakiel prior to sale. Market development of the products is continuing. Commercial testing of titanomagnetite as a coal washing heavy medium will commence next month at a central Queensland coal washing plant. Installation of grinding equipment for preparation of the titanomagnetite product at the Goondicum plant has been deferred pending the successful completion of the commercial test. Following a visit by the Board of Monto to the Goondicum site this week, Monto Chairman Mr Peter Slaughter said directors were pleased with the progress in bringing the production and infrastructure requirements of the project into operation in a timely manner. "The multi-product strategy we have pursued over the last four years has enabled us to bring on line an internationally significant industrial minerals producer," he said. "The Company is particularly grateful for the support of the Monto community for which the project has economic and social importance. Hiring of the local workforce has commenced with the engagement of four supervisors, two tradespeople and 20 operators." Enquiries to: +-------------------------------------------------------------------+ | Geoffrey Moore | | |----------------------------------------------+--------------------| | Monto Minerals Ltd | +61 (0)7 3034 3100 | |----------------------------------------------+--------------------| | | | |----------------------------------------------+--------------------| | Rob Bain / Samantha Robbins / Duncan | | | McCormick | | |----------------------------------------------+--------------------| | Redleaf Communications | 020 7822 0200 | |----------------------------------------------+--------------------| | | | |----------------------------------------------+--------------------| | Richard Brown | | |----------------------------------------------+--------------------| | Ambrian Partners Limited | 020 7776 6400 | +-------------------------------------------------------------------+ ---END OF MESSAGE---


 

Billam Plc Change of Nominated Adviser For immediate release 29 June 2007 The Board of Billam Plc ("Billam") is pleased to announce the appointment of Dawnay, Day Corporate Finance Ltd as Billam's Nominated Adviser with immediate effect. KBC Peel Hunt Ltd will continue to act as broker. Enquiries: Billam Plc Simon Bennett, Chairman 020 7222 1918 Dawnay, Day Corporate Finance Ltd David Floyd 020 7509 4570 ---END OF MESSAGE---


 

STOCK EXCHANGE RELEASE JUNE 29, 2007 BasWare Corp. has on June 29 sold its Tampere office premises to Varma Mutual Pension Insurance Company and agreed to stay in the premises on a long-term lease. The selling price is EUR 2 771 thousand. Earlier in the spring BasWare has sold the office premise in Lassila, Helsinki, and together these sales have a positive effect on the financial result. The sales of the business premises have a EUR 439 thousand one off improvement on the quarterly result of BasWare Corporation. BasWare Corp. rents the sold office premises from Varma Mutual Pension Insurance Company based on a seven-year lease contract and the company's operations at Tampere continue as before. For more information, please contact CEO Ilkka Sihvo, BasWare Corp., tel. +358 40 501 8251 BASWARE CORP. Ilkka Sihvo Distribution: Helsingin Stock Exchange Key media www.basware.com


 

SimCorp announces that Victorian Funds Management Corporation (VFMC) has licensed SimCorp Dimension. Located in Melbourne, Australia, VFMC is responsible for managing investments of AUD 39.7 billion on behalf of 14 clients, all of whom are Victorian Government entities.


 

Royal DSM N.V. has repurchased 607,831 of its own shares in the period from 21 June 2007 up to and including 27 June 2007 at an average price of EUR 36.48. This is in accordance with the second phase of the share buyback program announced on 27 April 2007. The consideration of this repurchase was EUR 22.2 million. The total number of shares repurchased under the second phase of this program to date is 6,559,243 shares for a total consideration of EUR 238.8 million. DSM DSM is active worldwide in nutritional and pharma ingredients, performance materials and industrial chemicals. The company develops, produces and sells innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM's strategy, named Vision 2010 - Building on Strengths, focuses on accelerating profitable and innovative growth of the company's specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over ¤8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with locations in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at www.dsm.com. For more information: DSM Corporate Communications DSM Investor Relations Elvira Luykx Dries Ausems tel. +31 (0) 45 tel. +31 (0) 45 5782864 5782035 fax +31 (0) 45 5782595 fax +31 (0) 45 e-mail 5740680 investor.relations@dsm.com e-mail media.relations@dsm.com


 

People can now order prints directly from their compatible Nokia Nseries device Espoo, Finland - Nokia launches a fully integrated mobile printing service in Europe*. The new Nokia service enables people to order high-quality prints easily and directly from the device, over cellular** or wireless LAN (WLAN) networks, and have them delivered to your home or to a friend. "Remember when you had to drag yourself to the store to have your film developed?" asks Mikko Pilkama, director, Multimedia, Nokia. "Now you can order prints directly from your Nokia Nseries device, and have them delivered to your doorstep - hassle-free!" Users of compatible Nokia Nseries multimedia computers now only need one device to capture images, edit them and order prints. You can also have your favorite images printed on stickers or gift items like mugs, jigsaw puzzles and T-shirts, and have them delivered to a friend. The mobile printing service is accessible from the device's Gallery application. Simply select the images to be printed, insert address and other requested information, and press 'Order now'. The order is then processed by CeWe Color and prints are delivered to the entered address. Payment methods commonly include credit card as well as other possible local payment solutions depending on the country. In order to familiarize people with the service, each new user can order their first ten prints free of charge**. Owners of compatible Nokia Nseries multimedia computers can download the necessary Nokia XpressPrint application for free directly from the Download! application on their device** or from www.nseries.com/orderprints. The Nokia mobile printing service is available now and covers most of Europe*. * For a full list of countries where the service is available, please visit: www.nseries.com/orderprints ** To check the cost of data transfer services, contact your network operator or service provider. Notes to editors: To find out more about the Nokia mobile printing service, please visit: www.nseries.com/orderprints Related photos in print quality can be found at: www.nokia.com/press/photos About Nokia Nseries Nokia Nseries is a range of high performance multimedia computers that delivers unparalleled mobile multimedia experiences by combining the latest technologies with stylish design and ease of use. With Nokia Nseries products, consumers can use a single device to enjoy entertainment, access information and to capture and share pictures and videos, on the go at any time. www.nseries.com About Nokia Nokia is the world leader in mobility, driving the transformation and growth of the converging Internet and communications industries. Nokia makes a wide range of mobile devices and provides people with experiences in music, navigation, video, television, imaging, games and business mobility through these devices. Nokia also provides equipment, solutions and services for communications networks. Media Enquiries: Nokia, Multimedia Communications Tel. +358 7180 45667 Nokia Communications Tel. +358 7180 34900 Email: press.office@nokia.com www.nokia.com --- End of Message --- NOKIA P.O. Box 226<br>FIN-00045 NOKIA GROUP Espoo WKN: 870737; ISIN: FI0009000681; Index: DJ STOXX Large 200, DJ STOXX 50; Listed: Nordic list (Large Cap) in THE HELSINKI STOCK EXCHANGE;


 

B&B TOOLS has concluded an agreement to acquire 100 percent of the shares outstanding in SA-Maskiner AB. SA-Maskiner is one of the largest suppliers of tools and other industrial consumables as well as steel goods to industry in Skaraborg. SA-Maskiner has net revenues of approximately MSEK 95 per annum and has 32 employees. SA-Maskiner offers a comprehensive product range from world-leading suppliers in combination with specialist competence in, among others, cutting workings and measuring technique. The company is today represented at four locations: Skövde, Lidköping, Skara and Habo. "The acquisition of SA-Maskiner will further strengthen the TOOLS chain's offering of industrial consumables to the industrial customers in western Sweden", says Johan Falk, Executive Vice President in B&B TOOLS. "SA-Maskiner has a strong market position and the intent is to co-ordinate the business with the Group's other businesses in the region; Jerngruppen Skaraborg and Götene Stål & Verktyg. TOOLS will now have strong representation in six locations in Skaraborg." Closing is expected to take place in the beginning of July 2007. The acquisition is expected to have a marginally positive effect on B&B TOOLS' earnings per share during the current financial year. Stockholm, 29 June 2007 B&B TOOLS AB (publ) For further information, contact: Johan Falk, Executive Vice President, B&B TOOLS AB, telephone +46-8-660 10 30 Mats Karlqvist, Vice President - Investor Relations, B&B TOOLS AB, telephone +46-70-660 31 32 B&B TOOLS provides the industrial and construction sectors in northern Europe with tools, industrial consumables and industrial components, and related services. The Group has annual revenues of approximately SEK 7.6 billion and has approximately 2,700 employees. Bergman & Beving changed its name to B&B TOOLS at the end of March 2007.


 

* Presentation of efficacy trends from ongoing phase I/II trial of oncolytic HSV * Poster selected by ESMO for presentation in press conference Martinsried, June 29, 2007. The biotech company MediGene AG (Frankfurt, Prime Standard: MDG) announces that a case report from the ongoing clinical trial of MediGene's cancer killing virus will be presented in a press conference held by the European Society for Medical Oncology. Out of more than 300 posters accepted for the conference, only five were chosen for presentation in the press conference. The event will take place on Friday, July 6, at 12:30 MEST at the ESMO conference in Lugano, Switzerland (ECLU). Dr. Axel Mescheder, Head of Clinical Research and Development at MediGene, will present the data in the press conference as well as in a poster presentation during the conference. The phase I/II trial of NV1020 for the treatment of liver metastases of colorectal cancer is being conducted at seven leading cancer centers in the US. In September 2006, MediGene announced positive safety and efficacy data from an interim analysis of this study. The poster presented at the ESMO conference shows efficacy data in a case study for the first time. Dr. Ulrich Delvos, Chief Operating Officer of MediGene, comments. "We are delighted and proud that the European Society for Medical Oncology has decided to present a case study from our trial in a press conference. Considering the number of studies presented on Europe's largest cancer congress, this emphasizes the innovation and the potential of this approach to fight cancer." Journalists interested in joining the press conference please contact media@esmo.org This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGeneTM is a trademarks of MediGene AG - ends - MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company with a drug on the market. A second drug has been approved by the FDA. A third drug was recently inlicensed to market this drug in Europe. In addition, several drug candidates are currently in clinical development. MediGene also possesses innovative platform technologies. Contact MediGene AG: Email: investor@medigene.com Fax: ++49 - 89 - 85 65 - 2920 Julia Hofmann/Dr. Georg Dönges, Public Relations Tel.: ++49 - 89 - 85 65 - 3317 Dr. Michael Nettersheim, Investor Relations Tel.: ++49 - 89 - 85 65 - 2946 --- End of Message --- MediGene AG Lochhamer Strasse 11 Martinsried / München Germany WKN: 502090; ISIN: DE0005020903 ; Index: Prime All Share, CDAX, TECH All Share, HDAX, MIDCAP, TecDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Geregelter Markt in Frankfurter Wertpapierbörse;


 

Netza AS, a company controlled by Mr Asbjørn Vavik, CEO, has today acquired 100,000 shares in Songa Offshore at NOK 57.8327 per share. After the transaction, Mr Vavik and his close associates hold 100,000 shares, and have options to buy a further 300,000 shares at NOK 54.25 per share in Songa Offshore. Oslo, 2007-06-28


 

ALMA MEDIA CORPORATION PRESS RELEASE JUNE 29, 2007 AT 9:00AM ALMA MEDIA SOLD THE BUSINESS OPERATIONS OF KAINUUN SANOMAT NEWSPAPER PRINTING HOUSE Alma Media Corporation has sold the business operations of the newspaper printing house of Kainuun Sanomat Oy, together with its machinery and equipment, to Pyhäjokiseudun Kirjapaino Oy. The employees of the printing house will continue in the employment of the new owner with existing status and benefits when the deal is finalised on July 1, 2007. The sale does not cover the sheet printing works of Kainuun Sanomat Oy, which will continue operations as before. In connection with the divestment, Pyhäjokiseudun Kirjapaino has entered a long-term lease agreement with Kainuun Sanomat Oy on continuing the printing operation in its present property in Kajaani, Finland. In addition, the new owner has given a pledge to invest in a new printing press. "This solution secures the printing services of the Kainuun Sanomat newspaper in future, as well as the jobs in the business in Kajaani", says Matti Ilmivalta, managing director, Alma Media Northern Newspapers business unit. "This deal is the most important ever in the history of Pyhäjokiseudun Kirjapaino. We see it as a token of trust and a new opportunity for our printing house. The decision now made will affect our operation long into the future", comments Asko Talvi, managing director, Pyhäjokiseudun Kirjapaino. Of Alma Media's publications, the Kainuun Sanomat and Koti-Kajaani are printed in the divested printing house. In addition, the Kajaani press prints Ylä-Kainuu, Kuhmolainen and Sotkamo-lehti, all publications belonging to Suomen Paikallissanomat Oy, part of Alma Media. More information: Matti Ilmivalta, managing director, Alma Media Northern Newspapers, tel. +358 40 728 3180. Distribution: Helsinki Exchanges, principal media Alma Media is a profitably growing and internationally expanding company that invests in the future of newspapers and the online media. Its best known products are Aamulehti, Iltalehti, Kauppalehti and Etuovi.com. Net sales in 2006 totalled EUR 302 million and the operating margin was 16 %. The company's share is listed in the Mid Cap segment of the OMX Nordic Exchange's Nordic List, trading code ALN1V. More information at http://www.almamedia.fi/home.


 

With reference to the power of attorney granted at the ordinary general meeting of emgs on 1 March 2007, the board of Directors has in a board meeting 28 June 2007 approved a share issue of 236,750 shares, each with a face value of NOK 0.25. As a result, the share capital will be increased by NOK 59,187,50 from NOK 18,361,643.25 to NOK 18,420,830.75. The share issue is completed through exercising of stock options in connection with emgs' stock option program to key employees. The following primary insiders have decided to exercise options: Bjarte Bruheim 50,000 shares at a subscription price of NOK 26.00. After the transaction Bruheim has 1,460,302 shares and 610,000 options. Svein T. Knudsen 40,000 shares at a subscription price of NOK 10.95 and 30,000 shares at a subscription price of NOK 26.00. After the transaction Knudsen has 74,227 shares and 200,000 options. Svein Ellingsrud 20,000 shares at a subscription price of NOK 26.00. After the transaction Ellingsrud has 770,214 shares and 180,000 options. Ståle Emil Johansen 15,000 shares at a subscription price of NOK 26.00. After the transaction Johansen has 526,214 shares and 130,000 options. Odd Tjelta 10,000 shares at a subscription price of NOK 26.00. After the transaction Tjelta has 215,214 shares and 110,000 options. An updated Company Certificate of Registration will be sent to OSE when received from the Register of business enterprises. For further information, please contact: Svein Knudsen, CFO, tel. +47 73 56 88 10


 

Full Press Release (in PDF format) Please, find enclosed the press release issued today by RHJ International announcing its condensed consolidated financial results for the fiscal year ended March 31, 2007. RHJ International (Euronext: RHJI) is a diversified holding company focused on creating long-term value for its shareholders by acquiring and operating businesses in attractive industries in Japan and elsewhere. For further information visit www.rhji.com. Arnaud Denis Investor Relations Director RHJ International Tel. +32 2 643 60 13 http://www.rhji.com investor-relations@rhji.com


 

Stockholm - Tele2 AB, ("Tele2"), (Stockholm Stock Exchange: TEL2 A and TEL2 B), Europe's leading alternative telecom operator, today announced that it expects a negative one time effect of approximately MSEK 600 in the second quarter 2007. The effect is attributable to the earlier announced divestments of Alpha Telecom and C3, which was completed in the second quarter 2007. During the second quarter 2007 the divestment of Alpha Telecom and C3 was completed, which will result in a negative one time effect of approximately MSEK 600. The sale of Tele2 Denmark and UNI2 Denmark will have a positive one time effect of approximately MSEK 400 and is expected to be presented in the third quarter 2007. ____________________________________________________________________ Further information can be obtained from: Lars-Johan Jarnheimer, President and CEO Tele2 AB, Telephone: +46 8 5626 4000 Lars Torstensson, Investor Inquiries, Telephone: +46 702 73 48 79 Tele2 is Europe's leading alternative telecom operator Tele2's mission is to provide cheap and simple telecoms for everyone in Europe. Tele2 always strives to offer the market's best prices. We have 29 million customers in 22 countries. Tele2 offers fixed and mobile telephony, broadband, data network services and cable TV. Ever since Jan Stenbeck founded the company in 1993, it has been a tough challenger to the former government monopolies and other established providers. Tele2 has been listed on OMX Nordic Exchange since 1996. In 2006 we had operating revenue of SEK 50.3 billion and we reported an operating profit (EBITDA) of SEK 5.7 billion.


 

Start of Xetra-Trading Announced Berlin, June 28, 2007 - Today's annual shareholder meeting of design hotels AG (Regulated Market, Munich: LBA; ISIN: DE0005141006) resolved the succession of Mr. Peter Wackerbauer and Mr. Thomas Willms as members of the supervisory board. Mr. Heinz Horrmann and Mr. Holger Lösch were elected as new members of the board. In total, 71.5% of the admitted capital was represented at the annual shareholder meeting. The election of the two new members of the board was met with vast approval. The vote for all agenda items will be published on the website www.designhotels.com . In course of the annual meeting, management announced the initiation of continuous trading of the shares of the company at the electronic trading platform of the German stock exchange as of July 1, 2007. The Munich based securities trading bank Gebhard & Co. AG was mandated as Designated Sponsor and Market Maker in order to provide liquidity for the trading. Contact: design hotels AG Claus Sendlinger (CEO) Stralauer Allee 2c 10245 Berlin Tel. +49 (0)30 420 940-30 Fax +49 (0)30 259 330-17 ir@designhotels.com Schwarz Financial Communication Frank Schwarz Tel. +49 (0)611 17453 9811 Fax +49 (0)611 17453 9829 schwarz@schwarzfinancial.com design hotels AG (formerly: lebensart global networks AG) is an integrated provider of communication and positioning services and acts as a consultant for individually managed hotels and small hotel groups. The service range of design hotels begins with the concept for a hotel. Clients of design hotels AG can choose from a modular service portfolio. With the brand design hotels(TM) the company currently represents and markets a unique collection of more than 150 individual hotels in over 40 countries. Through its marketing and communication activities design hotels AG forms the connection between the member hotel and a global clientele looking for self-determination and individuality. --- End of Message --- design hotels AG Paul-Lincke-Ufer 20-22 Berlin Germany WKN: 514100; ISIN: DE0005141006; Listed: Freiverkehr in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Geregelter Markt in Bayerische Börse München;


 

Metso Paper will supply a complete deinking line to Subburaj Papers Private Ltd. in India. The new DIP line will have a daily capacity of 320 tons and the value of the investment is close to EUR 8 million. The greenfield printing and writing paper project is scheduled to start up in mid-2008. The line will feature the latest deinking technology, including the energy efficient OptiSlush drum pulper and OptiBright flotation cells. The delivery is Metso Paper's first recycled fiber system to be installed in India. The pulp is used for manufacturing high-quality printing and writing paper based on 100 % recovered fiber as raw material. Subburaj Papers Private Ltd. is a part of the Subburaj Industries Ltd. group of companies, based in Tirunelveli, southern Tamil Nadu, India. In the textile industry Subburaj is a well-established 100 % EOU (Export Oriented Units) company. The mill is located approximately 20 km from the town of Tirunelveli. Metso is a global engineering and technology corporation with 2006 net sales of approximately EUR 5 billion. Its 25,500 employees in more than 50 countries serve customers in the pulp and paper industry, rock and minerals processing, the energy industry and selected other industries. www.metso.com For further information, please contact: Mauri Lattunen, Vice President, Stock Preparation and Recycled Fiber Sales, Metso Paper, tel. +358 20 482 9474 N K Jain, Vice President, Metso Paper India, tel. +91 9873251858


 

Leiden, The Netherlands, June 28, 2007. Biotech company Pharming Group NV ("Pharming" or "the Company") (Euronext: PHARM) will present an update of its portfolio of products and technologies during a meeting for analysts and specialized reporters today commencing at 1:30 pm CET. Dr. Jan Hoeijmakers, member of Pharming's Scientific Advisory Board and professor at the Erasmus Medical Center in Rotterdam, will provide an overview of the current state of the art in the field of DNA-damage and repair. In particular, the link between DNA-damage and ageing will be highlighted. Recent scientific results and their impact on developing therapies for ageing diseases will be discussed. Dr. Frank Pieper, Chief Science and Technology Officer, one of the driving forces behind the development of Pharming's transgenic technology, will discuss the science behind the production of proteins in milk. Dr. Bruno Giannetti, Chief Operations Officer, will present an update on the development of the various products in Pharming's portfolio. With respect to Rhucin®, Pharming's lead product developed as a treatment for heredetary angioedema ("HAE"), Dr. Giannetti will review the clinical program and summarize the relevant data generated so far. He will confirm that the product appears to be safe, well-tolerated and provides rapid relief to patients suffering from acute HAE attacks. He will also discuss the scientific and clinical rationale in developing the product for other indications, in particular for transplantation. With respect to Pharming's lactoferrin product, Dr. Giannetti will confirm that the product has an excellent safety profile with no significant toxicity observed so far after considerable testing. In very recent interactions with the US-FDA, who are reviewing the dossier in relation to Pharming's request to obtain GRAS ("Generally Recognized As Safe") status, it appears that there are no further questions outstanding, and that the FDA will communicate on possible next steps with GRAS review of lactoferrin in the third quarter of 2007. Pharming expects that a final opinion by the FDA will be provided to Pharming later this year. On Pharming's fibrinogen product, Dr. Giannetti will confirm efforts to develop fibrinogen as a pharmaceutical product for the treatment of bleeding disorders, along with its development for medical device applications in partnership with third parties. The Company expects to provide further details on the pharmaceutical applications of fibrinogen and its development in the second half of 2007. The commercial outlook for the Company, although not on the agenda of today's meeting,remains positive with the main product-development related events anticipated for the second half of 2007 being presentation of results from the clinical trials of Rhucin® for HAE, the opinion of the European authorities (EMEA) on market authorization of Rhucin® in Europe, the opinion of FDA on GRAS status of lactoferrin, and clinical development of Rhucin® for new indications. The presentation made at the meeting of today will be made available on the website of the Company (www.pharming.com) after the meeting has ended. Background on Pharming Group NV Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (MAA under review by EMEA) and human lactoferrin for use in food products (GRAS notification under review by US FDA). The advanced technologies of the Company include innovative platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with NovaThera) and DNA repair (via its acquisition of DNage). Additional information is available on the Pharming website, http://www.pharming.com and on http://www.dnage.nl. This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version. Contact: Carina Hamaker Rein Strijker Investor Voice Pharming Group NV T: +31 (0)6 537 499 59 T: +31 (0)71 52 47 400 T: +31 (0)71 52 47 431


 

FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | AXA Investment Managers UK | | | Limited/AXA Framlington | | | Investment Management Limited | |-----------------------------------+-------------------------------| | Company dealt in | Taylor Woodrow | |-----------------------------------+-------------------------------| | Class of relevant security to | Ordinary shares | | which the dealings being | | | disclosed relate (Note 2) | | |-----------------------------------+-------------------------------| | Date of dealing | 27/06/07 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------------------------------+ | | Long | Short | | | | | |---------------+--------------------------+------------------------------------------------| | |Number |Number | | | (%) | (%) | |---------------+--------------------------+------------------------------------------------| |(1) Relevant |8,728,522 (1.50%) | | |securities | | | | | | | |---------------+--------------------------+------------------------------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+--------------------------+------------------------------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+--------------------------+------------------------------------------------| |Total |8,728,522 (1.50%) | | | | | | +-------------------------------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +--------------------------------------------------------------------------+ |Class of | Long | Short | |relevant | | | |security: | | | | | | | |---------------+----------------------------+-----------------------------| | |Number |Number | | | (%) | (%) | |---------------+----------------------------+-----------------------------| |(1) Relevant | | | |securities | | | | | | | |---------------+----------------------------+-----------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+----------------------------+-----------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+----------------------------+-----------------------------| |Total | | | | | | | +--------------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | Sell | 100,000 | 3.70p | | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short (Note | Number of securities | Price per | | name, | 6) | (Note 7) | unit (Note | | e.g. CFD | | | 5) | |----------+------------------+------------------------+------------| | | | | | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 28/06/2007 | |---------------------------------------------------+---------------| | Contact name | Maria Mauro | |---------------------------------------------------+---------------| | Telephone number | 0207 003 2812 | |---------------------------------------------------+---------------| | If a connected EFM, name of offeree/offeror with | N/A | | which connected | | |---------------------------------------------------+---------------| | If a connected EFM, state nature of connection | N/A | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

Orkla will report second quarter results on Thursday 9 August 2007 at 7.00 a.m. A presentation of the second quarter results will be held at 8.00 a.m. in Oslo (Vika Atrium, Munkedamsvn. 45). The presentation and Q&A-session will be simultaneous translated to English. Both the presentation and the following Q&A-session can be viewed via WebCast at www.orkla.com. It will be possible to ask questions through e-mail. For registration to the presentation at Vika Atrium please send an e-mail to info@orkla.no. Contacts Investor Relations: Rune Helland, Tel: +47 22 54 44 11 Siv M. Skorpen Brekke, Tel: +47 22 54 44 55


 

VIENNA, AUSTRIA -- (MARKET WIRE) -- June 28, 2007 -- For some time MagnaBet, the online betting portal for horse races of the Magna Entertainment Corp., has been counting on SENACTIVE's "Predictive Fraud Detection System". All transactions are examined for conspicuous activities in order to prevent fraudulent intentions and ensure the highest possible level of security for the customers. Therewith SENACTIVE managed to position itself successfully in the gaming industry. Real-time betting analysis prevents financial damages to players and betting providers For betting providers like www.MagnaBet.com, it is a standard course of action to undertake that comprehensive safety precautions are in place in order to protect customers and the company itself against financial damages. With the SENACTIVE InTime(TM) Predictive Fraud Detection System, security is increased through the continuous and intelligent inspection of online activities. The real-time analysis already examines payment and betting activities for fraud patterns before any bets are placed. If such a case of suspicious behavior is identified, the system automatically triggers counter measures, thereby ensuring the highest possible level of security for customers and the betting provider. Please click on link below: http://www.ccnmatthews.com/docs/senactive.jpg Easy integration, "visual fraud mining" and flexible adjustments The interaction of SENACTIVE InTime(TM) with the existing IT-infrastructure of www.MagnaBet.com works optimally with the available interfaces. With the user-friendly graphic modelling interface, new fraud patterns can be defined without any programming. The time that is saved is used by the security analysts for analysis, evaluation and refinement of the safety precautions. This work is significantly simplified with the possibility to visually depict and discover fraud patterns with the SENACTIVE EventAnalyzer. The use of adaptive rules enables the automatic adjustment of the system and uses the newly gained knowledge to rapidly identify new threats and to react accordingly. Security and player protection for the MagnaBet betting portal "The protection of customers and, accordingly, the careful recognition and prevention of fraudulent activities has the highest priority for MagnaBet. Only a safe offer can instill the necessary confidence in customers in this sensitive industry," commented DI Rene Schneider, General Manager of MagnaBet. "With SENACTIVE InTime(TM), we can implement these safety precautions in a timely manner and, at the same time, minimize the costs for their continuous update." THE COMPANY Since 2000, the experts from SENACTIVE have been researching and developing solutions that enable companies to monitor and control their business in real time. SENACTIVE InTime, the innovative and patented software solution, makes it possible for companies to event-dependently monitor, simulate and control their organizational processes. Close customer contact and accelerated processing times give our customers a significant head start on their competition. Contacts: SENACTIVE IT-Dienstleistungs GmbH Mag. Peter Kühnberger AUSTRIA A-1040 Wien, Phorusgasse 8 Tel: +43 1 890 15 85 - 0 GERMANY D-69123 Heidelberg, Waldhofer Strasse 102 Tel: +49 6221 82563 - 0 Internet: http://www.senactive.com E-Mail: publicrelations@senactive.com SOURCE: SENACTIVE


 
Hitt og þetta
28. júní 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |-------------------------------------------------+-----------------| | Company dealt in | Homeserve Plc | |-------------------------------------------------+-----------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |-------------------------------------------------+-----------------| | Date of dealing | 27th June 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price | | securities | (Note 3) | paid | | purchased | | (Note 3) | |---------------------------+--------------------+------------------| | 0 | | | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |------------------------+--------------------+---------------------| | 220 | 1,794p | 1,778.60p | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +-------------------------------------------------------------------+ | Date of disclosure | 28th June 2007 | |---------------------------------------+---------------------------| | Contact name | Edward Hodge | |---------------------------------------+---------------------------| | Telephone number | 0207 991 6661 | |---------------------------------------+---------------------------| | Name of offeree/offeror with which | Domestic & General Group | | connected | Plc | |---------------------------------------+---------------------------| | Nature of connection (Note 6) | Connected Advisor | +-------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

28th June 2007 RE : Exercise of Options Options to subscribe for 100,000 Ordinary Shares of ¤0.06c in the capital of Kenmare have been exercised. Application has been made to the Irish Stock Exchange and the UK Listing Authority for the new Ordinary Shares to be admitted to, respectively, the Official List of the Irish Stock Exchange and the Official List of the UK Listing Authority and to the London Stock Exchange for the new shares to be admitted to trading. The new Ordinary Shares rank pari passu in all respects with the existing Ordinary Shares. ____________________ Deirdre Corcoran Financial Controller ---END OF MESSAGE---


 

Wärtsilä Corporation, Trade and Technical Press Release, 28 June 2007 Wärtsilä's joint venture company in China, Wartsila CME Zhenjiang Propeller Co Ltd, today inaugurated its new propeller factory at Zhenjiang in Jiangsu province. The company will be the biggest fixed-pitch propeller manufacturer in China and one of the biggest in the world in this sector. The new factory doubles Wärtsilä's capacity to manufacture this type of propellers. Shipbuilding is growing very fast in China. During the past ten years the output has increased by 500%. In 2007 up to May, there are 425 vessels contracted in China, which is 45% of the global vessel order intake, ranking China number one in the world. "Doubling the production capacity is a logical step, as shipbuilding in China is experiencing such tremendous growth. Together with our joint venture company, we are now able to offer advanced propulsion systems up to the largest sizes required," said Mr Ole Johansson, President & CEO of Wärtsilä Corporation in the inauguration event in Zhenjiang today. The new factory has more than doubled the annual production output to 6500 tonnes of propellers. The new maximum size of propeller that can be produced at the new factory is suitable for the world's largest container ships that are currently envisaged with propellers individually weighing up to as much as 140 tonnes. The joint venture Wartsila CME Zhenjiang Propeller Co Ltd was set up in 2004 by Wärtsilä (55%) and Zhenjiang CME Ltd (45%), a subsidiary of China State Shipbuilding Corporation (CSSC). The total investment in the new factory is EUR 10 million. Serving both Chinese and global markets As about 80% of the world's newbuildings use fixed-pitch (FP) propellers of the type manufactured in the new factory, Wärtsilä has gained great opportunities in world markets in addition to the Chinese market. Most of the propellers are sold to the rapidly-growing market in China. About 15 to 20% of the production is exported. Wartsila CME Zhenjiang delivers propellers to a significant number of Chinese shipyards. In addition to the large state-owned yards there are also a growing number of privately-owned shipyards. The company has been successful in being selected as the sole supplier for several recently-established shipyards. China has the strategic goal of being the world's largest shipbuilder in about ten years time. This means huge growth in both the number and capacity of shipyards. Scope for expansion The new factory will concentrate on larger FP propellers, with diameters of more than 5m. It is designed for an annual production of some 200 propellers of that size, with individual weights up to a maximum of 140 tonnes. In the present factory Wartsila CME Zhenjiang manufactures FP propellers up to a maximum of 70 tonnes unit weight. The new factory also allows the company to commence machining of propeller shafts so that the company can deliver complete FP propeller packages with complete shaft lines and accessories. The land area of the production site will give ample scope for further expansion. The new factory began test production on 11 June 2007. By September 2007, it will have 150 employees. It will be up to full production in the second half 2008 when it will have about 240 employees. Production methods at the two factories are very similar, with an identical emphasis on high-quality manufacturing. There is a single quality management team serving both factories according to ISO 9000 accreditation and high Wärtsilä quality standards and procedures. There are clear procedures for every task with particular emphasis to ensure that relevant procedures are followed. New factory is conveniently located The new factory is conveniently located about five minutes drive from the current propeller factory of Wartsila CME Zhenjiang towards the Zhenjiang port at the Yangtze River. The large FP propellers can be readily shipped from the Zhenjiang port to the shipyard customers. The existing propeller factory of Wartsila CME Zhenjiang will be developed as a modern manufacturing unit for small FP propellers with diameters from 0.5 m up to 5m, together with components for controllable-pitch propellers (CPP). The company has invested, among other equipments, in a state-of-the-art CNC machine for CPP blades. The head office of Wartsila CME Zhenjiang will remain at the current factory. Wärtsilä is growing in China Wärtsilä is steadily expanding its capacity in China to serve the country's rapidly growing shipbuilding industry. Wärtsilä now has five manufacturing works and three engine-building licensees. Propellers and thrusters In addition to the two Zhenjiang factories for propellers and shaft lines, Wärtsilä has another propulsion production facility in China at Wuxi. That factory, set up in 2005, now manufactures all of Wärtsilä's transverse thrusters. Deliveries are to both China's shipbuilding industry and global markets. Engines The joint venture company Wärtsilä Qiyao Diesel Co Ltd (Shanghai) began the manufacture of complete marine diesel generating sets in June 2006. The joint venture Qingdao Qiyao Wärtsilä MHI Linshan Marine Diesel Co Ltd (QMD) was established in 2007 to manufacture low-speed marine diesel engines. Wärtsilä has three licensees in China: Dalian Marine Diesel Works (DMD), Hudong Heavy Machinery Co Ltd (HMM) and Yichang Marine Diesel Engine Plant (YMD). Wärtsilä and the licensees have a long established cooperation in the manufacture of Wärtsilä low-speed engines. Link to pictures Media contact: Marit Holmlund-Sund Public Relations Manager Wärtsilä Corporation Direct tel: +358 10 709 1439 Direct fax: +358 10 709 1425 e-mail: marit.holmlund-sund@wartsila.com Internet: www.wartsila.com Notes to the editor: Wärtsilä enhances the business of its customers by providing them with complete lifecycle power solutions. When creating better and environmentally compatible technologies, Wärtsilä focuses on the marine and energy markets with products and solutions as well as services. Through innovative products and services, Wärtsilä sets out to be the most valued business partner of all its customers. This is achieved by the dedication of more than 14,000 professionals manning 130 Wärtsilä locations in close to 70 countries around the world. www.wartsila.com


 

OUTOKUMPU OYJ PRESS RELEASE JUNE 28, 2007 AT 11.00 A.M. The independent investigator, Roschier Attorneys Ltd, that Outokumpu retained for an internal investigation has in their examination not found evidence that Tornio Works employees would have committed the crimes alleged by the Finnish Customs. Outokumpu and exports to Russia Outokumpu is one of the world's largest stainless steel producers with an annual production capacity of 1.9 million tons of finished products. Outokumpu's Tornio Works business unit is the largest of the Group's units with an annual capacity on 1.2 million tons of finished products. In 2006, the Group delivered some 18 600 tons of stainless steel to Russian customers, out of which Tornio's share was some 8 300 tons. Tornio's deliveries to Russia in 2006 represent some 0.7% of its annual production capacity. Customs' investigation into stainless steel exports from Tornio to Russia In March 2007, the Finnish Customs launched an investigation into Outokumpu Stainless' ("Tornio Works") export trade of stainless steel to Russia. The Customs authorities made a search in the Tornio Works premises in Tornio, and seized a large amount of documentation from its offices, and questioned eleven of Outokumpu personnel. According to information received from the Customs authorities, seven of the persons have been interrogated under suspicion of gross forgery and gross accounting offence. According to a press release by the Finnish Customs on April 10, 2007, "The preliminary investigation by Customs targeted at the export to Russia by Outokumpu Stainless is connected to another preliminary investigation concerning a forwarding agency based in Southeastern Finland. It is suspected that defective and/or forged invoices have been prepared at the forwarding agency as regards export of stainless steel to Russia. The preliminary investigation is focused on the complicity of Outokumpu Stainless in the preparation of defective and/or forged invoices in the forwarding agency in question." Following the start of the investigation, Outokumpu has co-operated fully with the Customs authorities and has volunteered any additional documentation requested and granted electronic access to any databases pertinent to the inquiry. Outokumpu immediately initiated its own investigation Immediately after the start of the investigation by Finnish Customs, Outokumpu initiated its own investigation into the trade practices of stainless steel exports from Tornio to Russia. Roschier, a leading law firm based in Helsinki, was retained to carry out an independent investigation. On the investigation, Roschier has concentrated on Tornio Works' export trade process to Russia and, in particular, whether there is any basis for the Finnish Customs authorities' suspicions against Outokumpu's personnel regarding the alleged gross forgery and gross accounting offence. Roschier was granted full access to any documentation it wanted to review and to all personnel it wanted to interview. However, documentation confiscated by the Customs and the Customs' interrogation minutes were not available to Roschier. No further instructions as to how the investigation should be carried out were given to Roschier. Conclusions of the Roschier investigation As a result of the investigation, Roschier has concluded that it has not found evidence that any of Tornio Works employees or the company would have committed any of the crimes, alleged by the Customs. Process going forward The management of Outokumpu welcomes the conclusion of Roschier's investigation and is confident that neither the company nor its employees are guilty of wrongdoing as alleged by the Finnish Customs. However, as the investigation by the Finnish Customs is on going and is estimated to last until the end of 2007, Outokumpu will continue to cooperate with the authorities in order to reach a conclusive outcome on the issue at hand. For further information, please contact Matti Louhija, SVP - Corporate General Counsel, tel. +358 9 421 5508, mobile + 358 40 501 5056


 

BRUSSELS, Belgium - June 28, 2007 - Delhaize Group, the Belgian international food retailer (Euronext Brussels: DELB, NYSE: DEG) announced today that it has successfully closed its offering of EUR 500 million and USD 450 million Senior Notes. In addition, Delhaize Group announced the final results of Delhaize America's debt tender offer. "This tender offer and related refinancing have improved substantially our financial flexibility and debt profile," said Pierre-Olivier Beckers, President and Chief Executive Officer of Delhaize Group. "We have been particularly pleased with the attractive refinancing conditions and the success of our first benchmark euro bond, reflecting the recognition by the financial markets of the operational and financial strengths of Delhaize Group." Tender Offer The tender offer by Delhaize America to purchase for cash up to USD 1.1 billion of its 8.125% Notes due 2011, 9.000% Debentures due 2031 and 8.050% Notes due 2027, in order of purchase priority (together, the "Debt Securities") expired on June 26, 2007 at midnight, New York City time (the "Expiration Time"). The tender offer was made upon the terms, and subject to the conditions, set forth in the Offer to Purchase dated May 30, 2007 and the related Letter of Transmittal. According to Global Bondholders Services Corporation (the "Depositary"), USD 1,049,557,000 in aggregate principal amount of 8.125% Notes were validly tendered and not withdrawn prior to the Expiration Time. Delhaize America has accepted for payment all of the tendered 8.125% Notes. USD 662,524,000 in aggregate principal amount of 9.000% Debentures were validly tendered and not withdrawn prior to the Expiration Time. Delhaize America has accepted for payment USD 50,443,000 of the tendered 9.000% Debentures. The offer for the 9.000% Debentures is subject to proration as described in the Offer to Purchase at a proration factor of 7.63%. Because the aggregate principal amount of the 8.125% notes due 2011 and 9.000% debentures due 2031 validly tendered and not validly withdrawn on or before 5:00 p.m., New York City time, on June 12, 2007 (the "Withdrawal Deadline") exceeded the Tender Cap, Delhaize America will not purchase any of the 8.050% notes due 2027 in the offer. Debt Securities of this series that have been tendered were returned promptly to tendering holders following the Withdrawal Deadline. The principal amount of each series of Debt Securities validly tendered and not validly withdrawn and the principal amount accepted for purchase are shown in the table below. +---------------------------------------------------------------------------------------------+ | |Acceptance| Principal |Principal Amount | | | | Title of | Priority | Amount | of Securities |Principal Amount Accepted|Proration| | Security | Level | Outstanding | Tendered | for Purchase | Factor | |------------+----------+---------------+-----------------+-------------------------+---------| |8.125% Notes| 1 | USD |USD 1,049,557,000| USD 1,049,557,000 | N/A | | due 2011 | | 1,100,000,000 | | | | |------------+----------+---------------+-----------------+-------------------------+---------| | 9.000% | | | | | | | Debentures | 2 |USD 855,000,000| USD 662,524,000 | USD 50,443,000 | 7.63% | | due 2031 | | | | | | +---------------------------------------------------------------------------------------------+ Delhaize America expects to pay today, June 28, 2007 (the "Settlement Date") for the Debt Securities purchased pursuant to the tender offer. It will pay holders who validly tendered and did not withdraw their Debt Securities at or prior to 5:00 p.m., New York City time, on June 12, 2007 (the "Early Tender Time") the total consideration (the "Total Consideration") of USD 1,085.70 for each USD 1,000 principal amount of 8.125% Notes accepted for purchase and USD 1,225.64 for each USD 1,000 principal amount of 9.000% Debentures accepted for purchase, plus, in each case, accrued and unpaid interest up to, but not including, the Settlement Date. The Total Consideration includes an early tender premium of USD 40 per USD 1,000 principal amount of Debt Securities tendered. Delhaize America will pay holders who validly tendered after the Early Tender Time and did not withdraw their Debt Securities prior to the Expiration Time the applicable Total Consideration minus the early tender premium, which will result in tender offer consideration of USD 1,045.70 for each USD 1,000 principal amount of 8.125% Notes accepted for purchase and USD 1,185.64 for each USD 1,000 principal amount of 9.000% Debentures accepted for purchase, plus, in each case, accrued and unpaid interest up to, but not including, the Settlement Date. +-------------------------------------------------------------------+ | | Total | | | | | Consideration | Tender Consideration | Accrued | | Series | (Including | (Excluding Early | Interests | | | Early | Tender Premium) | | | | Tender Premium) | | | |--------------+-----------------+----------------------+-----------| | 8.125% Notes | USD 1,085.70 | USD 1,045.70 | USD 16.48 | | due 2011 | | | | |--------------+-----------------+----------------------+-----------| | 9.000% | | | | | Debentures | USD 1,225.64 | USD 1,185.64 | USD 18.25 | | due 2031 | | | | +-------------------------------------------------------------------+ Because the outstanding debt has been purchased above its book value, Delhaize Group incurred a one-time pre-tax charge of approximately EUR 103 million (at current exchange rates of 1 EUR = 1.3450 USD; approximately EUR 110 million at identical exchange rates of 1 EUR = 1.2556 USD in 2006) to be recorded as a financial expense in the second quarter of 2007. The net impact of the transaction on 2007 net earnings, including the one-time charge, interest cost reduction and tax effects, is expected to be approximately EUR -53 million at current exchange rates (EUR 57 million at identical exchange rates). From 2008, Delhaize Group expects a positive annual net earnings impact of approximately EUR 18 million at current exchange rates because of lower financial and tax expenses. New Debt Issuance A condition of the tender offer was to obtain funds, which included the sale of new debt securities by Delhaize Group, adequate to pay the costs of the tender offer. Delhaize Group has completed the sale of EUR 500 million principal amount of 5.625% Senior Notes due 2014 issued at 99.915% of the principal amount and USD 450 million principal amount of 6.50% Senior Notes due 2017 issued at 99.656% of the principal amount, in each case excluding underwriter discounts. The offering of the senior notes was made only to qualified investors, in reliance upon applicable private placement exemptions. No public offering was made in respect of the senior notes, whether in Belgium, the United States or any other jurisdiction. The private placement was conducted pursuant to Rule 144A and Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The securities offered have not been registered under the Securities Act or any U.S. state securities laws, and unless so registered, may not be offered or sold in the U.S., except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Contacts Guy Elewaut: + 32 2 412 29 48 Geoffroy d'Oultremont: + 32 2 412 83 21 Amy Shue: + 1 704 633 82 50 (ext. 2529) Delhaize Group Delhaize Group is a Belgian food retailer present in seven countries on three continents. At the end of March 2007, Delhaize Group's sales network consisted of 2,717 stores. In 2006, Delhaize Group posted EUR 19.2 billion (USD 24.1 billion) in net sales and other revenues and EUR 351.9 million (USD 441.8 million) in net profit. At the end of 2006, Delhaize Group employed approximately 142,500 people. Delhaize Group is listed on Euronext Brussels (DELB) and the New York Stock Exchange (DEG). This press release is available in English, French and Dutch. You can also find it on the website http://www.delhaizegroup.com. Questions can be sent to investor@delhaizegroup.com. Disclaimers This press release is not an offer to purchase any Debt Securities, which was made only pursuant to the terms of the Offer to Purchase and the Letter of Transmittal and in accordance with applicable securities laws. This press release shall not constitute a notice of redemption of any Debt Securities. CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS Statements that are included or incorporated by reference in this press release and other written and oral statements made from time to time by Delhaize Group and its representatives, other than statements of historical fact, which address activities, events and developments that Delhaize Group expects or anticipates will or may occur in the future, including, without limitation, statements about raising funds through a private placement of senior notes and the use of proceeds of such private placement of senior notes, strategic options, future strategies and the anticipated benefits of these strategies, are "forward-looking statements" within the meaning of the U.S. federal securities laws that are subject to risks and uncertainties. These forward-looking statements generally can be identified as statements that include phrases such as "guidance", "outlook", "projected", "believe", "target", "predict", "estimate", "forecast", "strategy", "may", "goal", "expect", "anticipate", "intend", "plan", "foresee", "likely", "will", "should" or other similar words or phrases. Although such statements are based on current information, actual outcomes and results may differ materially from those projected depending upon a variety of factors, including, but not limited to, changes in the general economy or the markets of Delhaize Group, in consumer spending, in inflation or currency exchange rates or in legislation or regulation; competitive factors; adverse determination with respect to claims; inability to timely develop, remodel, integrate or convert stores; and supply or quality control problems with vendors. Additional risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements are described in Delhaize Group's Annual Report on Form 20-F for the year ended December 31, 2005 and other filings made by Delhaize Group with the U.S. Securities and Exchange Commission, which risk factors are incorporated herein by reference. Delhaize Group disclaims any obligation to update developments of these risk factors or to announce publicly any revision to any of the forward-looking statements contained in this release, or to make corrections to reflect future events or developments.


 

- Next generation renin inhibitor to continue Phase II profiling in diabetic patients - Basel/Switzerland and Bridgewater NJ/USA, 28 June 2007 Speedel (SWX: SPPN) today announced that it has reached another significant milestone in the development of its family of renin inhibitors with the successful completion of a Phase IIa proof-of-concept clinical trial with SPP635 for the treatment of hypertension. Based on these positive results, the company is to continue developing SPP635 in Phase II in a special population of diabetic patients with mild-to-moderate hypertension. This compound is the first of a next generation of renin inhibitors following Speedel's lead product SPP100 (aliskiren, Tekturna/Rasilez[1]), which is partnered with Novartis and recently obtained US marketing approval from the FDA and a positive opinion from the CHMP in Europe[2]. SPP635 is the most advanced compound in the SPP600 series and is one of several new proprietary renin inhibitors invented by Speedel Experimenta, the company's late-stage research unit. Phase IIa results demonstrate strong efficacy and good tolerability The trial had a double-blind, placebo-controlled, randomised, parallel design and it evaluated patients treated with a single dosage level of SPP635 once-daily for 4 weeks. It studied the safety and efficacy of SPP635 in 35 male and female patients (20 patients receiving SPP635 and 15 receiving placebo) with mild-to-moderate hypertension by measuring office and ambulatory blood pressure[3]. SPP635 was safe and well tolerated over the 4 week period. There were no serious adverse events reported nor were there any clinically significant changes in laboratory safety parameters. Sitting systolic blood pressure was significantly reduced by 17.9 mmHg from 156.6±9.1 mmHg at baseline (mean ± SD) to 138.7±13.3 mmHg in the SPP635 treated group after 4 weeks (p<0.001). The placebo group remained unchanged (156.1±9.0 to 153.2±8.9 mmHg; baseline vs. end of treatment). Diastolic blood pressure was also significantly reduced by 9.8 mmHg from 91.3±7.8 to 81.5±8.2 mmHg (p<0.001) in the SPP635 treated group compared to the placebo treatment (95.3±5.1 to 93.3±5.4 mmHg). These blood pressure measurements were taken at trough, 24 hours after the previous medication. Similar results were observed for ambulatory blood pressures, which were reduced both during the day as well as in the night. The half-life of SPP635 had been previously reported to be approximately 24 hours suggesting once daily administration; these latest ambulatory blood pressure data confirm the use as of SPP635 as an once-a-day drug. The extent of blood pressure reduction is similar to those reported for the renin inhibitor SPP100 (aliskiren,Tekturna/Rasilez)[4]. Hans R. Brunner, Professor Emeritus of Medicine at the University of Lausanne, and acting Speedel Medical Director, commented: "These positive results show that SPP635 has comparable efficacy to other blood pressure lowering therapies. It will be exciting to see the first follow-on renin inhibitor to SPP100 demonstrate its potential in diabetic patients in further clinical trials." Alice Huxley, CEO of Speedel, commented: "This success with SPP635 reinforces Speedel's strategy of building a family of renin inhibitors which can be profiled for both general and special patient populations. We continue to leverage our exceptional knowledge in renin inhibition which we believe has the potential to be the next gold standard for the treatment of different cardiovascular diseases." Continued Phase II development Clinical profiling of SPP635 will continue this year in special populations with a further study planned in diabetic patients with mild-to-moderate hypertension. This harder to manage patient group has been shown to respond to SPP100 to controlling blood pressure alone and in combination with an ACE-I[5][6]. Further details about this proof-of-concept Phase II trial will be announced later in 2007 when it commences. The trial will be carried out in Europe with results due in the second half of 2008. Speedel's next generation renin inhibitors include other compounds in the SPP600 series, the SPP1100 series with SPP1148 due to report first Phase I results in Q42007, and the SPP800 series currently in late-stage pre-clinical profiling. Each series is a different chemical class with distinct properties and is protected by different patent applications. About SPP600 series SPP635 is the most advanced compound of the SPP600 series of renin inhibitors being developed by Speedel. The company has made significant progress in the optimisation and development of this series of newly synthesised compounds by using rational drug design, including computer assisted molecular modelling techniques, state-of-the art preclinical disease models and human microdosing. In December 2001, Speedel acquired a worldwide exclusive license from Roche covering its entire programme in renin inhibition. This license allows Speedel to use the acquired know-how for lead optimisation of its own compounds designated as the SPP600 series. Speedel holds full development and commercialization rights for these product candidates under the license agreement with Roche. If Speedel decides to offer rights to any Speedel compound from the series to a third party, Roche has a right of first negotiation with respect to such rights. If Roche has not expressed its interest in acquiring such rights within a defined period of time, or the parties have not reached an agreement on the terms of such rights, Speedel is free to grant such rights to any third party. About Hypertension Hypertension is a common disorder in which blood pressure is abnormally high, placing undue stress on the heart, blood vessels and other organs such as the kidney and the brain. Blood pressure is determined in two phases as the heart contracts and relaxes. Systolic blood pressure represents the force that blood exerts on the walls of arteries as the heart contracts to pump out blood. Diastolic blood pressure represents the force as the heart relaxes to allow the blood to flow into the heart. Due to its wide prevalence and impact on cardiovascular health, hypertension is a major cause of disease and death in Europe and North America. More than one in three Europeans and North Americans over the age of 35 suffers from hypertension - but for the vast majority of patients who undergo hypertension treatment, the causes of high blood pressure are unknown. More than 40 % of patients undergoing treatment with current therapies do not reach targeted blood pressure levels, and so there is a considerable unmet medical need. The latest potential therapeutic agents for hypertension are renin inhibitors. Renin is an enzyme produced in the kidneys in response to reduced renal perfusion. Through a cascade of biological events, renin acts to bring about sodium retention, an increase in blood pressure, and restoration of renal perfusion, which shuts off the signal for renin release. For hypertensive individuals, renin inhibitors are currently being investigated as a therapy that may provide benefits over current therapies to reduce blood pressure, decrease salt retention and may protect end organs such as the kidney, heart and brain. About Speedel Speedel is a public biopharmaceutical company that seeks to create value for patients, partners and investors by developing innovative therapies for cardiovascular and metabolic diseases. Speedel is a world leader in renin inhibition, a promising new approach with significant potential for treating cardiovascular diseases. Our lead compound SPP100 (Tekturna/Rasilez [i]), the first-in-class direct renin inhibitor, was in-licensed from Novartis in 1999 and licensed-back to Novartis Pharma in 2002 for further development and commercialisation; SPP100 was approved by the FDA in the US in March 2007, and filed by Novartis with the EMEA in the EU in Q3 2006. Our pipeline covers three different modes of action, and in addition to SPP100, includes SPP301 in Phase III (on hold), SPP200 in Phase II, SPP635 in Phase Il, SPP1148 in Phase I and several pre-clinical projects. Speedel develops novel product candidates through focused innovation and smart drug development from lead identification to the end of Phase II. We either partner with big pharma for Phase III and commercialisation in primary-care indications, or we may ourselves complete Phase III development in specialist indications. Candidate compounds for development and the company's intellectual property come from our late-stage research unit Speedel Experimenta and from in-licensing. Our team of approximately 70 employees, including over 30 experienced pharmaceutical scientists, is located at our headquarters and laboratories in Basel, Switzerland and at offices in New Jersey, USA and Tokyo, Japan. In January 2007 the company raised gross proceeds of CHF 55.5 million (approximately EUR 34.3 million or USD 44.5 million) through a convertible bond issue. In March 2006 the company raised gross proceeds of CHF 83.95 million (approximately EUR 53m or USD 64m) through the public offering of 500,000 treasury shares. Previously, as a private company, we raised gross proceeds of CHF 255 million (approximately EUR 157 million or USD 204 million) from private placements of equity securities and two convertible loans including the conversion premiums. We have had total revenues, principally from milestone payments, of CHF 57.7 million (approximately EUR 37 million or USD 44 million). The company's shares were listed in September 2005 on the SWX Swiss Exchange under the symbol SPPN. Forward looking statements This press release includes forward-looking statements that involve substantial risks and uncertainties. These forward-looking statements are based on our current expectations and projections about future events. All statements, other than statements of historical facts, regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The word "may" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations described in these forward-looking statements and you should not place undue reliance on them. There can be no assurance that actual results of our research and development activities and our results of operations will not differ materially from these expectations. Factors that could cause actual results to differ from expectations include, among others: our or our partners' ability to develop safe and efficacious products; our or our partners' ability to achieve positive results in clinical trials; our or our partners' ability to obtain marketing approval and market acceptance for our product candidates; our ability to enter into future collaboration and licensing agreements; the impact of competition and technological change; existing and future regulations affecting our business; changes in governmental oversight of pharmaceutical product development; the future scope of our patent coverage or that of third parties; the effects of any future litigation; general economic and business conditions, both internationally and within our industry, including exchange rate variations; and our future financing plans. -- Ends -- [1] Tekturna® and Rasilez® are Novartis trademarks in the USA and Europe, respectively [2] Food and Drug Administration (FDA) and Committee for Medicinal Products for Human Use (CHMP) [3] Ambulatory blood pressure is measured by a portable device worn by the patient over 24 hours at pre-determined intervals Office blood pressure (systolic and diastolic) is measured when the patient is in the physician's office at pre-determined intervals [4] Aliskiren Reduces Blood Pressure and Suppresses Plasma Renin Activity in Combination With a Thiazide Diuretic, an Angiotensin-Converting Enzyme Inhibitor, or an Angiotensin Receptor Blocker O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A, Hypertension. 2007;49:276-284. [5] Angiotensin Converting Enzyme Inhibitor [6] Uresin Y et al. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. European Society of Hypertension. 16th European Meeting on Hypertension. June 12-15, 2006; Madrid, Spain. [i] Tekturna/Rasilez® are Novartis trademarks For further information please contact Nick Miles Director Communications & Investor Relations Speedel Hirschgässlein 11 CH - 4051 Basel Switzerland T +41 (0) 61 206 40 00 D +41 (0) 61 206 40 14 F +41 (0) 61 206 40 01 M +41 (0) 79 446 25 21 E nick.miles@speedel.com www.speedel.com Frank LaSaracina Managing Director Speedel Pharmaceuticals Inc 1661 Route 22 West P.O. Box 6532 Bridgewater, NJ 08807 United States of America T +1 732 537 2290 F +1 732 537 2292 M +1 908 338 0501 E frank.lasaracina@speedel.com www.speedel.com


 

Adecco S.A. Chéserex - Pursuant to art. 20 of the Federal Act on Stock Exchanges and Securities Trading, Adecco S.A. has received the following notification: 1. Name of the listed company Adecco S.A. 2. Number and type of shares and proportion of voting rights (total holdings as a percentage) 9,162,800 registered shares; 4.85 percent 3. Identity of the parties concerned * Harris Associates L.P. Two North LaSalle Street Suite 500 Chicago, Illinois 60602-3790 USA 4. Indirect sale, relationship between the beneficial owner and the direct vendor n.a. 5. Time (date) of acquisition, sale or understanding through which the shareholding reached, exceeded or fell below the percentage threshold June 20, 2007 6. Further remarks none Adecco S.A. June 27, 2007 --- End of Message --- Adecco SA Sagereistrasse 10 Glattbrugg Switzerland WKN: 922031; ISIN: CH0012138605; Index: SLCI, SMI, SPI, SMIEXP; Listed: Main Market in SWX Swiss Exchange;


 

Transactions in Adecco securities by Directors and Senior Management 1. Details of the Liable Person 1.1 Family Name Marcel 1.2 Forename Philippe 1.3 Street Adecco, 4, rue Louis Guérin 1.4 Postcode / City / Country F-69100 Villeurbanne, France 1.5 Function Non-executive member of the Board of Directors 1.6 This transaction has been executed n.a. not by the liable person, but by or on behalf of a person closely associated with the liable person. 2. Details of the product acquired / sold 2.1 Type of transaction 2.2 Type of security Call option 2.3 Key conditions - 2000 calls at CHF 10.00 & 2000 calls attached to unlisted at CHF 11.- strike CHF 88.- 12/07 conversion and purchase - 2000 calls at CHF 8.75 & 2000 calls at rights and financial CHF 9.50 strike CHF 90.- 12/07 instruments (e.g. exercise - 2000 calls at CHF 7.60 & 2000 calls at price, exercise period, CHF 8.50 strike CHF 92.- 12/07 duration, - 2000 calls at CHF 5.70 & 2000 calls at american/european style, CHF 6.50 strike CHF 96.- 12/07 etc.) - 2000 calls at CHF 4.75 & 2000 calls at CHF 5.25 strike CHF 98.- 12/07 2.4 Number of units 20'000 calls traded 2.5 Price paid / received CHF 154'090.00 2.6 Date of trade 20 June 2007 and place ("relevant binding transaction") 2.7 Reason for transaction (optional) ---END OF MESSAGE---


 

FOR IMMEDIATE RELEASE 27 June 2007 Intellego Holdings plc ("Intellego" or "the Company") Report and Accounts Notice of Annual General Meeting ("AGM") The Company announces that it has posted the Report and Accounts for the year ending 31 March 2007, together with a Notice of AGM, to shareholders. The AGM will be held at 09.30 on 19 July 2007 at the offices of Intellego, 1, Orlando House, High Street, Teddington, Middlesex, TW11 8LZ. Copies are available, free of charge, from the address given above. Enquiries Ranjit Roy-Choudhuri Tel: 0870 428 1250 Intellego Holdings plc Roland Cornish Tel: 020 7628 3396 Beaumont Cornish Limited ---END OF MESSAGE---


 

Chrysalis VCT plc Interim Statement for the six months ended 30 April 2007 Recent Performance Summary 30 April 31 Oct 30 April 2007 2006 2006 pence pence pence Ordinary shares Net asset value per share 88.70 84.70 77.80 Cumulative dividends paid per ordinary 13.45 10.45 10.45 share Total return 102.15 95.15 88.25 'D' share Net asset value per share 104.30 96.50 94.50 Cumulative dividends paid per ordinary 1.25 - - share Total return 105.55 96.50 94.50 'E' share Net asset value per share 95.00 95.40 94.50 Cumulative dividends paid per ordinary 1.25 - - share Total return 96.25 95.40 94.50 CHAIRMAN'S STATEMENT Introduction Once again, it is very pleasing to report that Chrysalis VCT has continued to perform well throughout the period under review. During the six months to 30 April 2007, a number of further profitable exits were achieved, while other portfolio companies made good progress and a significant number of new investments were made. Net Asset Value Ordinary Shares At 30 April 2007, the Net Asset Value per Ordinary Share ("NAV") had risen to 88.7p, an increase of 7.0p (8.6%) since the previous year end of 31 October 2006 (after adjusting for the 3p per Ordinary Share dividend paid in the period). Total Return to original Ordinary Shareholders (NAV plus cumulative dividends paid since launch) now stands at 102.15p per share, compared to an original net of income tax cost of 80p per share. 'D' shares The NAV of the 'D' Shares has risen to 104.3p over the period, being an increase of 9.05p or 9.4% since 31 October 2006 (after adding back the 'D' share dividend of 1.25p paid in the period). 'E' shares The NAV of the 'E' Shares stood at 95.0p at 30 April 2007, an increase of 0.85p or 0.9% since 31 October 2006 (after adding back the 'E' share dividend of 1.25p paid in the period). Venture Capital Investments During the period, the Company made six new investments and five follow on investments at a total cost of £3.7 million. These investments were allocated as follows between the individual share pools: Number of Investments £'000 Ordinary Share pool 9 3,377 'D' Share pool 5 248 'E' Share pool 2 100 3,725 At the period end, the 'D' Share pool held eight investments valued at £448,000 and the 'E' Share pool held two investments valued at £100,000. As mentioned in earlier reports, although the 'E' share pool is no longer limiting the scope of its investments to the art and antiques sector, it is seeking to select potentially less risky investments than would be accepted by the 'D' share and Ordinary share pools. As a result of this approach, the rate of investment for the 'E' share pool has been slower than the other pools. During the period, the Company achieved a series of successful disposals within the Ordinary share pool, generating £6.7 million of proceeds and realising gains against the previous carrying values of £1.2 million and profit over cost of £4.4 million. The most notable disposals were Ma Potters and ProTx Group, which produced profits against cost of £1.3 million and £1.8 million respectively. At the period end, the Board has reviewed the valuations of the unquoted investments and made some adjustments to the carrying values. Although there were a small number of reductions, a greater number of investments justified increases. The most notable has been to the investment in ILG Digital Limited (formerly i-Level), a digital advertising agency held by the Ordinary share pool, where trading has been particularly strong, supporting an increase of £660,000 to £2.1 million. Overall (including the AIM-quoted stocks) the Ordinary share portfolio gave rise to £1.2 million (3.6p per share) of unrealised gains and the 'D' Share portfolio, unrealised gains of £45,000 (8.4p per share). Both of the 'E' Share portfolio's investments continue to be held at cost. Results and dividend The return after taxation for the Company for the period amounted to a gain of £2,305,000 comprising a revenue return of £213,000 and a capital surplus of £2,092,000. Share buybacks The Company continues to operate a share buyback policy in order to provide liquidity in the market for its shares. Any Shareholders wishing to sell their holding should consult their financial adviser to ensure they understand the potential tax implications of such a disposal. Shares cannot be sold directly to the Company but must be sold via the Stock Market through a stockbroker. During the period, the Company repurchased 834,725 Ordinary shares, at an average price of 73.8p per share for cancellation. Outlook It is now three years since the current investment management team and Board took over the running of the Company. Although the performance in the initial years under the original management was poor, the current management team have been able to emphatically turn around the Company's fortunes and have now delivered strong increases in NAV over each of the last six half-yearly reporting periods. Over that time, the NAV per Ordinary share has risen from 60.7p to 88.7p with a further 8p of dividends being paid. This is equivalent to a return on capital of 59.3% and is an excellent performance for which the Board congratulates the investment management team. The investment exits achieved over the last year or so have not only returned significant levels of cash to your Company, but have also changed the profile of the Company's investment portfolio. With a more immature portfolio than has been the case for some time, it is in unrealistic in the short term to expect the rate of increase in the Company's NAV and Total Return to continue at the levels seen in recent periods. However, the Board remains confident that attractive returns will be made over the medium term. Over the remainder of the year, the management team's focus will remain split between making new investments for the 'D' share, 'E' share and Ordinary pools, while also working with the more mature portfolio companies within the Ordinary share pool with a view to achieving further profitable exits. The Board is confident that the management team will continue to be effective in these roles. Robert Drummond Chairman UNAUDITED SUMMARISED BALANCE SHEET as at 30 April 2007 As at 30 Apr 2007 As at As at 30 Apr 31 Oct 2006 2006 Ordinary 'D' 'E' shares Shares Shares Total Total Total £'000 £'000 £'000 £'000 £'000 £'000 Investments 23,789 448 100 24,337 23,900 24,776 Net current assets 5,856 111 471 6,438 4,280 5,348 Net assets 29,645 559 571 30,775 28,180 30,124 Capital and reserves Called up share capital 335 5 6 346 360 354 Capital redemption 41 - - 41 27 33 reserve Share premium - 502 562 1,064 1,064 1,064 Merger reserve 8,694 - - 8,694 8,694 8,694 Special reserve 8,007 - - 8,007 10,404 9,436 Capital reserve - 9,529 (5) (6) 9,518 3,657 5,782 realised Capital reserve - 2,734 50 - 2,784 4,166 4,639 unrealised Revenue reserve 305 7 9 321 (192) 122 Total equity 29,645 559 571 30,775 28,180 30,124 Net asset value per: Ordinary share 88.7p 77.8p 84.7p 'D' share 104.3p 94.5p 96.5p 'E' share 95.0p 94.5p 95.4p RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS for the period ended 30 April 2007 30 Apr 2007 30 Apr 31 Oct 2006 2006 Ordinary 'D' 'E' shares Shares Shares Total Total Total £'000 £'000 £'000 £'000 £'000 £'000 Opening 29,033 517 574 30,124 27,401 27,401 shareholders' fund Issue of shares - - - - 1,075 1,137 Purchase of own (619) - - (619) (1,153) (733) shares Total recognised gains in the period 2,252 49 4 2,305 1,148 3,512 Distributions (1,021) (7) (7) (1,035) (711) (711) 29,645 559 571 30,775 28,180 30,124 UNAUDITED INCOME STATEMENT for the six months ended 30 April 2007 Six months ended Company Total 30 April 2007 Revenue Capital Total £'000 £'000 £'000 Income 522 - 522 Gains on investments: Realised - 1,207 1,207 Unrealised - 1,195 1,195 522 2,402 2,924 Investment management fees (62) (188) (250) Performance incentive fees - (219) (219) Other expenses (150) - (150) Return on ordinary activities 310 1,995 2,305 Share issue costs - - - Return on ordinary activities before 310 1,995 2,305 taxation Taxation (97) 97 - Return attributable to equity shareholders 213 2,092 2,305 Return per Ordinary share 0.6p 6.0p 6.6p Return per 'D' share 1.1p 8.0p 9.1p Return per 'E' share 1.3p (0.5p) 0.8p Six months ended Year ended Company Total 30 April 2006 31 October 2006 Revenue Capital Total Total £'000 £'000 £'000 £'000 Income 446 - 446 1,149 Gains on investments: Realised - 87 87 1,119 Unrealised - 1,523 1,523 2,636 446 1,610 2,056 4,904 Investment management fees (58) (175) (233) (465) Performance incentive fees Other expenses (165) - (165) (333) Return on ordinary 223 1,435 1,658 4,106 activities Share issue costs (507) - (507) (520) Return on ordinary (284) 1,435 1,151 3,586 activities before taxation Taxation (36) 33 (3) (74) Return attributable to (320) 1,468 1,148 3,512 equity shareholders Return per Ordinary share (0.9p) 4.1p 3.2p 9.9p Return per 'D' share - - - 1.9p Return per 'E' share - - - 0.9p Six months ended Ordinary shares 30 April 2007 Revenue Capital Total £'000 £'000 £'000 Income 496 - 496 Gains on investments: Realised - 1,207 1,207 Unrealised - 1,150 1,150 496 2,357 2,853 Investment management fees (60) (180) (240) Performance incentive fees - (219) (219) Other expenses (144) - (144) Return on ordinary activities 292 1,958 2,250 Share issue costs - - - Return on ordinary activities before 292 1,958 2,250 taxation Taxation (93) 95 2 Return attributable to equity shareholders 199 2,053 2,252 Six months ended Year ended Ordinary shares 30 April 2006 31 October 2006 Revenue Capital Total Total £'000 £'000 £'000 £'000 Income 446 - 446 1,122 Gains on investments Realised - 87 87 1,119 Unrealised - 1,523 1,523 2,631 446 1,610 2,056 4,782 Investment management fees (58) (175) (233) (456) Performance incentive fees Other expenses (165) - (165) (328) Return on ordinary 223 1,435 1,658 4,088 activities Share issue costs (507) - (507) (520) Return on ordinary (284) 1,435 1,151 3,568 activities before taxation Taxation (36) 33 (3) (72) Return attributable to (320) 1,468 1,148 3,496 equity shareholders Six months ended 'D' Shares 30 April 2007 Revenue Capital Total £'000 £'000 £'000 Income 11 - 11 Gains on investments: Realised - - - Unrealised - 45 45 11 45 56 Investment management fees (1) (3) (4) Other expenses (2) - (2) Return on ordinary activities before 8 42 50 taxation Taxation (2) 1 (1) Return attributable to equity shareholders 6 43 49 Six months ended Year ended 'D' Shares 30 April 2006 31 October 2006 Revenue Capital Total Total £'000 £'000 £'000 £'000 Income - - - 13 Gains on investments Realised - - - - Unrealised - - - 5 - - - 18 Investment management fees - - - (5) Other expenses - - - (2) Return on ordinary - - - 11 activities before taxation Taxation - - - (1) Return attributable to - - - 10 equity shareholders Six months ended 'E' Shares 30 April 2007 Revenue Capital Total £'000 £'000 £'000 Income 15 - 15 Gains on investments Realised - - - - - - Unrealised 15 - 15 Investment management fees (1) (5) (6) Other expenses (4) - (4) Return on ordinary activities before 10 (5) 5 taxation Taxation (2) 1 (1) Return attributable to equity shareholders 8 (4) 4 Six months ended Year ended 'E' Shares 30 April 2006 31 October 2006 Revenue Capital Total Total £'000 £'000 £'000 £'000 Income - - - 14 Gains on investments: Realised - - - - Unrealised - - - - - - - 14 Investment management fees - - - (4) Other expenses - - - (3) Return on ordinary - - - 7 activities before taxation Taxation - - - (1) Return attributable to - - - 6 equity shareholders UNAUDITED CASH FLOW STATEMENT for the six months ended 30 April 2007 Six months Six months Year ended ended ended 30 April 30 April 31 October 2007 2006 2006 Note £'000 £'000 £'000 Cash (outflow)/inflow from operating activities and 1 returns on investments (1,639) 72 349 Capital expenditure Purchase of investments (5,585) (885) (3,671) Proceeds on disposal of 8,426 34 4,337 investments Net cash (outflow)/inflow 2,841 (851) 666 from capital expenditure Acquisitions Purchase of subsidiary - 3 (18) undertakings - 3 (18) Equity dividends paid (1,035) (711) (711) Net cash (outflow)/inflow 167 (1,487) 286 before financing Financing Issue of shares - 1,137 1,137 Share issue costs (6) (431) (527) Purchase of own shares (588) (681) (1,120) Net cash inflow/(outflow) (594) 25 (510) from financing (Decrease)/increase in cash 2 (427) (1,462) (224) Notes to the cash flow statement: 1 Cash inflow from operating activities and returns on investments Net revenue return on 310 223 700 ordinary activities Expenses charged to capital (407) (175) (349) Provision against bad debts - - 8 Costs relating to prior - - 21 year merger (Increase)/decrease in (1,608) 3 (39) other debtors Increase/(decrease) in 66 21 8 other creditors Net cash (outflow)/inflow (1,639) 72 349 from operating activities 2 Analysis of net funds Beginning of period 5,418 5,642 5,642 Net cash (outflow)/inflow (427) (1,462) (224) End of period 4,991 4,180 5,418 SUMMARY OF INVESTMENT PORTFOLIO as at 30 April 2007 Ordinary Share pool Movement % of in the portfolio Cost Valuation period by value £'000 £'000 £'000 Top twenty venture capital investments Babel Media Limited 1,555 2,786 - 9.9% Precision Dental Laboratories 2,100 2,167 - 7.7% Group plc ILG Digital Limited 806 2,100 660 7.4% Wessex Advanced Switching 699 1,292 116 4.6% Products Limited Centre Design Limited 1,350 1,205 - 4.3% Glisten plc * 188 940 33 3.3% Spice Inns Limited 850 850 - 3.0% Triaster Limited 758 829 (92) 2.9% British International 700 700 - 2.5% Holdings Limited Mentorion Limited 700 700 - 2.5% Mentorion II Limited 700 700 - 2.5% Advanced Media Information 615 695 - 2.5% Limited RFTRAQ Limited (formerly Core 325 680 68 2.4% Control) Ensign Communications Limited 500 624 124 2.2% The Capital Pub Company 505 580 - 2.1% Limited YouGov plc * 44 318 79 1.1% CPI Acquisition UK Limited 300 300 - 1.1% Planet Sport (Holdings) 250 225 - 0.8% Limited Berkeley Scott Group plc * 320 218 158 0.8% Forward Media Limited 440 204 (48) 0.7% 13,705 18,113 1,098 64.3% Other venture capital 2,507 1,016 86 3.6% investments Listed fixed income 16.5% securities 4,843 4,660 (34) Subtotal 21,055 23,789 1,150 84.4% Cash at bank and in hand 4,403 15.6% Ordinary Share Pool - Total 28,192 100.0% Movement % of in the portfolio Cost Valuation period by value £'000 £'000 £'000 'D' Share pool Brainjuicer plc * 48 80 32 14.4% Hat Pin plc * 50 68 13 12.2% British International 50 50 - 8.9% Holdings Limited CPI Acquisition UK 50 50 - 8.9% Limited Mentorion Limited 50 50 - 8.9% Mentorion II Limited 50 50 - 8.9% Rhino Sports and Leisure 50 50 - 8.9% Limited Spice Inns Limited 50 50 - 8.9% 398 448 45 80.0% Cash at bank and in hand 112 20.0% 'D' Share pool - Total 560 100.0% 'E' Share pool CPI Acquisition UK 50 50 - 8.7% Limited Spice Inns Limited 50 50 - 8.7% 100 100 - 17.4% Cash at bank and in hand 476 82.6% 'E' Share pool - Total 576 100.0% NOTES TO THE UNAUDITED FINANCIAL STATEMENTS 1. Accounting policies Basis of accounting The Company has prepared its financial statements under UK Generally Accepted Accounting Practice ("UK GAAP") and in accordance with the Statement of Recommended Practice "Financial Statements of Investment Trust Companies" revised December 2005 ("SORP"). Except as stated in note 2, consistent accounting polices have been applied to both this year and the prior years' accounts. The financial statements are prepared under the historical cost convention as modified by the revaluation of certain financial instruments Presentation of Income Statement InvestmentsAll investments are designated as "fair value through profit or loss" assets and are initially measured at cost, equivalent to their fair value. Thereafter the investments are measured at subsequent reporting dates at fair value. Listed fixed income investments and investments quoted on AIM are measured using bid prices with illiquidity discounts applied where deemed appropriate. In respect of unquoted instruments, fair value is established by using International Private Equity and Venture Capital Valuation Guidelines. Where no reliable fair value can be estimated for such unquoted equity investments they are carried at cost, subject to any provision for impairment. Where an investee company has gone into receivership or liquidation the investment, although not physically disposed of, is treated as being realised. Gains and losses arising from changes in fair value are included in the income statement for the year as a capital item and transaction costs on acquisition or disposal of the investment expensed. It is not the Company's policy to exercise either significant or controlling influence over investee companies. Therefore the results of these companies are not incorporated into the revenue account except to the extent of any income accrued. Income Dividend income from investments is recognised when the shareholders' rights to receive payment has been established, normally the ex dividend date. Interest income is accrued on a timely basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount, and only where there is reasonable certainty of collection. Expenses All expenses are accounted for on an accruals basis. In respect of the analysis between revenue and capital items presented within the income statement, all expenses have been presented as revenue items except as follows: Expenses which are incidental to the disposal of an investment are deducted from the disposal proceeds of the investment. Expenses are split and presented partly as capital items where a connection with the maintenance or enhancement of the value of the investments held can be demonstrated. The Company has adopted the policy of allocating investment managers fees, 75% to the capital reserve and 25% to the revenue account as permitted by the SORP. The allocation is in line with the Board's expectation of long term returns from the Company's investments in the form of capital gains and income respectively. Performance incentive fees arising from the disposal of investments are deducted from the capital account. Issue costs Issue costs have been deducted from the share premium account. Deferred taxation Deferred taxation is provided in full on timing differences that result in an obligation at the balance sheet date to pay more tax, or a right to pay less tax, at a future date, at rates expected to apply when they crystallise based on current tax rates and law. Timing differences arise from the inclusion of items of income and expenditure in taxation computations in periods different from those in which they are included in financial statements. 2. All revenue and capital items in the Income Statement derive from continuing operations. 3. The Company has only one class of business and derives its income from investments made in shares, securities and bank deposits. 4. The comparative figures were in respect of the period ended 30 April 2006 and the year ended 31 October 2006 respectively. 5. Net Asset Value per share calculations are based on the following: Ordinary Shares 'D' Shares 'E' Shares Net Assets (£'000) 29,645 559 571 Number of shares in issue 33,431,034 536,072 601,376 at period end 6. Return per share calculations are based on the following: Ordinary Shares 'D' Shares 'E' Shares Revenue return per share based on: Net revenue return after 199 6 8 taxation (£'000) Weighted average number of 34,006,157 536,072 601,376 shares in issue Capital return per share based on: Net capital gain/(loss) 2,053 43 (43) after taxation (£'000) Weighted average number of 34,006,157 536,072 601,376 shares in issue 7. Dividends 30 April 2007 31 Oct 2006 Revenue Capital Total Total £'000 £'000 £'000 £'000 Paid in year Ordinary shares 2006 interim - 1,021 1,021 - (paid 02/03/2007) 'D' shares 2006 final (paid 7 - - - 27/03/2007) 'E' shares 2006 final (paid 7 - - - 27/03/2007) Ordinary shares 2005 final - - - 711 (paid 04/04/2006) 14 1,021 1,035 711 Proposed 'D' shares 2006 final - - - 7 'E' shares 2006 final - - - 7 - - - 14 8. Reserves Share Capital Merger Special Capital Capital Revenue premium redemption reserve reserve reserve reserve reserve reserve unrealised realised £'000 £'000 £'000 £'000 £'000 £'000 £'000 At 1 November 1,064 33 8,694 9,436 4,639 5,782 122 2006 Shares - 8 - (619) - - - repurchased Expenses - - - - - (407) - capitalised Tax on - - - - - 97 - capital expenses Realised - - - - - 1,207 - gains Unrealised - - - - 1,195 - - gains Transfer between - - - (810) (3,050) 3,860 - reserves Retained net revenue for - - - - - - 213 the year Distributions paid - - - - - (1,021) (14) in year At 30 April 1,064 41 8,694 8,007 2,784 9,518 321 2007 The above figures relate to the Company as a whole. The Special Reserve, Capital Reserve - Realised and Revenue Reserve are all distributable reserves. 9. The unaudited financial statements set out herein do not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985 and have not been delivered to the Registrar of Companies. The figures for the year ended 31 October 2006 have been extracted from the financial statements for that year, which have been delivered to the Registrar of Companies; the auditors' report on those financial statements was unqualified. 10. Copies of the unaudited interim results will be sent to shareholders shortly. Further copies can be obtained from the Company's Registered Office. ---END OF MESSAGE---


 

SAGA Oil has through the successful completion of the drilling on Pad 1 fully proven its capability to fulfil the strategic plan of adapting western technology and know-how to a Russian workforce, equipment and technology. DRILLING THE LAST WELL ON PAD 1. SAGA has completed the last well (# 104) on Pad 1 to a targeted depth of 2175 meters. Well # 104 was the first well where SAGA could apply a complete new concept of well design and drilling, comprising of: * New type of well trajectory for vertical penetration of production zones after desired deviation. * New modern type of drilling fluid and fluid management. * Newly upgraded rig and equipment to meet western standard of performance. * Proven new method of 1 stage cementing of the production casing using patented new cement additive to reduce hydrostatic pressure and improve bonding between casing and rock strata. MAIN ACHIEVEMENTS OF WELL #104 * The well was completed with a new record of only 32 days drilling time compared to previous 48 days and closer to the target of 1 mUSD drilling cost pr. well. * The well logging did for the first time give 100% reliable information about all the well parameters. * The coring of the lower Ardatovsky formation yielded a record recovery of 120% of cored strata without washout of the sandstone * The new and more accurate drilling, logging and core data are now being used in finalizing the 3D seismic, placement of new wells and assessment of resources. * Well # 104 has also been a success in correct placement, as all the three main production layers has been penetrated through a thicker part of the reservoirs. The three reservoirs should therefore yield a good production capacity. SPUDDING OF WELL # 120 ON THE NEW PAD 3. SAGA spudded the new well # 120 on PAD 3 on June 24th using a modern modular based electric drilling rig. This well is classified as an exploration well and will be part of the ongoing assessment of the East Shaltinsky resources. The well design will however allow for reclassifying of all the wells, on PAD 3 from exploration to production wells when the drilling on PAD 3 has been completed later this year. DRILLING START ON THE SOUTHERN PETROVSKY FIELD SAGA concluded a new contract that covers drilling of 6 new wells on the Petrovsky oil field in the Rodnikovsky licence. The drilling is to commence as soon as the rig has been re-located from Pad 1 to the new Pad 4. The target is to open up and confirm all extractable resources on the Petrovsky oil field where SAGA currently has an estimated extractable P2 reserve of 6.2 Mboe, based on the old exploration and 2D data. The new 3D data, and the last well (#104) on Pad 1, East Shaltinsky, has enabled SAGA to pinpoint the location for the new Petrovsky well placement. Malvin Hoeydal, President and CEO of SAGA Oil ASA comments: "We are very proud to be able to announce the good operational news so soon after successfully concluding the private placement of NOK 180 mill. This last private placement brings SAGA Oil close to being fully financed for the entire 40 well development that will yield a daily production rate of between 10 000 and 14 000 BOE by year 2009. The successful completion of the well # 104 is a new milestone for SAGA as it has proven that its Russian subsidiary PROMGEOTEK has developed into becoming a professional oil field developer. SAGA has by this proven its capability of achieving its strategic defined goals in record time by using the right approach for the Russian market conditions. Well #104 has been very rewarding and encouraging for both SAGA and its subcontractors, as "seeing is truly believing", in drilling for oil and gas. Retrieving core samples from a depth of 2100 meters that are dripping of oil, and splitting the sandstone core to see it is fully saturated with light oil, still gives the best motivation. We expect to be able to keep the new high quality results for all our coming wells after such encouraging achievements. Our Russian employees and subcontractors have really shown an outstanding ability to adapt to new systems and technologies, and most of all, actively contribute to achieving the best possible result" For further information, please contact: SAGA Oil ASA - CEO Mr. Malvin Høydal, cell: +47 97422959, email: malvin.hoeydal@sagaoil.no SAGA Oil ASA - CFO Mr. Stian Vemmestad, cell: +47 92805787, email: sve@sagaoil.no


 

` FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | DEEPHAVEN CAPITAL | | | MANAGEMENT LLC | |-----------------------------------------------+-------------------| | Company dealt in | EMI Group Plc | |-----------------------------------------------+-------------------| | Class of relevant security to which the | 14p Ordinary | | dealings being disclosed relate (Note 2) | | |-----------------------------------------------+-------------------| | Date of dealing | 26 June 2007 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------+ | | Long | Short | | | | | |-------------------------------+--------------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (2) Derivatives (other than | 7,700,000 | 0.9495 | | | | options) | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | Total | 7,700,000 | 0.9495 | | | | | | | | | +-------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +-------------------------------------------------------------------+ | Class of relevant security: | Long | Short | | | | | |-------------------------------------+--------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (2) Derivatives (other than | | | | | | options) | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | Total | | | | | | | | | | | +-------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short | Number of securities | Price per | | name, | (Note 6) | (Note 7) | unit (Note 5) | | e.g. CFD | | | | |----------+------------+---------------------------+---------------| | | | | | | CFD | SHORT | 1,000,000 | 267.7000 | | | | | | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 27th June 2007 | |--------------------------------------------------+----------------| | Contact name | James Feast | |--------------------------------------------------+----------------| | Telephone number | 0207 469 1901 | |--------------------------------------------------+----------------| | If a connected EFM, name of offeree/offeror with | | | which connected | | |--------------------------------------------------+----------------| | If a connected EFM, state nature of connection | | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

Correction: Title of release updated with correct date for presentation of result for second quarter 2007 The press release with the result for the second quarter will be published approx. 8.00 CET. Press conference Time: 10.00 CET Place: Smålandsgatan 17, Stockholm Christian Clausen, President and Group CEO, will present the results and answer questions. The press conference is conducted in English and can be viewed live on www.nordea.com where you will also be able to find the presentation material. Analyst presentation Time: 14.00 CET. Place: Smålandsgatan 17, Stockholm. Christian Clausen, President and Group CEO, Arne Liljedahl, Group CFO, Carl-Johan Granvik, Group CRO, and Johan Ekwall, Head of Investor Relations, will present the results for analysts. The presentation material will be available on www.nordea.com. International telephone conference for analysts Time: 16.00 CET. To participate: dial +44 (0) 208 817 9301 latest ten minutes prior (15.50 CET). Access code is Nordea. Christian Clausen, President and Group CEO, Arne Liljedahl, Group CFO, Carl-Johan Granvik, Group CRO, and Johan Ekwall, Head of Investor Relations, will participate. The telephone conference can be monitored live on www.nordea.com and an indexed on demand replay will be available on www.nordea.com. A replay will also be available through 26 July by dialling +44 (0) 207 769 6425, access code 956677#. Analyst and investor presentation in London on 20 July Time: 9.30 GMT. Place: The Great Eastern Hotel, Great Eastern Room, Liverpool Street, London EC2 Arne Liljedahl, Group CFO, Carl-Johan Granvik, Group CRO and Johan Ekwall, Head of Investor Relations will be present. The presentation, including Q & A, starts at 9.30 and is expected to last approx. one hour. A continental buffet breakfast will be served from 9.00. To attend: please contact Julia Clark by fax +44 (0) 20 7888 6151, telephone +44 (0) 20 7888 4563 or e-mail julia.clark@credit-suisse.com For further information: Boo Ehlin, Chief Press Officer Sweden, +46 8 614 8464 Johan Ekwall, Head of Investor Relations, +46 8 614 7852


 

In September, Lars Ingman, 46, will assume the position of Chief Financial Officer (CFO) of CashGuard. He joins CashGuard from FOREX Bank AB, where he was CFO. Prior to this, Lars acquired a broad financial background from working for Swedish companies with international operations, including positions such as Chief Financial Officer for the airline Skyways and the investment company Salénia. For further information, please contact:Agne Pettersson, Managing Director and Chief Executive Officer, CashGuard AB (publ); Tel: +46-8-732 22 36, agne.pettersson@cashguard.se Facts about CashGuard AB (publ) CashGuard develops and sells products and services for secure and fully automatic cash handling and cash logistics. Via direct sales and distribution partners, CashGuard focuses on retail companies, post offices and banks, as well as on security companies. The CashGuard Group has approximately 170 employees and had sales of SEK 323 million in 2006. CashGuard shares are listed on the Stockholm Stock Exchange.


 

ICA Fastigheter Sverige AB has sold a portfolio of 28 store properties in Sweden at a price of SEK 601 M. The sale will have a positive effect on ICA's operating profit in the amount of approximately SEK 90 M during the forth quarter 2007. The effect in the accounts on earnings for Hakon Invest, which owns 40 percent of ICA AB, taking into account the reported surplus value, is approximately SEK 20 M. For more information, contact: CFO Göran Hesseborn tel. +46-8-553 399 99 Head of Investor Relations Pernilla Linger tel. +46-8-553 399 55 Hakon Invest, which is listed on the Nordic Exchange Large Cap, conducts active and long-term investment operations in retail-oriented companies in the Nordic region. Hakon Invest owns 40% of ICA AB, the Nordic region's leading retail company with focus on food. In addition have holdings in Forma Publishing Group, Kjell & Company, Hemma and Cervera. Further information about Hakon Invest is available at www.hakoninvest.se.


 

- Positive clinical data from collaborative study with Charité - Potential to address a high unmet medical need as no IVD test for lung cancer available thus far - Successful clinical proof-of-concept in third cancer screening test development program - Further step towards building an early cancer detection franchise with diagnostic industry partners Berlin, Germany and Seattle, WA, USA, June 27, 2007 - Epigenomics AG (Frankfurt, Prime Standard: ECX) takes a further step towards launching a convenient blood-based lung cancer screening test that could considerably improve the early detection of lung cancer, the most common cause of cancer-related death. The molecular diagnostics company today announced positive data resulting from a clinical study as part of its lung cancer screening test development program. The program aims at developing a blood based test for the reliable and convenient early detection of lung cancer. In an initial study last year Epigenomics identified numerous candidate DNA methylation biomarkers that appear in lung tumors, but not in normal lung tissue. The objective of this most recent study, run in cooperation with the Department of Pneumology at the Charité in Berlin headed by Prof. Dr. Christian Witt, was to show that the most promising candidate biomarker identified previously can also be detected in blood plasma of lung cancer patients. This is an important prerequisite for developing a convenient blood based early detection test for this cancer. The study was carried out on a group of patients with either lung cancer or benign lung disease. The study came to the result that the most promising candidate biomarker detects patients with lung cancer, and differentiates them from individuals with positive computer tomography (CT) due to non-cancerous lung diseases. Based on this proprietary novel DNA methylation biomarker and the encouraging results, Epigenomics will continue the development of its lung cancer screening test. With these results in lung cancer, Epigenomics has achieved clinical proof-of-concept in the third major cancer indication, after successful clinical studies in colorectal cancer and prostate cancer screening programs. In the clinical study, Epigenomics analyzed data for two DNA methylation biomarkers, a novel biomarker from Epigenomics' own discovery and a control biomarker, measured in 100 patients. The novel proprietary biomarker demonstrated a sensitivity of 69% at a specificity of 91% in discriminating non-small cell lung cancer (NSCLC) from controls with non-cancerous lung diseases in blood plasma. This means that no more than 9% false positive test results occurred and69% of the non-small cell lung cancer patients were found through a simple blood test. The proprietary biomarker performed statistically significantly better than the control biomarker RASSF1A, one of the best described lung cancer DNA methylation biomarkers in the scientific literature, and will now be used as the central biomarker in Epigenomics' lung cancer screening test development program. The whole process from discovering novel lung cancer biomarkers to clinical proof-of-concept in blood took less than 12 months. "Lung Cancer is responsible for 1.3 million deaths worldwide annually. Most patients are diagnosed when their disease is advanced, and nearly 90 percent die within two years, but catching lung cancer early could improve survival substantially. A convenient, blood based screening test such as the one being developed by Epigenomics with a high performance addresses an urgent unmet medical need, as the early and reliable detection of lung cancer offers better treatment options for patients," said Dr. Bernd Schmidt, responsible clinician for the project at Charité, Berlin. "Currently no such test is available for the mass screening, especially for the high risk group of more than 90 million smokers in the major markets. We aim at developing such a test and have now made substantial progress to this end", said Christian Piepenbrock, Chief Operating Officer of Epigenomics. "In the next step, we will further improve the performance of the test based on our newly identified biomarker and potentially other complementary biomarkers." "The clinical proof-of-concept for our lung cancer biomarker is an important step towards building an early cancer detection franchise together with diagnostic industry partners," said Geert W. Nygaard, Chief Executive Officer of Epigenomics. "The lung cancer test complements our colorectal and prostate cancer programs and increases our opportunities in our ongoing partnering discussions". Epigenomics estimates the overall worldwide (U.S., Europe and Japan) peak sales potential for a lung cancer screening test when applied to the high risk target population of about 90 million smokers to reach ¤800 million for IVD companies, and if extended for use in the general population aged 45 or older, to reach more than ¤2 billion. Over the next years Epigenomics will conduct further clinical studies to validate its lung cancer test in large patient cohorts, and in collaboration with diagnostics industry partners, aims to develop in vitro diagnostic (IVD) test kits that may be taken through clinical trials to support regulatory approvals. About Lung Cancer Screening With about 386,300 new cases of lung cancer in Europe and over 174,000 new cases in the US in 2006, lung cancer is one of the most common cancers in men and women and accounts for about 20 percent of all cancer deaths, more than any other cancer. Due to the lack of effective tests, screening guidelines currently do not recommend screening for lung cancer. Today, diagnosis mostly relies on diagnostic imaging procedures such as x-rays, Computed Tomography (CT) scans or Positron Emission Tomography (PET) scans followed in some cases by invasive bronchoscopy for definitive diagnosis. As these procedures are not suitable for screening, they are used once a patient reports symptoms that could be indicative of lung cancer. The five-year survival rate is 15% for all stages of lung cancer cases, but 49% for cases detected when the disease is still localized. Thus, the currently most promising approach to improve outcome of lung cancer is to start treatment at an early stage. However, only 16% of lung cancers are diagnosed at this early stage as symptoms occur late and the majority of lung cancer cases are diagnosed in stages too advanced for effective treatment. Non- or minimally invasive screening tests for lung cancer with high sensitivity and specificity that can be applied to large populations in a convenient, safe, and cost-effective way are urgently needed. About Epigenomics AG Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. Using DNA methylation biomarkers, Epigenomics' tests can potentially diagnose disease at an early stage and help guide physicians to select an appropriate therapy. Epigenomics' defined business strategy covers two complementary core business areas: The company develops diagnostic screening tests for the early detection of cancer. Based on body fluid samples (e.g. blood and urine), these tests are aimed at finding cancer at an early stage before symptoms occur. Epigenomics' product pipeline contains a validated biomarker panel for the early detection of colorectal cancer in blood plasma, and further proprietary DNA methylation biomarkers at various stages of development for prostate and lung cancer detection in body fluids. Epigenomics aims at giving patients and doctors early access to these biomarkers through reference laboratory testing services. For development and global commercialization as in vitro diagnostic test kits, Epigenomics pursues a non-exclusive partnering strategy with diagnostics industry players. As a second core business area, Epigenomics develops specialty diagnostics for individuals at high risk for cancer and cancer patients. These tests include surveillance applications of our colorectal cancer biomarkers and a tissue-based prognostic cancer molecular classification test for prostate cancer patients. Our tissue-based prostate cancer application is developed in strategic partnerships with Qiagen (pre-analytics) and Affymetrix (diagnostic device platform). The biomarkers for cancer specialty diagnostic applications will be made available through testing services in centralized reference laboratories. Epigenomics retains the flexibility to decide on further commercialization as in vitro diagnostic test kits in Europe. Pharma, diagnostics and biotech partners can access Epigenomics' portfolio of proprietary DNA methylation technologies and biomarkers protected by more than 200 patent families through Biomarker Services, IVD Development Collaborations, and Licensing. The company is headquartered in Berlin, Germany, and has a wholly owned subsidiary in Seattle, WA, USA. For more information, please visit Epigenomics' website at www.epigenomics.com. ### Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. Contact: Epigenomics AG Dr. Achim Plum VP Corporate Communications +49 30 24345 368 achim.plum@epigenomics.com


 

Innovative rice enrichment technology - a boost for public health DSM and Bühler today announce the opening of Wuxi NutriRice® Co. Ltd, a production facility operated in a joint venture between Bühler and DSM. This facility - the first commercial scale production of its kind in the world - produces NutriRice®: nutritional enriched rice kernels to be mixed with natural rice that are produced via a patented process that protects the stability of the nutrients while at the same time ensuring high bio-availability and good taste. Wuxi NutriRice Co. Ltd. will market the enriched rice kernels (NutriRice®) to rice millers working closely with not only rice mills but also retailers to introduce the concept and benefits of NutriRice® enriched rice to consumers. The newly opened facility will start production as of August 2007. It will start with limited capacity, which is sufficient to enrich approximately 80,000 tonnes of rice. As it is the first facility of its kind, it is primarily intended for market development and it is anticipated that the capacity will be increased in the coming years. The project is a result of the joint research efforts of the two companies combining DSM's over 70 years experience in nutrient formulation and Bühler's advanced technology in grain processing and food extrusion. The decision to create this project together is an indication of DSM's continuing commitment to innovation in the field of nutrition and at the same time Bühler's dedication to advancements in grain processing technology. "The long term partnership in research into ingredient processing technologies between Bühler and DSM is the foundation of the success for our joint venture in Wuxi," comments Stephan Tanda, member of the Managing Board of Directors of DSM. "The company will carry out further research in the field of rice enrichment to better fulfill the nutrient and health needs of the people worldwide. The project is again a step forward in DSM's strategy Vision 2010 - Building on Strengths, contributing to the pillars market-driven growth and innovation and increased presence in emerging economies, whilst at the same time it is an example of sustainable and socially responsible entrepreneurship." The need for enriched rice in China Over the last few decades, the health and nutritional status of the Chinese population has improved significantly. Although great improvements have been made, the problems of nutritional deficiency and imbalance still exist. Micronutrient deficiencies such as nutritional anemia and Vitamin A deficiency are still common even in urban populations. As a staple food, rice provides a high percentage of the daily caloric intake of the Chinese population. However, since many of the nutrients in rice are lost during the rice whitening and polishing process, milled rice has relatively low micronutrient content in comparison to un-milled rice. The traditional rinsing of rice is another challenge to rice enrichment since vitamins and minerals can potentially be washed off. In response to these hurdles, the NutriRice® process offers the unique possibility to efficiently encapsulate multiple micronutrients inside the rice kernel. Nutrients such as vitamin A and B as well as Iron and Zinc can be chosen for inclusion. Due to the patented process in which micro nutrients are encapsulated into the rice kernel, NutriRice® shows superior physical stability with excellent retention of vitamins and minerals during storage, washing and cooking. In addition to this, NutriRice® kernels can be adapted to the shape and length of regional rice varieties, making it acceptable to consumers whatever their cultural or regional preference. Creating opportunities for the rice industry In addition to the production of enriched kernels, Wuxi NutriRice Co. Ltd. expects to continue research in rice and rice product enrichment with the aim of rolling out the NutriRice® concept not only in China but also around the world. By producing a range of enriched rice formulations, Wuxi NutriRice® will offer consumers greater choice and retailers unique products that will provide them opportunities to differentiate in the marketplace. "Wuxi NutriRice Co Ltd. can make use of Buhler's multiple years of experience and legendary high precision extrusion technology to guarantee this unique customized kernel quality," outlines Mr. Dieter Voegtli, President of Bühler China. Combating micronutrient deficiencies "As a responsible corporate citizen with extensive worldwide experience in the nutrition field, DSM is committed to improving public health in China", says Weiming Jiang, President of DSM China. Since 1995, DSM has partnered with international organizations such as the United Nations World Food Program, UNICEF, the International Life Sciences Institute as well as Chinese government affiliated organizations such as the Center for Public Nutrition and Development and the Ministry of Education to contribute to the improvement in people's health via development of a staple food fortification program. The government flour fortification program in China supported by DSM represents the company's commitment to public health. "Vitamin enriched foods have been proven easy and convenient ways of attaining nutritional balance. Staple food fortification programs are able to cover a large segment of the population and are sustainable over time," adds Professor Yu Xiaodong, Director of the Center for Public Nutrition and Development of China. "Rice enrichment, in addition to flour fortification, will greatly contribute to China's plan to improve the overall nutrition intake of its citizens." DSM DSM is active worldwide in nutritional and pharma ingredients, performance materials and industrial chemicals. The company develops, produces and sells innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM's strategy, named Vision 2010 - Building on Strengths, focuses on accelerating profitable and innovative growth of the company's specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over ¤8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with locations in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at www.dsm.com. Bühler Bühler is a global leader in the supply of process engineering solutions, especially production technologies for making foods and engineering materials. Bühler is a leader in the field of mechanical and thermal process engineering such as grinding, blending and mixing, thermal treatment and shaping for processing cereal grains and foods, producing and upgrading engineering materials, and for die casting. Bühler collaborates closely with its customers throughout the life cycles of their production plants by generating new added value for their products in order to improve their performance in terms of productivity and competitiveness. Bühler is present in over 140 countries and employs some 6,600 people. For further company information please visit www.buhlergroup.com For more information: DSM Corporate Communications DSM Investor Relations Nelleke Barning Dries Ausems tel. +31 (0) 45 tel. +31 (0) 45 5782864 5782017 fax +31 (0) 45 5782595 fax +31 (0) 45 e-mail 5740680 investor.relations@dsm.com e-mail media.relations@dsm.com Bühler AG Corporate Communications Corina Atzli Tel. +41 71 955 33 99 Fax +41 71 955 3851 e-mail corina.atzli@buhlergroup.com


 

Delen Investments has reached an agreement with the partners of Capital & Finance regarding the acquisition of their participation (90%) in Capital & Finance ('Capfi') and its 100% subsidiary Capital & Finance Asset Managment. Together, Bank Delen and Capfi will manage client portfolios in an amount of ¤ 15.2 billion (figures 22 June 2007). Through this transaction, the 'Best Private Bank in Belgium 2007 - Euromoney' (Bank Delen) and the 'Great Price for the best fund manager in the Specialised Products 2007' (Capfi) join forces on the Belgian private banking market. This transaction is still subject to the approval of the BFIC ('CBFA'). Capital & Finance was established in 1989 as an independent asset manager and founded in 1991 its 100% subsidiary Capital & Finance Asset Management. Today, they manage ¤ 2,748 million of assets of a mainly private clientele. Capfi applies an extremely performing business model, built on mixed, flexible investment funds. 4 of their funds continuously have ranked first in their S&P category in Belgium/Luxemburg: the starfund Universal Invest Global Flexible (started in 1996), but also Universal Invest Low (1994), Universal Invest High (1997) and the European sharefund C+F Euro Equities (1998). This combination will enable the partners and the personnel of Capfi to concentrate even more on their fund management business and client relations, thanks through the support of banking services, information technology and the administrative services of Bank Delen. Bank Delen and Capfi have chosen to cooperate as their company culture and their investment strategy are closely related, with a strong and direct focus on the personal relation with the clientele. Both Bank Delen and Capfi already offer their clientele the full range of asset management services: dynamic portfolio management with good returns at a limited risk and a limited volatility and a global patrimonial advice on succession and family law. The investment fund Athena managed by Bank Delen is as for investment policy and historical results similar to the above-mentioned Capfi funds. Through this cooperation with Capfi, Bank Delen will strengthen considerably its presence on the Brussels and Walloon market, where it has been actively present since its integration of Banque de Schaetzen in 1994 and Havaux in 2000. The clientele of the new group Delen-Capfi will now almost be equal on both country sides. All partners and the entire personnel of Capfi remain at the service of their clients. The headquarters of Capfi will remain at Watermaal-Bosvoorde, just as the headquarters of Bank Delen-Brussels at the Tervurenlaan. In Brussels, Bank Delen will convert its name into Bank Delen-Capfi. The partners of Capfi will be represented at the board of directors and the management of Finaxis NV, Bank Delen NV and Beursfondsenbeheer NV, which takes care of the administrative and financial management of the Belgian investment funds of the group and which name will be changed into Capfi-Delen Fund Management NV. After this transaction, the assets managed by Bank Delen-Capfi amount to ¤ 15.2 billion (on ¤ 12.2 billion without taking into account the investment funds of Bank Delen held by its own clientele of which the size amounts approximately ¤ 3 billion. The group has branches in Antwerp, Brussels, Liege, Kortrijk-Roeselaere, Ghent, Luxemburg and Geneva. Delen Investments will pay for the acquisition of Capfi a price of ¤ 125 million (for 100%). The partners have the intention to reinvest a part of the purchase price in the AvH-group and will participate in the future evolution of the activities of the new Bank Delen-Capfi via earn outs. In 2006, the new combination Delen-Capfi realised (pro forma) a gross turnover of ¤ 96 million and a combined result of ¤ 37 million. The cost-income ratio amounts to only 44%. Finaxis controls besides Delen Investments also Bank J.Van Breda & C°, a specialised niche bank for entrepreneurs and liberal professions, which realised in 2006 a total bankproduct of ¤ 79 million and a net profit of ¤ 24.4 million. Approximately 18%, i.e. ¤ 1.7 billion, of the funds under management by Bank Delen originate from the Van Breda clientele. The Executive Committee of Bank Delen and the partners of Capfi are enthusiastic about the growth potentials that are created by this common platform, both in terms of autonomous growth in Belgium and in terms of external growth abroad. Ackermans & van Haaren is a diversified group active in 4 key sectors: dredging, environmental and construction services (DEME, one of the largest dredging companies in the world - Algemene Aannemingen Van Laere, a leading contractor in Belgium), Real Estate and related services (Leasinvest Real Estate, a listed real-estate investment trust with real estate assets of approximately ¤ 450 million - Extensa, an important land and real estate developer focused on Belgium and Luxemburg), private banking (Bank Delen, one of the largest independent private asset managers in Belgium - Bank J.Van Breda & C°, niche bank for entrepreneurs and liberal professions) and private equity (Sofinim, one of the largest private equity providers in Belgium, and GIB). The group concentrates on a limited number of strategic participations with an important potential for growth. Market capitalisation of AvH is approximately ¤ 2.4 billion. Since March 2nd 2007, the AvH share has been included in the reference index BEL20 of Euronext Brussels. All press releases issued by AvH and its most important group companies as well as the 'Investor Presentation' can also be consulted on the AvH website: www.avh.be. For further information please contact: At Ackermans & van Haaren: at Bank Delen: at Capital & Finance: Luc Bertrand Jacques Delen Arnaud Van Doosselaere CEO-President of the Executive Committee President of the Executive Committee Partner Tel. +32 (0)3 231 87 70 Tel.: +32 (0)3 244 55 66 Tel: 32 (0)2 663 64 64 e-mail : dirsec@avh.be e-mail: jacques.delen@delen.be e-mail: arnaud@capfi.be website: www.avh.be website: www.delen.be website: www.capfi.be Jan Suykens Bernard Woronoff Member of the Executive Committee Partner Tel. +32 (0)3 897 92 36 Tel: 32 (0)2 663 64 35 e-mail : dirsec@avh.be e-mail: bernard@capfi.be website: www.avh.be website: www.capfi.be


 

As reported on 7 December 2006 Norske Skog has decided to move one paper machine from Union in Norway to Norske Skog Pisa in Brazil. This requires the authorization of the Brazilian authorities and such authorization has now been given. The machine is expected to be operational during the second quarter of 2009. Oxenøen, 27 June 2007 Norske Skog Corporate communication


 

Eitzen Chemical ASA (the Company) announced today that five of its senior chartering employees in Eitzen Chemical (USA) LLC have decided not to continue with the Company after their current commitment expires 5 October 2007. The five employees will be replaced with internal as well as external resources, and the recruitment process is well underway. The Company's strategy and commitment to the US market and its Westport office are unchanged. Terje Askvig, CEO said "I would like to thank the team for excellent service and wish them all the best with their next endeavors." Terje Askvig +47 67 11 98 00 Chief Executive Officer Snorre Krogstad +47 67 11 98 44 Chief Financial Officer


 

1. CONDITIONAL VOLUNTARY PUBLIC TAKE-OVER COUNTER OFFER IN CASH In accordance with article 6(1) of the Luxembourg Law of 19 May 2006 on public take-over bids, Leasinvest Real Estate SCA (Leasinvest) announces the launch in the Grand Duchy of Luxembourg (Luxembourg) and in Belgium of a conditional voluntary public take-over counter-offer in cash (the Counter-Offer) on all distribution shares and capitalisation shares (the Shares) which Leasinvest does not yet own, issued by the Luxembourg investment company Immo-Croissance (Immo-Croissance). The prices offered per share amount to: * EUR 296.59 per distribution share (coupon Nr. 20 and following attached); and * EUR 834.54 per capitalisation share. The prices offered by Leasinvest correspond to a premium of 5% per Share compared to the conditional voluntary public take-over offer launched by Cofinimmo SA announced on 21 May 2007 and modified on 21 June 2007. On the basis of the prices offered, the acquisition of the Shares of Immo-Croissance represents an investment of approximately EUR 130.7 million (assuming an acquisition of 100% of all the shares of Immo-Croissance) based on 46,084 capitalisation shares and 310,853 distribution shares. The Counter-Offer is subject to the condition that Leasinvest will have received Counter-Offer acceptances covering, at the close of the Counter-Offer, more than 50% of all the Shares of Immo-Croissance (including the 2.9% Shares currently owned by Leasinvest). In addition, the Counter-Offer is, until the close of the Counter-Offer, subject to: * there being no decision or order by or before any judicial, administrative or arbitral authority which shall seek to restrain, prohibit, invalidate or make the realisation of the Counter-Offer more cumbersome for Leasinvest; * no exceptional event or exceptional circumstance occurring which is independent from and beyond the control of Leasinvest and which has, or would be likely to have, a material adverse effect, that, considered individually or in conjunction with other elements, is or would be expected, according to an independent expert, to cause a significant decrease of (i) the value of the portfolio of assets or (ii) the net inventory value of Immo-Croissance; the implementation of this condition being always subject to the prior approval of the CSSF (Commission de Surveillance du Secteur Financier); * the board of directors (or the shareholders' meeting) of Immo-Croissance not proceeding or not deciding to proceed to an increase of the capital or of the number of shares of Immo-Croissance. These conditions are to the sole benefit of Leasinvest which has the right to waive, in whole or in part, all or some of them. Leasinvest's decision hereon will be announced in a press release. The Counter-Offer will be reopened in case Leasinvest acquires at the close of the Counter-Offer, at least 33 1/3% of the total voting rights attached to the Shares of Immo-Croissance under the same conditions. If at the close of the Counter-Offer or its possible reopening, Leasinvest holds Shares representing at least 95% of the capital giving right to voting rights and 95% of the voting rights at the shareholders' meeting of Immo-Croissance, a squeeze-out of the remaining Shares of Immo-Croissance shall be carried out in compliance with Article 15 of the Luxembourg Law of 19 May 2006 on public take-over bids. If at the close of the Counter-Offer or its possible reopening, Leasinvest holds Shares (on its own or with persons acting in concert with it) entitling it to more than 90% of the voting rights at the shareholders' meeting of Immo-Croissance, the holders of shares that have not been brought into the Counter-Offer may require from Leasinvest the purchase of their remaining shares in compliance with Article 16 of the Luxembourg Law of 19 May 2006 on public take-over bids. 2. IMMO-CROISSANCE Immo-Croissance, a Luxembourg investment company with variable capital (Société d'investissement à capital variable - SICAV) having its registered office at 69 Route d'Esch, L-1470 Luxembourg, registered with the Luxembourg Trade and Companies Register under the number B 28872), is listed on the Luxembourg Stock Exchange and on Eurolist by Euronext Brussels. As at 31 December 2006, Immo-Croissance held a real estate portfolio valued at EUR 160.5 million in fair value, comprising office buildings mainly located in Luxembourg (84% of the total value) and incidentally in Belgium and Germany. The net asset value of Immo-Croissance as at 31 December 2006 amounted to EUR 110.3 million (before the dividend distributed in May 2007). 3. FURTHER GROWTH AND DIVERSIFICATION OF LEASINVEST IN LUXEMBOURG Thanks to this acquisition and the acquisition in mid-2006 of Leasinvest Immo Lux (ex-Dexia Immo Lux) Leasinvest would be the only Belgian SICAFI which will have invested in such an important way in Luxembourg. As of today and since the acquisition of Leasinvest Immo Lux in mid-2006, Luxembourg represents 31% of the consolidated real estate portfolio of Leasinvest. With the acquisition of Immo-Croissance, the real estate portfolio of Leasinvest in Luxembourg would consist of 21 buildings with a total surface of 81,457 sqm, representing approximately 50% of the consolidated real estate portfolio of Leasinvest, which would improve the position of both Leasinvest Immo Lux and Immo-Croissance in the real estate market of Luxembourg. The combination in Luxembourg of the experience, market knowledge and personnel of Immo-Croissance on the one hand and Leasinvest Immo Lux on the other will make it possible to constitute an obvious strategic economical project in Luxembourg which can lead to synergies. This is why Leasinvest possibly contemplates to merge Immo-Croissance and Leasinvest Immo Lux to create one of the largest real estate funds in Luxembourg. 4. DETAILS ON THE COUNTER-OFFER Additional details on the launch of the Counter-Offer, including the start and the duration of the acceptation period of the Counter-Offer, will be announced by a press release in the Belgian and Luxembourg press. A public offer document will in the short term be submitted to the CSSF in Luxembourg for approval. It will also have to be submitted for recognition to the Banking, Finance and Insurance Commission (Commission Bancaire, Financière et des Assurances - CBFA) in Belgium. LEASINVEST REAL ESTATE Leasinvest is a listed Belgian real estate fund (SICAFI) which invests in quality and well-situated buildings: offices, logistics and retail in Belgium and in Luxembourg. The fair value of the real estate portfolio of Leasinvest on 31 March 2007 amounted to EUR 457 million. As of today, the portfolio in Belgium and in Luxembourg represents a surface of 272,303 sqm, in 26 locations and spread across 52 buildings. Leasinvest is listed on Euronext in the NextPrime segment. Leasinvest has a market capitalisation of EUR 301.8 million (on 25 June 2007). For more information, please contact: Leasinvest Real Estate Jean-Louis Appelmans T: +32 3 238 98 77 E: jeanlouis.appelmans@leasinvest-realestate.com


 

VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- June 26, 2007 -- Rocher Deboule Minerals Corp. (NEX: RD.H)(PINK SHEETS: RDBHF) is pleased to report the NI 43-101 Mineral Resource Evaluation Report prepared by N. Tribe & Associates Ltd. (NT& A) of Kelowna, BC has been filed on Sedar at www.sedar.com. The property is accessible by 28 miles of road from Wikieup, Arizona and is approximately 6 miles from the Bill Williams River and hydro-power is located 6 miles from the property on Signal Road. The Artillery Peak manganese deposit was mined for the U.S. government strategic stockpile during and after the Second World War up until the stockpiling ceased in 1955. The manganese deposits of the Artillery Mountain basin are of the strata bound sedimentary type. The manganese mineralization consists of manganite, psilomelane and wad with minor pyrolusite. In 1964 D.A. Elkins, undertook a study for the U.S. Department of the Interior to design a beneficiation process for the Artillery Mountain manganese ores. Two possible methods are effective in providing concentrate from these ores (Elkins report is included as Appendix VII of the NI 43-101 report). Mineral Resource Estimate At the present time, there are no exploration drill holes on the manganese beds on the Chapin West Showings. Surface sampling has established the presence of the manganese in economic grades and although Rocher Deboule Resource Corp. has not generated the engineering parameters for mining this mineral deposit there is little doubt that the volume and grade will be of economic interest. The historical resource for the Artillery Mountain manganese deposits is estimated at 175,000,000 tonnes averaging 3.5 - 4% Mn as reported in Manganese Deposits of Western Arizona 1958 Information Circular #7843 by (L.L. Farmham and L.A. Stewart). Approximately half of the deposits are on the Rocher Deboule Minerals Corp. claims. - Where historical estimates are referred to, the Company has no classification of the resource or reserve, and the Company has not obtained enough of the original data and has not done the work necessary to verify the classification of a resource or reserve, the Company is not treating the estimates as a NI 43-101 defined resource or reserve verified by a Qualified Person, and the historical estimate should not be relied upon. The NT & A report recommends a Two Phase Exploration Program as follows: Phase I additional staking, geological mapping and sampling and baseline studies $ 90,000.00 Phase II drilling of 8 1000 foot holes and engineering report $324,000.00 Norm Tribe, P. Eng. prepared this report on behalf of NT & A for Rocher Deboule Resources Corp. and is a qualified person pursuant to National Instrument 43-101. On behalf of Management ROCHER DEBOULE MINERALS CORP. Larry W. Reaugh, President and Chief Executive Officer This news release may contain certain "Forward-Looking Statements" within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time with the Toronto Venture Exchange, the British Columbia Securities Commission and the US Securities and Exchange Commission. The TSX-Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Contacts: Rocher DeBoule Minerals Corp. Larry W. Reaugh President and Chief Executive Officer (604) 531-9639 (604) 531-9634 (FAX) Email: info@rdminerals.ca Website: www.rdminerals.ca


 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons The following announcement replaces the announcement released 22nd June 2007 at 17.22. This form is intended for use by an issuer to make a RIS notification required by the Market Abuse Rules and section 53 (as extended by section 64 of the Companies Act 1990) or entered into the issuer's register in accordance with section 59 of the Companies Act 1990. (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. (2) An issuer making a notification in respect of a derivative relating to the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. (3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24 (4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete the boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. All relevant boxes should be completed in block capital letters +-------------------------------------------------------------------+ | 1 | Name of the Issuer | 2 | State whether the | | | | | notification relates to: | | | IRISH CONTINENTAL GROUP | | (i) a transaction | | | PLC | | notified in accordance | | | | | with Market Abuse Rules; | | | | | | | | | | (ii) a disclosure made | | | | | in accordance with section | | | | | 53 (as extended by section | | | | | 64 of the Companies Act | | | | | 1990) or entered into the | | | | | issuer's register in | | | | | accordance with section 59 | | | | | of the Companies Act 1990; | | | | | or | | | | | (iii) both (i) and (ii). | | | | | | | | | | (iii) both | | | | | | |----+----------------------------+----+----------------------------| | 3 | Name of person discharging | 4 | State whether notification | | | managerial | | relates to a person | | | responsibilities/director | | connected with a person | | | EAMONN ROTHWELL | | discharging managerial | | | | | responsibilities/director | | | | | named in 3 and identify | | | | | the connected person | | | | | N/A | |----+----------------------------+----+----------------------------| | 5 | Indicate whether the | 6 | Description of shares | | | notification is in respect | | (including class) | | | of a holding of the person | | debentures or derivatives | | | referred to in 3 or 4 | | or financial instruments | | | above or in respect of a | | relating to shares | | | non-beneficial interest | | ICG UNITS (each consisting | | | Yes, EAMONN ROTHWELL | | of 1 ordinary share and 3 | | | | | redeemable shares) | |----+----------------------------+----+----------------------------| | 7 | Name of registered | 8 | State the nature of the | | | shareholder(s) and, if | | transaction | | | more than one, number of | | (I) ACQUISITION OF | | | shares held by each of | | INTEREST IN ICG UNITS, AND | | | them | | (II) ENTRY INTO CONTRACT | | | EAMONN ROTHWELL - | | FOR DIFFERENCE IN RESPECT | | | 3,052,771 ICG UNITS | | OF ICG UNITS | |----+----------------------------+----+----------------------------| | 9 | Number of shares, | 10 | Percentage of issued class | | | debentures or financial | | acquired (treasury shares | | | instruments relating to | | of that class should not | | | shares acquired | | be taken into account when | | | 1,750,200 ICG UNITS | | calculating percentage) | | | (OF WHICH 736,00 HELD VIA | | 7.4% (4.28% ACQUISITION OF | | | A CONTRACT FOR DIFFERENCE) | | SHARES ; 3.12% CONTRACTS | | | | | FOR DIFFERENCE) | |----+----------------------------+----+----------------------------| | 11 | Number of shares, | 12 | Percentage of issued class | | | debentures or financial | | disposed (treasury shares | | | instruments relating to | | of that class should not | | | shares disposed | | be taken into account when | | | N/A | | calculating percentage) | | | | | N/A | |----+----------------------------+----+----------------------------| | 13 | Price per share or value | 14 | Date and place of | | | of transaction | | transaction | | | ¤22.00 | | 20TH JUNE 2007, DUBLIN | |----+----------------------------+----+----------------------------| | 15 | Total holding following | 16 | Date issuer informed of | | | notification and total | | transaction | | | percentage holding | | 20TH JUNE 2007 | | | following notification | | | | | (any treasury shares | | | | | should not be taken into | | | | | account when calculating | | | | | percentage) | | | | | 3,052,711 ICG | | | | | UNITS 12.9% | | | | | (IN ADDITION, EAMONN | | | | | ROTHWELL HAS A CONTRACT | | | | | FOR DIFFERENCE IN RESPECT | | | | | OF 736,000 ICG UNITS) | | | +-------------------------------------------------------------------+ If a person discharging managerial responsibilities has been granted options by the issuer, complete the following boxes: +-------------------------------------------------------------------+ | 17 | Date of grant | 18 | Period during which or | | | | | date on which it can be | | | | | exercised | |----+-------------------------------+----+-------------------------| | 19 | Total amount paid (if any) | 20 | Description of shares | | | for grant of the option | | or debentures involved | | | | | (class and number) | |----+-------------------------------+----+-------------------------| | 21 | Exercise price (if fixed at | 22 | Total number of shares | | | time of grant) or indication | | or debentures over | | | that the price is to be fixed | | which options are held | | | at the time of exercise | | following notification | |----+-------------------------------+----+-------------------------| | 23 | Any additional information | 24 | Name of contact and | | | | | telephone number for | | | | | queries | | | | | TOM CORCORAN - 01 | | | | | 8552222 | |-------------------------------------------------------------------| | Name and signature of duly designated officer of issuer | | responsible for making notification | | ____________________________________________________ | | Date of notification ________________26TH JUNE | | 2007___________________ | +-------------------------------------------------------------------+ ---END OF MESSAGE---


 

ANNOUNCEMENT DATED 25 JUNE 2007 Bear Stearns Global Asset Holdings, Ltd. Issue of up to SEK 500,000,000 Notes Linked to the a Basket Of Currencies due 2010 (the "Notes") ISIN Code: SE0002015867 under the U.S.$30,000,000,000 Euro Medium Term Note Programme NOTICE OF ISSUE AMOUNT The offer period for the Notes (described above) ended at 5:00pm (Central European Time) on 31 May 2007. Pursuant to the Prospectus for the issue of the Notes dated 24 April 2007, the Aggregate Nominal Amount of the Notes to be issued on 26 June 2007 will be SEK 237,410,000. Enquiries: Transaction Management Group Bear, Stearns International Limited One Canada Square London E14 5AD Tel: +44 20 7516 6817 Fax: +44 20 7516 5001 ---END OF MESSAGE---


 
Hitt og þetta
26. júní 2007

Final Results

PENNINE DOWNING AIM VCT PLC UNAUDITED PRELIMINARY ANNOUNCEMENT OF RESULTS FOR THE YEAR ENDED 28 FEBRUARY 2007 FINANCIAL SUMMARY Unaudited Audited Year ended 28 Year ended 28 February February 2007 2006 pence pence Net asset value (per share) 73.4 78.9 Cumulative gross distributions paid to 20.0 16.0 date Total return (net asset value plus 93.4 94.9 cumulative distributions paid) Final proposed distribution (per share) - 4.0 The statement to shareholders by the Chairman, Andrew Griffiths, includes the following comments: Introduction The year to 28 February 2007 has seen mixed performance by the investments in the Company's portfolio. Unfortunately, the Company was exposed to the well-publicised troubles encountered by Torex Retail plc and this has been a significant factor in the flat performance for the year. Net Asset Value The net asset value ("NAV") at the year-end stood at 73.4p, a small decrease of 1.5p per share (2.0%) after adjusting for the dividend of 4p per share that was paid during the year. There is, however, a little encouragement to be taken from the performance in the second half of the year, where, despite the collapse of Torex Retail plc, the NAV increased by 1.8p (2.5%). Venture capital investments During the year the Company made three new investments and three follow on investments at a total cost of £358,000. At 28 February 2007, the portfolio comprised of investments in 39 companies and was valued at £5.6 million. Highlights include good performance from Interserve plc, Oasis Healthcare plc, Synergy Healthcare plc and Pennant International Group plc, each of which accounted for unrealised gains in excess of £100,000. However, the portfolio also included several poor performers, the most significant of which was Torex Retail plc which showed a loss in the year of £392,000 (equivalent to 4.8p per share). A number of full and part disposals were made during the year which produced realised gains of £28,000. Along with net unrealised losses of £65,000 generated by the investments that continue to be held, the venture capital portfolio produced a small net loss of £37,000 over the year. Results and dividend The loss on ordinary activities after taxation was £155,000 (2006: profit £33,000), comprising a revenue loss of £70,000 and a capital loss of £85,000. In view of some potential developments described below, the Board is not proposing to declare a final year end dividend at this time. Share buybacks The Board is conscious that the Company's share price is affected by the illiquidity of its shares in the market and, in line with accepted practice of VCTs, has operated a policy of purchasing its own shares. During the year the Company purchased a total of 354,999 shares at an average cost of 66.8p, being approximately a 10% discount to NAV. These shares were subsequently cancelled. Shareholders should note that, as a result of the discussions mentioned below, the Company may be prohibited from buying in shares until those discussions have reached a conclusion. The Board is mindful of the fact that buying in shares for cancellation reduces the size of the Company, and such a policy cannot be operated indefinitely. Future The reducing size of the VCT has become a matter of increasing concern for the Board. As a result of the strong dividend policy and a continuing high level of share buybacks, the Company's net assets have fallen to a little over £6 million. The cost burden of being fully listed is particularly heavy for a company of this size, and although annual running costs of the Company are capped by the Investment and Administration Managers at 3.5% of net assets, reducing costs is seen as essential to provide a foundation for improved performance. I can confirm that the Board is in discussions with two other VCTs regarding the possibility of merging the three companies together, by way of schemes of reconstruction under Section 110 of the Insolvency Act 1986, to create a single larger entity. These discussions may or may not lead to an offer being made for the Company. Shareholders will be updated as soon as there is any firm news. The Company's Articles of Association require that a resolution as to whether the Company should continue as a Venture Capital Trust be put to Shareholders at the forthcoming Annual General Meeting. In view of the discussions noted above, directors recommend Shareholders to vote in favour of Resolution 6 at the AGM, while they formulate plans for the future. Annual General Meeting The ninth Annual General Meeting of the Company will be held at 159 New Bond Street, London, W1Y 9PA at 2 pm on 24 July 2007. Notice of the meeting is at the end of this document. Two items of Special Business are proposed; to authorise the Company to make market purchases of its shares and to continue as a Venture Capital Trust as described above. Outlook With a Total Return (NAV plus cumulative dividends paid since launch) of 93.4p per share compared to an original cost net of income tax relief of 80p, the overall performance of your Company has been disappointing. In recent years, the general climate for investing has been healthier, but a small number of poor performing investments along with relatively high running costs have held back performance. The Board feels that a merger with another VCT (or VCTs) may address some of the issues which have held back Company's performance in recent years and may also have other benefits for Shareholders. I therefore hope to be in a position to bring you firm news of developments in the near future. UNAUDITED INCOME STATEMENT for the year ended 28 February 2007 Unaudited Audited Year ended 28 February 2007 Year ended 28 February 2006 Revenue Capital Total Revenue Capital Total £'000 £'000 £'000 £'000 £'000 £'000 Income 95 - 95 93 - 93 Net (losses)/ - (37) (37) - 187 187 gains on investments 95 (37) 58 93 187 280 Investment (16) (48) (64) (18) (55) (73) management fees Other (149) - (149) (174) - (174) expenses Return on ordinary (70) (85) (155) (99) 132 33 activities before tax Tax on - - - - - - ordinary activities Return attributable (70) (85) (155) (99) 132 33 to equity shareholders Return per (0.8p) (1.0p) (1.8p) (1.1p) 1.5p 0.4p share All Revenue and Capital items in the above statement derive from continuing operations. The total column within the Income Statement represents the profit and loss account of the Company. A Statement of Total Recognised Gains and Losses has not been prepared as all gains and losses are recognised within the Income Statement as noted above. RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS for the year ended 28 February 2007 Unaudited Audited Year ended Year ended 28 February 2007 28 February 2006 £'000 £'000 Opening shareholders' funds 6,800 7,453 Purchase of own shares (239) (318) Total recognised net (losses)/gains (155) 33 for the year Distributions paid in year (342) (368) Closing shareholders' funds 6,064 6,800 BALANCE SHEET as at 28 February 2007 Unaudited Audited 2007 2006 £'000 £'000 £'000 £'000 Fixed Assets Investments 5,609 6,260 Current assets Debtors 29 5 Cash at bank and in hand 496 587 525 592 Creditors: amounts falling due within one (70) (52) year Net current assets 455 540 Net assets 6,064 6,800 Capital and reserves Called up share capital 413 431 Capital redemption reserve 99 81 Special reserve 3,492 4,187 Capital reserve - realised 2,596 2,499 Capital reserve - unrealised (296) (228) Revenue reserve (240) (170) Equity shareholders' funds 6,064 6,800 Net asset value per ordinary share 73.4p 78.9p CASH FLOW STATEMENT for the year ended 28 February 2007 Unaudited Audited Year ended Year ended 28 Feb 2007 28 Feb 2006 £'000 £'000 Net cash outflow from operating activities (148) (128) Capital expenditure Purchase of venture capital investments (358) (840) Sale of listed fixed income securities - 254 Sale of venture capital investments 972 1,348 Net cash inflow from capital expenditure 614 762 Equity distributions paid (354) (368) Net cash inflow before financing 112 266 Financing Purchase of own shares (203) (349) Net cash outflow from financing (203) (349) Decrease in cash (91) (83) NOTES TO THE UNAUDITED PRELIMINARY ANNOUNCEMENT for the year ended 28 February 2007 1. Accounting policies Basis of accounting The Company has prepared its financial statements under UK Generally Accepted Accounting Practice ("UK GAAP") and in accordance with the Statement of Recommended Practice "Financial Statements of Investment Trust Companies" revised December 2005 ("SORP"). Consistent accounting policies have been applied to both this year end and the prior year's accounts. The financial statements are prepared under the historical cost convention except for the revaluation of certain financial instruments. Presentation of Income Statement In order to better reflect the activities of an investment trust company and in accordance with guidance issued by the Association of Investment Companies ("AIC"), supplementary information which analyses the income statement between items of a revenue and capital nature has been presented alongside the income statement. The net revenue is the measure the directors believe appropriate in assessing the Company's compliance with certain requirements set out in Section 842 Income and Corporation Taxes Act 1988. Investments All investments are designated as "fair value through profit or loss" assets and are initially measured at cost. Thereafter the investments are measured at subsequent reporting dates at fair value. Listed fixed income investments, investments quoted on AIM and those traded on the PLUS Market (formerly OFEX) are valued using bid prices, in accordance with International Private Equity and Venture Capital Valuation Guidelines. In respect of unquoted instruments, fair value is established by using International Private Equity and Venture Capital Valuation Guidelines. Where no reliable fair value can be estimated for such unquoted equity investments they are carried at cost, subject to any provision for impairment. Where an investee company has gone into receivership or liquidation the investment, although not physically disposed of, is treated as being realised. Gains and losses arising from changes in fair value are included in the income statement for the year as a capital item and transaction costs on acquisition or disposal of the investment expensed. It is not the Company's policy to exercise either significant or controlling influence over investee companies. Therefore the results of these companies are not incorporated into the revenue account except to the extent of any income accrued. Income Dividend income from investments is recognised when the shareholders' rights to receive payment has been established, normally the ex dividend date. Interest income is accrued on a timely basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount, and only where there is reasonable certainty of collection. Expenses All expenses are accounted for on an accruals basis. In respect of the analysis between revenue and capital items presented within the income statement, all expenses have been presented as revenue items except as follows: * Expenses which are incidental to the disposal of an investment are deducted from the disposal proceeds of the investment. * Expenses are split and presented partly as capital items where a connection with the maintenance or enhancement of the value of the investments held can be demonstrated and accordingly the investment management fee and finance costs have been allocated 25% to revenue and 75% to capital, in order to reflect the directors' expected long-term view of the nature of the investment returns of the Company. Taxation The tax effects on different items in the Income Statement are allocated between capital and revenue on the same basis as the particular item to which they relate using the Company's effective rate of tax for the accounting period. Due to the Company's status as a Venture Capital Trust and the continued intention to meet the conditions required to comply with Section 842AA of the Income and Corporation Taxes Act (1988), no provision for taxation is required in respect of any realised or unrealised appreciation of the Company's investments which arises. Deferred taxation is provided in full on timing differences that result in an obligation at the balance sheet date to pay more tax, or a right to pay less tax, at a future date, at rates expected to apply when they crystallise based on current tax rates and law. Timing differences arise from the inclusion of items of income and expenditure in taxation computations in periods different from those in which they are included in the accounts. 2. Return per ordinary share Revenue return per ordinary share is based on the net revenue loss after taxation of £70,000 (2006: £99,000) in respect of 8,534,754 ordinary shares (2006: 8,939,212), being the weighted average number of ordinary shares in issue during the year. Capital return per ordinary share is based on the net capital loss for the financial year of £85,000 (2006: surplus £132,000) in respect of 8,534,754 ordinary shares (2006: 8,939,212), being the weighted average number of ordinary shares in issue during the year. As the Company has not issued any convertible securities or share options, there is no dilutive effect on return per ordinary share. The return per share disclosed therefore represents both basic and diluted return per ordinary share. 3. Net asset value per ordinary share 2007 2006 Net asset Net asset value value per share Net asset per share Net asset value value pence £'000 pence £'000 Ordinary 73.4 6,064 78.9 6,800 shares Net asset value per ordinary share is based on net assets at the year end, and on 8,258,814 ordinary shares (2006: 8,613,813), being the number of ordinary shares in issue at the year end. As the Company has not issued any convertible securities or share options, there is no dilutive effect on net asset value per ordinary share. The net asset value per share disclosed therefore represents both basic and diluted net asset value per ordinary share. 4. Reconciliation of net revenue return before taxation to net cash flow from operating activities 2007 2006 £'000 £'000 Net revenue loss before taxation (70) (99) Expenses charged to capital (48) (55) (Increase)/decrease in other debtors (12) 4 (Increase)/decrease in prepayments and accrued income (12) 21 (Decrease)/increase in accruals and deferred income (6) 1 Net cash outflow from operating activities (148) (128) 5. Analysis of changes in cash during the period 2007 2006 £'000 £'000 Beginning of year 587 670 Net cash outflow (91) (83) End of year 496 587 Announcement based on unaudited accounts The financial information set out in the announcement does not constitute the Company's statutory accounts in accordance with section 240 Companies Act 1985 for the year ended 28 February 2007. The statutory accounts for the year ended 28 February 2007 will be finalised on the basis of the financial information presented by the Directors in this preliminary announcement and will be delivered to the Registrar of Companies following the Company's Annual General Meeting. The statutory accounts for the year ended 28 February 2006 have been delivered to the Register of Companies and received an Auditors Report which was unqualified and did not contain statements under s237 (2) and (3) of the Companies Act 1985. A copy of the full annual report and financial statements for the year ended 28 February 2007 will be printed and posted to shareholders. Copies will also be available to the public at the registered office of the Company at Kings Scholars House, 230 Vauxhall Bridge Road, London, SW1V 1AU. The financial information contained within this Preliminary Announcement was approved by the Board on 26 June 2007. ---END OF MESSAGE---


 

Seminar topics: atomic layer engineering for manufacturing, second-generation ALD high-k materials and strain engineering, advanced packaging and 3D technologies BILTHOVEN, the Netherlands, June 26, 2007 --- ASM International N.V. (NASDAQ: ASMI and Euronext Amsterdam: ASM) today announced it will host a technology seminar at the SEMICON West trade show in San Francisco, CA on July 18, 2007 from 8:30 to 10:00 a.m. Pacific Daylight Time. The presentations will be held in Room 276, West Mezzanine, Moscone Center and simultaneously webcast on www.asm.com. Presenting at the ASMI seminar are Dr. Ivo Raaijmakers, Chief Technology Officer and Director of Research and Development for ASM's front-end semiconductor equipment operations and Charles J. Vath III, Vice President Process & Packaging Technology for ASM Pacific Technology Ltd. Dr. Raaijmakers' presentation, "Breakthrough Technologies - From R&D to Manufacturing" will address today's reality of ASM's milestone technologies that incorporate atomic-level engineered interfaces and materials in manufacturing, as well as new developments in second-generation high-k atomic layer deposition and strain engineering. Mr. Vath's remarks, "Space - The Final Frontier", will cover advanced packaging including 3-D technologies. Those interested in attending the seminar should reply to maryjo.dieckhaus@asm.com. SEMICON West attendees are also invited to visit ASM International's booth #618, South Hall and the ASM Pacific Technology booth #7821, Level 1, West Hall. About ASM and ASMPT ASM International N.V. and its subsidiaries design and manufacture equipment and materials used to produce semiconductor devices. The company provides production solutions for wafer processing (Front-end segment) as well as assembly and packaging (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International's common stock trades on NASDAQ (symbol ASMI) and the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI's web site at www.asm.com. ASM Pacific Technology Ltd. is the world's largest supplier of a full line of assembly and packaging equipment and process solutions for the semiconductor, photonics, and optoelectronics industries. With its financial strength and R&D resources, ASMPT offers its customers total solutions, process innovations, package development and factory automation. With headquarters in Hong Kong, ASMPT has manufacturing operations in China, Singapore and Malaysia. ASMPT is 53%-owned by ASM International N.V. ASM Pacific Technology Ltd. common shares trade on the Hong Kong Exchanges under the symbol: 0522. For more information, visit ASMPT's web site at www.asmpacific.com. Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: All matters discussed in this statement, except for any historical data, are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, the timing of significant orders, market acceptance of new products, competitive factors, litigation involving intellectual property, shareholder and other issues, commercial and economic disruption due to natural disasters, terrorist activity, armed conflict or political instability, epidemics and other risks indicated in the Company's filings from time to time with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's reports on Form 20-F and Form 6-K. The Company assumes no obligation nor intends to update or revise any forward-looking statements to reflect future developments or circumstances.


 

Mortsel (Belgium) - In full agreement with the Board of Directors, Marc Olivié, President and CEO of the Agfa-Gevaert group has announced his decision to resign from his positions effective June 30, 2007. In view of the announced demerger of Agfa-Gevaert into three independently listed companies, which will each operate with a dedicated management team, Marc Olivié had already indicated at an earlier stage that he considered his task to be fulfilled and that he would look for other challenges. The demerger project is fully designed and its implementation entirely on track. Both parties therefore agreed to separate now in order to allow each of them to better concentrate on their respective futures. Agfa recognizes and appreciates the contribution of Marc Olivié in the reorganization process of the last years and is confident that it will be successfully completed before year-end. To assure the continuity, the Board has requested its Chairman and previous CEO, Ludo Verhoeven, to assume the day to day follow-up of the demerger and its implementation and has requested him for this purpose to act during this interim period as the President of the Executive Committee. Agfa-Gevaert wishes Marc Olivié all the best in his future endeavours. Contact: Agfa-Gevaert Katia Waegemans Director Corporate Communication tel. ++32 (0)3/444.7124 fax. ++32 (0)3/444.7485 e-mail: katia.waegemans@agfa.com


 

Pursuant to article 26 sec 1 WpHG BB MEDTECH AG, Vordergasse 3, 8200 Schaffhausen, Switzerland hereby declares that its wholly-owned subsidiary Medhealth N.V., Snipweg 26, Curaçao, Netherlands Antilles increased the holding in own shares as of June 22, 2007 to more than 3% of the proportion of voting rights (447 735 bearer shares / 3.09% of the proportion of voting rights). Pursuant to article 22 sec 1 clause 1 no 1 WpHG 3.09% of the proportion of voting rights need to be added to the voting rights of BB MEDTECH AG, Schaffhausen. BB MEDTECH AG did not hold any own shares as of June 22, 2007. For further information please contact: Bellevue Asset Management AG, Seestrasse 16, CH-8700 Küsnacht/Zürich Adrian Brüngger or Dr. Christian Lach, Tel. +41 44 267 67 00. --- End of Message --- BB MEDTECH AG Vordergasse 3 Schaffhausen Switzerland WKN: 898194; ISIN: CH0000428661; Index: IGSP; Listed: Investment Companies in SWX Swiss Exchange;


 

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Funcom N.V. has retained ABG Sundal Collier Norge ASA and Carnegie ASA to advise on and effect a contemplated private placement of up to 4.7 million new shares directed towards professional investors in Norway and internationally after the close of the Oslo Stock Exchange today. The private placement will be carried out through a book-building process. -------------------------------------------------------------------------------- NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Funcom N.V. has retained ABG Sundal Collier NORGE ASA and Carnegie ASA to advise on and effect a contemplated private placement of issue of new shares directed towards professional investors in Norway and internationally after the close of the Oslo Stock Exchange today. The private placement will be carried out through a book-building process, and will consist of up to 4.7 million new shares, equal to approximately 10% of the number of outstanding shares in Funcom N.V. On the back of significantly growing external and internal expectations related to Age of Conan, Funcom's upcoming Massively Multiplayer Online Game (MMO), the company seeks additional funding. Age of Conan is progressing according to plan towards the announced launch date of 30 October 2007. The game has recently received strong early sales indications from partners and retail channels both in the U.S. and in Europe and press and gamer expectations for Age of Conan also continue to grow strongly. To ensure an optimal launch of Age of Conan, Funcom and its key partners view it as important to further strengthen Funcom's marketing and operational capacity prior to launch. Funcom has furthermore decided to enter the casual MMO segment and is currently evaluating several possible expansion opportunities. As some of these opportunities may involve near term acquisitions, Funcom would also benefit from an increased strategic flexibility. The issue of new shares (in the form of depository receipts registered with the VPS) will be subject to approval by the supervisory board of Funcom N.V. and the general meeting of Funcom N.V. The required general meeting will be called as soon as possible following completion of the book-building process. Shareholders representing approximately 50% of the issued shares in the company have undertaken to vote in favour of the share issue at the general meeting. In order to facilitate prompt delivery of the shares subscribed in the private placement the managers, ABG Sundal Collier Norge ASA and Carnegie ASA, have entered into a stock loan agreement with one of the main shareholders of the company, Stelt Holding N.V. The shares to be offered have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the `U.S. Securities Act`), or any state securities laws, and will be offered within the United States only to qualified institutional buyers (`QIB`), as defined in Rule 144A under the U.S. Securities Act (`Rule 144A`), through ABG Sundal Collier Inc. and Carnegie, Inc., in reliance upon the exemption from the registration requirements provided by section 4(2) of the U.S. Securities Act Rule 144A, and to certain non-U.S. persons in offshore transactions in reliance on Regulation S under the U.S. Securities Act. ABG Sundal Collier Inc. is a U.S. affiliate of ABG Sundal Collier Norge ASA and Carnegie, Inc. is a U.S. affiliate of Carnegie Investment Bank AB. The shares to be offered will be subject to certain restrictions on transfer. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful. 26 June 2007 Funcom N.V. For further enquiries: Olav Sandnes, CFO Funcom N.V. E-mail: olav.sandnes@funcom.com Phone: +47 92225540


 

Oceanteam Power & Umbilical ASA announced today that it has signed a contract with Perry Slingsby Systems Ltd, to purchase two Triton XLS 150 HP Heavy Work class ROV systems. The ROVs are a proven design which has a track record of excellent performance utilising state of the art technology to provide a highly competent subsea tool. It is planned that the spreads will be utilised in support of Oceanteam's installation projects onboard the North Ocean Vessels, but they will also be available to the general market when not engaged on those projects. The first vehicle will be delivered in August 2007. This investment represents a further step forward for Oceanteam's commitment to providing a complete solution to flexible product installation and maintenance. The total investment is estimated at GBP 5 million. For further information about Oceanteam, please contact: CEO Haico Halbesma +47 95 80 98 73 haico@oceanteam.no COO Jon Mears +44 77 74 44 22 56 jon.mears@oceanteam.net


 

FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | Tisbury Capital | | | Management LLP | |-------------------------------------------------+-----------------| | Company dealt in | EMI Group Plc | |-------------------------------------------------+-----------------| | Class of relevant security to which the | 14p ordinary | | dealings being disclosed relate (Note 2) | | |-------------------------------------------------+-----------------| | Date of dealing | 25 June 2007 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------+ | | Long | Short | | | | | |---------------------+----------------------+----------------------| | | Number | (%) | Number | (%) | | | | | | | |---------------------+-------------+--------+-------------+--------| | (1) Relevant | | | | | | securities | | | | | | | | | | | |---------------------+-------------+--------+-------------+--------| | (2) Derivatives | | | | | | (other than | 44,208,710 | 5.451 | | | | options) | | | | | | | | | | | |---------------------+-------------+--------+-------------+--------| | (3) Options and | | | | | | agreements to | 69,000,000 | 8.508 | 118,000,000 | 14.550 | | purchase/sell | | | | | | | | | | | |---------------------+-------------+--------+-------------+--------| | Total | 113,208,710 | 13.959 | 118,000,000 | 14.550 | | | | | | | +-------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +-------------------------------------------------------------------+ | Class of relevant security: | Long | Short | | | | | |-------------------------------------+--------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (2) Derivatives (other than | | | | | | options) | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | Total | | | | | | | | | | | +-------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | | | | | | | | |---------------+----------------------+-------------------------| | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short | Number of securities | Price per | | name, | (Note 6) | (Note 7) | unit (Note 5) | | e.g. CFD | | | | |----------+------------+---------------------------+---------------| | CFD | Long | 250,000 | 270.0000 GBp | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ | Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | | name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| | option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | None | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) YES +-------------------------------------------------------------------+ | Date of disclosure | 26/06/2007 | |------------------------------------------------+------------------| | Contact name | Julien Naginski | |------------------------------------------------+------------------| | Telephone number | +44 20 7268 8642 | |------------------------------------------------+------------------| | If a connected EFM, name of offeree/offeror | | | with which connected | | |------------------------------------------------+------------------| | If a connected EFM, state nature of connection | | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk SUPPLEMENTAL FORM 8 DETAILS OF OPEN POSITIONS (This form should be attached to Form 8.1, Form 8.1(b)(ii) or Form 8.3, as appropriate) OPEN POSITIONS (Note 1) +----------------------------------------------------------------------+ |Product |Written or|Number of |Exercise|Type, e.g.|Expiry date| |name, |purchased |securities to |price |American, | | |e.g. call| |which the option |(Note 2)|European | | |option | |or derivative | |etc | | | | |relates | | | | |---------+----------+-----------------+--------+----------+-----------| |Short |Written | 20 000 000 |270 GBp | American |17/08/2007 | |call | | | | | | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Long call|Purchased | 8 000 000|240 GBp | American |28/09/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Long call|Purchased | 15 000 000|240 GBp | American |14/09/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Long call|Purchased | 5 000 000|240 GBp | American |21/09/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Long call|Purchased | 21 000 000|240 GBp | American |21/09/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Short |Purchased | 15 000 000 |250 GBp | American |21/09/2007 | |call | | | | | | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Long call|Purchased | 20 000 000 |250 GBp | American |21/09/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Short |Written | 8 000 000|260 GBp | American |28/09/2007 | |call | | | | | | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Short |Written | 15 000 000|260 GBp | American |14/09/2007 | |call | | | | | | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Short |Written | 30 000 000|260 GBp | American |21/09/2007 | |call | | | | | | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Short |Written | 15 000 000 |280 GBp | American |21/09/2007 | |call | | | | | | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Short |Written | 15 000 000|300 GBp | American |21/09/2007 | |call | | | | | | |option | | | | | | +----------------------------------------------------------------------+ Notes 1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell should also be given on this form. 2. For all prices and other monetary amounts, the currency must be stated. For details of the Code's dealing disclosure requirements, see Rule 8 and its Notes which can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

-- Investments provide boost for clinical development of Enceladus' Nanocort® -- Amsterdam, the Netherlands June 26th 2007 Enceladus Pharmaceuticals and Clinquest Group, both based in Amsterdam, the Netherlands, today announce the signing of an investment and collaboration agreement. Under the terms of the agreement, Clinquest acquires a stake in Enceladus and has led a syndicate of investors to provide additional funding. Financial details are not disclosed. Enceladus will use the new funds for the ongoing clinical development of its proprietary anti-inflammatory drug Nanocort® as a treatment for active Rheumatoid Arthritis. "The participation of Clinquest in our activities allows us to complete the phase IIa clinical proof of concept trial with Nanocort that is currently ongoing in the Netherlands. Therefore this means a major boost to our clinical development track", said Bart Metselaar, founder and CEO of Enceladus. "Furthermore, this collaboration means that we can tap into Clinquest's vast expertise in drug development and start development of Nanocort for other indications. I am particularly pleased that, as part of the deal, Clinquest's CEO Cees Wortel will be joining the Enceladus management team as acting chief medical officer. This way, we can really benefit from his longstanding experience in clinical development." Cees Wortel, CEO of Clinquest Group, commented on the agreement: "We strongly believe in Enceladus' technology position and the promise of Nanocort. By entering in this risk-sharing arrangement, we are able to support the further development of Nanocort and the entire liposomal development platform most efficiently. " About Enceladus Pharmaceuticals Enceladus Pharmaceuticals is a young drug development company originating from Utrecht University, the Netherlands. Enceladus develops Nanocort®, an innovative pharmaceutical that consists of corticosteroids (anti-inflammatory agents) packaged in specifically designed small lipid vesicles. After intravenous injection, the vesicles selectively accumulate in diseased sites in the body, where they release their anti-inflammatory content. As such, Nanocort allows for target-specific corticosteroid therapy, which is expected to result in a higher efficacy and less side effects when compared with systemic corticosteroid treatment. Potential applications of Nanocort are inflammatory disorders such as Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS) and certain types of cancer. Nanocort is currently Enceladus' main product. The company envisions finding inventive combinations of drugs and drug carrier systems, both of which in separate form have been previously evaluated in the clinic. Using this practical approach, Enceladus can effectively design new prototype therapeutics that require relatively straightforward clinical development tracks. The company is based in Amsterdam, the Netherlands. www.enceladus.nl About Clinquest Group The Clinquest Group is a trusted Healthcare Product Development Organization (PDO), which offers comprehensive product development services to the bio-pharmaceutical, medical device, diagnostics and medical data industries worldwide. Clinquest provides high-level strategic consulting as well as hands-on implementation services. Clinquest is recognized as a leader in the development of new, breakthrough technologies, first-in-man clinical trials and complex clinical studies. The Clinquest Group operates through three wholly-owned subsidiaries: Clinquest Inc., Clinquest Europe and Clinquest Pharmaceutical Innovations. The company is headquartered in Amsterdam, the Netherlands, and has offices in the USA and Singapore. www.clinquest.com ========================================================== Contact: Enceladus Pharmaceuticals B.V. Bart Metselaar, CEO T: +31 (0)626 946 014 E: info@enceladus.nl Kruislaan 406 1098 SM Amsterdam The Netherlands


 

Wärtsilä Corporation Press Release 26 June 2007 A number of recent orders and ongoing projects has consolidated Wärtsilä's dominance of the Italian market for power generation from liquid biofuels (LBF). Orders received in the first five months of 2007 alone totalled close to 280 MW, of which 172 MW were received in the first 3 months. Wärtsilä currently has about 620 MW of LBF power plants either in operation, under construction or on order in Italy - the most recent orders being a 52 MW plant for CEG in April this year and an 8 MW plant for Ricciarelli in Molfetta in May. Both projects will be commissioned in spring 2008. "Power generation from LBF is becoming a significant market for us. We are expecting to receive significant orders during this and next year," says Christoph Vitzthum, Group Vice President, Wärtsilä Power Plants, "We also believe that some other countries in Europe will follow. There are 'green licences or subsidies' issued to a number of companies in the Netherlands and Belgium. We are working on several projects and a few of them are at an advanced stage," Christoph Vitzthum continues. Projects received during the last few years The most recent orders follow a string of contracts in Italy dating back to 2004 when two Wärtsilä 32 generating sets were delivered to ItalGreen Energy's combined heat and power (CHP) plant in Monopoli, with a third engine going on line in 2005, increasing the baseload power output to 24 MW. In May 2006, following the success of the installation at Monopoli, ItalGreen Energy, the energy company of the Casa Olearia Italiana Group, ordered a 100 MW plant. When fully commissioned later this year, ItalGreen II will be the largest LBF power plant in the world. Other contracts concluded in 2006 included a 75 MW LBF power plant for an independent power producer, Fri-El Acerra Srl and a 50 MW plant in Conselice for the food processing company Unigrà. Both of these projects are scheduled to come on line this year. Under Italian law, all power producers and importers are required to supply around 3 percent of their power to the grid from renewable sources or they must buy green certificates to make up the shortfall. For further information please contact Ms Eeva Kainulainen, VP Corporate Communications, tel. +358 40 568 0591. Related material: Liquid Biofuel Power Plants Article about Fuels Wärtsilä in brief: Wärtsilä enhances the business of its customers by providing them with complete lifecycle power solutions. When creating better and environmentally compatible technologies, Wärtsilä focuses on the marine and energy markets with products and solutions as well as services. Through innovative products and services, Wärtsilä sets out to be the most valued business partner of all its customers. This is achieved by the dedication of more than 14,000 professionals manning 130 Wärtsilä locations in close to 70 countries around the world. www.wartsila.com


 

Component Software Group (CSG) has changed the day for the release of its financial figures for 2nd quarter 2007 from Wednesday 23 August 2007 to Friday 31 August 2007. The reason for the change of date is related to the CSG stock exchange releases from Monday 11 June and Tuesday 19 June where an announced bid from Affecto Plc had been pre-accepted by Component Software Group shareholders owning above 67%. Investor relations: CEO Åge Lønning tel. +47 40 20 10 00, a.lonning@componentsoftware.no


 

Hafslund ASA has issued a second tranche in the10 year bond with fixed interest: ISIN NO 001 0373194 - 6.00 % Hafslund ASA open bond 2007/2017. The second tranche of the issue amounts to NOK 100 million. The outstanding amount in the loan after this issue will be NOK 600 million. Payment date is 25 July 2007. Arranger: DnB NOR Markets The proceeds will be used for general refinancing. Hafslund ASA Oslo, 26 June 2007. For further information, please contact: Group Treasurer Ketil Wang, tel + 47 975 13 135


 

26 June 2007 - Northumbrian Water Ltd (NWL) has awarded Aker Kvaerner a GBP 28 million contract to design, construct, install and commission a facility to extend the treatment capabilities of the existing regional sludge treatment centre (RSTC) at Bran Sands on Teesside, in the UK. All engineering work including civil design will be carried out by Aker Kvaerner's Engineering Services' business in Stockton-on-Tees. Scope of services also includes supply of specialist advanced digestion thermal hydrolysis equipment and performance testing after commissioning. Following a strategic review of its sludge strategy, including Bran Sands, which is one of Northumbrian Water's largest sites, the company concluded that current processes are maintenance and energy intensive. The new project is therefore seeking to minimise whole life plant costs, whilst producing an enhanced, treated product suitable for disposal to agriculture. Donna Rawlinson, Project Manager for Northumbrian Water Ltd. commented, "Aker Kvaerner already delivers projects at the site as part of the five-year capital maintenance framework that was awarded in 2005. This new project will require extensive integration with the existing assets, so Aker Kvaerner's project execution capability was a deciding factor in this contract award." Dave Ley, President of Aker Kvaerner Engineering Services, added, "Aker Kvaerner is proud to have won this important contract with Northumbrian Water Ltd. and, to have the opportunity to build upon the successful framework we have already established. We have key specialists within the water sector and specific project experience with Northumbrian Water to draw upon to help further improve the environmental performance of the facility." Engineering will start immediately with a project completion date set for June 2009. Plant start up is expected in December 2008. Northumbrian Water opted for advanced digestion using the thermal hydrolysis process to deliver an enhanced treated product and operational cost savings. This will generate energy for the site and also offer best solids destruction capability. Aker Kvaerner concluded that Cambi THP provided the most appropriate solution. The scope is for a 40,000 Total Dry Solids (TDS)/annum advanced digestion thermal hydrolysis plant and associated ancillary systems including Combined Heat and Power (CHP) and extensive cake handling equipment. ENDS For further information, please contact: Media: Torbjørn S. Andersen, SVP Group Communications, Aker Kvaerner. Tel: +47 67 51 30 36, Mob: +47 928 85 542 Vanessa Mourant, Communications Manager, Aker Kvaerner, UK. Tel: +44 (0) 207 339 1064 Mob: +44 (0)7771 806566 Sarah Weyell, Aker Kvaerner, UK. Tel: +44 (0)1642 343217 Investor relations: Lasse Torkildsen, VP Investor Relations, Aker Kvaerner. Tel: +47 67 51 30 39 Suppliers: For further information about sourcing and potential subcontracts for this project, please contact Jeff Clark, Manager of Supply Management, on Tel: +44 (0)1642 331714 Career opportunities: www.akerkvaerner.com/careers AKER KVÆRNER ASA, through its subsidiaries and affiliates ("Aker Kvaerner"), is a leading global provider of engineering and construction services, technology products and integrated solutions. The business within Aker Kvaerner comprises several industries, including Oil & Gas, Refining & Chemicals, Mining & Metals and Power Generation. The Aker Kvaerner group is organised in a number of separate legal entities. Aker Kvaerner is used as the common brand/trademark for most of these entities. The parent company in the group is Aker Kværner ASA. Aker Kvaerner has aggregated annual revenues of approximately NOK 50 billion and employs approximately 23 000 people in about 30 countries. Aker Kvaerner is part of Aker (www.akerasa.com), a group of premier companies with a focus on energy, maritime and marine-resources industries. The Aker companies share a common set of values and long traditions of industrial innovation. As an industrial owner with a 40.1 per cent holding in Aker Kvaerner, Aker ASA takes an active role in the development of its holdings. Aker Kvaerner's Process and Construction business area is a world leader in the project management, design and construction of major projects spanning refining, petrochemical processing, metals and mining, power generation, and acid plants. From initial concept through technology development, process technology application, design, procurement, construction, operations, maintenance, modification and decommissioning, we provide our customers with the full life cycle of services. Process and Construction provides sound local expertise, combined with the depth and strength of global project operations. Aker Kvaerner Engineering Services is the trading name of Aker Kvaerner Engineering Services Ltd., the legal entity responsible for the execution of the contract. Aker Kvaerner Engineering Services is part of the Process & Construction business area and is one of the core businesses of the Aker Kvaerner group in Europe. It is a leading provider of both turnkey and reimbursable engineering solutions and life cycle services to the nuclear, water, metals, energy and process industries in the UK and worldwide. This press release may include forward-looking information or statements and is subject to our disclaimer, see our web-pages www.akerkvaerner.com


 
Hitt og þetta
26. júní 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |-------------------------------------------------+-----------------| | Company dealt in | Homeserve Plc | |-------------------------------------------------+-----------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |-------------------------------------------------+-----------------| | Date of dealing | 25th June 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price | | securities | (Note 3) | paid | | purchased | | (Note 3) | |---------------------------+--------------------+------------------| | 1,540 | 1,840.15p | 1,838p | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |------------------------+---------------------+--------------------| | 1,960 | 1,843.80p | 1,838p | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +-------------------------------------------------------------------+ | Date of disclosure | 26th June 2007 | |---------------------------------------+---------------------------| | Contact name | Edward Hodge | |---------------------------------------+---------------------------| | Telephone number | 0207 991 6661 | |---------------------------------------+---------------------------| | Name of offeree/offeror with which | Domestic & General Group | | connected | Plc | |---------------------------------------+---------------------------| | Nature of connection (Note 6) | Connected Advisor | +-------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 
Hitt og þetta
26. júní 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |--------------------------------------------+----------------------| | Company dealt in | C.I. Traders Limited | |--------------------------------------------+----------------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |--------------------------------------------+----------------------| | Date of dealing | 25th June 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price | | securities | (Note 3) | paid | | purchased | | (Note 3) | |---------------------------+--------------------+------------------| | 2 | 92p | 92p | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |-------------------------+--------------------+--------------------| | 0 | | | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +-------------------------------------------------------------------+ | Date of disclosure | 26th June 2007 | |--------------------------------------------+----------------------| | Contact name | Edward Hodge | |--------------------------------------------+----------------------| | Telephone number | 0207 991 6661 | |--------------------------------------------+----------------------| | Name of offeree/offeror with which | C.I. Traders Limited | | connected | | |--------------------------------------------+----------------------| | Nature of connection (Note 6) | Connected Advisor | +-------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

Two Veidekke companies, Veidekke Entreprenør AS and Br. Reme AS, have been commissioned to build the new factory buildings for Elkem Solar's investment in silicon products for the solar cell industry. The main contract has a value of approximately NOK 335 million. This contract will be administered by American industrial consultancy company Fluor, which is acting as Elkem Solar AS' agent during the construction phase. The contract covers the construction of three new factory buildings with a total floor area of 20,000 m2 and renovation of the existing buildings. The new buildings will be built of concrete with load-bearing structures of steel. Preparation of the outdoor areas is also included in the contract. The work, which will be carried out jointly by Veidekke Entreprenør AS (75 per cent) and Br. Reme AS (25 per cent), has already started. A contract has also been signed with Elkem Solar AS for excavation and concrete work for a building administered by Hydro Production Partner. This contract has a value of approximately NOK 15 million and the work is due for completion by 31 October 2007. For further information, please contact: Project Manager Kristian Senland, Veidekke Entreprenør AS tel. +47 21055000, mobile + 47 91128356 Managing Director Helge Reme, Br. Reme AS tel. +47 38125800, mobile +47 90928875 VEIDEKKE ASA Veidekke ASA is a leading Scandinavian building contractor and property developer with 6,350 employees and an annual turnover of NOK 16.4 billion (2006). Veidekke is listed on the Oslo Stock Exchange. It has a wide group of shareholders and 14% of the shares are held by the company's employees. The company's activities cover a large range of building and construction contracts, development of housing and commercial projects for private and public customers, asphalt operations and road maintenance, and collection and recycling of waste. Veidekke ASA, Information Dept., P.O. Box 505 Skøyen, N-0214 Oslo, phone +47 21 05 50 00 E-mail: firmapost@veidekke.no - Internet: http://www.veidekke.no Financial information is also accessible at http://www.huginonline.com/Norway/VEI/


 

FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | AXA Investment Managers UK | | | Limited/AXA Framlington | | | Investment Management Limited | |-----------------------------------+-------------------------------| | Company dealt in | Reuters Group Plc | |-----------------------------------+-------------------------------| | Class of relevant security to | Ordinary shares | | which the dealings being | | | disclosed relate (Note 2) | | |-----------------------------------+-------------------------------| | Date of dealing | 25/06/07 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------------------------------+ | | Long | Short | | | | | |---------------+--------------------------+------------------------------------------------| | |Number |Number | | | (%) | (%) | |---------------+--------------------------+------------------------------------------------| |(1) Relevant |13,243,423 (1.05%) | | |securities | | | | | | | |---------------+--------------------------+------------------------------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+--------------------------+------------------------------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+--------------------------+------------------------------------------------| |Total |13,243,423 (1.05%) | | | | | | +-------------------------------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +--------------------------------------------------------------------------+ |Class of | Long | Short | |relevant | | | |security: | | | | | | | |---------------+----------------------------+-----------------------------| | |Number |Number | | | (%) | (%) | |---------------+----------------------------+-----------------------------| |(1) Relevant | | | |securities | | | | | | | |---------------+----------------------------+-----------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+----------------------------+-----------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+----------------------------+-----------------------------| |Total | | | | | | | +--------------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | Sell | 34,925 | 6.24p | | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short (Note | Number of securities | Price per | | name, | 6) | (Note 7) | unit (Note | | e.g. CFD | | | 5) | |----------+------------------+------------------------+------------| | | | | | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 26/06/2007 | |---------------------------------------------------+---------------| | Contact name | Maria Mauro | |---------------------------------------------------+---------------| | Telephone number | 0207 003 2812 | |---------------------------------------------------+---------------| | If a connected EFM, name of offeree/offeror with | N/A | | which connected | | |---------------------------------------------------+---------------| | If a connected EFM, state nature of connection | N/A | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

The Nordic region's leading window and door manufacturer Inwido has concluded an agreement to acquire 100% of the shares in A-gruppen. In 2006/2007, A-gruppen's sales totalled SEK 160 million with an operating profit (EBITA) of SEK 12 million. A-gruppen originated in a company that was formed in 1962 and has had a growth rate of approximately 30% over the past ten years with good profitability. The company's operations comprise painting and processing of aluminium extrusions and it is one of the largest players in northern Europe within this field. The company has three production plants in Sweden and one in Poland. Denmark and Sweden account for approximately 90% of sales. "A-gruppen has shown fantastic development in recent years and is a good strategic acquisition for Inwido within surface treatment of aluminium. We have noted an increased demand for maintenance-free products such as aluminium window frames," says Inwido's CEO Sven-Gunnar Schough commenting on today's acquisition. Ratos, which owns 95% of Inwido, will not provide any capital in conjunction with today's acquisition. For further information, please contact: Leif Johansson, Investment Director Ratos, +46 8 700 17 00 Sven-Gunnar Schough, CEO Inwido, +46 706 02 34 78 Clara Bolinder-Lundberg, Head of Corporate Communications Ratos, +46 8 700 17 63 Financial calendar from Ratos: Interim report January-June 21 August 2007 Interim report January-September 9 November 2007 Year-end report 2007 22 February 2008 AGM 2008 9 April 2008 Ratos is a listed private equity company. The business concept is to maximise shareholder value over time by investing in, developing and divesting primarily unlisted companies. Ratos thus offers stock market players a unique investment opportunity. The equity of Ratos's investments is approximately SEK 11 billion. Ratos's holdings include Anticimex, Arcus Gruppen, Bisnode, Bluegarden, Camfil, DIAB, GS-Hydro, Haendig, Haglöfs, HL Display, HÅG/RH/RBM, Hägglunds Drives, Inwido, Jøtul, Lindab, MCC, Medifiq Healthcare, Superfos and Other holdings.


 

26 June 2007 - Aker Kvaerner has been selected by BP, Associated British Foods Plc (ABF) and DuPont to execute the Front End Engineering and Design (FEED) for a planned new world-scale bioethanol plant in the UK. Aker Kvaerner's joint venture partner Praj Industries (Praj) from India will provide the technology and process package. BP and ABF subsidiary British Sugar Plc will each own 45 percent of the new grass roots facility planned for BP's Saltend site, near Hull, with DuPont owning the remaining 10 percent. The world-scale wheat to ethanol plant will produce some 420 million litres of fuel ethanol a year. The contract value to Aker Kvaerner is not disclosed. "BP is already a leading and very committed player in the biofuels market, and we see this new facility as a very important milestone as we move towards the 2010 Renewable Fuel Obligation," says Phil New, Head of BP Biofuels. "Aker Kvaerner's engineering capability combined with the technology expertise of Praj offers an integrated and customised solution to our requirements." "This is a very exciting project to be involved with. It represents a significant development in the UK's progress in renewable fuels, and brings together specialists who are at the forefront of the biofuels industry," adds Ronald van der Vlist, SVP Aker Kvaerner-Praj Biofuels (Managing Director of BioCnergy). "A commitment to delivering environmentally-sound solutions is a long-term priority for Aker Kvaerner, and biofuels is therefore a core business for the company." Using bioethanol technology provided by Praj Industries, the grass roots plant will seek to utilise locally grown wheat as feedstock to produce the fuel ethanol. The award of this project underlines the co-operation between Aker Kvaerner and Praj, which was recently reinforced by the formation of the BioCnergy Joint Venture (JV) - announced 12 June 2007. "This is indeed a very good start for the Aker Kvaerner and Praj JV in Europe and this is a very distinguished opportunity for Praj to supply technology to one of the largest plants to be set up in the UK," said Pramod Chaudhari, Chairman Praj Industries. "The Aker Kvaerner and Praj JV will ensure better value to customer's setting up biofuel projects, as we will work in absolute cohesion, end-to-end. And the award of this contract demonstrates that project developers and sponsors have recognized our strength." Work on this preparatory phase of the project begins immediately and should be completed by the end of 2007. Subject to the necessary regulatory approvals, construction on the plant would commence next year, with commissioning and start-up scheduled for late 2009. The award of the FEED scope follows the successful completion of the feasibility study for this complex, which was completed by Aker Kvaerner and Praj in December 2006. Aker Kvaerner has been a long term engineering partner for BP at the Hull site - the largest producer of acetic acid in Europe - and has executed a range of EPC projects at this site and also at other BP sites worldwide. Aker Kvaerner is also a long-standing engineering partner for DuPont globally. Praj is currently providing the process license to the British Sugar Wissington bioethanol plant in the UK. Biofuels help to reduce overall emissions of greenhouse gases and are a sustainable alternative to fossil fuels. Bioethanol can be blended in various proportions in petrol. Using bioethanol can reduce overall carbon dioxide emissions compared to a traditional petrol-only engine. ENDS For further information, please contact: Media: Vinati Moghe, Praj Industries Limited. Tel: (020) 22952214 / 22951718, Fax: (020) 22951718 / 22951515, Mobile: 9822430906 Email: vinatimoghe@praj.net Urvashi Kada/Anu Soman, Genesis. Tel: (020) 24335460/90 Ext. 234, Mobile: 9923590387/ 982309881/ 9850837393, Email: urvashi.kadam@bm.com or anu.soman@bm.com Torbjørn S. Andersen, SVP Group Communications, Aker Kvaerner. Tel: +47 67 51 30 36, Mobile: +47 928 85 542 Ronald van der Vlist, BioCnergy, Zoetermeer, Tel: +31 (0)79 368 8402 Vanessa Mourant, Communications Manager, Aker Kvaerner, Mobile: +44 (0)7771 806566 Investor relations: Lasse Torkildsen, VP Investor Relations, Aker Kvaerner. Tel: +47 67 51 30 39 Career opportunities: Visit http://www.akerkvaerner.com/Internet/CareerCentre AKER KVÆRNER ASA, through its subsidiaries and affiliates ("Aker Kvaerner"), is a leading global provider of engineering and construction services, technology products and integrated solutions. The business within Aker Kvaerner comprises several industries, including Oil & Gas, Refining & Chemicals, Mining & Metals and Power Generation. The Aker Kvaerner group is organised in a number of separate legal entities. Aker Kvaerner is used as the common brand/trademark for most of these entities. The parent company in the group is Aker Kværner ASA. Aker Kvaerner has aggregated annual revenues of approximately NOK 50 billion and employs approximately 23 000 people in about 30 countries. Aker Kvaerner is part of Aker (www.akerasa.com), a group of premier companies with a focus on energy, maritime and marine-resources industries. The Aker companies share a common set of values and long traditions of industrial innovation. As an industrial owner with a 40.1 per cent holding in Aker Kvaerner, Aker ASA takes an active role in the development of its holdings. Aker Kvaerner's Process and Construction business area is a world leader in the project management, design and construction of major projects spanning refining, petrochemical processing, metals and mining, power generation, and acid plants. From initial concept through technology development, process technology application, design, procurement, construction, commissioning, operations, maintenance, modification and decommissioning, we provide our customers with the full life cycle of services. Process and Construction provides sound local expertise, combined with the depth and strength of global project operations. AK Process is a trading name of Aker Kvaerner Projects Ltd., the legal entity responsible for the execution of the work. AK Process is one of the core businesses of the Aker Kvaerner group in Europe. AK Process serves the onshore oil & gas, petrochemical and biofuels industries. We provide our customers with services covering the entire value chain of a project, from technology development and selection through to engineering, project management, procurement, construction, and complete life cycle support. Our extensive capabilities are offered through a variety of commercial arrangements from reimbursable services to lump-sum turnkey supply. Also offered are consultancy services in reliability, business modelling and environmental, health, safety and risk management. Praj Industries Ltd is a global Indian company that offers innovative solutions to significantly add value in alcohol and brewery technology and related wastewater treatment systems for customers in India and around the world. Praj is a Knowledge-based company with expertise and experience in bio-processes and engineering. It delivers know how, license, engineering design, plant & equipment, project management, commissioning and customer care and turnkey projects. Led by an accomplished and caring leadership, Praj is a socially responsible corporate citizen. www.praj.net BioCnergy Europa B.V. is an Aker Kvaerner - Praj company. Praj holds 60 percent in BioCnergy, while Aker Kvaerner holds 40 percent of the shareholding. BioCnergy offers European customers access to customised solutions for their biofuels projects - providing the technology package, engineering services, equipment and systems, project management services, construction and erection services, and commissioning, as well as turnkey biofuel plant. BP is of one of the world's largest energy companies, providing its customers with fuel for transportation, energy for heat and light, retail services and petrochemicals products for everyday items. It is the largest oil and gas producer in the U.S. and one of the largest refiners. BP has a global network of around 25,000 service stations, 1,300 of which are in the UK. British Sugar Plc is the UK's leading supplier of sugar products to the food manufacturing and consumer markets. Recognised as the most efficient sugar producer in Europe, the company has considerable expertise in asset utilization, energy efficiency and process technology. With operations in Poland and China, British Sugar has considerable experience in operating in developing countries and in joint venture operations. DuPont is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in more than 70 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation. This press release may include forward-looking information or statements and is subject to our disclaimer, see our web-pages www.akerkvaerner.com


 

Aspocomp Group Oyj Investor news June 26, 2007 at 11:50 am The Executive Committee of Aspocomp Group Oyj has been renewed to expedite the Group's transformation into a more efficient global organization with the primary focus of operations in Asia. Consequently, all customer-related functions have been centralized under sales and marketing. The new Executive Committee of Aspocomp: - Maija-Liisa Friman, President and CEO - Harry Gilchrist, Chief Operating Officer. In addition to the business units, he is responsible for the Group's information technology, sourcing and technical services as well as human resource administration and development. - Rami Raulas, Senior Vice President, Sales and Marketing, including technical and commercial customer service functions. He is also responsible for the Group's research and development. - Tapio Engström, Chief Financial Officer - Maire Laitinen, Group General Counsel For further information, please contact Maija-Liisa Friman, CEO, tel. +358 9 7597 0711. ASPOCOMP GROUP OYJ Maija-Liisa Friman President and CEO Aspocomp: Innovative interconnection solutions for the electronics industry The Aspocomp Group develops and offers high technology interconnection solutions for the electronics industry in close cooperation with its customers. Aspocomp supplies printed circuit boards for mobile data terminal equipments, data communications networks and automotive industry. The company supports its global customers in developing new technologies and offers a fast route from product development to applications and volume production. The Group's production facilities are located in Finland, China and Thailand. In 2006, its net sales stood at EUR 149 million and it had about 3,350 employees. Distribution: The Nordic Exchange Major media www.aspocomp.com


 

European telecom leaders envision significant challenges ahead, but are confident about the future * Customer behavior will increase traffic volume dramatically, driving the need for substantial network investments * Most conference participants expect internet players to play a prominent or even "disruptive" role in shaping the future of the industry * Private equities and other active investors are expected to play a key role in driving the future of the sector Madrid - 19 June 2007 - Changes in customer behavior strongly influenced by the younger generations are configuring a new landscape in the telecommunications world, challenging the comfort zones for all players involved: telco operators, internet players, media companies and equipment providers. This was one of the recurring messages at a by-invitation-only conference of senior telecoms industry executives hosted by strategy consultants A.T. Kearney in Madrid. For Martin Sonnenschein, Head of A.T. Kearney's European Communications and High Tech Practice, "the telecommunications industry continues to be attractive, with EBIT margins of 18% versus the 13% average for all sectors." "The global telco market is expected to grow 5% annually between 2006 and 2010, chiefly driven by mobile," Mr. Sonnenschein continued. Mr. Antonio Viana-Baptista, General Manager of Telefónica España, sees "four elements that are challenging the basics of the business: consumer behavior, technology, competition and regulation". In Mr. Viana-Baptista's opinion, "changes in consumer patterns are even stronger in the younger generations, that is, those below 30; teenagers are doing things that we don't know and that will shape the future of our sector." Several speakers agreed that the new usage patters are increasing the volume of traffic and loading the networks and will continue to do so dramatically in the next few years, therefore determining the need to heavily invest in fiber development. "We expect the total communication traffic in Spain to multiply by 20 between 2005 and 2009," stated Mr. Viana-Baptista. He cautioned, however, that fiber deployment in Europe is lagging behind the United States, potentially posing a threat to the productivity of European companies. Mr. Louis-Pierre Wenes, Senior Executive Vice President of Group Transformation and French Operations at France Télécom, also sees a new industry landscape being developed. "We are facing a new telco ecosystem formed by equipment and infrastructure providers, telco operators, internet players and content providers," he says. In Mr. Wenes's view, telco operators can legitimately aspire to a more prominent role in this new ecosystem, drawing on their deep knowledge and direct relationship with their broad customer base - for example, by better targeting advertisements based on customer profiling. Failing to do so, he said, could make network operators vulnerable to becoming mere utilities. For Eduardo Montes, President of Siemens Enterprise Communications GmbH, as well as Management Board Member and Senior Vice President of Siemens AG, new players such as Apple, Microsoft and HP are entering the vendors' field and reshaping it. "We need to expect the unexpected. Technology is no longer a limitation, so now the real challenge is to detect customers' needs rather than to look for killer applications we can 'push' to them as in the old days," he stated. Santiago Moreno, Director of Institutional Relations at Vodafone Spain, and Miguel Martins, President of Portuguese broadband operator AR Telecom, concur that customers simply want their communication needs to be met and are not concerned about what technologies operators use (e.g., fixed vs. mobile, DSL vs. cable) to do so, as long as they are competitive in terms of price and quality of service. An informal poll of the conference participants, comprising top executives from European operators, vendors, media and internet companies, showed that over 90% expect convergent offers to account for more than one-fifth of European market revenues in 2010, although less than half (42%) think that more integrated operators enjoy a substantial, sustainable advantage. Asked about the role the "new kids on the block" will play in shaping the future landscape of the industry, over 60% expect internet players (similar to Google or Microsoft) to have a substantial role, while 50% believe new device providers (similar to Apple or Nintendo) will play such a role. Thomas Kratzert, head of A.T. Kearney's telecommunications practice in the Nordic unit remarked: "We've been talking about convergence for several years now. Convergence is already here and it will continue to evolve. What traditional telco operators need to do is to rethink their business models so that they can continue to be at the center of the stage and avoid becoming a mere 'bit pipe.' Development of new innovative relationship models involving players from adjacent sectors - like media, internet, vendor providers - is becoming imperative." Among those surveyed, 82% expect active investors such as private equity firms to play an increased role over the next three years, a circumstance that 66% believe to be positive or, at least, neutral. Finally, in the conference poll, over half the respondents - 54% - unofficially predict that their own companies will enjoy annual growth rates in cash flow of greater than 5% over the next five years. Should these predictions prove to be true, they would meet exactly what the equity markets are looking for at present. According to Jake Donovan, Head of Telecom EMEA for JP Morgan, the markets are currently placing greater emphasis on growth as opposed to yield, although they are now at what he calls an "event phase," as expectant markets await mergers & acquisitions, breakups, etc. In his view, if a company's share price is performing well in the absence of growth, it may well be because markets consider it to be a takeover target. Another important topic of the conference was approached in the "search for integration synergies" panel. Mr. Georg Polzl, Chief Transformation Officer of Deutsche Telekom, set the tone of the discussion by mentioning that "we need to be careful not to abuse the word 'synergy.'" Along the same lines, Joaquín Coronado - Chief Operating Officer of Spanish cable and broadband operator ONO - and Peter Foyo - President of Nextel de México's - agreed that synergies are about setting clear targets and aligning the organization to achieve them. Mr. Carlos Calvo, Chief Operating Officer of Telefónica España, emphasized the importance of leadership to carry out organizational transformations and overcome internal resistance, adding that "we not only have to seek cost synergies, but also revenue synergies." In that quest, Mr. Calvo said: "Resistance to achieving synergy targets is overcome with lots of communication and, above all, lots of leadership." "All in all, reinvention of the business is not planned; instead, players will try to change the wheel while driving the car" concluded Mr. Sonnenschein of A.T. Kearney. # Ends # For further information, please contact: Thomas Kratzert Partner, Head Nordic Unit A.T. Kearney AB Biblioteksgatan 11 Box 1751 S-111 87 Stockholm +46 8 679 39 00 +46 70 896 6918 +46 8 678 18 80 Fax Note on A.T. Kearney A.T. Kearney is an innovative, corporate-focused strategy consulting firm known for high quality tangible results and its working-partner style. The firm was established in 1926 to provide management consulting advice concerning issues on the CEO's agenda. Today, we serve the largest global clients in all major industries. A.T. Kearney's offices are located in 48 cities in 32 countries in Europe, Asia Pacific and the Americas.


 

First Olsen Ltd ("FOL"), the majority shareholder in Fred. Olsen Production ("FOP") and a company owned 50% by Bonheur ASA and 50% by Ganger Rolf ASA, has acquired 5.116.600 shares in FOP at an average purchase price of NOK 26 per share. Following the transaction FOL owns 65.191.200 shares in FOP, constituting 61.5 % of the shares and votes. FOL's managing director Per-Oscar Lund is the chairman of the board of FOP and Anette S. Olsen, board member of FOP, is the chairman of FOL and managing director and board member of Ganger Rolf ASA and Bonheur ASA. Contact person: Per-Oscar Lund, Managing Director First Olsen Ltd., phone +47 22 34 11 81 / +47 90 78 02 54


 

Kaupthing Bank hf. has issued subordinated bonds in the amount of EUR 250 million classified as Tier 1 capital according to regulation no. 156/2005 on additional own funds items for financial undertakings. These are perpetual bonds carrying a fixed coupon of 6.75 per cent and are callable by Kaupthing Bank five years after the date of issue provided that the conditions of the above mentioned rules are met. The bonds were sold to 66 investors, mostly European. The bookrunners were Citigroup, Credit Suisse, Deutsche Bank and HSBC. For further information please contact: Gudni Adalsteinsson, Global Treasurer, at +354 444 6126 Jónas Sigurgeirsson, Chief Communication Officer, at + 354 444 6112.


 

ANNOUNCEMENT DATED 25 JUNE 2007 Bear Stearns Global Asset Holdings, Ltd. Issue of up to SEK500,000,000 Notes linked to the PACER Index (the "Notes") (Offer price 110%) ISIN Code: SE0001994419 under the U.S.$30,000,000,000 Euro Medium Term Note Programme NOTICE OF ISSUE AMOUNT The offer period for the Notes (described above) ended at 5:00pm (Central European Time) on 8 June 2007. Pursuant to the Prospectus for the issue of the Notes dated 19 April 2007, the Aggregate Nominal Amount of the Notes to be issued on 27 June 2007 will be SEK146,580,000. Enquiries: Transaction Management Group Bear, Stearns International Limited One Canada Square London E14 5AD Tel: +44 20 7516 6817 Fax: +44 20 7516 5001 ---END OF MESSAGE---


 

OUTOKUMPU OYJ PRESS RELEASE JUNE 26, 2007 AT 9.45 A.M. Outokumpu and Belvedere Resources Ltd. of Canada have finalized the transaction, whereby Outokumpu sold the Hitura nickel mine in Finland to Belvedere. The total consideration, currently valued at some EUR 25 million, is in Belvedere shares and warrants entitling to subscribe for additional Belvedere shares, resulting in a maximum 19.2% ownership in Belvedere, on a fully-diluted basis. Outokumpu has agreed to a 4 to 8 months lock-up with respect to a sale of the shares. Outokumpu will recognise a non-recurring gain of some EUR 24 million, which will be entered above operating profit in the second quarter results. The shareholding in Belvedere will be classified as an available-for-sale financial asset with changes in fair value recognized directly in equity and the warrants as derivative instruments with changes in fair value recognized in financial income and expenses. The Hitura mine was the last remaining asset in Outokumpu's Exit Mining program that started in 1999. Hitura produces some 2 200 tons of nickel in concentrate annually and has 90 employees. In addition to the transaction with Outokumpu, Belvedere has acquired full ownership in Suomen Nikkeli Oy, of which it previously owned 45%. With the Hitura assets combined with the nickel exploration targets of Suomen Nikkeli, Belvedere is targeting significant nickel mining in Finland. The Kemi chromite mine is an essential part of Outokumpu's integrated stainless steel production chain in Tornio, Finland, and will continue to be part of the Group. For further information, please contact: Tuomo Mäkelä, President - Outokumpu Mining Oy, tel. +358 9 421 2217, mobile +358 40 540 0620 Eero Mustala, SVP - Corporate Communications, Outokumpu Group, tel. +358 9 421 2435, mobile +359 40 504 5146


 

Martinsried/Munich (Germany) and Princeton, N.J., June 26, 2007 - GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ: GPCB) today announced that its partner, Pharmion Corporation (NASDAQ: PHRM), has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for satraplatin in combination with prednisone for the treatment of patients with metastatic hormone refractory prostate cancer (HRPC) who have failed prior chemotherapy. This filing is based primarily on data from the SPARC Phase 3 registrational trial. "We are delighted that Pharmion has submitted the European marketing application for satraplatin," said Bernd R. Seizinger, M.D., Ph.D., Chief Executive Officer. "With over 60,000 people expected to die from prostate cancer in the European Union this year, there is an urgent need for new therapies. We believe that, if approved, satraplatin has the potential to become an important new treatment option for advanced prostate cancer patients who today have very little hope." GPC Biotech will receive an $8 million milestone payment from Pharmion in connection with the EMEA's acceptance of this filing. Under the terms of GPC Biotech's agreement with Spectrum Pharmaceuticals, the acceptance of the MAA by the EMEA will also trigger payments by GPC Biotech to Spectrum in a total amount of $3.2 million, representing a direct milestone payment plus Spectrum's share of the $8 million milestone payment from Pharmion. About Satraplatin Satraplatin, an investigational drug, is a member of the platinum family of compounds. Platinum-based drugs are a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. All platinum drugs currently on the market require intravenous administration. Satraplatin is an oral compound that clinical trial patients are able to take at home. Satraplatin is not currently approved by the FDA in the United States, by the EMEA in the European Union or any other regulatory authority and no conclusions can or should be drawn regarding its safety and efficacy. A Phase 3 registrational trial, called SPARC, is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer whose prior chemotherapy has failed. Data from the trial on progression-free survival and on safety have been presented at recent medical conferences. Satraplatin is currently under review by the U.S. FDA for hormone-refractory prostate cancer patients whose prior chemotherapy has failed. GPC Biotech has a co-development and license agreement with Pharmion GmbH, a wholly owned subsidiary of Pharmion Corporation, under which Pharmion has been granted exclusive commercialization rights to satraplatin for Europe and certain other territories. GPC Biotech in-licensed satraplatin from Spectrum Pharmaceuticals, Inc. in 2002. Satraplatin has been studied in clinical trials involving a range of tumors. Trials evaluating the effects of satraplatin in combination with radiation therapy, in combination with other cancer therapies and in a number of cancer types are underway or planned. About GPC Biotech GPC Biotech AG is a publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs. GPC Biotech's lead product candidate satraplatin is currently under review by the U.S. FDA for hormone-refractory prostate cancer patients whose prior chemotherapy has failed. GPC Biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany), and has a wholly owned U.S. subsidiary headquartered in Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at www.gpc-biotech.com. This press release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech AG, including statements relating to results of the SPARC trial and statements relating to the potential efficacy and safety profile of satraplatin. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. In particular, there can be no guarantee that additional information relating to the safety, efficacy or tolerability of satraplatin may be discovered upon further analysis of data from the SPARC trial or analysis of additional data from other ongoing clinical trials for satraplatin. Furthermore, we cannot guarantee that satraplatin will be approved for marketing in a timely manner, if at all, by regulatory authorities nor that, if marketed, satraplatin will be a successful commercial product. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2006 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of GPC Biotech. Forward-looking statements speak only as of the date on which they are made and GPC Biotech undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. For further information, please contact: GPC Biotech AG Martin Braendle Director, Investor Relations & Corporate Communications Phone: +49 (0)89 8565-2693 ir@gpc-biotech.com In the U.S.: Laurie Doyle Director, Investor Relations & Corporate Communications Phone: +1 609 524 5884 usinvestors@gpc-biotech.com Additional Media Contacts: In Europe: Maitland Brian Hudspith Phone: +44 (0)20 7379 5151 bhudspith@maitland.co.uk In the U.S.: Russo Partners, LLC David Schull Phone: +1 212 845 4271 david.schull@russopartnersllc.com --- End of Message --- GPC Biotech AG Fraunhoferstr. 20 Martinsried WKN: 585150; ISIN: DE0005851505; Index: CDAX, MIDCAP, Prime All Share, TecDAX, HDAX, TECH All Share; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Geregelter Markt in Frankfurter Wertpapierbörse;


 

(Asslar, June 26, 2007) - PVA TePla AG, Asslar, the established manufacturer of crystal growing and plasma systems for the semiconductor industry, has won second place in an overall category in the 10 BEST customer satisfaction survey conducted by VLSI Research Inc, Santa Clara, USA. In the annual, independent survey by the renowned US institute for market analysis in the semiconductor industry, the Company achieved this outstanding result in the overall category "Focused Suppliers of Chip Making Equipment". The customer satisfaction survey by VLSI Research, for which over 48,000 questionnaires are sent out this year, is the only publicly available opportunity for semiconductor manufacturers to provide critical feedback on their suppliers. The 10 BEST rankings award special recognition to the suppliers that are rated highest by their customers. This independent survey questioned systems users in the semiconductor industry covering around 95% of the global chip market. On a scale of 1 to 10, PVA TePla scored an excellent 8.32. Among all the companies in the focused supplier category, the Company was rated the best in cost of ownership, uptime, usable throughput, and product performance. This award confirms the reliability of PVA TePla systems and the Company's successful customer service all over the world. Dr. Christian Schaefer, head of PVA TePla's Plasma Systems division, is also delighted by the study: "This outcome is the result of years of efforts to provide our customers with the best-possible systems and optimal service. Satisfying the most demanding customer requirements is the key to our success. We would like to thank all our customers who took part in the survey in 2007. We see this customer rating as both a motivation and a tool for recognizing and implementing further potential for improvement in systems technology and service." For further information please contact: Dr. Gert Fisahn Phone: +49(0)6441/5692-342 Fax: +49(0)6441/5692-118 gert.fisahn@pvatepla.com www.pvatepla.com --- End of Message --- PVA TePla AG Emmeliusstr. 33 Asslar Germany WKN: 746100; ISIN: DE0007461006; Index: CDAX, GEX, Prime All Share; Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Stuttgart, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Düsseldorf;


 

LONDON, United Kingdom: Crew Gold Corporation ("Crew" or "the Company") (TSX: CRU) (OSE: CRU) (Frankfurt: KNC) (OTC-BB-Other; CRUGF.PK) today announced:- Notification of Trade On June 25, 2007, Simon Booth, Executive Vice President and COO of Crew bought 20,000 shares in Crew at CAD $2.22 per share. Mr Booth's total exposure is 2,770,000 Crew shares, including common shares, convertible bonds, forward contracts and options. Jan A Vestrum President & CEO Safe Harbour Statement This news release contains forward-looking statements which reflect the expectations of management and the board of directors, and are made pursuant to applicable and relevant national legislation (including the Safe-Harbour provisions of the United States Private Securities Litigation Reform Act of 1995) in countries where Crew Gold Corporation is conducting business and/or investor relations. Forward looking statements typically contain words such as "believes", "anticipates", "continue", "could", "expects", "indicates", "plans", "will", "may", "projects", "would" or similar expressions suggesting future outcomes or events, although not all forward-looking statements contain these identifying words. Such forward-looking statements reflect the current beliefs of management and the board of directors based on information currently available to them. Forward-looking statements involve inherent risks and uncertainties, and Crew cautions readers not to place undue reliance on these statements as a number of important factors could cause Crew's actual results to differ materially from the beliefs and expectations expressed in such forward-looking statements. Factors that could cause actual results to differ materially from the results discussed in the forward-looking statements, include, but are not limited to, the factors discussed under the heading "Risks and Uncertainties" in Crew's Annual Information Form dated October 10, 2006, as filed on SEDAR at www.sedar.com. Although the forward-looking statements contained in this news release are based upon what management and the board of directors believes to be current and reasonable assumptions, Crew cannot assure readers that actual results will be consistent with these forward-looking statements. The forward-looking statements contained herein are made as of the date of this news release and are expressly qualified in their entirety by this cautionary statement. Crew undertakes no obligation to publicly update or revise these forward-looking statements to reflect subsequent events or circumstances. Cautionary Note to US Investors - The United States Securities and Exchange Commission permits US mining companies, in their filings with the SEC, to disclose only those mineral deposits that a company can economically and legally extract or produce. We use certain terms on this website (or press release), such as "measured", "indicated", and "inferred" "resources", which the SEC guidelines strictly prohibit US registered companies from including in their filings with the SEC. US Investors are urged to consider closely the disclosure from the SEC's website at http://www.sec.gov/edgar.shtml. --- End of Message --- Crew Gold Corporation Abbey House, Wellington Way, Weybridge Surrey United Kingdom WKN: 226534105 ; ISIN: CA2265301036; ;


 

This is a joint press release of Stork N.V. and London Acquisition B.V. pursuant to the provisions of Section 9b, subsection 2.a, of the Dutch Securities Trade Supervision Decree 1995 (Besluit toezicht effectenverkeer 1995). This is not a public announcement that a public offer is to be made, but that the expectation is justified that agreement can be reached on the terms and conditions of an offer agreement. Not for release, distribution or publication, in whole or in part, in the United States of America, Japan or Canada. Intended recommended cash offer of EUR 47 per share for Stork Key Highlights l London Acquisition B.V. ("the Offeror"), a holding company controlled by funds managed and advised by, or affiliated with, Candover[1], intends to make a recommended cash offer of EUR 47 ex dividend per ordinary share in Stork N.V. ("Stork" or the "Company") which represents a total value of EUR 1.5 billion; l The Intended Offer price represents a 19% premium over Stork's average closing share price of EUR 39.38 for the three months prior to 19 June 2007, the day on which Stork announced that it was discussing the Intended Offer with Candover; l The Supervisory Board, including the Extraordinary Supervisory Board members, and the Management Board of Stork fully and unanimously support and recommend the Intended Offer; l The Stork Works Council has been informed and believes the transaction is a good step to allow Stork to continue with its strategy; l Stork's shareholders Centaurus and Paulson, who collectively own approximately 33% of the issued ordinary share capital of Stork, have expressed their support for the Intended Offer and have irrevocably committed to tender their shares in Stork under the Intended Offer, when made; l The Offeror supports the strategy of the Management Board of growing the three businesses autonomously and by selective acquisition which it believes will create a more stable environment for Stork, its employees and customers; l All existing rights of the employees will be respected by the Offeror. There will be no direct negative consequences for the existing employment level of Stork as a result of the Intended Offer, when made. [1] Candover means Candover Investments plc and / or one or more of its subsidiaries, including Candover Partners Limited as Manager of the Candover 2005 Fund. Please open the link below to view the complete press release:


 

Brussels (Belgium) and Cambridge, MA (USA) - June 26, 2007- 7:00 am CET - UCB (Euronext Brussels: UCB) and Biogen Idec (NASDAQ: BIIB) today announced the initiation of a Phase II study of CDP323 - an oral VLA-4 antagonist - under development for relapsing-remitting multiple sclerosis (MS). The double-blind, randomized Phase II study commenced this week with dosing of the first patient. The study is designed to enroll over 200 patients with relapsing-remitting MS who have failed earlier treatment with a beta-interferon. Last October the companies entered an agreement to co-develop and co-commercialize this small molecule compound. The trial compares the safety and efficacy of two doses of CDP323 monotherapy to placebo over a period of six months. This is the first time that patients with MS will be exposed to CDP323. Approximately 50 medical centers in Europe and in the U.S. are expected to participate in this study. The results of this Phase II study are expected by the end of 2008. "Multiple sclerosis affects more than a million people worldwide and so far, no oral treatment has been available. An oral therapy would represent a significant advance for patients as it could provide them with a new, non-invasive option of drug delivery," said Professor Chris Polman, Professor of Neurology, VU Medical Centre, Amsterdam, the Netherlands, Lead Investigator for this study. About CDP323 CDP323 is an orally active small molecule VLA-4antagonist. The safety, tolerability and pharmacokinetic profile of CDP323 have been evaluated in healthy volunteers in three separate Phase I studies. Data from these studies were reported at the 2006 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The data from these early studies supports further development of CDP323. About Multiple Sclerosis MS is a chronic disease of the central nervous system that affects approximately 400,000 people in North America and more than one million people worldwide. It is a disease that affects more women than men, with onset typically occurring between 20 and 50 years of age. MS is caused by damage to myelin, the protective sheath surrounding nerve fibers in the central nervous system, which interferes with messages from the brain to the body. Symptoms of MS may include vision problems, loss of balance, numbness, difficulty walking and paralysis. About UCB Headquartered in Brussels (Belgium), UCB (www.ucb-group.com) is a leading global biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing more than 8,400 people in over 40 countries, UCB achieved revenue of 2.5 billion euro in 2006. UCB is listed on the Euronext Brussels Exchange and owns 87.6% of Schwarz Pharma. About Biogen Idec Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com. UCB and Biogen Idec Safe Harbor This press release contains forward-looking statements regarding the development of CDP323. Drug development involves a high degree of risk. Only a small number of research and development programs result in commercialization of a product. Factors which could cause actual results to differ materially from UCB's and Biogen Idec's current expectations include the risk that the companies may not be able to demonstrate the safety and efficacy of CDP323 at each stage of the clinical trial process; technical hurdles relating to the manufacture of CDP323 may be encountered; applicable regulatory standards may not be met or regulatory authorities may fail to approve CDP323; and other unexpected hurdles may be encountered. For more detailed information on the risks and uncertainties associated with Biogen Idec's drug development activities, see the section entitled "Risk Factors" in Biogen Idec's quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2007 which was filed with the Securities and Exchange Commission, as well as other periodic and current reports of Biogen Idec filed with the Securities and Exchange Commission. Biogen Idec assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. For further enquiries, please contact: UCB Media & Investor Relations contact: Biogen Idec Jean-Christophe Media Donck contact: Tel. +32 2 559 9346 Amy jc.donck@ucb-group.com Brockelman Reilly UCB Investor Relations contact: Tel. +1 Mareike Mohr (617) 914 Tel. +32 2 559 9264 6524 mareike.mohr@ucb-group.com Biogen Idec Investor Relations contact: Eric Hoffman, Ph.D. Tel. +1 (617) 679 2812 For the pdf-version of this press release, please click on the link below:


 

VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- June 25, 2007 -- Capstone Mining Corp. ("Capstone") (TSX: CS) will release its third quarter earnings results on Wednesday, June 27th, 2007 after market close and will host a conference call on Thursday, June 28th, 2007 at 8:00am PST (11:00am ET) to discuss these results. The conference call may be accessed by dialing 1.866.651.2245 in North America and 1.416.849.7332 Internationally. Please ask for the Capstone Mining Corp. conference call. The conference call will be archived for later playback until July 5th, 2007 and can be accessed by dialing 1.866.501.5559 and the passcode is 21238256#. ABOUT CAPSTONE Capstone is a Canadian based mining company currently operating the Cozamin copper-silver-zinc mine located in Zacatecas State, Mexico. Capstone has approximately 82.0 million shares outstanding and is well financed with no bank debt. More information is available online at: www.capstonemining.com. Contacts: Capstone Mining Corp. Chris Tomanik (604) 684-8894 (604) 688-2180 (FAX) Email: ctomanik@capstonemining.com Website: www.capstonemining.com SOURCE: Capstone Mining Corp.


 

Amsterdam, 25 June 2007 - Heineken N.V. today announced that Peter van Campen, Group Commerce Director will leave the business in order to pursue other career opportunities and interests. Mr. van Campen will leave on July 1, 2007 and a successor will be named shortly. Commenting on the departure, Jean-François van Boxmeer, Heineken N.V. CEO said, "I would like to thank Peter for the significant contribution he has made to our business over the last 15 years, in particular, for the important role he has played in professionalising our commercial approach and building a strong platform for growth of the Heineken brand. However, given some differing views that we both acknowledge, we have mutually agreed to part company. Peter leaves with our thanks and sincere best wishes for his next career step." Peter van Campen said "Heineken has been my real passion for 15 years where I have enjoyed a great career but I see this as the right moment to pursue new opportunities." Mr. van Campen joined Heineken in 1992 and worked in the Dutch and Thai operating companies before moving to Head Office in Amsterdam as Director Commercial Excellence in 2003. He was appointed Group Commerce Director and a member of the Heineken N.V. Executive Committee in October 2005. Editorial information: Heineken N.V. is the most international brewer in the world. The Heineken brand is sold in almost every country in the world and the company owns over 115 breweries in more than 65 countries. With a Group beer volume of 132 million hectolitres Heineken ranks fourth in the world beer market by volume. Heineken strives for an excellent sustainable financial performance through marketing a portfolio of strong local and international brands with the emphasis on the Heineken brand, through a carefully selected combination of broad and segment leadership positions and through a continuous focus on cost control. In 2006, revenues amounted to ¤ 12 billion and net profit before exceptional items and amortisation of brands amounted to ¤ 930 million. Heineken employs over 57,500 people. Heineken N.V. and Heineken Holding N.V. shares are listed on the Amsterdam stock exchange. Prices for the ordinary shares may be accessed on Bloomberg under the symbols HEIA NA and HEIO NA and on the Reuter Equities 2000 Service under HEIN.AS and HEIO.AS. Additional information is available on Heineken's home page: http//www.heinekeninternational.com. Press enquiries Véronique Schyns Tel: +31 (0)20 52 39 355 veronique.schyns@heineken.com Investor and analyst enquiries Jan van de Merbel Tel: +31 (0)20 52 39 590 investors@heineken.com


 

~ Birdstep has been awarded a contract with 3 Scandinavia to deliver EasyConnect GO and the Device Management Server. The products will be a used as core components in their current market leading mobile broadband campaigns~ Oslo - June 25, 2007 -Birdstep Technology ASA, the leading provider of secure seamless connectivity and mobility software for laptop, PDA's and Smartphones, today received a new order for EasyConnect GO and Device Management Server (DMS) from 3 Scandinavia. 3 will use the Birdsteps products to further enhance the end-users experience of high-speed mobile broadband through a branded and customized 3 connection manager. The DMS will provide advanced provisioning, marketing and over the air roaming control, giving 3 full flexibility and power to support the mass deployment of clients on customers laptops/notebooks. The 3 connection manager will cover high-speed data support for leading USB-modems and PC-cards. Mobile broadband has been 3's most successful service mobile offering during the latest 3 months, resulting in data now representing up to 80% of all the traffic in their mobile network. Birdstep has developed EasyConnect GO, a high-speed connection client designed specifically to embrace this growing market and specially designed for support of leading USB-modems. "Thanks to Birdstep, our customers will have the best available connection manager to connect to the markets best mobile broadband network. In addition, they are providing simplified handling of over the air updates for policies and software, but most importantly was the benefits this gives our customers, said Peter Ramel, CEO of 3 Scandinavia 3 Sweden & Denmark will use the EasyConnect GO product in their mobile broadband offerings utilizing the easy to use USB Cellular Modems. The EasyConnect software will be preinstalled on the USB modem and when the user attaches the USB modem to the computer, the software will be automatically installed. Birdstep will also deliver the Device Management Server giving 3 the flexibility to provision service enhancements and automatic updates directly to their consumers over the air. "USB Modems are currently making high in-roads to the market, being packaged together with aggressive mobile broadband campaigns from operators such as 3. This order recognizes Birdstep EasyConnects continued value in a rapidly expanding mass market. As subscriber numbers quickly grow, deployment control and usability, as provided by Birdstep, will only continue to rise in importance" Said Petri Markkanen, CEO, Birdstep Technology (398 words) For further information, please contact: Petri Markkanen, CEO of Birdstep Technology ASA, phone +46 70 323 33 22 Peder Ramel, CEO, 3 Scandinavia, Mobile: +46 (0)735-333 023, E-post: peder.ramel@tre.se. or Erik Hörnfeldt, Information & PR, 3, Mobile: +46 (0)735-33 74 04, E-post: erik.hornfeldt@tre.se NOTES TO EDITORS About Birdstep (www.birdstep.com) Birdstep Technology ASA is a public company listed on the Oslo Stock Exchange (OSE) under ticker 'BIRD'. The company is headquartered in Oslo, Norway with five wholly-owned subsidiaries: Birdstep Technology AB in Sweden, Birdstep Technology Inc. in Seattle, Birdstep Technology in San Francisco, US, Birdstep Technology in Finland and Birdstep Technology Ltd in Cambridge, UK. Birdstep Technology is a global software development, marketing and sales company offering seamless connectivity and mobility client software for mobile data users on laptops, pocket PC and Smartphones as well as state-of-the-art embedded database technologies. Birdstep has an installed base at more than 50 operators globally including T-mobile Group, Vodafone Group, Orange, TIM, Turkcell, TMN, KPN, Sprint, Telenor and TeliaSonera as well as more than 30 Enterprise Customers including Nordea, Handelsbanken, Ministry of Justice in Finland, Finnish defence force, etc. The company also cooperates with global partners such as Nokia, SonyEricsson, CMG Logica/VMdata, Motorola, Cisco, Intel, Ericsson, Nortel Networks, HP and Fujitsu Siemens Computers. About 3 3-gruppen är världens ledande operatör av mobila bredbandsnät och mediatjänster med drygt 12 miljoner kunder i nio länder. I Sverige och Danmark är 3 ett joint venture mellan Hong Kong-baserade Hutchison-Whampoa Limited (60%) och Investor AB (40%). 3 Skandinavien har även en licens att driva 3G-nät i Norge. För mer information, gå till www.tre.se.


 

` FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | DEEPHAVEN CAPITAL | | | MANAGEMENT LLC | |-----------------------------------------------+-------------------| | Company dealt in | Hanson Plc | |-----------------------------------------------+-------------------| | Class of relevant security to which the | 10p Ordinary | | dealings being disclosed relate (Note 2) | | |-----------------------------------------------+-------------------| | Date of dealing | 22 June 2007 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------+ | | Long | Short | | | | | |-------------------------------+--------------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (2) Derivatives (other than | 8,500,000 | 1.1908 | | | | options) | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | Total | 8,500,000 | 1.1908 | | | | | | | | | +-------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +-------------------------------------------------------------------+ | Class of relevant security: | Long | Short | | | | | |-------------------------------------+--------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (2) Derivatives (other than | | | | | | options) | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | Total | | | | | | | | | | | +-------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short | Number of securities | Price per unit | | name, | (Note 6) | (Note 7) | (Note 5) | | e.g. CFD | | | | |----------+------------+--------------------------+----------------| | | | | | | CFD | SHORT | 1,252,861 | 1076.5000 | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 25th June 2007 | |-------------------------------------------------+-----------------| | Contact name | James Feast | |-------------------------------------------------+-----------------| | Telephone number | 0207 469 1901 | |-------------------------------------------------+-----------------| | If a connected EFM, name of offeree/offeror | | | with which connected | | |-------------------------------------------------+-----------------| | If a connected EFM, state nature of connection | | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

Addtech Components, a division of Addtech AB, has today, 25 June 2007, signed a contract to acquire all shares in Chemo Electric A/S. The sale is being handled on behalf of Chemo Electric Holding ApS by Leif Nielsen. Chemo Electric A/S supplies electro-mechanical components to major OEM customers in Denmark operating within the field of medical technology and other manufacturing industries. The company employs eleven people and has a turnover of DKK 59 million. Chemo Electric A/S complements Addtech's existing operations in Denmark with regard to both product range and customer base. Chemo Electric A/S's long experience of developing customer-centred solutions is expected to contribute to continued growth for Addtech's Danish components companies. It is believed the acquisition will have a marginally positive effect on the performance of Addtech shares over the current financial year. The acquisition is expected to be completed on 2 July 2007. Stockholm, 25 June 2007 Addtech AB For further information please contact: Roger Bergqvist, Managing Director, Addtech AB, +46 8 470 49 04 Anders Dafnäs, Managing Director, Addtech Components AB, +46 708 303 368


 

"Advancing Uranium" NEWS RELEASE Crosshair Begins Expansion Drilling of High Grade Gold Zone at Golden Promise Dated: June 25, 2007 AMEX: CXZ, TSX-V: CXX Crosshair Exploration and Mining Corp. (AMEX: CXZ, TSX-V: CXX) is pleased to announce that a 3,750 meter summer diamond drilling program has commenced on the Golden Promise Project located 35 kilometers west of Grand Falls - Windsor in central Newfoundland. The Golden Promise Project is host to the Jaclyn Zone, a gold mineralized composite vein system defined over a strike length of 750 meters and to a depth of 225 meters, which remains open for expansion. The current program is aimed at further testing this zone and further expanding it along strike and to depth. Jaclyn Main Zone Drilling A total of 2,945 meters of drilling in 19 holes are planned for the Jaclyn Main Zone. The drilling is designed to: * expand the higher grade portion of the zone identified in previous drill programs, and * firm up resources in the near surface portion of the vein to allow incorporation into a 43-101 resource estimate planned for release later in 2007. The expansion holes in this drill program will follow up on positive results from the previous drill program, which intersected some of the highest grades at depth thus far, including: GP06-65: 20.65 g/t gold over 1.60 metres, including 55.03 g/t gold over 0.60 metres; GP06-66: 11.90 g/t gold over 1.05 metres, including 21.87 g/t gold over 0.55 metres. The drilling will also test the eastern portion of the Main Zone at vertical depths of 300 meters, where mineralization, including the higher grade core, remains open. Additional drilling will be proposed once the current program has been completed and all results interpreted. Jaclyn North Zone Drilling A total of 805 meters are planned in 4 holes at Jaclyn North to follow up on earlier drilling, which returned several high grade intercepts, including 14.01 g/t gold over 0.35 meters. The Jaclyn North zone, which lies 250 meters north of the Main Zone, is a parallel vein system that strongly resembles the Main Zone, and which has only been tested along strike for 150 meters. The drill program is designed to expand the known limits of mineralization both to depth and along strike to the east and west. Maps have been posted on the company website: http://www.crosshairexploration.com/s/GoldenPromise.asp Other Work A trenching program is also planned to further expose a mineralized gabbro unit discovered in the southeastern portion of the property where prospectors collected grab samples assaying up to 10 g/t Au from an area measuring 50 meters by 50 meters. The showing has the potential to host bulk minable open pit style gold mineralization. The Golden Promise Project is a joint venture between the Company and Paragon Minerals Corporation. The Golden Promise Project work is being carried out by David Mullen, consulting geologist to Paragon and supervised by Qualified Person David Copeland, M.Sc., P.Geo., Exploration Manager for Paragon. Mr. Copeland has verified that the results presented above have been accurately summarized from the official assay certificates. Spin-Out This is the final work program on Golden Promise before Crosshair begins to take formal steps to spin out its Golden Promise, South Golden Promise and Victoria Lake properties into a new public company by way of shareholder dividend. It is currently management's intention to call a special meeting of shareholders in early 2008 to obtain shareholder approval to the proposed transaction, which will also be subject to regulatory approval. About Crosshair Crosshair is a dominant player in the exploration for uranium in the Central Mineral Belt of Labrador Canada's most promising emerging uranium district. The 750 sq km Central Mineral Belt Uranium Project is host to potentially three types of uranium mineralization - Iron Oxide Copper Gold (IOCG - Olympic Dam), structurally controlled, shear zone and unconformity types of mineralization. In addition, through option agreements with Paragon Minerals Corporation, Crosshair has secured a position in one of the most prospective massive sulphide districts in Canada as well as a promising high grade gold project at South Golden Promise and Golden Promise. For more information of the Company and its properties, please visit the website at www.crosshairexploration.com. ON BEHALF OF THE BOARD "Mark J Morabito" President and CEO Crosshair Exploration & Mining Corp. - Vancouver T: 604-681-8030 F: 604-681-8039 E: greg@crosshairexploration.com: or dan@crosshairexploration.com www.crosshairexploration.com Cautionary Note Regarding Forward-Looking Information Information set forth in this news release may involve forward-looking statements. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address a company's expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: the risks associated with outstanding litigation, if any; risks associated with project development; the need for additional financing; operational risks associated with mining and mineral processing; fluctuations in uranium, gold and other commodity prices; title matters; environmental liability claims and insurance; reliance on key personnel; the potential for conflicts of interest among certain officers, directors or promoters with certain other projects; the absence of dividends; competition; dilution; the volatility of our common share price and volume; and tax consequences to U.S. Shareholders. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of the content of this News Release.


 

Clean energy league tables 2006 by New Energy Finance Limited Fortis came top of the league for its syndicated financing of clean energy projects in 2006, with a total of USD 1.4 billion financing 12 projects. Fortis also moved up the league of 'lead arrangers' - coming in at number 13 for 2006. Frans van Lanschot, CEO of Fortis Energy, Commodities and Transportation department said: "Fortis's meteoric rise up the clean energy league tables demonstrates the company's dedication to sustainability. Clean energy is a Fortis speciality, and we remain fully committed to expanding our services in this field." The 'Clean Energy League Tables' are drawn up by New Energy Finance Ltd - a specialist provider of information and research to investors in renewable energy, low carbon technology and carbon emission credits. The 2006 league tables cite Fortis as the "clear leader in the space" for syndicated lending for project finance. Projects financed The clean energy technologies financed by Fortis in 2006 include among others, wind, landfill gas, biomass and waste management, covering projects in Europe and the US. Over the last decade, Fortis has provided financing for over 60 projects, which provide almost 9GW of electricity - enough to power five million households. Fortis' solid clean energy credentials As part of a far-reaching corporate social responsibility programme, Fortis is fully committed to caring for the environment. Since January 2007, Fortis has been carbon-neutral across the globe. This involves saving energy, buying green electricity and offsetting any residual CO2 emissions. Fortis is furthermore fully committed to carbon banking operations - a field where we are already a leader. Fortis also offers a wide range of sustainable products - from 'clean car' insurance and cheaper loans for less-polluting vehicles, to sustainable investment funds. Moreover, Fortis Investments has developed a website devoted to sustainable development allowing you, among other things, to calculate your own ecological footprint: http://www.footprint.fortis.com/calculator About Fortis Fortis is an international financial services provider engaged in banking and insurance. We offer our personal, business and institutional customers a comprehensive package of products and services through our own channels, in collaboration with intermediaries and through other distribution partners. With a market capitalisation of EUR 40.3 billion (31/05/2007), Fortis ranks among the twenty largest financial institutions in Europe. Our sound solvency position, our presence in 50 countries and our dedicated, professional workforce of 60,000 enable us to combine global strength with local flexibility and provide our clients with optimum support. More information is available at www.fortis.com. Contacts: Brussels: +32 2 565 35 84 Utrecht: +31 30 226 32 19 Investor Relations: Brussels: +32 2 510 53 91 Utrecht: +31 30 226 32 20


 
Hitt og þetta
25. júní 2007

AGM Statement

Resolutions passed at Kenmare's Annual General Meeting The Directors of the Company wish to announce that each of the resolutions proposed at the Annual General Meeting of the Company held today, Monday, 25 June were passed. The full text of each resolution was set out in the Notice of Annual General Meeting that Kenmare circulated to the Shareholders in June, 2007. For further information: Michael Carvill Managing Director Tel: +353-1-671 0411 Mob: +353-87-674 0110 Murray Consultants Elizabeth Headon Tel: +353-1-498 0300 Mob: +353 87 989 7234 Conduit PR Ltd Leesa Peters +44-207-429 6600 Mob: +44 781 215 9885 www.kenmareresources.com ---END OF MESSAGE---


 

Expanded Certification, Training Program and Localization Efforts Help Meet Worldwide Demand for Networking Talent SAN JOSE, CA -- (MARKET WIRE) -- June 25, 2007 -- Cisco® (NASDAQ: CSCO) today announced the addition of a new entry-level certification, CCENT(TM) (Cisco Certified Entry Network Technician), to its Career Certification Program, along with significant enhancements to the popular Cisco CCNA® associate-level certification. Simultaneously, Cisco also plans to localize both the curricula and certification exams to meet the worldwide demand for networking skills. As networks continue to drive economic growth, collaboration and human interaction, the need for networking talent grows in importance. IDC is predicting as much as a 40 percent gap between the demand and supply of technical networking skills by year 2012. To address these needs, Cisco is making significant investments in its education and certification programs to equip more people for successful careers in networking. CCENT presents a new point of entry to those just beginning to build a career in networking. As an optional stepping-stone to CCNA, CCENT validates the skills required to successfully install and verify basic networks -- a requirement for most entry-level network support positions. At the same time, Cisco's foundational CCNA curriculum has been revised to include a greater breadth of networking topics and more focus on performance-based skills to differentiate Cisco certified applicants in the IT job market. The CCNA curriculum will be released in English on July 26, 2007 and the exams will be released in English on August 1, 2007. Additional languages will be announced as translation plans are finalized. "Cisco is committed to transforming how people interact and share information across the world. By powering the human network, we will enable a new approach for our customers to work in the global marketplace," said Wim Elfrink, chief globalization officer and senior vice president of customer advocacy at Cisco. "We are dedicated to leading worldwide development of the right technical expertise, in the right place and at the right time, to make sure our customers and partners have the best possible experience with our technology. The introduction of CCENT and localization plans for our foundational curricula, underscore our commitment to accelerate the learning curve for technical talent across the globe." Laying the groundwork for more rigorous certification, CCENT validates the knowledge and skills needed to configure and verify small routed and switched networks, including the ability to configure IP addressing, implement basic security measures and understand the concepts of wireless networking. A comprehensive understanding of networking fundamentals is the focus of CCNA. Certification at this level validates the knowledge and skills required to install, operate and troubleshoot a small to medium-sized routed and switched network, including the ability to implement and troubleshoot protocols to manage addressing and authentication, as well as establish and troubleshoot connections to service providers over a wide-area network. The CCENT learning path includes: -- Required Exam: ICND1 640-822 -- Recommended Course: Interconnecting Cisco Networking Devices, Part 1 The CCNA learning path includes: Required Exams: -- ICND1 640-822 and ICND2 640-816 or -- CCNA 640-802 composite exam Recommended Courses: -- Interconnecting Cisco Networking Devices, Part 1 -- Interconnecting Cisco Networking Devices, Part 2 The CCNA Prep Center (www.cisco.com/go/prepcenter) is available to anyone with a Cisco.com login to help candidates prepare for the CCENT and CCNA exams. The CCNA Prep Center provides certification candidates access to a wide variety of resources to accelerate learning including, practice questions, labs, games, simulations, tips, expert advice, success stories and peer discussion forums. "Career opportunities in networking are abundant and span a wide array of experiences from software applications and systems design to troubleshooting global networks that span all business, government and person-to-person communications," said Jeanne Beliveau-Dunn, senior director for Learning@Cisco. "Networking offers people a broad opportunity for career advancement while learning about the world, about business and about ways to improve human interaction. The Cisco training and certification program provides network designers and engineers with a solid foundation on which they will change how people collaborate and communicate in the future." "Networks underpin nearly every industry today, including travel, fashion and entertainment, and their presence is not likely to be diminished in the future," said Christopher Cugno, senior network engineer for DreamWorks Animation SKG. "Holding a Cisco certification enabled me to enter the career of my dreams, and now I have the opportunity to work for one of the most recognized production studios in the world." To learn more about the Cisco certification programs, please visit: http://www.cisco.com/go/getcertified In a related announcement, the Cisco Networking Academy® today announced the introduction of the new CCNA curriculum. The CCNA curriculum now consists of two tracks, CCNA Discovery and CCNA Exploration, that target different student segments based on their academic experience and goals. Additional information is available at: http://newsroom.cisco.com/dlls/2007/prod_062507c.html Training and Availability Authorized Cisco training is available from a global network of Cisco Learning Solutions Partners and the Partner E-Learning Connection. For complete details about the training and exam requirements for the Specialist and other certifications, visit: http://www.cisco.com/go/certifications. Cisco Press, the leader in CCNA self-study products, will offer a comprehensive set of materials for the new CCNA exams, including CCNA ICND1 Exam Certification Guide (1587201828), CCNA ICND2 Exam Certification Guide (158720181X), and the CCNA Flash Cards and Exam Practice Pack (1587201909). All products will be available for purchase at: http://www.ciscopress.com/ccna About Cisco Career Certifications The widely respected Cisco Career Certifications bring valuable, measurable rewards to network professionals, their managers and the organizations that employ them. Cisco offers three levels of general certification: Associate, Professional and Expert in various tracks such as Routing and Switching, Network Security and Service Provider. A variety of Cisco Specialist certifications are also available to show knowledge in specific technologies, solutions or job roles. For Cisco Career Certifications information, visit: http://www.cisco.com/en/US/learning. About Cisco Systems Cisco (NASDAQ: CSCO) is the worldwide leader in networking that transforms how people connect, communicate and collaborate. Information about Cisco can be found at http://www.cisco.com. For ongoing news, please go to http://newsroom.cisco.com. Cisco, the Cisco logo, Cisco Systems, CCENT, CCNA and Networking Academy are registered trademarks or trademarks of Cisco Systems, Inc. and/or its affiliates in the United States and certain other countries. All other trademarks mentioned in this document are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company. This document is Cisco Public Information. For direct RSS Feeds of all Cisco news, please visit "News@Cisco" at the following link: http://newsroom.cisco.com/dlls/podcasts/rss.html Press Contact: Cara Sloman Cisco Systems, Inc. 831-440-2411 csloman@cisco.com


 

Affärsstrategerna's subsidiary Samba Sensors AB, Sweden and Raumedic AG, Germany, have initiated business collaboration with the aim of developing new and innovative catheter systems for clinical use. The parties intend to seek common business opportunities related to catheters that combine Samba Sensors' unique fiber-optic pressure monitoring technology and Raumedic's vast state-of-the-art capabilities in catheter design and manufacturing. "Raumedic is an ideal partner for us since the company possesses all the frontline competence and resources needed to integrate our technology into truly innovative pressure catheters. In addition they can provide first-class manufacturing capacity and facilities for large scale production", says Lennart Nilsson, President of Samba Sensors AB. 'Samba Sensors' ultra-miniature pressure sensing technology will allow Raumedic to pursue new exciting business opportunities in the high-tech catheter segments. Through collaboration with Samba Sensors we foresee smaller, smarter and more competitive pressure catheters in Raumedic's portfolio in the future", comments Dr. Christian von Falkenhausen, Director of R&D at Raumedic AG. "We see big commercial possibilities through this collaboration" says Claes-Göran Fridh, CEO Affärsstrategerna AB. SAMBA SENSORS (www.samba.se) is a world leading developer and manufacturer of advanced fiber-optic technology for pressure measurements. Company expertise is focused today on the design, development and marketing of ultra-miniature pressure transducers and control systems, primarily for applications in the life sciences. RAUMEDIC (www.raumedic.com) is a worldwide development partner and system supplier to the medical and pharmaceutical industry. Supported by in-house R&D as well as Engineering department, Raumedic develops and manufactures innovative, high-quality, customer specific products in all common polymers and elastomers at its head-office in Münchberg/Bavaria and its manufacturing locations in Feuchtwangen and Zwönitz. Raumedic's high innovative multi parameter sensor (pressure, oxygen, temperature) is already well established in the field of neuromonitoring. AFFÄRSSTRATEGERNA (www.astrateg.se) listed at OMX Nordic Exchange Stockholm is a venture capital company investing in value-added capital in companys with large growth potential and good prospects of becoming a world-leading niche company. In addition Affärsstrategerna invests in mature and profitable companys. Some of the companys in the portfolio are: A3TL, AlphaHelix M.D., Innate Pharmaceuticals, M.O.R.E. Invest, Munax, Naty, Photometric, Samba Sensors, SchoolSoft and Starlounge. Contacts Samba Sensors AB Gruvgatan 6 421 30 Göteborg Sweden Contact person: Lennart Nilsson,President Phn: +46-(0)31 704 9160 Email: lennart.nilsson@samba.se Raumedic AG Hermann-Staudinger-Str. 2 DE-95233 Helmbrechts Germany Contact person: Dr. Christian von Falkenhausen, Director of R&D Phn: +49-(0)9252 359 1739 Email: christian.von.falkenhausen@raumedic.com Affärsstrategerna AB Artillerigatan 6 114 51 Stockholm Sweden Contact person: Claes-Göran Fridh CEO, Affärsstrategerna AB Phn: +468-545 831 95 Mob: +46 708 66 24 03 E-mail: cgfridh@astrateg.se www.astrateg.se


 

25 June 2007, London, UK - Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that its Director of Communications, Dr Daniel Elger, will be presenting at the Jeffries Healthcare Conference in New York, USA, on Wednesday June 27th. Dr Elger's presentation is scheduled for 16:10 EDT (21:10 BST). A webcast of the presentation will be available to all on Antisoma's website at www.antisoma.com. It is recommended that viewers log on 15 minutes early in order to register and download any necessary software. Enquiries: Chris Elston +44 (0)20 8799 8200 Communications Manager Antisoma plc Background on Antisoma Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit www.antisoma.com for further information. ---END OF MESSAGE---


 

(Oslo, 25 June 2007) First Confederal Secretary Ellen Stensrud, CEO Egil Nordvik and Project Director Berit Johanne Rødseth were elected to the board of directors of Statkraft SF and Statkraft AS at an ordinary general meeting of Statkraft SF held today. They will succeed Gunn Wærsted, Olav Fjell and Marit Büch-Holm. Ellen Stensrud is First Confederal Secretary in The Norwegian Confederation of Trade Unions (LO), where her main responsibilities include industrial democracy and trade- and industry policy. Stensrud has been a union representative since 1986 and an elected member of LO management since 2001. She has served on a number of committees and boards, including at Arbeiderbladet and Statoil. Egil Nordvik is CEO of Rana Gruber AS, where he has held a number of management positions since 1981. He serves on several boards, including at Norvag AS (the Euroskilt Group), SMA-Nordland (Svenska Mineral) and A/S Bleikvassli Gruber Entreprenør, where he is board chair. Berit Rødseth is Project Director at Moelven Industrier ASA. She was previously a director at the sawmill operator Nössemark Trä AB. Rødseth is a trained agronomist and took over the family farm at the age of twenty. She also has financial training. Statkraft SF's and Statkraft AS's board of directors now comprises: Chair: Arvid Grundekjøn Deputy chair Ellen Stensrud Board member: Aud Mork Board member: Halvor Stenstadvold Board member: Egil Nordvik Board member: Berit Rødseth The following employee-elected members also serve on the board: Board member: Odd Vanvik Board member: Thorbjørn Holøs Board member: Astri Botten Larsen The Statkraft Group is a leading player in Europe within renewable energy. The Group generates hydropower, wind power and district heating and constructs gas power plants in Norway and Germany. Statkraft is a major player on the European energy exchanges. In Norway the company supplies electricity and heat to around 600,000 customers through its shareholdings in other companies. In 2006 Statkraft recorded a profit after tax of NOK 6.3 billion, and employed more than 2,100 employees in eight countries. The world needs pure energy. Statkraft works to deliver this every day. For further information, please contact: EVP Ragnvald Nærø, tel.: +47 24 06 71 00/ +47 900 80 303 www.statkraft.com


 

Intelecom Group's subsidiary, Intelecom Norge AS, has received an extension to existing service and operation contracts within the oil- and gas sector. The extensions apply to the period 1 July 2007 until 30 June 2008 and have an estimated contract value of 12.7 MNOK. The contracts include service and operation of communication systems both offshore and onshore. About Intelecom Intelecom Norge is a subsidiary of Intelecom Group ASA (previously Consorte Group ASA). Intelecom is a leading company in development, integration, delivery and operation of communication solutions to the enterprise market. In addition to the subsidiary in Norway, the Group has subsidiaries in Sweden, Denmark and the UK. The company supplies services and solutions that are adapted to the individual customer's business and requirements. Intelecom's customers regard communication as business critical and Intelecom addresses this by combining business understanding with advanced communication technology. For more information: CEO Eivind Hauglie-Hanssen; Phone: +47 03050


 

Arnhem, the Netherlands, June 25, 2007 - Akzo Nobel (Euronext Amsterdam: AKZ; Nasdaq: AKZOY) has announced that, in line with the launch of its EUR 1.6 billion share buyback program on May 3, 2007, the company has repurchased 1,150,300 common shares in the period June 18 until June 22, 2007. Shares were repurchased at an average price of EUR 62.23 for a total amount of EUR 71.6 million. For detailed information on the daily repurchased shares, see the Akzo Nobel website at www.akzonobel.com/com/Investor+Relations/Financial+FAQ. The total number of shares repurchased under this program to date is 8,788,800 common shares for a total consideration of EUR 528.2 million. The completion of the share buyback program is expected by the end of 2007. - - - Note to editors Akzo Nobel is a Fortune Global 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with coatings, chemicals and human and animal healthcare products. We employ around 62,000 people and conduct our activities in these four segments, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2006 totaled EUR 13.7 billion. The financial results for the second quarter will be published on July 24, 2007. Internet: www.akzonobel.com Not for publication - for more information Akzo Nobel nv Corporate Media Relations, tel. +31 26 366 43 43 Contact: Tim van der Zanden


 
Hitt og þetta
25. júní 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |-------------------------------------------------+-----------------| | Company dealt in | Freeport Plc | |-------------------------------------------------+-----------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |-------------------------------------------------+-----------------| | Date of dealing | 22nd June 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price | | securities | (Note 3) | paid | | purchased | | (Note 3) | |---------------------------+--------------------+------------------| | 118 | 335p | 335p | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |-------------------------+--------------------+--------------------| | 500 | 340.75p | 340.75p | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +------------------------------------------------------------------+ | Date of disclosure | 25nd June 2007 | |----------------------------------------------+-------------------| | Contact name | Edward Hodge | |----------------------------------------------+-------------------| | Telephone number | 0207 991 6661 | |----------------------------------------------+-------------------| | Name of offeree/offeror with which connected | Freeport Plc | |----------------------------------------------+-------------------| | Nature of connection (Note 6) | Connected Advisor | +------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | AXA Investment Managers UK | | | Limited/AXA Framlington | | | Investment Management Limited | |-----------------------------------+-------------------------------| | Company dealt in | Reuters Group Plc | |-----------------------------------+-------------------------------| | Class of relevant security to | Ordinary shares | | which the dealings being | | | disclosed relate (Note 2) | | |-----------------------------------+-------------------------------| | Date of dealing | 22/06/07 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------------------------------+ | | Long | Short | | | | | |---------------+--------------------------+------------------------------------------------| | |Number |Number | | | (%) | (%) | |---------------+--------------------------+------------------------------------------------| |(1) Relevant |13,278,348 (1.05%) | | |securities | | | | | | | |---------------+--------------------------+------------------------------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+--------------------------+------------------------------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+--------------------------+------------------------------------------------| |Total |13,278,348 (1.05%) | | | | | | +-------------------------------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +--------------------------------------------------------------------------+ |Class of | Long | Short | |relevant | | | |security: | | | | | | | |---------------+----------------------------+-----------------------------| | |Number |Number | | | (%) | (%) | |---------------+----------------------------+-----------------------------| |(1) Relevant | | | |securities | | | | | | | |---------------+----------------------------+-----------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+----------------------------+-----------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+----------------------------+-----------------------------| |Total | | | | | | | +--------------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | Sell | 50,000 | 6.21p | | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short (Note | Number of securities | Price per | | name, | 6) | (Note 7) | unit (Note | | e.g. CFD | | | 5) | |----------+------------------+------------------------+------------| | | | | | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 25/06/2007 | |---------------------------------------------------+---------------| | Contact name | Maria Mauro | |---------------------------------------------------+---------------| | Telephone number | 0207 003 2812 | |---------------------------------------------------+---------------| | If a connected EFM, name of offeree/offeror with | N/A | | which connected | | |---------------------------------------------------+---------------| | If a connected EFM, state nature of connection | N/A | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

B&B TOOLS has concluded an agreement to acquire 100 percent of the shares outstanding in TOOLS AS Maskin ("AS Maskin"). AS Maskin is one of the largest suppliers of tools, fastening elements and other industrial consumables as well as related services to companies in the offshore industry in western Norway. AS Maskin has net revenues of approximately MSEK 135 per annum and has 27 employees. "AS Maskin is one of the largest partners in the TOOLS chain in Norway and has a strong position in Bergen and Stavanger", says Johan Falk, Executive Vice President in B&B TOOLS. "With this acquisition TOOLS' offering to the offshore industry is further strengthened. TOOLS has representation in approximately 60 locations in Norway today." After elimination of the B&B TOOLS Group's current sales to AS Maskin, the Group's consolidated net annual revenues are expected to increase by approximately MSEK 110. Closing is expected to take place in mid-July 2007 after approval has been obtained from the relevant authorities. The acquisition is expected to have a marginally positive effect on B&B TOOLS' earnings per share during the current financial year. Stockholm, 25 June 2007 B&B TOOLS AB (publ) For further information contact: Johan Falk, Executive Vice President, B&B TOOLS AB, telephone +46-8-660 10 30 Mats Karlqvist, Vice President - Investor Relations, B&B TOOLS AB, telephone +46-70-660 31 32 B&B TOOLS provides the industrial and construction sectors in northern Europe with tools, industrial consumables and industrial components, and related services. The Group has annual revenues of approximately SEK 7.6 billion and approximately 2,700 employees. Bergman & Beving changed its name to B&B TOOLS in the end of March 2007.


 

Stove and fireplace manufacturer Jøtul is acquiring Hammerstrøm AS - Norway's leading supplier of flue pipes and chimney accessories. Jøtul, which was founded in 1853, has increased its sales by an average of 10% per year in recent years. The company's products are sold globally, primarily through specialty stores but also via DIY outlets in some markets. Jøtul's market share in Scandinavia amounts to approximately 25% while the global market share is almost 10%. Erik Moe, CEO of Jøtul, comments: "The acquisition of Hammerstrøm is well in line with Jøtul's acquisition strategy. Through Jøtul's distribution channels Hammerstrøm, which currently holds a strong position in Norway, will be given excellent opportunities to increase sales in other markets as well." Hammerstrøm had sales of NOK 40m in 2006 with an operating profit of NOK 7.4m and has 34 employees. In addition to flue pipes, Hammerstrøm manufactures a number of products for chimney renovation and also supplies maintenance products for stoves and fireplaces. The company has carried out extensive investments in a more effective production structure in recent years. The Jøtul group which is 62.5 % owned by Ratos has 820 employees in 10 countries. The group had sales of NOK 904m in 2006 with an operating profit (EBITA) of NOK 81m. The acquisition of Hammerstrøm will not require additional capital from the owners. For further information, please contact: Erik Moe, CEO Jøtul, +47 906 92 419 Anna-Karin Celsing, Head of Corporate Communications Ratos, +46 703 99 62 39 Per Frankling, Senior Investment Manager Ratos, +46 8 700 17 80 Financial calendar from Ratos: Interim report January-June 21 August 2007 Interim report January-September 9 November 2007 Ratos is a listed private equity company. The business concept is to maximise shareholder value over time by investing in, developing and divesting primarily unlisted companies. Ratos thus offers stock market players a unique investment opportunity. The equity of Ratos's investments is approximately SEK 11 billion. Ratos's holdings include Anticimex, Arcus Gruppen, Bisnode, Bluegarden, Camfil, DIAB, GS-Hydro, Haendig, Haglöfs, HL Display, Hägglunds Drives, Inwido, Jøtul, Lindab, MCC, Medifiq Healthcare, HÅG/RH/RBM, Superfos and Other holdings.


 

Amsterdam (June 25, 2007) - Wolters Kluwer, a leading global information services and publishing company, today announces that in line with the launch of its ¤475 million share buy-back program on June 15, 2007, the company has repurchased 1,346,704 ordinary shares in the period June 18 until June 22, 2007. Shares were repurchased at an average price of ¤22.78 for a total amount of ¤30.7 million. For detailed information on the daily repurchased shares, see the Wolters Kluwer website at http://www.wolterskluwer.com/WK/Investors/Share+Information/Share+Buy-back+Program/ The total number of shares repurchased under this program to date is 1,346,704 ordinary shares for a total consideration of ¤30.7 million. About Wolters Kluwer Wolters Kluwer is a leading global information services and publishing company. The company provides products and services for professionals in the health, tax, accounting, corporate, financial services, legal and regulatory sectors. Wolters Kluwer has annual revenues (2006) of ¤3.4 billion, employs approximately 18,450 people worldwide, and maintains operations across Europe, North America, and Asia Pacific. Wolters Kluwer is headquartered in Amsterdam, the Netherlands. Its shares are quoted on the Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. For more information, visit www.wolterskluwer.com. Contact: Caroline Wouters Kevin Entricken Vice President, Vice President, Corporate Communications Investor Relations Wolters Kluwer nv Wolters Kluwer nv + 31 (0)20 6070 459 + 31 (0)20 6070 407 press@wolterskluwer.com ir@wolterskluwer.com Forward-looking Statements This press release contains forward-looking statements. These statements may be identified by words such as "expect," "should," "could," "shall," and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


 

Petrojack ASA has on 22 June 2007 bought a forward contract of 12.383.000 shares in PetroProd Ltd, with 20 September delivery, at NOK 11,5572 After the above mentioned transaction, Petrojack ASA controls 36.833.800 shares in PetroProd Ltd, corresponding to 42,09 % of the shares outstanding in PetroProd Ltd. Bergen 25.06.2007


 

KAUFBEUREN, GERMANY - Inova Holding plc ("Inova"; LSE-AIM: INA), a leading manufacturer of robust embedded computer systems for harsh environments and multimedia solutions for the transport sector, announces that it has won two contracts with a combined value of ¤2.75 million of which more than ¤1 million will contribute to revenues for 2007. The first contract is from Thales Security Solutions and Services for an on-board CCTV security and surveillance system for the Dubai Urban Transit System ("DUTS") operated by the UAE Roads and Transport Authority. DUTS is a driverless rail metro system connecting the business and entertainment centres of Dubai. Under the contract, the first won by Inova's UK office, 64 trains running on the Red Line of the Dubai metro will be equipped with Inova's state-of-the-art digital CCTV system linked via wireless network to a central control room. As a result, a total of 768 on-board cameras will deliver real-time front-of-train and internal surveillance, enabling system operators to monitor progress and ensure the comfort and safety of passengers. This contract, which forms part of a turnkey project of which Mitsubishi Heavy Industries is the main contractor, will be completed by the end of 2007. The second contract is with Bombardier Transportation Canada Inc. for multimedia systems for the Metro in Toronto, Canada. Each train will have several LCD information screens providing travel information driven by Inova's proprietary rugged hardware, software and communications technologies. Inova is a preferred supplier of passenger infotainment systems to the Bombardier Transportation Group. Josef Kreidl, Inova's Chief Executive, said: "These orders are with blue-chip companies as well as having a positive impact on Inova's trading performance in 2007. "The prestigious Dubai contract illustrates the growing demand for real-time CCTV surveillance systems from mass transit systems operators. In the case of Bombardier, Inova has demonstrated the success of its strategy of forging relationships with key OEMs which are experiencing strong demand from transport operators with wide-ranging passenger infotainment requirements. "In both areas, Inova, with its proprietary ruggedised technology and expertise in delivering solutions to the transport sector, is uniquely qualified to satisfy the demand and to become a significant player." ENDS CONTACTS Inova: Rod Hoare, Chairman +44-7714-223452 Josef Kreidl, CEO +49-8341-916265 Daniel Stewart: +44 20-7776-6550 Alastair Cade Bankside: +44 20-7367-8888 Simon Bloomfield or Steve Liebmann About Inova Established in 1997, Inova is a developer, manufacturer and distributor of embedded computer systems, with particular expertise in systems for rugged environments in industry, transport and traffic systems. From this base it has also developed an expanding passenger infotainment business which provides information and entertainment systems on public transport including trains, trams and buses. These systems are able to provide one single solution for real time entertainment and news alongside passenger information, on-board monitoring of systems and CCTV. The business uses Inova's core embedded computers and additional technology as the basis for these applications. Inova is based in Germany with headquarters for Inova Computers GmbH (the embedded computer business) in Kaufbeuren, Bavaria, and Inova Multimedia (the on-board Passenger Infotainment business) in Hildesheim, near Hannover. The Group also has offices in Austria, the USA, Switzerland, the UK and France. Inova has established a broad international customer base for its two business segments, embedded computing and passenger infotainment. The press release can be downloaded from the following link:


 

LOS ANGELES, CA -- (MARKET WIRE) -- June 25, 2007 -- The recipients of cash prizes totaling $268,000 for the First Annual José Iturbi International Music Competition at UCLA -- the biggest cash bounty of any classical piano and singing competition worldwide -- were announced today (piano) and yesterday (vocal) at Schoenberg Hall. The winners of the piano competition were: $50,000 First Prize -- Rufus Choi, USA, Age 30 $25,000 Second Prize -- Anastasia Markina, Russia/USA, Age 29 $15,000 Third Prize -- Evgheny Brakhman, Russia, Age 26 $10,000 Spanish Prize -- Angel Cabrera, Spain, Age 29 $10,000 People's Choice -- Rufus Choi, USA, Age 30 The winners of the vocal competition were: $50,000 First Prize -- Karen Slack, USA, Age 31 $25,000 Second Prize -- David Lomeli, Mexico, Age 26 $15,000 Third Prize -- Jamie Chamberlin, USA, Age 28 $10,000 Spanish Prize -- Michael Todd Simpson, USA, Age 29 $10,000 People's Choice -- David Lomeli, Mexico, Age 26 Photos and biographies of the cash prize recipients, finalists, semi-finalists and judges can be viewed at www.joseiturbifoundation.org. Representatives from 15 countries were selected to compete. "We were delighted that Los Angeles embraced this new world-class competition, and the public filled Schoenberg Hall to applaud the work of some of the world's most talented classical pianists and singers," said Donelle Dadigan, President of the José Iturbi Foundation. "The feedback and support from the community has been overwhelming. We are already at work planning next summer's competition." The six finalists in each category received cash stipends of $2,000. The 12 semi-finalists in each category received cash stipends of $1,000. The following is a list of the 12 semi-finalists in each category (finalists have *): Piano: Ran Dank, Israel, 26 Rufus Choi, USA, 30 * Jie Chen, China, 21 Cathal Breslin, Northern Ireland, 29 Angel Cabrera, Spain, 29 * Michelle Yelin Nam, South Korea, 22 Jie Yuan, China, 21 Claire Huangei, USA, 17 * Tommaso Cogato, Italy, 26 * Alexey Koltakov, Ukraine, 28 Evgheny Brakhman, Russia, 26 * Anastasia Markina, Russia, 29 * Vocal: Karen Vuong, USA, 23 Brian Cali, Italy, 24 Kalil Wilson, USA, 25 * Michael Todd Simpson, USA, 29 * David Lomeli, Mexico, 26 * Karen Slack, USA, 31 * Christopher Bolduc, USA, 27 Jamie Chamberlin, USA, 28 * Christin Wismann, USA, 23 Alison Cambridge, USA, 28 * Rebecca Ringle, USA, 27 Erica Strauss, USA, 31 Created in 1985 by Marion Seabury and Donelle Dadigan, The José Iturbi Foundation is a not-for-profit 501(c)(3) organization dedicated to continuing the legacy of José Iturbi, to fulfill his wish to make classical music accessible and enjoyable to people of all ages and walks of life, and to fulfill his desire of bringing to the public's attention today's greatest emerging vocal talents and musicians. The foundation's goal is to globally expand the passion for classical music through dynamic competition and compelling live performance. One of the greatest concert pianists of his time, José Iturbi was a composer, conductor and performer of international acclaim who starred as himself in seven MGM musicals including "Anchors Away" (1945) starring Frank Sinatra and Gene Kelly. He was the first classical musician to receive a Gold Record representing record sales in excess of one million and a star on the Hollywood Walk of Fame. Contact: Hans Fideau The Michael Russell Group (310) 939-9024 hans@michaelrussellgroup.com


 

Aftonbladet increases the cover price of its paper edition from SEK 9,- to SEK 10,- for the weekdays Monday to Saturday. The price increase will be valid from today, Monday the 25th of June. Given the level of circulation in Q2 2007, the price increase will contribute with approximately SEK 80 million yearly to the pre-tax profit of Aftonbladet. The decline in circulation for Aftonbladet is approx. 31,000 copies per publication day in Q2. The development for Aftonbladet in Q2 is otherwise in line with earlier observed trends; strong development for Blocket and Hitta, somewhat weaker development for Aftonbladet Nya Medier and continued high expenditure in relation to new initiatives (Punkt SE and TV7). Punkt SE has a strong growth in readership and has now 492,000 readers. Contact person: Managing director of Aftonbladet, Carl Gyllfors tel.: +46 706 762 107 Oslo, 25 June 2007 SCHIBSTED ASA --- End of Message --- Schibsted Apotekergt 10, Pb 1178 Sentrum Oslo Norway ISIN: NO0003028904; ;


 

* Deal includes $10 million upfront payment * Yakult responsible for all development, marketing and sales costs for Japan Martinsried/Munich (Germany) and Princeton, N.J., June 25, 2007 - GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ: GPCB) today announced that the Company has entered into a license agreement with Yakult Honsha Co. Ltd. for satraplatin in Japan. Under the terms of the agreement, Yakult gains exclusive commercialization rights to satraplatin for Japan and will take the lead in developing the drug in Japan. Yakult is to provide an upfront payment of ¥1.2 billion (~$10 million) to GPC Biotech as reimbursement for past satraplatin clinical development expenses. Yakult will also make GPC Biotech additional payments based on the achievement of certain regulatory filing and approval milestones. GPC Biotech will also receive a minimum of 21% royalties on sales of satraplatin in Japan. Bernd R. Seizinger, M.D., Ph.D., Chief Executive Officer of GPC Biotech, said: "We are delighted to have Yakult as our partner for Japan. Yakult's pharmaceutical business specializes in cancer and cancer-related ailments and has expanded its operations in this area. They are the inventor of irinotecan, which is a global standard drug for colorectal cancer, and have a solid track record of successfully commercializing another platinum-based drug, oxaliplatin, in Japan. They also share the development philosophy of GPC Biotech and plan to develop satraplatin for additional cancer indications for Japan. We look forward to a productive working relationship with Yakult." Teruo Yokokura, Ph.D., Head of Pharmaceutical Division of Yakult Honsha Co., Ltd., said: "We are excited to have the opportunity to develop and commercialize satraplatin for the Japanese market. We look forward to building on the solid foundation of the Phase 3 data from the satraplatin SPARC trial conducted by GPC Biotech in second-line hormone-refractory prostate cancer to bring this product through development, the regulatory process and onto the market in Japan. We believe that, if shown to be effective and well-tolerated, satraplatin, which is given as capsules that patients can take at home, could be an important option for cancer patients in Japan." About Satraplatin Satraplatin, an investigational drug, is a member of the platinum family of compounds. Platinum-based drugs are a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. All platinum drugs currently on the market require intravenous administration. Satraplatin is an oral compound that clinical trial patients are able to take at home. Satraplatin is not currently approved by the FDA in the United States, by the EMEA in the European Union or any other regulatory authority and no conclusions can or should be drawn regarding its safety and efficacy. A Phase 3 registrational trial, called SPARC, is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer whose prior chemotherapy has failed. Data from the trial showing a statistically significant improvement in progression-free survival and data on prostate specific antigen (PSA) have been presented at recent medical conferences. The satraplatin NDA, filed on February 15 2007, is currently under review by the U.S. FDA for hormone-refractory prostate cancer patients whose prior chemotherapy has failed and will be reviewed by the Oncologic Drugs Advisory Committee (ODAC) on July 24, 2007. The FDA has accepted for filing the Company's NDA and granted the NDA priority review status. An action from the FDA on the application is expected in August of this year. GPC Biotech has a co-development and license agreement with Pharmion GmbH, a wholly owned subsidiary of Pharmion Corporation, under which Pharmion has been granted exclusive commercialization rights to satraplatin for Europe and certain other territories. Pharmion has indicated it expects to complete the Marketing Authorization Application (MAA) for satraplatin for Europe in the second quarter of 2007. GPC Biotech in-licensed satraplatin from Spectrum Pharmaceuticals, Inc. in 2002. Satraplatin has been studied in clinical trials involving a range of tumors. Trials evaluating the effects of satraplatin in combination with radiation therapy, in combination with other cancer therapies and in a number of cancer types are underway or planned. About GPC Biotech GPC Biotech AG is a publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs. GPC Biotech's lead product candidate satraplatin is currently under review by the U.S. FDA for hormone-refractory prostate cancer patients whose prior chemotherapy has failed. GPC Biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany), and has a wholly owned U.S. subsidiary headquartered in Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at www.gpc-biotech.com. This press release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech AG, including statements relating to results of the SPARC trial and statements relating to the potential efficacy and safety profile of satraplatin. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. In particular, there can be no guarantee that additional information relating to the safety, efficacy or tolerability of satraplatin may be discovered upon further analysis of data from the SPARC trial or analysis of additional data from other ongoing clinical trials for satraplatin. Furthermore, we cannot guarantee that satraplatin will be approved for marketing in a timely manner, if at all, by regulatory authorities nor that, if marketed, satraplatin will be a successful commercial product. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2006 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of GPC Biotech. Forward-looking statements speak only as of the date on which they are made and GPC Biotech undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. For further information, please contact: GPC Biotech AG Fraunhoferstr. 20 82152 Martinsried/Munich, Germany Martin Braendle Director, Investor Relations & Corporate Communications Phone: +49 (0)89 8565-2693 ir@gpc-biotech.com In the U.S.: Laurie Doyle Director, Investor Relations & Corporate Communications Phone: +1 609 524 5884 usinvestors@gpc-biotech.com Additional Media Contacts: In Europe: Maitland Brian Hudspith Phone: +44 (0)20 7379 5151 bhudspith@maitland.co.uk In the U.S.: Russo Partners, LLC David Schull Phone: +1 212 845 4271 david.schull@russopartnersllc.com --- End of Message --- GPC Biotech AG Fraunhoferstr. 20 Martinsried WKN: 585150; ISIN: DE0005851505; Index: CDAX, MIDCAP, Prime All Share, TecDAX, HDAX, TECH All Share; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Geregelter Markt in Frankfurter Wertpapierbörse;


 

Seadrill has today entered into an agreement with Keppel O&M in Singapore to build a new semi-submersible self-erecting tender rig (semi-tender). Total capital expenditure for the semi-tender is estimated at US$195 million. The new rig is scheduled for delivery in the first quarter 2010 and will be based on a similar but improved design and specification as Seadrill's West Setia and West Berani. The new unit is targeted for deepwater drilling operations in combination with floating wellhead platforms such as TLPs and Spars in benign waters. Mr Kjell Jacobsen, Chief Executive Officer of Seadrill Management AS said: "The decision to add another advanced semi-tender rig to our existing tender rig fleet of fourteen units is based on the continued strength of the offshore drilling market. We expect future growth in demand for tender rigs both in West Africa and Southeast Asia". Analyst contact: Trond Brandsrud Chief Financial Officer Seadrill Management AS +47 51 30 99 19 Media contact: Kjell E Jacobsen Chief Executive Officer Seadrill Management AS +47 51 30 99 19 Seadrill Limited Hamilton, Bermuda June 25, 2007


 

The AGM on 12 April decided to demerge the non-operational properties owned by Norske Skog. The demerger was finalised on 23 June. The properties are now organised as separate limited companies under a property holding company, wholly owned by Norske Skogindustrier ASA. The group balance sheet and the shareholders will not be affected by the transaction. Oxenøen, 25 June 2007 Norske Skog Investor relations


 

* Significant blood sugar reductions seen across range of patient populations, including varied ethnic groups, the elderly, and those at high risk of developing diabetes * Galvus lowers blood sugar when added to a sulfonylurea, reinforcing efficacy in combination with commonly used diabetes medicines * Data confirm good tolerability in humans with studies showing incidence of side effects similar to placebo in monotherapy trials * European regulatory decision anticipated by end 2007; discussions continue on steps to gain US approval Basel, June 25, 2007 - Galvus® (vildagliptin), a new once-daily oral treatment for type 2 diabetes submitted for approval in the US and Europe, has been shown in new clinical data to deliver consistent and robust blood sugar reductions in patients with this progressive disease estimated to affect about 246 million people worldwide[1]. The findings, presented at the 67th Annual Scientific Sessions of the American Diabetes Association (ADA), are consistent with earlier results demonstrating the efficacy and tolerability of Galvus both as a monotherapy and when added to many commonly used diabetes medicines in a range of patients across the type 2 diabetes disease spectrum[2],[3],[4]. These include varied ethnic groups[3] and the elderly[4] as well as patients with impaired glucose tolerance at high risk of developing diabetes[5] and those with uncontrolled blood sugar levels[6]. "These results further reinforce the clinical benefits of Galvus as an important new treatment option for patients with type 2 diabetes," said James Shannon, MD, Global Head of Development at Novartis Pharma AG. "We remain convinced that Galvus is safe and effective and will continue to work with health authorities to ensure this medicine can be made available to patients worldwide as soon as possible." A member of a new class of diabetes medicines called DPP-4 inhibitors, Galvus is currently approved in Brazil and Mexico. A European regulatory decision is anticipated by the end of 2007. In the US, Novartis received an approvable letter in February 2007, and discussions are ongoing with the US Food and Drug Administration on steps needed to move forward to approval. New data presented at the ADA showed that Galvus, when added to the sulfonylurea glimepiride, produced an additional significant blood sugar reduction of 0.6% in HbA1c compared to glimepiride alone[2]. HbA1c is a measure of plasma glucose levels over the preceding three months, and indicates how well diabetes is being controlled over time. These data supplement existing findings with Galvus when used in combination with widely prescribed diabetes medicines such as metformin, an oral thiazolidinedione (TZD) and insulin. In the Galvus clinical program no evidence has been seen of overall weight gain[7] or hypoglycemia (dangerously low blood sugar levels)[8], side effects commonly associated with some type 2 diabetes medications. The overall incidence of side effects, including edema (fluid retention), was similar to placebo in monotherapy trials[8]. "Taken together, these data provide evidence that vildagliptin could provide a safe, effective and well-tolerated therapy when used alone or in combination with other anti-diabetic therapies," said Alan J. Garber, MD, Ph.D, Professor of Medicine, Biochemistry and Molecular Biology, and Molecular and Cellular Biology at the Baylor College of Medicine in Houston, Texas. "The majority of patients with type 2 diabetes have not achieved their A1c goals and it may therefore be helpful to have additional therapeutic options such as vildagliptin." In most developed nations, diabetes is the fourth leading cause of death[9]. Controlling blood sugar levels is difficult even among patients receiving treatment, and more than half of patients with type 2 diabetes currently taking medicines are still not reaching their blood sugar goals[10]. When left untreated or not kept under control, type 2 diabetes can lead to heart and kidney disease, blindness, and vascular or neurological problems[1]. Galvus works through a novel mechanism of action, targeting a dysfunction in the pancreatic islets that causes high blood sugar levels in people with type 2 diabetes. In clinical studies, Galvus has demonstrated significant reductions in blood sugar sustained at two years[8]. At a special ceremony during the congress, Novartis presented its 9th annual Novartis Prize in Diabetes to recognize five recipients for innovative patient-oriented diabetes research. For more information about the Novartis Prize in Diabetes, please visit www.diabetesaward.novartis.com. Disclaimer The foregoing press release contains forward-looking statements that can be identified by the use of forward-looking terminology such as "anticipated,", "continue," "could," "may," "will" or by express or implied discussions regarding potential future regulatory filings, approvals or future sales of Galvus. Such forward-looking statements reflect the current views of Novartis regarding future events and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any future regulatory filings will satisfy regulatory requirements regarding Galvus, that Galvus will be approved by regulatory authorities for any indication, that Galvus will be brought to market in the EU, the US or any additional market or that Galvus will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of Galvus could be affected by, among other things, additional analysis of clinical data; new clinical data; unexpected clinical trial results; unexpected regulatory actions or delays in government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures, as well as the additional risks and factors discussed in Novartis AG's Form 20-F filed with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Novartis is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. About Novartis Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com. References [1] International Diabetes Federation. Diabetes Atlas. Third Edition 2006. [2] Garber, A J et al. Efficacy and Tolerability of Vildagliptin Added to a Sulfonylurea (SU) in Patients with Type 2 Diabetes (T2DM). Presented at ADA 22-26 June 2007 (501-P). [3] Rosenstock, J et al. Consistent Efficacy and Safety of Vildagliptin Monotherapy Across Ethnicities. Presented at ADA 22-26 June 2007 (2141-PO). [4] Pratley, R E et al. Benefit/Risk Assessment of Vildagliptin in the Elderly: Pooled Analysis of 5 Monotherapy Studies. Presented at ADA 22-26 June 2007 (507-P). [5] Rosenstock, J et al. Effects of Vildagliptin in Subjects with IGT. Presented at ADA 22-26 June 2007 (505-P). [6] Scherbaum, W A et al. Efficacy and Tolerability of Vildagliptin in Drug-Naïve Patients with Type 2 Diabetes (T2DM) and Mild Hyperglycemia. Presented at ADA 22-26 June 2007 (503-P). [7] Foley, JE et al. Effect of Vildagliptin Monotherapy on Body Weight in Drug-Naive Patients With Type 2 Diabetes (T2DM). Presented at IDF, December 2006 (Abstract 826). [8] Novartis. Data on file. [9] International Diabetes Federation. "Did You Know?" 2007: http://www.idf.org/home/index.cfm?node=37 [10] Saydah, S H et al. Poor Control of Risk Factors for Vascular Disease Among Adults with Previously Diagnosed Diabetes. JAMA 2004; 291(3):335-342. # # # Novartis Media Relations Corinne Hoff Richard Booton Novartis Global Media Relations Novartis Pharma Communications +41 61 324 9577 (direct) +41 61 324 4356 (direct) +41 79 248 5717 (mobile) +41 79 753 2593 (mobile) corinne.hoff@novartis.com richard.booton@novartis.com e-mail: media.relations@novartis.com Novartis Investor Relations International North America Ruth Metzler-Arnold +41 61 324 Ronen Tamir +1 212 830 7944 2433 Katharina Ambühl +41 61 324 5316 Jill Pozarek +1 212 830 2445 Nafida Bendali +41 61 324 3514 Edwin Valeriano +1 212 830 2456 Jason Hannon +41 61 324 2152 Thomas Hungerbuehler +41 61 324 8425 Richard Jarvis +41 61 324 4353 e-mail: investor.relations@novartis.com --- End of Message --- Novartis International AG Posfach Basel WKN: 904278; ISIN: CH0012005267; Index: SLCI, SMI, SPI, SLIFE; Listed: Main Market in SWX Swiss Exchange, ZLS in BX Berne eXchange;


 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons This form is intended for use by an issuer to make a RIS notification required by the Market Abuse Rules and section 53 (as extended by section 64 of the Companies Act 1990) or entered into the issuer's register in accordance with section 59 of the Companies Act 1990. (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. (2) An issuer making a notification in respect of a derivative relating to the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. (3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24 (4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete the boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. All relevant boxes should be completed in block capital letters +-------------------------------------------------------------------+ | 1 | Name of the Issuer | 2 | State whether the | | | | | notification relates to: | | | IRISH CONTINENTAL GROUP | | (i) a transaction | | | PLC | | notified in accordance | | | | | with Market Abuse Rules; | | | | | | | | | | (ii) a disclosure made | | | | | in accordance with section | | | | | 53 (as extended by section | | | | | 64 of the Companies Act | | | | | 1990) or entered into the | | | | | issuer's register in | | | | | accordance with section 59 | | | | | of the Companies Act 1990; | | | | | or | | | | | (iii) both (i) and (ii). | | | | | | | | | | (iii) both | | | | | | |----+----------------------------+----+----------------------------| | 3 | Name of person discharging | 4 | State whether notification | | | managerial | | relates to a person | | | responsibilities/director | | connected with a person | | | EAMONN ROTHWELL | | discharging managerial | | | | | responsibilities/director | | | | | named in 3 and identify | | | | | the connected person | | | | | N/A | |----+----------------------------+----+----------------------------| | 5 | Indicate whether the | 6 | Description of shares | | | notification is in respect | | (including class) | | | of a holding of the person | | debentures or derivatives | | | referred to in 3 or 4 | | or financial instruments | | | above or in respect of a | | relating to shares | | | non-beneficial interest | | ICG UNITS (each consisting | | | Yes, EAMONN ROTHWELL | | of 1 ordinary share and 3 | | | | | redeemable shares) | |----+----------------------------+----+----------------------------| | 7 | Name of registered | 8 | State the nature of the | | | shareholder(s) and, if | | transaction | | | more than one, number of | | ACQUISITION OF INTEREST IN | | | shares held by each of | | SHARES | | | them | | | | | EAMONN ROTHWELL - | | | | | 3,788,771 ICG UNITS | | | |----+----------------------------+----+----------------------------| | 9 | Number of shares, | 10 | Percentage of issued class | | | debentures or financial | | acquired (treasury shares | | | instruments relating to | | of that class should not | | | shares acquired | | be taken into account when | | | 1,750,200 ICG UNITS | | calculating percentage) | | | | | 7.4% | |----+----------------------------+----+----------------------------| | 11 | Number of shares, | 12 | Percentage of issued class | | | debentures or financial | | disposed (treasury shares | | | instruments relating to | | of that class should not | | | shares disposed | | be taken into account when | | | N/A | | calculating percentage) | | | | | N/A | |----+----------------------------+----+----------------------------| | 13 | Price per share or value | 14 | Date and place of | | | of transaction | | transaction | | | ¤22.00 | | 20TH JUNE 2007, DUBLIN | |----+----------------------------+----+----------------------------| | 15 | Total holding following | 16 | Date issuer informed of | | | notification and total | | transaction | | | percentage holding | | 20TH JUNE 2007 | | | following notification | | | | | (any treasury shares | | | | | should not be taken into | | | | | account when calculating | | | | | percentage) | | | | | 3,788,711 ICG | | | | | UNITS 16.02% | | | +-------------------------------------------------------------------+ If a person discharging managerial responsibilities has been granted options by the issuer, complete the following boxes: +-------------------------------------------------------------------+ | 17 | Date of grant | 18 | Period during which or | | | | | date on which it can be | | | | | exercised | |----+-------------------------------+----+-------------------------| | 19 | Total amount paid (if any) | 20 | Description of shares | | | for grant of the option | | or debentures involved | | | | | (class and number) | |----+-------------------------------+----+-------------------------| | 21 | Exercise price (if fixed at | 22 | Total number of shares | | | time of grant) or indication | | or debentures over | | | that the price is to be fixed | | which options are held | | | at the time of exercise | | following notification | |----+-------------------------------+----+-------------------------| | 23 | Any additional information | 24 | Name of contact and | | | | | telephone number for | | | | | queries | | | | | TOM CORCORAN - 01 | | | | | 8552222 | |-------------------------------------------------------------------| | Name and signature of duly designated officer of issuer | | responsible for making notification | | ____________________________________________________ | | Date of notification ________________22 JUNE | | 2007___________________ | +-------------------------------------------------------------------+ ---END OF MESSAGE---


 

Kinepolis Group announces that the decline in visitor numbers recorded until mid-May has only been partly offset over the past few weeks. In the context of its general meeting (18/05/07), Kinepolis had previously reported that sales of cinema tickets were down compared with last year, in line with the decline in the market, as a result of the persistent fine weather and the mediocre range of films on offer up to and including the month of April. Some ground has been gained over the past few weeks thanks partly to box-office hits such as Spiderman 3, Ocean's 13, Pirates of the Caribbean and Shrek 3. However, the recovery is not going as smoothly as had been hoped. The fall in visitor numbers recorded will have an effect on the group's current half-yearly result and possibly on its current annual result. The process of organising the real-estate structure is continuing so as to be able to develop and diversify the assets comprising land and buildings. There are no plans to sell real estate, contrary to recent hypotheses put forward in the media. Kinepolis will be opening its 23rd cinema complex in Ostend (Belgium) on 8 July. On Tuesday, Kinepolis announced another Belgian construction project in Liège for 2009. Kinepolis will be publishing the visitor numbers for the first six months on 11/07/07 and the half-yearly results on 24/08/07.


 

ANNOUNCEMENT DATED 22 JUNE 2007 Bear Stearns Global Asset Holdings, Ltd. Issue of up to SEK 500,000,000 Notes Linked to the a Basket Of Currencies due 2010 (the "Notes") ISIN Code: SE0002015867 under the U.S.$30,000,000,000 Euro Medium Term Note Programme NOTICE OF ISSUE AMOUNT The offer period for the Notes (described above) ended at 5:00pm (Central European Time) on 31 May 2007. Pursuant to the Prospectus for the issue of the Notes dated 24 April 2007, the Aggregate Nominal Amount of the Notes to be issued on 26 June 2007 will be SEK 236,890,000. Enquiries: Transaction Management Group Bear, Stearns International Limited One Canada Square London E14 5AD Tel: +44 20 7516 6817 Fax: +44 20 7516 5001 ---END OF MESSAGE---


 
Hitt og þetta
22. júní 2007

Result of AGM

Centrom Group plc The Company is pleased to announce that at the annual general meeting held earlier today shareholders approved all resolutions set out in the notice of meeting. For further information please contact: Gerald Malone, Chairman 07711 085611 Centrom Group plc John Webb 020 7490 3788 Marshall Securities (Nominated adviser) ---END OF MESSAGE---


 

` FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | DEEPHAVEN CAPITAL | | | MANAGEMENT LLC | |-----------------------------------------------+-------------------| | Company dealt in | FKI Plc | |-----------------------------------------------+-------------------| | Class of relevant security to which the | 10p Ordinary | | dealings being disclosed relate (Note 2) | | |-----------------------------------------------+-------------------| | Date of dealing | 21 June 2007 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------+ | | Long | Short | | | | | |-------------------------------+--------------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (2) Derivatives (other than | 2,787,353 | 0.4993 | | | | options) | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | Total | 2,787,353 | 0.4993 | | | | | | | | | +-------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +-------------------------------------------------------------------+ | Class of relevant security: | Long | Short | | | | | |-------------------------------------+--------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (2) Derivatives (other than | | | | | | options) | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | Total | | | | | | | | | | | +-------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short | Number of securities | Price per | | name, | (Note 6) | (Note 7) | unit (Note 5) | | e.g. CFD | | | | |----------+------------+---------------------------+---------------| | | | | | | CFD | SHORT | 400,000 | 126.8999 | | CFD | SHORT | 500,000 | 126.3600 | | CFD | SHORT | 2,462,647 | 125.0757 | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 22nd June 2007 | |--------------------------------------------------+----------------| | Contact name | James Feast | |--------------------------------------------------+----------------| | Telephone number | 0207 469 1901 | |--------------------------------------------------+----------------| | If a connected EFM, name of offeree/offeror with | | | which connected | | |--------------------------------------------------+----------------| | If a connected EFM, state nature of connection | | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

-FINAL EU DECISION EXPECTED WITHIN THREE MONTHS- Basel/Switzerland and Bridgewater NJ/USA, 22 June 2007 Speedel (SWX: SPPN) today welcomed the announcement that Novartis has received a positive opinion recommending European Union approval of SPP100 (Rasilez[i]) as the first-in-class once daily direct renin inhibitor for the treatment of hypertension. The Committee for Medicinal Products for Human Use (CHMP) issued the positive opinion for Rasilez based on data from more than 7,800 patients in 44 clinical studies which was submitted by Novartis in September 2006. The European Commission generally follows the CHMP's recommendations and is expected to issue a decision within three months. SPP100 was approved by the US Food and Drug Administration (FDA) and launched by Novartis in the US in March 2007 under the trade name Tekturna to treat hypertension both as monotherapy and in combination with other anti-hypertensives. Speedel successfully developed SPP100 through Phase I and II clinical trials before Novartis exercised its license-back option in 2002. Dr. J. Chris Jensen, Speedel Head of Scientific Affairs, commented: "We welcome this positive opinion which brings SPP100 (Rasilez) one step closer to European patients as the first novel therapy for treating high blood pressure since 1995. There is a clear unmet medical need with more than 40% of treated patients not achieving control levels for their high blood pressure - even when using existing therapies." The clinical data submitted by Novartis showed that Rasilez provided significant blood pressure reductions for a full 24 hours [ii]. Furthermore, Rasilez provided added efficacy when used in combination with other commonly used blood pressure therapies [iii][iv]. In clinical trials, the FDA approved doses of Tekturna demonstrated a placebo-like tolerability profile [v]. About SPP100 (aliskiren, Tekturna/Rasilez [vi]) SPP100 (aliskiren, Tekturna/Rasilez) is the first-in-class oral direct renin inhibitor. The development of SPP100 is the result of over 20 years of research on renin. Renin is the rate-limiting enzyme at the top of the Renin Angiotensin System (RAS), one of the key regulators of blood pressure. The RAS is a cascade, starting with renin, leading to angiotensin I and finally to angiotensin II. Angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II receptor antagonists (ARBs) have been developed to block this system "down stream" and have shown clinical efficacy in patients with hypertension and other cardiovascular diseases. By inhibiting renin at the top of the RAS, SPP100 decreases the system's activity, as measured by plasma renin activity (PRA). Lowering PRA is believed to be very important in end-organ protection (e.g. heart and kidney). PRA is an independent risk factor and direct surrogate marker for several cardio-renal diseases, such as myocardial infarction and chronic renal disease. Renin inhibitors lower PRA whereas most current leading anti-hypertensive drug classes such as ACE-Is and ARBs increase PRA levels. Speedel in-licensed SPP100 from Novartis in 1999 and successfully completed 18 clinical trials, through Phase I and II in about 500 patients and healthy volunteers. Based on the results generated during this programme, Novartis exercised a license-back option in 2002, and subsequently Novartis started trials with SPP100 in Phase III as monotherapy for hypertension and in Phase IIb as combination therapy. Regulatory approval was given by the US FDA in March 2007 and a regulatory submission was made by Novartis in the EU during Q3 2006. Speedel believes that it is the first company to establish successfully a clinical proof of concept in Phase II and to have developed and filed for patent protection a commercially viable manufacturing process for a renin inhibitor, an area of industry research for over 20 years. In a Phase II study of 200 patients conducted by Speedel, it was demonstrated that SPP100 achieves dose-dependent blood pressure reduction. The study also showed that 150mg and 300mg SPP100 once daily were comparable to Losartan 100mg, which is double the usual starting dose of this ARB (Stanton, Jensen, Nussberger, O'Brien, Hypertension.2003; 42: 1137-1143). About Speedel Speedel is a public biopharmaceutical company that seeks to create value for patients, partners and investors by developing innovative therapies for cardiovascular and metabolic diseases. Speedel is a world leader in renin inhibition, a promising new approach with significant potential for treating cardiovascular diseases. Our lead compound SPP100 (Tekturna/Rasilez [vii]), the first-in-class direct renin inhibitor, was in-licensed from Novartis in 1999 and licensed-back to Novartis Pharma in 2002 for further development and commercialisation; SPP100 was approved by the FDA in the US in March 2007, and filed by Novartis with the EMEA in the EU in Q3 2006. Our pipeline covers three different modes of action, and in addition to SPP100, includes SPP301 in Phase III (on hold), SPP200 in Phase II, SPP635 in Phase Il, SPP1148 in Phase I and several pre-clinical projects. Speedel develops novel product candidates through focused innovation and smart drug development from lead identification to the end of Phase II. We either partner with big pharma for Phase III and commercialisation in primary-care indications, or we may ourselves complete Phase III development in specialist indications. Candidate compounds for development and the company's intellectual property come from our late-stage research unit Speedel Experimenta and from in-licensing. Our team of approximately 70 employees, including over 30 experienced pharmaceutical scientists, is located at our headquarters and laboratories in Basel, Switzerland and at offices in New Jersey, USA and Tokyo, Japan. In January 2007 the company raised gross proceeds of CHF 55.5 million (approximately EUR 34.3 million or USD 44.5 million) through a convertible bond issue. In March 2006 the company raised gross proceeds of CHF 83.95 million (approximately EUR 53m or USD 64m) through the public offering of 500,000 treasury shares. Previously, as a private company, we raised gross proceeds of CHF 255 million (approximately EUR 157 million or USD 204 million) from private placements of equity securities and two convertible loans including the conversion premiums. We have had total revenues, principally from milestone payments, of CHF 57.7 million (approximately EUR 37 million or USD 44 million). The company's shares were listed in September 2005 on the SWX Swiss Exchange under the symbol SPPN. Forward looking statements This press release includes forward-looking statements that involve substantial risks and uncertainties. These forward-looking statements are based on our current expectations and projections about future events. All statements, other than statements of historical facts, regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The word "may" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations described in these forward-looking statements and you should not place undue reliance on them. There can be no assurance that actual results of our research and development activities and our results of operations will not differ materially from these expectations. Factors that could cause actual results to differ from expectations include, among others: our or our partners' ability to develop safe and efficacious products; our or our partners' ability to achieve positive results in clinical trials; our or our partners' ability to obtain marketing approval and market acceptance for our product candidates; our ability to enter into future collaboration and licensing agreements; the impact of competition and technological change; existing and future regulations affecting our business; changes in governmental oversight of pharmaceutical product development; the future scope of our patent coverage or that of third parties; the effects of any future litigation; general economic and business conditions, both internationally and within our industry, including exchange rate variations; and our future financing plans. -- Ends -- For further information please contact Nick Miles Director Communications & Investor Relations Speedel Hirschgässlein 11 CH - 4051 Basel Switzerland T +41 (0) 61 206 40 00 D +41 (0) 61 206 40 14 F +41 (0) 61 206 40 01 M +41 (0) 79 446 25 21 E nick.miles@speedel.com www.speedel.com Frank LaSaracina Managing Director Speedel Pharmaceuticals Inc 1661 Route 22 West P.O. Box 6532 Bridgewater, NJ 08807 United States of America T +1 732 537 2290 F +1 732 537 2292 M +1 908 338 0501 E frank.lasaracina@speedel.com www.speedel.com [1] Tekturna/Rasilez® are Novartis trademarks [2] Mitchell B, Oh J, Chung J, et al. Once-Daily Aliskiren Provides Effective, Smooth 24-Hour Blood Pressure Control in Patients with Hypertension. Presented at the American Society of Hypertension 21st Scientific Meeting & Exposition, May 17, 2006 [3] Oparil S, Yarows S, Patel S, et al. "The Direct Renin Inhibitor Aliskiren in Combination With the Angiotensin Receptor Blocker Valsartan Provides Additional Blood Pressure-Lowering Effects Compared With Either Agent Alone in Patients With Hypertension." Poster presented at American College of Cardiology 56th Annual Scientific Session, March 2007 [4] Uresin Y, Taylor A, Kilo C, Tschope D, Santonastaso M, Ibram G, Fang H, Satlin A. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. Poster presented at the 16th Scientific Meeting of the European Society of Hypertension 2006 [5] Uresin Y, Taylor A, Kilo C, Tschope D, Santonastaso M, Ibram G, Fang H, Satlin A. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. Poster presented at the 16th Scientific Meeting of the European Society of Hypertension 2006 [6] Tekturna/Rasilez® are Novartis Trademarks [7] Tekturna/Rasilez® are Novartis Trademarks


 

* Strong need for new therapies like Rasilez as studies estimate that nearly 70% of patients with high blood pressure do not achieve treatment goals[1],[2] * Rasilez the first new type of high blood pressure medicine in more than a decade, launched in US in March 2007 * Used alone or in combination with other medicines, Rasilez provides significant blood pressure reductions for 24 hours and beyond[3] Basel, June 22, 2007 - Novartis has received a positive opinion recommending European Union approval of Rasilez® (aliskiren) as the first new type of high blood pressure treatment in more than a decade. The Committee for Medicinal Products for Human Use (CHMP), which reviews medicines for the European Commission, issued the positive opinion for Rasilez based on data from more than 7,800 patients in 44 clinical studies. The Commission generally follows the CHMP's recommendations and is expected to issue a decision within three months. The clinical trial program showed that Rasilez provided significant blood pressure reductions for 24 hours and beyond3. Furthermore, Rasilez provided added efficacy when used in combination with other commonly used blood pressure medications[4],[5]. Studies estimate that nearly one billion people may have high blood pressure and that nearly 70% of patients with high blood pressure never reach healthy blood pressure levels. As a result, they live at risk of complications like heart attack, stroke, blindness and premature death, creating a strong need for new therapies like Rasilez[1],[2],[3]. "This important milestone for Rasilez comes just days after the US approval of Exforge as our new fixed combination therapy. Following the anticipated EU approval of Rasilez, our new antihypertensive medicines will be made available to patients in the US, Europe and elsewhere as quickly as possible. We have made significant progress in developing a broad and complementary portfolio of medicines to help physicians worldwide treat patients with high blood pressure," said Thomas Ebeling, CEO of Novartis Pharma. Rasilez is the first in a new class of drugs called direct renin inhibitors. It acts by directly inhibiting renin, an enzyme that triggers a process leading to high blood pressure. The medication received its first approval in March 2007 from the US Food and Drug Administration under the trade name Tekturna®. "If approved, Rasilez will offer millions of Europeans an important new treatment option for high blood pressure," said James Shannon, MD, Global Head of Development at Novartis Pharma AG. "This positive opinion is highly encouraging since Rasilez has been shown to help a wide variety of people by providing long-lasting blood pressure control." In clinical trials, the approved doses of Rasilez demonstrated a placebo-like tolerability profile4. Rasilez was developed in collaboration with Speedel. Blood pressure measurements consist of two values: the first represents the pressure within blood vessels when the heart contracts, while the second represents the pressure when the heart is at rest between beats. Blood pressure is measured in millimeters of mercury (mmHg), with normal blood pressure levels between 120/80 mmHg and 140/90 mmHg. Disclaimer The foregoing release contains forward-looking statements which can be identified by the use of terminology such as "generally follows," "anticipated," "will," "expected," "may," "estimate" or similar expressions, or by express or implied discussions regarding the potential regulatory approval of Rasilez or future sales of Rasilez. Such forward-looking statements reflect the current views of Novartis regarding future events and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Rasilez will be approved for any indications or brought to market in the European Union or in any other market or that Rasilez will reach any particular sales levels. In particular, management's expectations regarding the approval and commercialization of Rasilez could be affected by, among other things, additional analysis of clinical data; new clinical data; unexpected clinical trial results; unexpected regulatory actions or delays or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; increased government, industry, and general public pricing pressures; as well as other risks and factors referred to in Novartis AG's Form 20-F on file with the U.S. Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com. References 1. Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007; 49:69-75. 2. Chobanian AV, Bakris GL, Black HR, et al. and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252. 3. American Heart Association. International Cardiovascular Disease Statistics fact sheet. www.americanheart.org. 4. Mitchell B, Oh J, Chung J, et al. Once-Daily Aliskiren Provides Effective, Smooth 24-Hour Blood Pressure Control in Patients with Hypertension. Presented at the American Society of Hypertension 21st Scientific Meeting & Exposition, May 17, 2006 5. Oparil S, Yarows S, Patel S, et al. "The Direct Renin Inhibitor Aliskiren in Combination With the Angiotensin Receptor Blocker Valsartan Provides Additional Blood Pressure-Lowering Effects Compared With Either Agent Alone in Patients With Hypertension." Poster presented at American College of Cardiology 56th Annual Scientific Session, March 2007. 6. Uresin Y, Taylor A, Kilo C, Tschope D, Santonastaso M, Ibram G, Fang H, Satlin A. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. Poster to be presented at the 16th Scientific Meeting of the European Society of Hypertension. 2006. # # # Novartis Media Relations Corinne Hoff Richard Booton Novartis Global Media Relations Novartis Pharma Communications +41 61 324 9577 (direct) +41 61 324 4356 (direct) +41 79 248 5717 (mobile) +41 79 753 2593 (mobile) corinne.hoff@novartis.com richard.booton@novartis.com e-mail: media.relations@novartis.com Novartis Investor Relations International Ruth Metzler-Arnold +41 61 324 7944 Katharina Ambühl +41 61 324 5316 Nafida Bendali +41 61 324 3514 Jason Hannon +41 61 324 2152 Thomas Hungerbuehler +41 61 324 8425 Richard Jarvis +41 61 324 4353 North America Ronen Tamir +1 212 830 2433 Jill Pozarek +1 212 830 2445 Edwin Valeriano +1 212 830 2456 e-mail: investor.relations@novartis.com --- End of Message --- Novartis International AG Posfach Basel WKN: 904278; ISIN: CH0012005267; Index: SLCI, SMI, SPI, SLIFE; Listed: Main Market in SWX Swiss Exchange, ZLS in BX Berne eXchange;


 

In accordance with announcement, dated 15 June 2007, shares owned by Kjalar Invest B.V. and Egla hf. in Kaupthing Bank hf., in total 73,153,352 shares, have now been transferred to a newly founded holding company, Egla Invest B.V.


 

Hamilton, Bermuda, June 22, 2007. Nordic American Tanker Shipping Limited (NYSE:NAT) today announced that it has changed the timing for its annual meeting for shareholders, formerly scheduled for June 20, 2007, to July 31, 2007, at 10:00 AM, New York City Time at the offices of Seward & Kissel LLP, One Battery Park Plaza, New York, New York. The timing of the meeting was changed due to technical problems with the distribution of the Company's proxy materials for the previously scheduled annual meeting. These problems were out of the Company's control. Updated proxy materials will be distributed to shareholders for the rescheduled meeting. Nordic American Tanker Shipping Limited owns 12 Suezmax oil tankers. The Company's common shares trade on the New York Stock Exchange under the ticker symbol "NAT". * * * * * Contacts: Scandic American Shipping Ltd Manager for: Nordic American Tanker Shipping Ltd. P.O Box 56, 3201 Sandefjord, Norway Tel: + 47 33 42 73 00 E-mail: nat@scandicamerican.com Web-site: www.nat.bm Rolf Amundsen, Investor Relations Nordic American Tanker Shipping Ltd. Tel: +1 800 601 9079 or + 47 908 26 906 Herbjørn Hansson, Chairman & CEO Nordic American Tanker Shipping Ltd. Tel: +1 866 805 9504 or + 47 901 46 291 Gary Wolfe Seward & Kissel LLP, New York, USA Tel: +1 212 574 1223


 

Kongsberg Defence & Aerospace and Data Respons is collaborating in developing and delivering Embedded Solutions for weapon control systems in military vehicles to the defence market. The development phase has a preliminary framework of NOK 18 million. The subsequent delivery phase is complex and represents a considerable potential for Data Respons. After increasing customer relations, Data Respons advances to be a strategically important partner for Kongsberg Defence & Aerospace within the Embedded Solutions area. - This undertaking is a milestone for Data Respons. We are very pleased that Kongsberg Defence & Aerospace have chosen to reinforce the cooperation with Data Respons, and that we are included in solution assignments with greater extent than we previously have been, says CEO of Data Respons ASA Kenneth Ragnvaldsen. - Data Respons will deliver a computer platform which will be integrated into our products for military vehicles, says Egil Haugsdal, Executive Vice President, Kongsberg Defence & Aerospace. An important reason for Data Respons being chosen is local presence, their broad competency within embedded design and their experience with serial delivery of advanced data solutions witch are exposed to extreme conditions. Kongsberg Defence & Aerospace is Norway's premier supplier of high-technology defence systems. The company delivers solutions to the Norwegian Armed Forces as well as the international defence market. FOR FURTHER INFORMATION PLEASE CONTACT: Kenneth Ragnvaldsen, CEO, Data Respons ASA, phone: +47 67 11 20 00 Mob: +47 913 90 918. ABOUT DATA RESPONS Data Respons` vision is to become leading in Europe within 2010 on Embedded Solutions in the industrial market. Embedded Solutions can be described as being the brains of a machine, system or industrial end product. Data Respons supplies Embedded Solutions to leading OEM companies, system integrators and vertical product suppliers in a range of market segments such as defence, offshore, automation, medical equipment, surveillance, transport, telecommunications and other industries. Data Respons` customers include Ericsson, Nera, ABB, Brüel & Kjær, Anritsu and Saab. Data Respons ASA is listed on the Oslo Stock Exchange (Ticker: DAT), and is part of the information technology index. The company has offices in Denmark, Finland, Norway, Sweden and Germany. At the close of the 1st quarter 2007 the company had a total of 259 employees. More information on Data Respons ASA can be found on our website: http://www.datarespons.com


 

REYKJAVIK, 22 June 2007. Bakkavör Group has, in cooperation with Glitnir Bank, acquired the remaining 60% stake in Creative Foods, a Chinese salad manufacturer. Bakkavör Group and Glitnir acquired a 40% stake in the company in March 2006 after co-founding Bakkavör China with the purpose of facilitating the transaction and exploring further investment opportunities in China. Today, Bakkavör Group holds an 80% share in Creative Foods while Glitnir Bank holds 20%. Glitnir provided advice and funded the deal. The acquisition price remains confidential. The acquisition will not have a material effect on the Group's overall trading results during this financial year. Creative Foods grows produce and packs around 250 salad products in five factories and employs around 750 people, supplying supermarkets and foodservice chains in China. Among its key customers is Yum! Brands, one of the largest restaurant chains in the world which manages outlets such as Kentucky Fried Chicken and Pizza Hut. Other customers include Wal*Mart, Carrefour, Starbucks and Burger King. Einar Gústafsson, Managing Director of Bakkavör Asia, commented: "Creative Foods' performance has exceeded our expectations with pro-forma sales growth of 23% in 2006 and 15% in the first quarter of 2007. Increased demand for healthy, convenient quality foods in China offers us great opportunities for growth. We aim to strengthen our position in the Chinese food market, which is forecast to grow by 30% in the next four years, and gain strong foothold in the various other high-growing markets across Asia." Magnús Bjarnason, Executive Vice President, International Banking, Glitnir, commented: "We are very pleased with the growth in our China operations. Glitnir's strategy is to work closely with our customers on profitable projects and the co-operation with Bakkavör is in line with that strategy. The food industry is one of the niche segments in which Glitnir aims to grow internationally and Creative Foods is a well run company with great growth potential. Our team in Shanghai has done a very good job working with the Bakkavör Asia team on the transaction." For further information, please contact: Hildur Árnadóttir, Chief Financial Officer, Bakkavör Group Tel: +354 858-9706 Einar Gústafsson, Managing Director of Bakkavör Asia Tel: +44 20 8728 5100 Magnús Bjarnason, Executive Vice President, International Banking, Glitnir Tel: +354 440-4523/844-4523 About Bakkavör Group Bakkavör Group is a leading international food manufacturing company specialising in fresh prepared foods and produce. The Group operates approximately 50 factories and employs over 17,000 people in seven countries. The Group's Head Office is in Reykjavík, Iceland, and the business is listed on the OMX Nordic Exchange in Iceland, (www.omxgroup.com/nordicexchange Ticker: BAKK). Bakkavör Group was founded in 1986 and during its 20-year history the business has grown significantly and today Bakkavör Group is a leading provider of fresh prepared foods and produce. Bakkavör Group has attained leading market positions in its key market areas of ready meals, pizzas, convenience salads and leafy salads. In total, the Group makes over 4,700 products in 17 product categories, which are developed and sold predominantly under its customers' own brands. In addition to the UK and Iceland, the Group also has business operations in France, Belgium, Spain, South Africa and China and is well-positioned for further expansion. To subscribe to Bakkavör Group's mailing list, please log onto: www.bakkavor.com/subscribe


 
Hitt og þetta
22. júní 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |----------------------------------------------+--------------------| | Company dealt in | Domestic & General | | | Group Plc | |----------------------------------------------+--------------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |----------------------------------------------+--------------------| | Date of dealing | 21st June 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price | | securities | (Note 3) | paid | | purchased | | (Note 3) | |---------------------------+--------------------+------------------| | | | | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |-------------------------+--------------------+--------------------| | 200 | 1,249.85 | 1,249.85 | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +-------------------------------------------------------------------+ | Date of disclosure | 22nd June 2007 | |----------------------------------------+--------------------------| | Contact name | Muz Petkar | |----------------------------------------+--------------------------| | Telephone number | 0207 991 6187 | |----------------------------------------+--------------------------| | Name of offeree/offeror with which | Domestic & General Group | | connected | Plc | |----------------------------------------+--------------------------| | Nature of connection (Note 6) | Connected Advisor | +-------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

(Oslo, 22. June, 2007) Northern Logistic Property ASA, Financial Calendar Northern Logistic Property ASA (NLP) will report financial result as follows in 2007: Friday 24. August 2007: 2nd Quarter 2007 Thursday 15. November 2007: 3rd Quarter 2007 Further information: Erik Dahl, CFO, Northern Logistic Property ASA, tel: +47 450 55 000


 

Aachen (Germany) 22 June 2007 - The biopharmaceutical company PAION AG (FSE: PA8) announced today that the management board and the supervisory board agreed on an action plan to significantly reduce external and internal costs. The decision was taken based on the unexpected results of the Phase III study DIAS-2 which was conducted with the drug candidate Desmoteplase. As part of the extensive package the company will adapt its personnel structure already on short notice and is going to reduce its workforce by 26 employees to a total of 70. Currently PAION is conducting a detailed analysis of the DIAS-2 results after which it will decide on the steps necessary to continue with its pipeline programmes. The personnel reduction affects almost every part of the company and is carried out with the proviso that the development organisation as such remains functional. PAION expects that the adopted action plan will result in cost savings of at least 2 million Euros per year. Contact Dr. Peer Nils Schröder, Investor Relations / Public Relations PAION AG Martinstrasse 10-12 52062 Aachen - Germany Tel. +49 241 4453 152 E-mail pn.schroeder@paion.de www.paion.de --- End of Message --- PAION AG Martinstrasse 10 - 12 Aachen Germany WKN: A0B65S; ISIN: DE000A0B65S3; Index: Prime All Share, CDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Amtlicher Markt in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;


 

Royal DSM N.V. has repurchased 1,130,184 of its own shares in the period from 14 June 2007 up to and including 20 June 2007 at an average price of EUR 37.24. This is in accordance with the second phase of the share buyback program announced on 27 April 2007. The consideration of this repurchase was EUR 42.1 million. The total number of shares repurchased under the second phase of this program to date is 5,951,412 shares for a total consideration of EUR 216.6 million. DSM DSM is active worldwide in nutritional and pharma ingredients, performance materials and industrial chemicals. The company develops, produces and sells innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM's strategy, named Vision 2010 - Building on Strengths, focuses on accelerating profitable and innovative growth of the company's specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over ¤8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with locations in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at www.dsm.com. For more information: DSM Corporate Communications DSM Investor Relations Elvira Luykx Dries Ausems tel. +31 (0) 45 tel. +31 (0) 45 5782864 5782035 fax +31 (0) 45 5782595 fax +31 (0) 45 e-mail 5740680 investor.relations@dsm.com e-mail media.relations@dsm.com


 

The minutes of the annual general meeting of DNO ASA on 21 June 2007 are attached hereto. All resolutions were made in accordance with the Board of Directors' proposals presented in the notice of the annual general meeting. The presentation made by Managing Director Helge Eide at the annual general meeting is available on DNO ASA's web site. 22 June 2007 DNO ASA Helge Eide Managing Director www.dno.no


 

22 June 2007 - Referring to the press releases published on 4 and 11 June 2007 Qurius N.V. announces that it has issued and placed 25,000,000 new A shares for a price of EUR 1.20 per share. The shares will be traded as of today on Euronext Amsterdam on an as-if-and-when issued basis. The settlement will take place on 27 June 2007. The Pricing Statement is filed with the AFM and available at Qurius N.V. (Hogeweg 129, 5301 LL, Zaltbommel, email: info@qurius.com) and Fortis (Rokin 55, 1012 KK Amsterdam). The lead manager Fortis was granted an over-allotment option of 3.75 million additional shares A to be purchased at a price of EUR 1.20 per share (EUR 4.5 million). This option is exercisable from the first day of quotation up to 30 days after the closing date of the offering. Qurius N.V. Qurius provides architecture, realization and systems management of Microsoft technology based business and IT solutions, including infrastructures. Qurius has over 725 staff members; its headquarters are located in Zaltbommel, the Netherlands. Its offices in Belgium, Denmark, Germany, Italy, the Netherlands, Norway, Spain, Sweden and the United Kingdom serve over 1,700 clients. Qurius has been publicly listed on Euronext Amsterdam since 1998. On 18 December 2006, Qurius' shareholders authorized the merger with Watermark, which created Europe's largest Microsoft Dynamics partner. For further information, see www.qurius.com. Contact Qurius, Fred Hermans: telephone +31 (0)418 683 500 or fred.hermans@qurius.com.


 

(Oslo, 22. June 2007) Northern Logistic Property ASA announces completion of listing on the Oslo Stock Exchange Northern Logistic Property ASA (NLP) will be listed on the Oslo Stock Exchange today under the ticker code NLPR. In connection with the listing, Göran Bengtsson, CEO, and Erik Dahl, CFO, will hold a presentation at the Oslo Stock Exchange today at 09:10 hrs. A copy of the presentation is attached. The listing follows the finalization of a successful Private Placement at 15. June of 7 million shares at NOK 56,50 per share. The Private Placement will strengthen NLP's equity to fund further property acquisitions in line with the company's strategy to be the leading Northern European logistic property company. About Northern Logistic Property ASA Northern Logistic Property ASA is a leading pure- play logistic property company based in Northern Europe. The company currently has a property portfolio of approximately NOK 5.0bn. The portfolio consist of 17 advanced logistic properties located in larger and regional cities in Sweden, with a total lettable area of 624 000 sq.m. See also www.nlpasa.com. Further information: Erik Dahl, CFO, Northern Logistic Property ASA, tel. +47 45055000 IMPORTANT INFORMATION: This notice is not an offer to sell or a solicitation of an offer to buy any of the securities described herein, and is not for distribution to United States news services or for dissemination in the United States or elsewhere where such dissemination is not appropriate.


 

Extraordinary General Meeting of Deep Sea Supply Plc was held on the 21st of June 2007 at the Company's registered office in Limassol, Cyprus. The Extraordinary General Meeting has been completed, and all proposals on the agenda were adopted, cf. the notice that was sent to Oslo Stock Exchange on the 22nd of May 2007. It was approved that a distribution of NOK 0,20 per share is paid out by way of reducing the Company`s share premium account. Settlement is expected to take place in end of July 2007. The shares in Deep Sea Supply Plc will be quoted ex-dividend from today, the 22nd of June 2007. Deep Sea Supply Plc, 22 June 2007 For further information, please contact: Finn Amund Norbye, CFO E-mail: finn@dess.no


 

Fortis, Royal Bank of Scotland and Santander (the "Banks") are announcing today an update on their proposed Offer for ABN AMRO: 1. The Banks are making good progress on regulatory change of control and anti-trust filings. 2. The Banks expect to file all the draft documentation relating to the proposed Offer with the AFM and UKLA by early next week, they expect to issue the offer documents and to make a public SEC filing by mid-July 2007. The Offer to ABN AMRO shareholders is expected to commence at this point. 3. The Extraordinary General Meetings of shareholders of each of the Banks in connection with the transaction are being convened starting next week and all the EGMs will be held by the first half of August 2007. The Banks remain convinced that their proposed Offer represents superior value for ABN AMRO shareholders and significant benefits for customers and employees. Important Information The AFM is The Netherlands Financial Markets Authority (Autoriteit Financiële Markten). The UKLA is the UK Listing Authority. This announcement is made pursuant to article 9b(1) of the Dutch Decree on the Supervision of the Securities Trade 1995. In connection with the proposed Offer for ABN AMRO, RBS expects to file with the U.S. Securities and Exchange Commission (the "SEC") a Registration Statement on Form F-4, which will constitute a prospectus, and the Banks expect to file with the SEC a Tender Offer Statement on Schedule TO and other relevant materials. INVESTORS ARE URGED TO READ ANY DOCUMENTS REGARDING THE PROPOSED OFFER IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors will be able to obtain a copy of such documents, without charge, at the SEC's website (http://www.sec.gov) once such documents are filed with the SEC. Copies of such documents may also be obtained from each Bank, without charge, once they are filed with the SEC. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This press release is not an offer of securities for sale into the United States. No offering of securities shall be made in the United States except pursuant to registration under the US Securities Act of 1933, as amended, or an exemption therefrom. Forward-Looking Statements This announcement includes certain "forward-looking statements". These statements are based on the current expectations of the Banks and are naturally subject to uncertainty and changes in certain circumstances. Forward-looking statements include any statements related to the benefits or synergies resulting from a transaction with ABN AMRO and, without limitation, statements typically containing words such as "intends", "expects", "anticipates", "targets", "plans", "estimates" and words of similar import. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements. These factors include, but are not limited to, the presence of a competitive offer for ABN AMRO, satisfaction of any pre-conditions or conditions to the proposed offer, including the receipt of required regulatory and anti-trust approvals, the successful completion of the offer or any subsequent compulsory acquisition procedure, the anticipated benefits of the proposed offer (including anticipated synergies) not being realized, the separation and integration of ABN AMRO and its assets among the Banks and the integration of such businesses and assets by the Banks being materially delayed or more costly or difficult than expected, as well as additional factors, such as changes in economic conditions, changes in the regulatory environment, fluctuations in interest and exchange rates, the outcome of litigation and government actions. Other unknown or unpredictable factors could cause actual results to differ materially from those in the forward-looking statements. None of the Banks undertake any obligation to update publicly or revise forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required. Any offer made in or into the United States will only be made by the Banks and/or RFS Holdings directly or by a dealer-manager that is registered with the SEC. Fortis N.V., Archimedeslaan 6, 3584 BA Utrecht, Netherlands; Fortis S.A./N.V., Rue Royale 20, 1000 Brussels, Belgium The Royal Bank of Scotland Group plc, Head Office, Gogarburn, Edinburgh EH12 1HQ, UK. Registered Office, 36 St Andrew Square, Edinburgh EH2 2YB. Registered in Scotland No 45551 Banco Santander Central Hispano, S.A., Ciudad Grupo Santander, Avenida de Cantabria, s/n, 28660 Boadilla del Monte, Madrid, Spain


 

Successor to Dr. Franz A. Wirtz Aachen, 22 June 2007 - The biopharmaceutical company PAION AG (FSE: PA8) announced today that Dr. Jörg Spiekerkötter, Berlin (Germany), has been elected to the company's supervisory board by the annual general meeting on 20 June 2007. He replaces Dr. Franz A. Wirtz, co-founder of the company, who will reach the age limit defined for members of the supervisory board of PAION AG this year and who has therefore relinquished his seat. Further members of the board are Dr. Walter Wenninger (chairman), Leverkusen (Germany), and Prof. Dr. Erich Schlick, Otterstadt (Germany). In addition, the resolutions proposed by the management board and supervisory board were accepted by the annual general meeting with large majorities. In its constituent meeting, the supervisory board of PAION appointed Prof. Dr. Schlick to its vice chairman. The supervisory board thanked Dr. Wirtz for his many years of commitment and support as well as his very active contribution to the success and growth of the company. Dr. Spiekerkötter has many years of experience in the pharmaceutical industry where he has held executive positions in the areas of finance, law and human resources. Until May 2007 he was the Chief Financial Officer of Organon BioSciences N.V., Oss (Netherlands), where he left after the acquisition of the company by the American pharmaceutical company Schering-Plough. Until September 2006 he was the Chief Financial Officer at Schering AG in Berlin (Germany), and before that Head of the Legal Department at Hoechst Schering AgrEvo GmbH in Berlin (Germany). Dr. Spiekerkötter, who has a Ph.D. in law, studied in Bielefeld (Germany), Lausanne (Switzerland) and Freiburg (Germany). About PAION PAION is a biopharmaceutical company based in Aachen, Germany (listed at Frankfurt Stock Exchange, Prime Standard, ISIN DE000A0B65S3). It aims to become a leader in developing and marketing innovative drugs for the treatment of stroke and other thrombotic diseases for which there is a substantial unmet medical need. Contact Dr. Peer Nils Schröder, Investor Relations / Public Relations PAION AG Martinstrasse 10-12 52062 Aachen - Germany Tel. +49 241 4453 152 E-mail pn.schroeder@paion.de www.paion.de --- End of Message --- PAION AG Martinstrasse 10 - 12 Aachen Germany WKN: A0B65S; ISIN: DE000A0B65S3; Index: Prime All Share, CDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Amtlicher Markt in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;


 

Indicated Resources Now Represent 83% of Total VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- June 21, 2007 -- Buffalo Gold Ltd. (TSX VENTURE: BUF.U)(OTCBB: BYBUF)(FRANKFURT: B4K) is pleased to announce that it has received an updated mineral resource estimate for the Mt. Kare gold project which sees a 22% increase of the total property resources into the indicated category compared to the previous estimate. The new resource estimate incorporates data from Buffalo's 2006 infill drilling program. That program was designed to convert inferred ounces to indicated ounces, as a requirement of the economic study for Buffalo to earn into the Mt. Kare project from Madison Minerals Inc. ("Madison") (TSX VENTURE: MMR). The resource estimate has been successfully increased from 1.1 Million ounces of gold (see Buffalo news release June 26th, 2006) to 1.4 Million ounces of gold in the indicated category, at a gold equivalent cut-off of 1 g/t. The drilling also delineates a higher grade core which runs most of the length of the Western Roscoelite zone and contains the majority of the 743,000 oz gold or 4.59 million tonnes at 5.04 g/t gold with a gold-equivalent cut-off of 3 g/t. Table 1. Mt. Kare Mineral Resource Estimate reported at a several AuEq g/t Cut-offs ----------------------------------------------------------------- Mineral Cut-off Resource Equivalent Au Ag Contained category (AuEq g/t) Ktonnes (g/t) (g/t) koz Au ----------------------------------------------------------------- Indicated 1.0 18,830 2.31 17.31 1,396 2.0 8,559 3.66 22.51 1,008 3.0 4,587 5.04 25.37 743 ----------------------------------------------------------------- Inferred 1.0 5,753 1.56 9.53 288 2.0 1,331 2.77 11.77 119 3.0 476 3.85 11.22 59 ----------------------------------------------------------------- These estimates are based on a block model where the gold-equivalent service variable is derived from the sum of the gold and silver grades under the assumptions of a gold price of US$550/oz and a silver price of US$10/oz (Aueq g/t equals Au g/t + (10/550) x Ag g/t). While the 2006 work increased the understanding and confidence in the mineralization at Mt. Kare, Buffalo believes that there is potential for significant additional mineralization outside of the known zones. Buffalo and Madison therefore agreed in May of 2007 to award Buffalo 60% of the Joint Venture immediately and defer the Type 2 Preliminary Economic Feasibility Study to instead complete detailed exploration work on the many targets throughout the property (see Buffalo news release May 18th 2007). Based on the recent aeromag survey, geological mapping and surface sampling, the Company has outlined 18 new targets on the Mt. Kare Joint Venture license area and the adjacent 100% owned Buffalo license. Buffalo is currently in the process of following-up on those targets. New geological team members have been hired and fly-in camps have been established to aid in exploration. In addition, Buffalo has applied for a new 100% owned license adjacent to the current holdings. The new license, if awarded, will increase the total land package by approximately 30%, to approximately 660 square kilometres. A map showing the new exploration targets is posted on the company's website www.buffalogold.ca/2006/MtKareProject.asp. Mineral Resource estimation method The resource model, including the underlying database and QA/QC verification, were completed by Robert Sim of Longview Technical (www.longviewtechnical.com) and Dr. Bruce Davis in accordance with accepted industry standards. The basic modeling parameters and approach are summarized as follows: - Total of 340 drill holes (55,300m) composited to standard sample length of 2 metres. - Nominal block size of 10x10x5mV. - Probability shell approach used to control domains of higher-grade gold and silver mineralization. - Top-cutting of outlier grades by domain. - Ordinary kriging used for grade estimates for gold and silver in model. - Inverse distance weighting (IDW to the power of 2) used for bulk density in model. The updated resource estimate was verified by Lynn Olssen of Snowden Mining Industry Consultants ("Snowden") (www.snowdengroup.com). Snowden validated the earlier estimate in its NI 43-101 technical report on the Mt. Kare Project delivered to Buffalo in May 2006. (see Buffalo News Release June 26th 2006). Snowden reviewed and validated the recent work, and will complete a NI 43-101 technical report incorporating the resource estimate on behalf of Buffalo to be filed on SEDAR within 45 days of this release. Snowden has reviewed the contents of this release. Mr. Brian McEwen, P.Geol., President and COO of Buffalo is the qualified person for the Mt. Kare project. About the Mt. Kare Project Buffalo's flagship project is the Mt. Kare gold property in Papua New Guinea. The property is contiguous to Barrick's Porgera Gold Mine property where the various styles of mineralization identified are very similar in geological setting and structural controls to those identified at Mt. Kare. Buffalo currently has a US$11.4 million exploration program underway at the Mt. Kare project. About Buffalo Gold Buffalo's management is dedicated to maximizing shareholder value through growth strategies that emphasize careful opportunity assessment and vigilant project management. The Company is actively acquiring and advancing gold resources to create producing assets. To find out more about Buffalo Gold Ltd. (TSX VENTURE: BUF.U), please visit the company website at www.buffalogold.ca. On behalf of the Board of Directors of BUFFALO GOLD LTD. Damien Reynolds, Chair of the Board of Directors and Chief Executive Officer Cautionary note to U.S. Investors - The United States Securities and Exchange Commission ("SEC") permits mining companies in filings with the SEC to disclose only those mineral deposits that a company can economically and legally extract or produce. The Company may use certain terms in this news release, such as "inferred resource", that the SEC guidelines strictly prohibit from including in filings with the SEC. U.S. Investors are urged to consider closely the disclosure contained in the company's Form 20-F Registration Statement, File No. 000-30150. The Company's filings are available on the SEC's website at http://www.sec.gov/edgar.shtml. This news release may contain information about adjacent properties on which we have no right to explore or mine. We advise U.S. Investors that the SEC's mining guidelines strictly prohibit information of this type in documents filed with the SEC. U.S. Investors are cautioned that mineral deposits on adjacent properties are not indicative of mineral deposits on our properties. The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy of this press release. Contacts: Buffalo Gold Ltd. Julie Hajduk Investor Relations (604) 685-5492 or Toll Free: 1-888-685-5492 Email: julie@buffalogold.ca Website: www.buffalogold.ca


 

TORONTO, ONTARIO -- (MARKET WIRE) -- June 21, 2007 -- Bombardier Aerospace has delivered the 800th Dash 8/Q-Series aircraft, a Q400 airliner, to Luxair of Luxembourg. Dash 8/Q-Series family aircraft have been ordered by more than 100 customers and, as of April 30, the order book numbered 892, more than any other regional airline turboprop. The original 37- to 39-seat Dash 8 Series 100 was launched in 1980, and the 50- to 56-seat Dash 8-300 in 1986; the 37- to 39-seat Dash 8-200 was introduced in 1992, and the 68- to 78-seat Dash 8-400 in 1995. With the introduction of the proprietary Noise and Vibration Suppression (NVS) system, and a new interior design in 1996, Dash 8 aircraft were renamed the Q-Series aircraft. The Q400 airliner is the fastest and highest capacity turboprop in production and is gaining in popularity to replace or supplement jet operations in the current environment of high fuel prices. The Q400 airliner has significant operating cost benefits over other regional aircraft. "We have made continuous improvements in the Q-Series family as new technologies and processes have become available," said Steven Ridolfi, President, Bombardier Regional Aircraft. "The Q-Series family is rugged, reliable and very cost effective both in airline and special mission roles." About Bombardier A world-leading manufacturer of innovative transportation solutions, from regional aircraft and business jets to rail transportation equipment, systems and services, Bombardier Inc. is a global corporation headquartered in Canada. Its revenues for the fiscal year ended Jan. 31, 2007, were $14.8 billion US, and its shares are traded on the Toronto Stock Exchange (BBD). News and information are available at www.bombardier.com. Bombardier, Dash 8, Q-Series and Q400 are trademarks of Bombardier Inc. or its subsidiaries. Notes to Editors Images of Luxair Q400 and other Q-Series aircraft are available in our Multimedia Library at: www.aero.bombardier.com/htmen/F15.jsp Contacts: Bombardier Aerospace Bert Cruickshank 416-375-3030 www.bombardier.com


 

Útsendingar Digital Íslands í uppsveitum Árnessýslu eru hafnar og því nást nú á svæðinu útsendingar Stöðvar 2, RÚV, Sýnar, Sýnar Extra 1, Stöðvar 2 bíó, Sirkuss, og Skjás eins að því er kemur fram í tilkynningu.


 
Hitt og þetta
21. júní 2007

AGM Statement

GLENCAR MINING PLC AGM Results 21 June 2007 The Board of Glencar Mining plc ("Glencar" or the "Company") is pleased to announce that all resolutions proposed to shareholders at the Company's Annual General Meeting held in Dublin earlier today were duly passed. For further information please contact: Glencar Mining plc Hugh McCullough, Managing Director Tel: +353 1 661 9974 e-mail: info@glencarmining.ie Heneghan PR Rachel Watchorn Tel: +353 1 6607395 e-mail: rachel@hpr.ie Bishopsgate Communications Maxine Barnes/Nick Rome Tel: +44 20 7562 3350 e-mail: nick@bishopsgatecommunications.com ---END OF MESSAGE---


 

Summary: Pharmexa-Epimmune, the U.S.-based subsidiary of Pharmexa A/S, presents selected data from its influenza vaccine program today at the Influenza Conference entitled, "Options for the Control of Influenza VI," held in Toronto, Ontario, Canada. The data show that a "universal" vaccine designed to induce cell-mediated immune responses can protect transgenic mice against lethal experimental influenza virus challenge. Pharmexa-Epimmune, the U.S.-based subsidiary of Pharmexa A/S, presented selected data from its influenza vaccine program today at the Influenza Conference entitled, "Options for the Control of Influenza VI," held in Toronto, Ontario, Canada. The company's "universal" vaccine strategy combines the use of multiple technologies developed over the past decade. Specifically, the experimental vaccine protected HLA transgenic mice, which are partially "humanized" against a lethal influenza virus infection. The vaccine is designed to induce T-cell responses to highly-conserved influenza epitopes that were identified using the proprietary Epitope Identification System (EIS®). Pharmexa-Epimmune's approach is unique to the field where most vaccines are designed with the explicit goal of inducing antibody responses. The goal is to design and test a vaccine that will be protective as a "universal" influenza virus vaccine against both seasonal and pandemic viral strains. Mark Newman, Ph.D., SVP, Global R&D Laboratories, noted: "These data are very promising and important to us for two reasons. First, we were able to demonstrate protection of the HLA transgenic mice from lethal influenza virus challenge using a vaccine designed to induce only T-cell responses. Second, we were able to demonstrate that the immune system of humans had recognized the selected vaccine epitopes as the result of past exposures to influenza virus and that the HLA transgenic mice responded in a similar manner." Hørsholm, June 21, 2007 Jakob Schmidt Chief Executive Officer Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525 Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558 Note to editors: Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, bone degeneration and Alzheimer's disease, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, ImmunoVaccine Technologies and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.


 

Reykjavik/Shanghai - 21 June 2007 - Glitnir, the leading Icelandic financial services group, has today announced a joint venture project with CGCOC (CGC Overseas Construction Co. Ltd), for the development of a residential compound in a prime location in the heart of Shenyang city, the capital of Liaoning province in northeast China. The development site covers 230,000 square metres, of which 85 percent will be committed to housing and 15 percent to commercial units. The project is scheduled to be completed in two years and is one of the largest residential projects in Shenyang to date. Glitnir will take a 20 percent stake in the new joint venture company, which is as yet un-named, with CGCOC holding the remaining 80 percent. A subsidiary of Sinopec Star Petroleum Co. Ltd, CGCOC is a major provider of infrastructure, energy exploitation and trade services. Signed on 5 June at CGCOC headquarters in Beijing, this deal marks Glitnir's first real estate joint venture project in China. "We believe this is a landmark transaction for Glitnir in China. We opened our representative office in Shanghai in December last year, and this prominent investment role in China's booming real estate market diversifies further our already established activities in China in geothermal energy, and in the shipping and seafood industries," explains Magnus Bjarnason, Executive VP of International Banking in Glitnir. Glitnir and Sinopec, China Petroleum and Chemical Corporation, are no strangers to each other. In May 2005 through its shareholding in Enex China, Glitnir and Sinopec subsidiary Shaanxi CGCO Energy Development Construction Co. Ltd., were involved in establishing a joint venture company in Xianyang city in the Shaanxi province to develop a geothermal heating supply for the city. The first phase was opened in December 2006. Geothermal energy is clean and renewable, and it is recognised in China's energy policy as having great potential to service the needs of China and other countries. Iceland has been a pioneer in the utilisation of geothermal resources for over 70 years. "We are pleased with the development in China, says Jon Gardar Gudmundsson, Managing Director of Glitnir International Region. " "Glitnir opened a representative office in Shanghai in order to best serve its customers in China and abroad. We believe our presence here will enable and encourage more Scandinavian and international investment to flow into China," says Jiang Zhu, Director and Chief Representative of Glitnir in China. For further information, please contact: Magnus Bjarnason, Glitnir's Executive Vice President, mobile: +354-844 4523, e-mail: magnus.bjarnason@glitnir.is Jiang Zhu, Director & Chief Representative, China, mobile: + 86 139 016 118 75 or e-mail: jiang.zhu@glitnirbank.com Bjørn Richard Johansen, Managing Director, Corporate Communication, Glitnir: e-mail: brj@glitnir.no, mobile +47-47 800 100 For photos, please contact: akj@glitnir.no About Glitnir The financial group Glitnir offers universal banking and is a leading niche player in three global segments; seafood/food, sustainable energy, and offshore services vessels. Glitnir considers Iceland and Norway its home markets. Services include retail, corporate and investment banking, stock trade and capital management. Glitnir is the sole owner of a bank in Luxembourg (Glitnir Bank Luxembourg S.A) and banks and financial services companies in Norway (BNbank, Glitnir Bank ASA, Glitnir Securities, Glitnir Factoring and 70% of Glitnir Property Holding. Glitnir's subsidiary BNbank owns 45 percent of the shares in Norsk Privatøkonomi ASA, an independent financial advisory company with 14 branches in key areas of Norway). Glitnir operate Glitnir Property Group with focus on the commercial real estate market in the Nordics. In Sweden, Glitnir owns the leading Swedish brokerage firm Glitnir AB, the corporate advisory firm Tamm & Partners and the leading commercial real estate advisor Leimdörfer AB. The group owns FIM, the leading asset management company, with operations around Finland and in Stockholm and Moscow. Glitnir operates branches in London and Copenhagen. The group has representative offices in Halifax, Canada and Shanghai, China, and plans to open an office in New York in 2007. Glitnir is listed on the Icelandic Stock Exchange. For more information: www.glitnirbank.com


 

Annual Information Document for the period from 1 June 2006, which is 12 months prior to the date of annual financial statements, up to and including 1 June 2007. Kenmare Resources plc (the "Company") published its annual financial statements in respect of the year ended 31 December 2005 on 1 June 2007. This Annual Information Document has been prepared by the Company in accordance with the provisions of Part 11 of the Prospectus (Directive 2003/71/EC) Regulations 2005 (S.I. No 324 of 2005) and has been submitted to the Irish Stock Exchange for filing with the Irish Financial Services Regulatory Authority (the Financial Regulator) in accordance with the provisions of the Prospectus Rules issued by the Financial Regulator. The publication obligations in respect of this Annual Information Document are being fulfilled by its issue today via RIS and by its publication on the website of the Company (www.kenmareresources.com) from today. The Company does not intend to rely solely on the Financial Regulator to publish the Annual Information Document. The information referred to in this document was up to date at the time it was published but some information may now be out of date. To avoid an unnecessarily lengthy document, information is referred to in this document rather than included in full. (1) Regulatory announcements and filings made to the Irish Stock Exchange and UK Listing Authority via a Regulatory Information Service All of the announcements listed below were published via RNS or Hugin, both Regulatory Information Services and are available for viewing on the Irish Stock Exchange website (www.ise.ie) and (www.londonstockexchange.com) respectively. 01-06-07 Document Availability 02-05-07 Exercise of Options 01-05-07 Block Listing Six Monthly Return 30-04-07 Kenmare Preliminary Results for the year ended 31 December 2006 25-04-07 Mining commences and 60% resource base upgrade at Moma Titanium Minerals Mine, Mozambique 29-03-07 Block Listing Six Monthly Return 27-03-07 Anthony Lowrie Appointed as Director of Allied Gold Limited 16-03-07 Re: Holding in Company 11-01-07 Exercise of Options 18-12-06 Award of Share Options 28-11-06 Exercise of Options 22-11-06 Block Listing Six Monthly Return 15-11-06 Notification of Holding in Company 25-10-06 Kenmare announces short delay in completion of Mineral Separation Plant at the Moma Project and early implementation of capacity expansion 03-10-06 Award of Share Options 28-09-06 2006 Interim Results 26-09-06 RE: Holding in Company 13-09-06 Director Declaration 12-09-06 Director Declaration 07-09-06 Director Appointment 14-07-06 Re: Holding in Company 12-07-06 Resolutions passed at Kenmare's Annual General Meeting 12-07-06 Kenmare announces progress on Moma and new Uranium exploration licences in Mozambique 06-07-06 Exercise of Options 30-06-06 Notification of Transactions of Directors 21-06-06 Annual Information Document 14-06-06 2005 Annual Report Document Availability (2) Companies Registration Office Filings All of the documents listed below were filed with the Register of Companies in Ireland on or around the dates indicated. Copies of documents filed with the Registrar of Companies are available from the Companies Registration Office (www.cro.ie). 23-06-06 B1 Annual Return 10-07-06 B5 Allotment of Shares 21-07-06 G1 Special Resolutions passed at AGM 21-07-06 G2 Ordinary Resolution passed at AGM 18-09-06 B10 Appointment of Director 07-09-06 B5 Allotment of Shares 19-02-07 B5 Allotment of Shares 20-04-07 B5 Allotment of Shares (3) Annual and Interim Report 2006 The Company's Annual Report for the period ended 31 December 2006 which was published on 1 June 2007 and which was filed with the Irish Stock Exchange, can be found on the Company's website, as can the Interim Report 2006 for the period ending 30 June 2006 published on 28 September 2006. A copy of the Annual Information Document and copies of the documents referred to in it can be obtained from the Company Secretary at the Company's registered office: Chatham House, Chatham Street, Dublin 2. 21 June 2007 Contact: Deirdre Corcoran Company Secretary Kenmare Resource plc Tel: 00 353 1 6710411 ---END OF MESSAGE---


 

Glencar Mining plc Komana West Project Drilling Update 21 June 2007 Highlights * The highest gold assay to date at Komana West, 733 grams/tonne over 1 metre, found in borehole KWDD095 from 42m to 43m downhole depth * 17m at 2.99 grams/tonne (cut) in KWDD095 from 42m to 59m downhole depth * 14m at 1.64 grams/tonne in KWDD086 from 123m to 137m downhole depth * Metallurgical studies commenced * Environmental studies to be started * Drilling suspended until after the rainy season Glencar Mining plc ("Glencar" or "the Company"), the AIM and IEX listed company with gold exploration interests in Africa, is pleased to report on additional drilling results from its Komana West project in southern Mali. The results include the highest ore grade mineralization yet encountered on the project, 1 metre grading 733 grams/tonne in borehole KWDD095, towards the southern end of the drilled area. This borehole is in an area south of the main intrusive porphyry body, where artisanal workers have consistently encountered very high gold grades in their surface pits. The main mineralised intersections are given in the table below. These results show the continuation of the mineralised zone south of the surface expression of the main porphyry body. The overall mineralised zone is much broader in this southern zone and while some spectacular gold grades have been seen in this area, continuity of the higher grade ore shoots has so far been harder to establish. Extensive current artisanal workings to the south of this area suggest that the mineralised corridor extends to the south and further drilling there will be carried out during the next drilling campaign. Over 12,490 metres of drilling has now been completed at Komana West, 9,886 metres of it reverse circulation drilling and 2,612 metres of diamond drilling. Assays are still awaited from seven holes which were drilled mainly to shallower depths within the northern zone of the ore deposit. A more complete and detailed report of the fourth phase of drilling at Komana West, including the assays from the remaining seven holes will be given when all outstanding assays have been received and collated. Drilling has recently been suspended at the project, due to the onset of heavy rains, and will recommence after the rains cease in early to mid October next. Metallurgical testwork is already underway to determine the characteristics of the gold mineralization and preliminary environmental studies will also be commissioned shortly. Announcing these results at the Company's Annual General Meeting in Dublin today, Glencar's Managing Director, Mr. Hugh McCullough said; "The presence of such high grade gold shoots as has been seen in borehole KWDD095 and in the surrounding artisanal pits, and also immediately to the north of our northernmost drill fenceline, suggests that one of the key factors in evaluating the full potential of the Komana West deposit will be the elucidation of the disposition and extent of these likely additional high grade shoots." A drillplan showing the drillholes described above will be posted shortly on the Company's website at www.glencarmining.ie Hugh McCullough, EurGeol., PGeo, Managing Director of Glencar, is a member of the Institute of Geologists of Ireland. He is a qualified person as defined in the Guidance Note for Mining, Oil and Gas Companies, March 2006, of the London Stock Exchange. He has reviewed and approved the technical information contained in this announcement. For further information please contact: Glencar Mining plc Hugh McCullough, Managing Director Tel: +353 1 661 9974 e-mail: info@glencarmining.ie Heneghan PR Rachel Watchorn Tel: +353 1 6607395 e-mail: rachel@hpr.ie Bishopsgate Communications Nick Rome/Fran Read Tel: +44 20 7562 3350 e-mail: nick@bishopsgatecommunications.com Hole ID From To Width Au (g/t) (m) (m) (m) Cut Off 30g/t Uncut grade KWDD082 69 70 1 0.93 0.93 114 115 1 2.18 2.18 146 147 1 1.26 1.26 KWDD 083 2 3 1 0.65 0.65 9 11 2 2.70 2.70 65 66 1 0.74 0.74 82 83 1 0.89 0.89 95 96 1 0.77 0.77 108 109 1 0.55 0.55 KWDD 084 41 44 3 0.60 0.60 85 89 4 0.59 0.59 95 96 1 1.01 1.01 111 112 1 4.12 4.12 133 134 1 10.55 10.55 146 147 1 6.65 6.65 153 154 1 0.86 0.86 KWRC 085 81 84 3 1.93 1.93 KWDD086 123 137 14 1.64 1.64 141 142 1 0.81 0.81 148 150 2 2.80 2.80 156 157 1 1.45 1.45 167 168 1 1.03 1.03 171 172 1 5.90 5.90 KWDD 087 13 14 1 2.25 2.25 51 54 3 0.84 0.84 64 65 1 1.58 1.58 80 83 3 1.88 1.88 95 96 1 2.70 2.70 129 135 6 3.73 3.73 KWDD 095 4 5 1 0.79 0.79 8 9 1 2.18 2.18 36 37 1 0.50 0.50 42 59 17 2.97 44.35 70 71 1 0.64 0.64 74 75 1 0.71 0.71 82 88 6 0.67 0.67 102 104 2 0.97 0.97 111 112 1 0.57 0.57 116 117 1 0.81 0.81 ---END OF MESSAGE---


 

Allied Irish Banks, p.l.c. ("AIB") [NYSE: AIB] is pleased to announce the appointment today of Mr David Pritchard (63 yrs) as a Non-Executive Director. After graduating in Aeronautics and Astronautics in 1966, Mr Pritchard worked for five years in the aircraft industry prior to spending his career in banking. He held senior positions in Citigroup and the Royal Bank of Canada before joining Lloyds TSB Group in 1995 as Group Treasurer. He was seconded for two years to the Financial Services Authority, and, subsequently, was appointed to the Board of Lloyds TSB Group plc and became Group Executive Director, Wholesale & International Banking. In 2003, he was appointed Non-Executive Deputy Chairman of Lloyds TSB Group plc. He retired from that role in 2005 and is now Non-Executive Chairman of Songbird Estates plc1, and a Non-Executive Director of LCH Clearnet Group2 and The Motability Tenth Anniversary Trust3. -Ends- For further information, please contact: Catherine Burke Head of Corporate Relations AIB Group Bankcentre Dublin 4 Tel: +353-1-6600311 ext. 13894 1 Songbird Estates plc is the holding company of Canary Wharf Group which is involved in integrated property development, investment and management. 2 LCH Clearnet Group Ltd. through its operating subsidiaries provides clearing and settlement services to London's derivatives exchanges and to the Stock Exchanges of London, Paris, Amsterdam, Brussels and Lisbon. 3 The Motability Tenth Anniversary Trust is a charity providing mobility support for the disabled.


 
Hitt og þetta
21. júní 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |----------------------------------------------+--------------------| | Company dealt in | Domestic & General | | | Group Plc | |----------------------------------------------+--------------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |----------------------------------------------+--------------------| | Date of dealing | 20th June 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price paid | | securities | (Note 3) | (Note 3) | | purchased | | | |--------------------------+--------------------+-------------------| | 771 | 1,287.57 | 1,287.57 | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |-------------------------+--------------------+--------------------| | 771 | 1,287.57 | 1,287.57 | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +-------------------------------------------------------------------+ | Date of disclosure | 21st June 2007 | |----------------------------------------+--------------------------| | Contact name | Seema Soni | |----------------------------------------+--------------------------| | Telephone number | 0207 992 1565 | |----------------------------------------+--------------------------| | Name of offeree/offeror with which | Domestic & General Group | | connected | Plc | |----------------------------------------+--------------------------| | Nature of connection (Note 6) | Connected Advisor | +-------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 
Hitt og þetta
21. júní 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |-------------------------------------------------+-----------------| | Company dealt in | Freeport Plc | |-------------------------------------------------+-----------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |-------------------------------------------------+-----------------| | Date of dealing | 20th June 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price | | securities | (Note 3) | paid | | purchased | | (Note 3) | |---------------------------+--------------------+------------------| | 212 | 338p | 338p | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |-------------------------+--------------------+--------------------| | 1,000 | 338.25p | 338.25p | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +------------------------------------------------------------------+ | Date of disclosure | 21st June 2007 | |----------------------------------------------+-------------------| | Contact name | Seema Soni | |----------------------------------------------+-------------------| | Telephone number | 0207 992 1565 | |----------------------------------------------+-------------------| | Name of offeree/offeror with which connected | Freeport Plc | |----------------------------------------------+-------------------| | Nature of connection (Note 6) | Connected Advisor | +------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

SEB's second quarter 2007 report will be announced on July 19, at 11.30 (CET). In addition presentations and an extensive package of Facts & Figures will be available on www.sebgroup.com in conjunction with the various events below. It is a pleasure for me to invite you to the following events regarding the results. Thursday, July 19 Press conference at 13.00 (CET) Annika Falkengren, President & CEO, will present and comment upon the results. The presentation will be held at Kungsträdgårdsgatan 8 in Stockholm, July 19 at 13.00 (CET). Please note that the presentation will be conducted in Swedish. Telephone conference at 15.00 (CET) A telephone conference will be held on the same day, July 19 at 15.00 (CET). Annika Falkengren and our CFO Per-Arne Blomquist will present the second quarter 2007 results, followed by a Q&A session. To participate, please call +44 (0) 20 7162 0025 at least 10 minutes in advance. The telephone conference audiocast will also be available live at www.sebgroup.com. Please note that an archived audiocast of the conference call will be available on www.sebgroup.com and for subscribers of RAW Communications Broadband Network/Thomson StreetEvents. SEB video webcast - executive summary Please also note that there will be an opportunity to see and listen to Per-Arne Blomquist, who will comment upon the results. The video webcast will be available on www.sebgroup.com during July 19. Friday, July 20 Result presentation in London for analysts and investors at 08.00 (GMT) Our regular analyst presentation and Q&A session on SEB's second quarter 2007 results will be held at SEB's office, Scandinavian House, 2 Cannon Street, London EC4M 6XX and start at 08.00 (GMT) Friday July 20. SEB will be represented by Per-Arne Blomquist and Ulf Grunnesjö. Please confirm your attendance to the London meeting to Anna Hanselid, by e-mail anna.hanselid@seb.se or via telephone +46 (0) 8 763 8289 as soon as possible. Yours sincerely, Ulf Grunnesjö Head of Investor Relations The SEB Group is a North European financial group for 400,000 corporate customers and institutions, and 5 million private customers. SEB has local presence in the Nordic and Baltic countries, Germany, Poland, the Ukraine and Russia and has a global presence through its international network in another 10 countries. On 31 December 2006, the Group's total assets amounted to SEK 1,934bn while its assets under management totalled SEK 1,262bn. The Group has about 20,000 employees. Read more about SEB at www.sebgroup.com. ________________________________________ For further information, please contact: Ulf Grunnesjö, Head of Investor Relations, +46 8-763 85 01, +46 70-763 85 01 Elisabet Linge Bergman, Press Officer, +46 8-763 88 04, +46 70-604 40 96


 

(Press Release) Kemira is increasing its production of calcium sulfate pigments in Siilinjärvi by 25,000 tons to 175,000 tons. The investment is worth of EUR 4.9 million. The project includes a new production line and a wet-refining unit in Siilinjärvi and pilot-scale research equipment at the Espoo research center in Finland. Kemira's paper pigments production plants are located in Finland, Siilinjärvi and in Spain, Besalu. The company's new filler and coating pigment solutions have been developed for the manufacture of high-quality magazine papers. The new pigment technology enables paper industry customers to save in raw materials consumption and improve efficiency. "The share of mineral pigments in paper production is due to increase as the degree of conversion rises. It has been estimated that the worldwide demand will increase at an annual rate of about 3% for the next ten years and that the consumption of calcium sulfate pigments will increase in both filler and paper coating applications," says Juha Savolainen, head of the Paper Pigments BU. The new calcium sulfate crystallization technology is opening up export markets from Finland to the paper industry in Continental Europe and in Scandinavia. At present, Kemira delivers the product in slurry form, but thanks to the new technology the product can be delivered in the future in dry format to the customers far away. Moreover, the use of new gypsum raw materials sources is enabling powerful expansion of the present production volume. The environmental friendliness of the product is underscored by the fact that pigment production does not involve traditional mining. Raw materials are created as by-products of other industries. Kemira has developed and brought to production stage the new calcium sulfate technology together with the Finnish forest industry and various research bodies within the forest cluster. Calcium sulfate pigments are used as filler and coating pigments in the manufacture of paper and board. It gives paper excellent brightness, opacity and printability. Among the applications are LWC, MWC and MFC printing papers, and various coated fine paper and cardboard grades. As regards its technical properties, this product challenges traditional pigments such as kaolin and calcium carbonates. Kemira Pulp&Paper is the leading supplier of pulp and paper chemicals. Its extensive solutions are spanning throughout the pulp and paper industry's value chain from pulp to paper coating. In 2006, Kemira Pulp&Paper business area had revenue of EUR 993 million and a payroll of approximately 2,300 employees. It is present in 30 countries. For further information, please contact: Kemira Pulp&Paper Juha Savolainen, Vice President, BU Paper Pigments, mobile +358 50 387 6216 Kari Savolainen, Vice President, Communications, mobile +358 500 701 729 Kemira is a chemicals group made up of four business areas: Kemira Pulp&Paper, Kemira Water, Kemira Specialty and Kemira Coatings. Kemira is a global group of leading chemical businesses with a unique competitive position and a high degree of mutual synergy. In 2006, Kemira recorded revenue of around EUR 2.5 billion and had a payroll of 9,000 employees. Kemira operates in 40 countries. www.kemira.com


 

21 June 2007 - Aker Kvaerner was awarded the basic engineering package by Compañía de Minas Buenaventura S.A.A. for a gold autoclave for their Poracota mine at the Orcopampa district, in the Province of Castilla, Peru. The project began February 2007 and will run through September 2007. Compañía de Minas Buenaventura, S.A.A. has contracted Aker Kvaerner Metals, to manage and provide the basic engineering for their Poracota Gold Autoclave Project, a gold ore pressure oxidation facility. Poracota is located 20 kilometers west of Buenaventura's wholly-owned Orcopampa Mine, at an elevation of approximately 4,000 meters, in the Peruvian Andes. Aker Kvaerner's scope of work includes the circuit design, equipment sizing, preparation of bid packages, and production of layouts to support the capital and operating cost estimates. The basic engineering package will then be followed by detailed engineering. The front end engineering package will require an estimated time of 33 weeks to complete. Plant capacity is 500 tpd and will use whole ore pressure oxidation of sulphides technology to liberate gold encapsulated in sulphides. This project is being executed by Aker Kvaerner Metals, Inc., located in Tucson, Arizona, USA. Compañía de Minas Buenaventura, S.A.A. is a major precious metals producer in Peru and is listed in the New York Stock Exchange (BVN). ENDS For further information, please contact: Media: Guy Carraux, Business Development Manager & Director of Project Services, Aker Kvaerner Metals, Inc., Tucson, Arizona USA. Tel: +1 520 917-5479, Fax: +1 520 882-4231 Lola Kolbach, Communications Manager, Aker Kvaerner Metals, Santiago, Chile. Tel: +56 2 336 3520 Torbjørn Andersen, SVP Group Communications, Aker Kvaerner. Tel: +47 67 51 30 36, Mob: +47 928 85 542 Investor relations: Lasse Torkildsen, VP Investor Relations, Aker Kvaerner. Tel: +47 67 51 30 39 Suppliers: For further information about sourcing and potential subcontracts for this project, please contact: Stan Bogiel, Senior Vice President Global Sourcing, Aker Kvaerner, Process & Construction. Tel: +1 713-270-3519, Mob: +1 832-274-4753, Fax: +1 713 270 2710. Career opportunities: Visit http://www.akerkvaerner.com/Internet/CareerCentre AKER KVÆRNER ASA, through its subsidiaries and affiliates ("Aker Kvaerner"), is a leading global provider of engineering and construction services, technology products and integrated solutions. The business within Aker Kvaerner comprises several industries, including Oil & Gas, Refining & Chemicals, Mining & Metals and Power Generation. The Aker Kvaerner group is organised in a number of separate legal entities. Aker Kvaerner is used as the common brand/trademark for most of these entities. The parent company in the group is Aker Kværner ASA. Aker Kvaerner has aggregated annual revenues of approximately NOK 50 billion and employs approximately 23 000 people in about 30 countries. Aker Kvaerner is part of Aker (www.akerasa.com), a group of premier companies with a focus on energy, maritime and marine-resources industries. The Aker companies share a common set of values and long traditions of industrial innovation. As an industrial owner with a 40.1 per cent holding in Aker Kvaerner, Aker ASA takes an active role in the development of its holdings. Aker Kvaerner's Process and Construction business area is a world leader in the project management, design and construction of major projects spanning refining, petrochemical processing, metals and mining, power generation, and acid plants. From initial concept through technology development, process technology application, design, procurement, construction, maintenance, modification and decommissioning, we provide our customers with the full life cycle of services. Process and Construction provides sound local expertise, combined with the depth and strength of global project operations. Aker Kvaerner Metals serves mining and mineral processing companies by providing studies, project management, EPCM, commissioning and start-up services. Offices are located in Santiago, Chile (Metals Headquarters); Toronto, Canada; and Tucson, Arizona, U.S.A. Services to the Metals industry are also provided by AK Engineering Services in Europe, Asia and Australia. These organisations work closely together in support of our clients. This press release may include forward-looking information or statements and is subject to our disclaimer, see our web-pages www.akerkvaerner.com


 

Veidekke Entreprenør AS has signed a contract with Larvik Strandhotell AS for the development of a new spa hotel, 'Farris Bad', in Larvik. This is a turnkey contract for structural work worth NOK 161.3 million, excl. VAT. The client is Larvik Strandhotell AS, which is owned by Treschow-Fritzøe AS and Canica AS. Choice Hotels Scandinavia AS will lease and operate the hotel. Veidekke started discussions with the client about this project in 2003 and negotiations have led to the contract that has now been signed. The hotel will be Norway's leading spa hotel, with full conference facilities on site. It will have 177 rooms and suites of different designs and different qualities. The six-storey hotel will have a total floor area of 15,700 sq.m. The excavation work has already started and the completion date for the hotel is 5 March 2009. For further information, please contact: Veidekke Entreprenør AS District Manager Rolf Christian Andersen tel. +47 33307979, mobile +47 90668576 e-post rolf-christian.andersen@veidekke.no VEIDEKKE ASA Veidekke ASA is a leading Scandinavian building contractor and property developer with 6,350 employees and an annual turnover of NOK 16.4 billion (2006). Veidekke is listed on the Oslo Stock Exchange. It has a wide group of shareholders and 14% of the shares are held by the company's employees. The company's activities cover a large range of building and construction contracts, development of housing and commercial projects for private and public customers, asphalt operations and road maintenance, and collection and recycling of waste. Veidekke ASA, Information Dept., P.O. Box 505 Skøyen, N-0214 Oslo, phone +47 21 05 50 00 E-mail: firmapost@veidekke.no - Internet: http://www.veidekke.no


 

Options in the Schibsted share have been issued to cover the three-year rolling options program targeted at key persons within Schibsted. The aim with the options program is to increase the top management's holdings in the Schibsted share. Associated with the option program there is an obligation to reinvest and to hold a minimum amount of Schibsted shares. The exercise price of NOK 302.1 is based on the share price one week prior to and one week following the Annual General Meeting on 10 May 2007. The options are earned during a three year period. This year's allotment may to be exercised between 1 January 2010 and 31 December 2011. As a consequence of the change of managing director in Aftenposten, the present managing director will step out of the option program on 31 July 2007. The coming managing director will enter the option program and will be given 7,500 options upon arrival on 1 August. The following persons are included in today's allotment of options: No of options No of (Issued 2007) shares Schibsted ASA: CEO Kjell Aamot 150,000(30,000) 22,769 Executive VP & Trond Berger 75,000(15,000) CFO 7,624 Executive VP Jan Erik 60,000(15,000) Knarbakk 8,014 Executive VP Birger Magnus 75,000(15,000) 11,056 Executive VP Sverre Munck 75,000(15,000) 6,037 Executive VP Gunnar Strömblad 37,500(15,000) 3,045 Aftenposten AS: Managing director Olav Mugaas 32,500(2,500) 2,620 Editor-in-Chief Hans Erik Matre 30,000(7,500) 85 Verdens Gang AS: Managing director Rolv Erik Ryssdal 22,500(7,500) 314 Editor-in-Chief Bernt Olufsen 37,500(7,500) 7,681 Svenska Dagbladet AB: Managing director Raoul Grünthal 15,000(7,500) 0 Editor-in-Chief Lena K. Samuelsson 30,000(7,500) 355 Aftonbladet AB: Managing director Carl Gyllfors 22.500(7,500) 106 Editor-in-Chief Anders Gerdin 22.500(7,500) 62 Metronome Managing director Mats Alders 15.000(7.500) 0 Contact person: Executive VP & CFO Trond Berger, mobile phone: +47 91686695. Oslo, 21 June, 2007 SCHIBSTED ASA --- End of Message --- Schibsted Apotekergt 10, Pb 1178 Sentrum Oslo Norway ISIN: NO0003028904; ;


 

80% of Rodamco Shares tendered to the offer of Unibail UNIBAIL DECLARES THE EXCHANGE OFFER FOR ALL OUTSTANDING SHARES OF RODAMCO EUROPE UNCONDITIONAL Remaining Rodamco Shares can be tendered in subsequent acceptance period ending 10 July 2007 Paris, France and Rotterdam, the Netherlands - 21 June 2007 Unibail Holding S.A. ("Unibail") and Rodamco Europe N.V. ("Rodamco") jointly announce that Unibail declares unconditional (gestanddoening) the public exchange offer (the "Exchange Offer") made for all the ordinary shares in the capital of Rodamco with a nominal value of eight euros (EUR 8) ("Rodamco Shares"). 71,378,392 Rodamco shares representing 79.63% of the share capital of Rodamco have been tendered in the Exchange Offer during the acceptance period that ended Wednesday 20 June 2007. The combination between Unibail and Rodamco is therefore unconditional and shall be effective on the date of settlement, being 25 June 2007. "We are pleased with this outcome, which now makes it possible to create the leading pan-European commercial property company. We can conclude a vast majority of our shareholders appreciate the strategic rationale as well as the Exchange Offer made by Unibail", says Rodamco CEO Maarten Hulshoff. Unibail's CEO Guillaume Poitrinal comments: "The support of the investment community for this project is impressive and we are very much looking forward to further build this new combination, together with our employees and management team." --- End of Message --- Rodamco Europe P.O. Box 1233 Rotterdam Netherlands ISIN: NL0000289320; Listed: Compartment A (Large Caps) in EURONEXT AMSTERDAM;


 

Oslo, June 20, 2007: Renewable Energy Corporation (REC) has decided to invest SEK 74 million to increase module production by 50 MW, bringing the total capacity up to 150 MW. The Glava module plant in Sweden is currently being expanded from an annual production level of 45 MW to approximately 100 MW, and this decision to invest approximately SEK 74 million in additional production capacity will bring the total capacity further up to around 150 MW. "REC is continuously working on plans for capacity expansions. This project is a relatively fast and cost efficient way of getting both additional capacity and improving the long-term cost position and profitability of our module production plant in Sweden", says Erik Thorsen President & CEO. The project consists mainly of adding tabbing and stringing machines as well as ancillary equipment. It will also include additional areas for test equipment for production of next generation modules and consequently facilitate more rapid and efficient technology/product development. The project will have a positive impact on direct labor cost and general overhead costs and only around 40 new employees will be added. The total number of employees at the plant will increase to around 220 people. Economies of scale will be improved as REC Solar takes on the position as the second largest module producer in Europe. "REC Solar is already well established as a supplier of high quality modules, and the expansion will enable us to effectively deliver additional volumes", says John Andersen Jr., EVP Solar. Production start-up is expected in April 2008, with a ramp-up period of only two quarters. Consequently, full capacity is expected in the fourth quarter of 2008. About REC REC is uniquely positioned in the solar energy industry with a broad presence across the solar value chain. REC Silicon and REC Wafer are the world's largest producers of polysilicon and wafers for solar applications. REC Solar produces solar cells and solar modules. REC Group had revenues in 2006 of NOK 4,334 million and an operating profit of NOK 1,574 million. Please also see www.recgroup.com For more information, please contact; Erik Thorsen, President & CEO, +47 90 75 66 85 Jon Andre Løkke, SVP & Investor Relation Officer, +47 67 81 52 65


 

Chromex Mining plc / Epic: CHX / Market: AIM / Sector: Mining & Exploration 21 June 2007 Chromex Mining plc ('Chromex' or 'the Company') Issue of new shares to Institutional Investors Chromex Mining plc, the AIM listed dedicated chrome company operating in Southern Africa, is pleased to announce the allotment of 140,000 new ordinary shares of 1p each in the Company at 25p per share to Integral Wealth Securities Limited ('IWS') in part settlement of fees due to them. IWS will also receive one warrant for every two shares allotted entitling them to apply for up to 70,000 further new ordinary shares at 35p per share at any time up to 30 June 2009. Application is being made for the 140,000 new ordinary shares to be admitted to trading on AIM, and such admission is expected to take place on Thursday 28 June 2007. Following admission of the new shares Chromex will have a total of 63,580,000 ordinary shares in issue. **ENDS** For further information please visit www.chromexmining.co.uk or contact: Nigel Wyatt Chromex Mining plc Tel: +27 82 900 6827 Brian Moritz Chromex Mining plc Tel: 07976 994300 William Vandyk Blue Oar Securities Limited Tel: 020 7448 4400 Hugo de Salis St Brides Media & Finance Ltd Tel: 020 7242 4477 ---END OF MESSAGE---


 

(Oslo, 20. June 2007) Northern Logistic Property ASA, share capital increase pursuant to incentive scheme. The Board of Directors of Northern Logistic Property ASA (`NLPR`) has today resolved to increase the share capital of NLPR with NOK 16,838 by issuing 16,838 new shares in relation to incentive scheme. 8,218 of the new shares were subscribed by the CEO of NLPR, Göran Bengtsson, at a subscription price of NOK 53 per share, and the remaining 8,620 shares were subscribed by the CFO of NLPR, Erik Dahl, at a subscription price of NOK 58 per share. The shares were issued pursuant to their employment contracts. Göran Bengtsson and Erik Dahl do not own any other shares or share options in NLPR, except pursuant to the company's incentive scheme. Following the completion of the share capital increase, NLPR's share capital will be NOK 27,092,308 consisting of 27,092,308 shares each with a par value of NOK 1. About Northern Logistic Property ASA Northern Logistic Property ASA is a leading pure- play logistic property company based in Northern Europe. The company currently has a property portfolio of approximately NOK 5.0bn. The portfolio consist of 17 advanced logistic properties located in larger and regional cities in Sweden, with a total lettable area of 624 000 sq.m. See also www.nlpasa.com. Further information: Erik Dahl, CFO, Northern Logistic Property ASA, tel: +47 45055000 IMPORTANT INFORMATION: This notice is not an offer to sell or a solicitation of an offer to buy any of the securities described herein, and is not for distribution to United States news services or for dissemination in the United States or elsewhere where such dissemination is not appropriate.


 

MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that an undisclosed partner has filed all necessary documentation to initiate a Phase 1 clinical trial with a HuCAL-derived fully human antibody in the therapeutic area of oncology. This achievement marks the third fully human antibody developed with MorphoSys's core technology within its partnerships to enter human clinical trials and triggers a clinical milestone payment to MorphoSys. "This is an exciting program for the treatment of cancer and we are therefore delighted to see the program move into human clinical trials," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "This latest addition to the roster of HuCAL antibodies in the clinic underlines the fact that our therapeutic pipeline is growing and maturing. The strength of this pipeline is a core asset of MorphoSys that will be a key driver of the company's future growth." For further information please contact: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications, Tel: +49 (0) 89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj, Manager Public Relations, Tel: +49 (0) 89 / 899 27-454, brkulj@morphosys.com About MorphoSys: MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the Company's proprietary Human Combinatorial Antibody Library (HuCAL) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing agreements and/or research collaborations with Astellas (Japan), Bayer-Schering (USA/Germany), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (USA), Centocor Inc. (USA), Daiichi Sankyo & Co., Ltd. (Japan), GPC Biotech AG (Germany), Hoffmann-La Roche AG (Switzerland), ImmunoGen Inc. (USA), Merck & Co., Inc. (USA), Novartis AG (Switzerland), Novoplant GmbH (Germany), OncoMed Pharmaceuticals, Inc. (USA), Pfizer Inc. (USA), ProChon Biotech Ltd. (Israel), Schering-Plough (USA), Shionogi & Co., Ltd. (Japan), Xoma Ltd. (USA) and others. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit was founded in 2003 for the purpose of exploiting the MorphoSys non-therapeutic antibody markets. MorphoSys' activities in the research antibody segment were significantly strengthened through the acquisition of the U.K. and U.S.-based Biogenesis Group in January 2005 and Serotec Group in 2006. For further information please visit the corporate website at: http://www.morphosys.com/ HuCAL® and HuCAL GOLD® are registered trademarks of MorphoSys AG Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the prospectus relating to the company's recent public offering.


 

* Exforge offers two of the most prescribed high blood pressure medicines in a convenient single-tablet form[1],[2],[3] * Powerful new treatment option for millions in the US with high blood pressure[4] * Nine out of 10 patients reach high blood pressure treatment goal while taking Exforge during clinical trials[5] Basel, June 21, 2007 - Exforge®, a single-tablet combination of two of the world's most prescribed high blood pressure medicines, has been granted final US regulatory approval and is expected to be available soon as an effective treatment option for millions in the US who suffer from high blood pressure[1],[2],[3]. Exforge is the first medicine of its kind to combine the active ingredients of an angiotensin receptor blocker - Diovan® (valsartan) - and a calcium channel blocker - Norvasc®* (amlodipine) - with the convenience of a single, once-daily tablet[1],[2],[3]. "High blood pressure continues to be a major public health issue in the US. Many patients will require multiple medications to achieve blood pressure control," said Bertram Pitt, MD, FACC, and a Professor of Medicine Emeritus at the University of Michigan School of Medicine Division of Cardiology. "This new treatment offers great efficacy and improved convenience with a single tablet that will simplify treatment for patients." The US approval of Exforge was supported by an extensive clinical program involving more than 5,000 patients[1]. The US Food and Drug Administration had tentatively approved Exforge in December 2006 and has now granted final approval. Exforge was approved in January 2007 in the European Union and has already been made available in nine EU countries, including Germany and the UK, with further launches planned. Exforge is also available in Switzerland. In two placebo-controlled trials, Exforge helped up to nine out of ten patients reach their treatment goal of diastolic blood pressure under 90 mmHg, or more than a 10 mmHg reduction in diastolic blood pressure from baseline levels[5]. Diastolic blood pressure is measured in millimeters of mercury (mmHg) when the heart is at rest between beats. In two further clinical trials, Exforge demonstrated superior blood pressure lowering efficacy in patients uncontrolled when taking either valsartan or amlodipine alone, the two high blood pressure drugs combined in Exforge[1]. "Exforge continues our strong heritage in treating high blood pressure, in this case bringing together two of the most widely-used medicines in a single pill," said James Shannon, MD, Global Head of Development at Novartis Pharma AG. "Aggressively treating high blood pressure is key, so we are excited to be able to provide physicians and patients with this first-of-a-kind combination to help patients reach recommended blood pressure treatment goals." Exforge combines the complementary actions of Diovan - which inhibits angiotensin II, a hormone that causes blood vessels to tighten and narrow - and amlodipine, which inhibits the entrance of calcium into the blood vessel walls. Both of these medicines allow blood vessels to relax so that blood can flow more easily[1],[2],[3]. High blood pressure causes damage to the arteries, burdening the heart, kidneys, brain and other vital organs[6]. At present, high blood pressure affects at least 29% of all adults in the U.S. and approximately one billion people suffer from the condition globally[7],[8]. The number of people with high blood pressure is expected to reach about 1.6 billion by 2025[9]. In the US, Exforge is not indicated for initial high blood pressure therapy. It has been approved for use in high blood pressure patients who have not been controlled through the use of any type of medicine in the angiotensin receptor blocker or calcium channel blocker classes, and for patients who have experienced dose-limiting side effects on either type of medicine. These include amlodipine-induced edema (swelling), dizziness or flushing[1]. In the Exforge clinical trials, adverse events were generally mild and transient in nature. Side effects that occurred more frequently with Exforge than placebo in clinical trials were peripheral edema (fluid retention), nasopharyngitis, upper respiratory tract infections and dizziness[1]. Disclaimer The foregoing release contains forward-looking statements which can be identified by the use of terminology such as, "powerful new treatment option", "expected", "will", "planned", "continues our strong heritage" or similar expressions, or by express or implied discussions regarding potential future revenue from Exforge. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Exforge will reach any particular sales levels. In particular, management's expectations regarding the approval and commercialization of Exforge in the US or in other markets could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected intellectual property issues involving the expiration of market exclusivity of amlodipine besylate; competition in general; increased government, industry, and general public pricing pressures; unexpected clinical trial results, including additional analysis of clinical data, or new clinical data; our ability to obtain or maintain patent or other proprietary intellectual property protection; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com. References [1] Exforge (amlodipine besylate and valsartan) Prescribing Information Draft. December 2006. [2] Diovan Web site. http://www.diovan.com/info/about/about_diovan.jsp. Accessed November 28, 2006. [3] Norvasc Web site. http://www.norvasc.com/high-blood-pressure-medicine/ about-norvasc.asp?print=true Accessed November 28, 2006. [4] Rosamond W, Flegal K, Friday G, et al. for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2007 update. A report from the American Heart Association Statistics Committee and Stroke Subcommittee. Circulation. 2007:115. [5] Philipp, T. Two multi-center, 8-week randomized, double blind, placebo controlled, parallel group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combinations and as monotherapy in adult patients with mild-to-moderate hypertension. Clinical Therapeutics Journal, 2007; 29:563-580. [6] Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75. [7] American Heart Association. "High blood pressure." Available at: http://americanheart.org/presenter.jhtml?identifier=2114. [8] Chobanian AV, Bakris GL, Black HR, et al. and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252. [9] Kearney et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223. * Norvasc is a registered trademark of Pfizer Inc. # # # Novartis Media Relations Corinne Hoff Novartis Global Media Relations +41 61 324 9577 (direct) +41 79 248 5717 (mobile) corinne.hoff@novartis.com Vivienne Schneider Novartis Pharma Communications +41 61 324 6162 (direct) +41 79 619 1335 (mobile) vivienne.schneider@novartis.com e-mail: media.relations@novartis.com Novartis Investor Relations International Ruth Metzler-Arnold +41 61 324 7944 Katharina Ambühl +41 61 324 5316 Nafida Bendali +41 61 324 3514 Jason Hannon +41 61 324 2152 Thomas Hungerbuehler +41 61 324 8425 Richard Jarvis +41 61 324 4353 North America Ronen Tamir +1 212 830 2433 Jill Pozarek +1 212 830 2445 Edwin Valeriano +1 212 830 2456 e-mail: investor.relations@novartis.com --- End of Message --- Novartis International AG Posfach Basel WKN: 904278; ISIN: CH0012005267; Index: SLCI, SMI, SPI, SLIFE; Listed: Main Market in SWX Swiss Exchange, ZLS in BX Berne eXchange;


 

EBIT increased by 37% from CHF 14.8 to CHF 20.2 million Dividend proposal: CHF 7.00 per bearer share Steinhausen, June 21, 2007 - In the financial year ended March 31, 2007, Carlo Gavazzi, the Zug-based electronics group, increased bookings from continuing operations by 10% from CHF 201.8 million to CHF 221.6 million and operating revenue by 7% from CHF 201.6 million to CHF 215.7 million. Earnings from continuing operations rose by 30% from CHF 11.5 million to CHF 14.9 million. The discontinuance of Computing Solutions' distribution activity required a goodwill write-off in the amount of CHF 3.3 million. After this one-time charge, the company is reporting a net income of CHF 11.5 million. With the current economic conditions prevailing, the group expects to further improve its market position and its financial performance during 2007/08. The group's operating revenue increased by 7% and operating expenses by a modest 1.5%. EBIT included CHF 1.8 million non-recurring legal and severance charges, while it benefited from the reversal of accruals of CHF 1.5 million in the previous year. Despite these differences totalling CHF 3.3 million, EBIT improved by CHF 5.4 million. Shareholders' equity at March 31, 2007, amounted to CHF 99 million or 54% of total assets. The board of directors will propose to the annual shareholders' meeting the payment of a dividend of CHF 7 per bearer share, corresponding to a payout ratio of 33% of earnings from continuing operations (previous year: capital repayment of CHF 35 per bearer share). Automation Components - improvement of earnings and gain of market share Continuing investments in sales and marketing personnel, broader geographical coverage and favourable market conditions enabled Automation Components to expand bookings and operating revenue by 11.5% and 9.1%, respectively, clearly outpacing global market growth of estimated 4%. While revenue in South-East-Asia grew by 24%, sales in Europe increased by 14% and, the less favourable economic conditions in the North American building and factory automation market, limited bookings growth in this region to 4% in local currency. While revenue of the priority market segments grew by 22%, revenue from non-core products stabilised. As operating expenses rose by only 4.6%, operating profit improved by 37.8% to CHF 24.1 million or 12.9% of revenue. Computing Solutions - concentration on core activities Revenue from core activities, electronic packaging and embedded computing, stabilised at the previous year's level and bookings improved by 3%. Actions were taken to further reduce the break-even point and, as a result, the business unit succeeded in improving operating profit by CHF 1.0 million compared with the previous year, after one-time restructuring charges of CHF 0.5 million. The goodwill amortisation of CHF 3.3 million and the small operating loss of CHF 0.1 million (last year profit of CHF 0.6 million) were accounted for as discontinued operations. Board of Directors After 40 years of services with Carlo Gavazzi and approaching the age of 65, Werner S. Welti, executive chairman of Carlo Gavazzi Holding AG since 2003, decided not to stand for re-election at the shareholders' meeting of July 26, 2007. The board of directors recognised his valuable contributions and expressed its great appreciation for the excellent services that were provided by him for many years in various top management and board functions. The board of directors will appoint Werner S. Welti as honorary chairman. Giulio Pampuro, member of the board of directors of Carlo Gavazzi Holding AG for two years and managing director of Barguzin Participation SA, Luxembourg, will succeed Werner S. Welti as chairman. The board of directors will propose to the next shareholders' meeting to elect Dr. Felix R. Ehrat, senior partner of the law firm Bär & Karrer, as new member of the board. Key figures group (CHF million) +-------------------------------------------------------------------+ | Income statement continuing | 2006/07 | 2005/06 * | % | | operations | | | | | | | | | |------------------------------------+---------+-----------+--------| | Bookings | 221.6 | 201.8 | + 9.8 | |------------------------------------+---------+-----------+--------| | Operating revenue | 215.7 | 201.6 | + 7.0 | |------------------------------------+---------+-----------+--------| | EBIT | 20.2 | 14.8 | + 36.5 | |------------------------------------+---------+-----------+--------| | EBIT-Margin | 9.4 % | 7.3 % | - | |------------------------------------+---------+-----------+--------| | Earnings | 14.9 | 11.5 | + 29.6 | |------------------------------------+---------+-----------+--------| | Employees | 1192 | 1126 | + 5.9 | |------------------------------------+---------+-----------+--------| | Discontinued operations | | | | | (Fulfilment Division) | | | | |------------------------------------+---------+-----------+--------| | Earnings (loss) from discontinued | - 0.1 | 0.6 | | | operations | | | | |------------------------------------+---------+-----------+--------| | Goodwill write-off | - 3.3 | - | | |------------------------------------+---------+-----------+--------| | Effect of discontinued operations | - 3.4 | 0.6 | | |------------------------------------+---------+-----------+--------| | Summary result | | | | |------------------------------------+---------+-----------+--------| | Earnings from continuing | 14.9 | 11.5 | | | operations | | | | |------------------------------------+---------+-----------+--------| | Effect of discontinued operations | - 3.4 | 0.6 | | |------------------------------------+---------+-----------+--------| | Group net income | 11.5 | 12.2 | - 5.7 | |------------------------------------+---------+-----------+--------| | Cash flow | 18.8 | 15.5 | + 21.3 | |------------------------------------+---------+-----------+--------| | | | | | |------------------------------------+---------+-----------+--------| | Balance sheets (as of March 31) | 2007 | 2006 | | |------------------------------------+---------+-----------+--------| | | | | | | Net working capital | 58.7 | 52.3 | + 12.2 | |------------------------------------+---------+-----------+--------| | Shareholders' equity | 98.9 | 111.6 | - 11.4 | |------------------------------------+---------+-----------+--------| | Total assets | 182.2 | 191.2 | - 4.7 | |------------------------------------+---------+-----------+--------| | Equity in percent of assets | 54.3 % | 58.4 % | - | +-------------------------------------------------------------------+ Key figures business units +-------------------------------------------------------------------+ | CHF million | 2006/07 | 2005/06 * | % | |------------------------------------+---------+-----------+--------| | Bookings | | | | | * Automation Components | 191.3 | 171.5 | + 11.5 | | * Computing Solutions | 30.4 | 30.3 | + 0.3 | |------------------------------------+---------+-----------+--------| | Operating revenue | | | | | * Automation Components | 186.6 | 171.0 | + 9.1 | | * Computing Solutions | 29.1 | 30.6 | - 4.9 | |------------------------------------+---------+-----------+--------| | Operating profit | | | | | * Automation Components | 24.1 | 17.5 | + 37.7 | | * Computing Solutions | 0.7 | - 0.3 | - | +-------------------------------------------------------------------+ * 2005/06 figures have been restated to reflect the effect of the discontinuance of Computing Solutions' distribution activity. For further information contact: Werner S. Welti Carlo Gavazzi Holding AG Phone +41 79 677 70 77 Note: 1) The group's annual report 2006/07 and the presentation made at the press conference scheduled for Thursday, June 21, 2007, will be available the same day at 2 pm on the company's website http://www.carlogavazzi.com. 2) Our press releases are also available by e-mail instead of fax. If you require this service, please register on our website or send an e-mail to the following address: mady_arnold@carlogavazzi.ch. About Carlo Gavazzi: Carlo Gavazzi is a publicly quoted (SWX: GAV) international electronics group with activities in the design and marketing of electronic control components for factory and building automation as well as in electronic packaging and embedded computing. Please visit our website: www.carlogavazzi.com The press release incl. tables can also be downloaded from the following link: --- End of Message --- Carlo Gavazzi Holding AG Sumpfstrasse 32 Steinhausen WKN: 869279; ISIN: CH0011003594; Index: SPI, SPIEX, SSCI; Listed: Main Market in SWX Swiss Exchange;


 

Land contract backlog grows; successful marine technology trial completed; eleven patent applications filed (June 21, 2007) Oil and gas exploration technology innovator Spectraseis announced today that it has won contracts with a host of major oil and gas producers. The company also announced its eleventh patent filing and successful completion of a marine technology trial in the North Sea. "Spectraseis has achieved extraordinary breakthroughs in technology development and customer support in the past six months" said Ross Newman, Chief Executive, Spectraseis. "The results of our recent survey work show the value our technology can bring to the E&P industry." New contracts The company announced that it has signed new contracts with Petrobras, Kuwait Oil Company, Statoil, Ecopetrol and two Saudi Aramco joint-ventures exploring for gas deposits in the remote Rub' al-Khali desert of Saudi Arabia. It also recently completed land surveys totaling over 500 square kilometers for Pemex in Mexico and Hydro in Libya. The surveys encompass a wide range of environments, including producing gas and oil fields, frontier exploration areas and environmentally sensitive locales. The technical challenges include mapping reservoir extensions in regions with poor active seismic response or limited access and exploration of areas too large for fast or cost-effective conventional seismic coverage. "We're now seeing accelerated adoption of low frequency surveying" said Newman. "The results of surveys delivered so far have exceeded expectations and the major challenge we currently face is providing sufficient data acquisition and processing capacity to meet the strong demand for services by new customers." Spectraseis directly addresses three of the industry's greatest challenges: reducing the risk of high-cost wells in many new exploration areas; environmental and access restrictions on the use of conventional surveying methods; and the shortcomings inherent in active seismic and electromagnetic techniques in locations with difficult surface conditions, such as sand dunes, forests and jungles, or obscuring acoustical and electrical subsurface features. "The industry has an immense need for geoscientific innovation" added Newman. "The mature technologies will not sustain required levels of efficiency as exploration costs increase and the development of existing reservoirs becomes more complex. E&P operators must get new and better information with a faster turnaround. Spectraseis is doing important work to meet this challenge." Successful marine trial In April, Spectraseis successfully completed the first offshore test of its technology. The 14-day pilot survey, over a proven oil field in the North Sea, demonstrated the feasibility of deploying and recovering broadband ocean bottom receivers to record passive low frequency data at more than 130 locations on the seabed. The program was a collaborative effort among field operator Hydro, Scripps Institution of Oceanography, Bergen Oilfield Services and Spectraseis, which developed the spectral analysis techniques being implemented. "We have acquired a dataset with rich low frequency spectra" said Rob Habiger, Chief Technical Officer, Spectraseis. "More than 90% of the recordings have passed initial quality checks. This is a pioneering project but we are able to apply much of what we have learned from our earlier work to this first full-scope marine survey". "We're transforming the technology from onshore to offshore for the first time," said Peter Hanssen, principal geophysicist at Norsk Hydro's oil and energy research centre in Bergen. "It's the first worldwide test offshore. For the future, if the test is positive, it will change how we look for oil worldwide in any area," Hanssen said. "It will have immense implications." Spectraseis' environmentally-friendly passive data acquisition approach is especially well-suited for sensitive marine mammal habitats. Patent filings Spectraseis said that it had filed its eleventh patent application covering signal processing technologies developed by the company and its research partners. "Spectraseis is developing what we believe will be a unique and valuable intellectual property portfolio" said David Walker, IP Counsel, Spectraseis. "The techniques we're seeking patents for are highly inventive and we're confident that we will achieve a protected position for our technology. This is a dynamic and exciting technical frontier and the really innovative concepts captured in the Spectraseis patent portfolio complement our proprietary technologies. We will work hard to maximize the commercial value and competitive advantage of our expanding intellectual property position." Software release The company also announced the first release of RIOviz, its customer software product for passive low frequency data. RIOviz allows a geoscientist to view and analyze low frequency data in both time and frequency domains. With this software the client can become an active partner in studying low frequency anomalies. Spectraseis delivered the package to a first end-user in April and will be licensing it to future survey customers. Tools in the software will to allow exploration and asset teams to perform additional interpretation of low frequency survey data and integrate the results with other geological and geophysical (G&G) data, such as the results of 3D seismic surveys. About Spectraseis Zurich-based Spectraseis provides advanced geophysical surveys and data processing services to help oil and gas companies more efficiently find and produce hydrocarbon reserves. Spectraseis researches, develops and applies proprietary technologies to acquire and analyze low frequency seismic background waves occurring in the Earth's subsurface in order to identify spectral anomalies indicating the presence or absence of hydrocarbon deposits. The resulting information can greatly reduce the risk and improve the success rate of costly oil exploration and drilling activities. Spectraseis has research and technology development partnerships with the Swiss Federal Institute of Technology (ETH) in Zurich and national oil companies in the Middle East, Latin America and Europe. The company was established in 2003 and is closely held. Hydro Technology Ventures, a unit of Norwegian oil producer Norsk Hydro ASA, owns 21%. www.spectraseis.com ### All product and company names herein may be trademarks of their respective owners. For further information, contact: Ross Newman Chief Executive Spectraseis AG Tel. +41 43 500 5828 or +41 78 697 5888 ross.newman@spectraseis.com Rob Habiger Chief Technical Officer Spectraseis AG Tel. +41 43 500 5827 rob.habiger@spectraseis.com For background information see: www.aapg.org/explorer


 

PERTH, AUSTRALIA and SINGAPORE -- (MARKET WIRE) -- June 20, 2007 -- Advanced Nanotechnology Limited (ASX: ANO) today announced that it has executed the agreements for its strategic partnership with, and placement of Advanced Nano shares to, the Energenics group, a Singapore-based supplier of alternative energy solutions and technologies. In accordance with the previously announced Letter of Intent, Advanced Nano and Energenics have now formally agreed their strategic relationship. The relationship is now in the form of a mutually exclusive five-year agreement for the supply of fuel-borne combustion catalyst products manufactured by Advanced Nano and sold by Energenics worldwide into the rapidly growing clean-burn fuel markets. The supply agreement, which supercedes the JV proposal previously announced, initially features Cercat(TM), a nanoparticulate cerium oxide dispersion manufactured by Advanced Nano for use with diesel engine fuels. However, the agreement's scope extends to all metallic oxide nanoparticulate fuel-borne combustion catalysts for all fuel types. As a condition of this strategic partnership, Energenics has agreed to subscribe for A$6 million of new Advanced Nano shares at a price of A$0.22 per share in two equal tranches. The first tranche of A$3 million will be issued within twenty eight days (being a total of 13,636,364 ordinary shares issued on the same terms as existing Advanced Nano ordinary shares and as approved at Advanced Nano's June shareholder meeting). The second tranche is expected to take place upon Advanced Nano achieving invoiced sales of 150,000 litres of 2% Cercat (or equivalent) or within 24 months. Advanced Nano will also issue Energenics with 4,545,455 options for each share tranche (being one option for every three new shares subscribed for) at an exercise price of A$0.308 per share expiring on 30 June 2012. Paul McCormick, CEO of Advanced Nano, commented, "After further discussions with Energenics, it became clear to both parties that the best way to pursue this strategic alliance with Energenics is through an exclusive supply agreement rather than the joint venture company envisaged in the Letter of Intent. The alliance will put Advanced Nano in a strong position to secure a pathway to the world energy markets which is expected to provide an important and growing revenue stream for the Company." Ronen Hazarika, Managing Director of Energenics, commented, "We are delighted to have concluded this strategic partnership with ANO. Energenics will now concentrate on rolling out cerium-oxide fuel-borne nanocatalyst technology globally. Our initial response from fleet and oil companies is very encouraging, and we are confident of being able to provide cost-effective solutions for global fuel markets." About Energenics Energenics is a supplier of alternative energy solutions and technologies, providing customers access to switched or phased renewable fuels programmes that deliver both energy use and gas emission reductions at zero or minimal capital cost. Energenics is incorporated in Singapore and is rapidly becoming a market leader in delivering turnkey biofuel & energy efficiency projects to fleet users using innovative technologies either developed in house or licensed in from technical partners. In conjunction with these turnkey projects, Energenics also provides a full Carbon emissions trading service, which involves the trading of permits to emit carbon dioxide (and other greenhouse gases). Ronen Hazarika, Managing Director of Energenics, is the original inventor of technology protected by patents relating to coated cerium oxide nanoparticles used as a fuel-borne catalyst. About Advanced Nano Advanced Nano develops, manufactures and sells advanced nanomaterials products worldwide that deliver significant performance and value improvements to its customers' products. Advanced Nano's MCP(TM) nanopowder manufacturing technology is a patented, platform technology that enables the production of a broad range of high quality nanopowders and nanomaterials. Advanced Nano is targeting four key markets with its commercial products -- Energy & Emerging Technologies; Personal Care & Life Sciences; Plastics & Polymers; and Coatings, Inks & Textiles. Advanced Nano's products are manufactured and marketed under four parent brands: ZinClear® -- sunscreen dispersions that allow SPF 30+ sunscreens containing only zinc oxide as the UV absorber; Alusion® -- soft focus effect pigments for masking ageing effects; Cercat(TM) -- fuel-borne nanocatalysts; and NanoZ® -- nano zinc oxide additives that allow stable UV absorber performance for coatings and plastics. Further Information Paul McCormick Chief Executive Officer Advanced Nanotechnology Limited Tel: +61 (8) 9458 0800 Ronen Hazarika Managing Director Energenics Holdings Pte Ltd Tel: +65 6341 9650


 

Pennine AIM VCT 5 plc 20 June 2007 Pennine AIM VCT 5 plc announces that its unaudited Net Asset Value at close of business on 31 May 2007 was 93.1 pence per share. ---END OF MESSAGE---


 

Ixonos Plc Stock Exchange Announcement 20 June 2007 A total of 59,500 shares have been subscribed through Ixonos Plc Stock Options Plan II, based on Ixonos Plc Stock Options Plan II series B1 (10,000 shares), C1 (10,000 shares) and D1 (39,500 shares) warrants. According to the terms of the Option Plan, the subscription price for warrants of series B1 was EUR 1.56, of series C1 EUR 3.32 and of series D1 EUR 3.22. Of the subscription price, EUR 0.04 per share, a total of EUR 2,380, will be added to the share capital. The Ixonos Option Plan II is based on the decision by the Board of Directors on 26 February 2002, with the authorization of the Annual General Meeting. The terms of the plan have been published as a Stock Exchange Release on 27 February 2002. The new shares subscribed with warrants as well as the increase of the share capital have been registered in the Trade Register today, 20 June 2007. The new shares provide the shareholders with full shareholder rights. After the increase, the share capital of Ixonos Plc is EUR 304,060 and the number of shares is 7,601,500. The new shares will be subject for public trading on the Helsinki Stock Exchange from 21 June 2007 in the same share class as the company's old shares. IXONOS PLC Kari Happonen President and CEO FOR ADDITIONAL INFORMATION, PLEASE CONTACT: IXONOS PLC Chief Financial Officer Petteri Mussalo, phone +358 424 2231, mobile +358 400 193 779, petteri.mussalo@ixonos.com DISTRIBUTION: Helsinki Stock Exchange Main media


 

Oslo, 20 June 2007 Biotec Pharmacon announced on June 11th 2007 that the European Medicines Agency ("EMEA") had confirmed that the company may be in a position to file for marketing authorization based on two positive confirmatory phase III clinical studies within each of the diabetic ulcer and oral mucositis therapeutic indications. The Board of Directors in Biotec Pharmacon has today resolved that the Company will initiate the needed phase III studies on its own. This is an exception to the current business model (which is to seek partnership following phase II). However it does not exclude bringing partners onboard during the phase III program. The Board's decision is based on the above mentioned positive feedback from EMEA. Now that the Company sees that the confirmatory studies require fewer resources and involve less risk than previously expected, the Board believes that it is in the best interest of the shareholders to fund and initiate phase III studies on its own. Biotech Pharmacon ASA has retained SEB Enskilda ASA and Pareto Securities ASA to advise on and effect an equity issue directed towards professional Norwegian and international investors after the close of Oslo Stock Exchange today. The equity issue will be carried out through a book-building process. The planned directed equity issue will amount to a maximum of up to 2,148,900 new shares, equal to maximum 10% of existing shares of the Company. In addition the Company will consider to sell up to a maximum of 698,318 of its own treasury shares at the discretion of the Board. For further information, please contact: CEO Lars Viksmoen, tel.: 40 62 08 70 CFO Finn Samuelsen, tel.: 95 14 87 51 About Biotec Pharmacon The biopharmaceutical company Biotec Pharmacon was founded in 1990 and develops pharmaceutical products for treatment of immune related diseases. The company has developed the bioactive compound SBG, which initiates mechanisms that strengthen the ability of the immune system to destroy cancer cells, repair wounds and fight infections. In addition the company manufactures and markets non-pharmaceutical health- and diagnostics products. Biotec Pharmacon maintains comprehensive collaborations with renowned institutions such as for example Memorial Sloan-Kettering Cancer Center in New York. Biotec Pharmacon today has 56 employees and offices in Tromsø, Oslo and Long Beach, USA. Further information can be found on www.biotec.no.


 

Arne Vraalsen has decided to leave his position as CEO and President of Polimoon. The decision was made some time ago and is based on a wish to dedicate more time in Denmark. After eight years in Polimoon, leading a group which successfully has implemented a global strategy, characterised by strong growth, improved productivity and good returns to shareholders, it is appropriate to pass on the challenge to others. With the arrival of a new ownership the moment is good to open up the organisation for a change in management. The board and Arne Vraalsen would like to underline that it has been a controlled decision and well prepared in its execution. "I would like to use this opportunity to thank colleagues, customers, suppliers, owners and other third parties which all have contributed to a period with a lot of good memories" - says Arne Vraalsen Arne Vraalsen will resign as President and CEO on June 30 2007. Until the end of the year he will act as an advisor on merger and acquisitions. "I would like to take this opportunity and thank Arne Vraalsen for his valuable efforts and contribution during the past 8 years. I am impressed with the development of Polimoon under his leadership" says Ragnhildur Geirsdóttir, Chairman of the Board of Polimoon Group AS and President & CEO of Promens hf. For further information, please contact: Ragnhildur Geirsdottir, tel +354 898 5001 Arne Vraalsen, tel +45 20 45 99 19


 

` FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | DEEPHAVEN CAPITAL | | | MANAGEMENT LLC | |-----------------------------------------------+-------------------| | Company dealt in | Hanson Plc | |-----------------------------------------------+-------------------| | Class of relevant security to which the | 10p Ordinary | | dealings being disclosed relate (Note 2) | | |-----------------------------------------------+-------------------| | Date of dealing | 19 June 2007 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------+ | | Long | Short | | | | | |-------------------------------+--------------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (2) Derivatives (other than | 9,752,861 | 1.3663 | | | | options) | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | Total | 9,752,861 | 1.3663 | | | | | | | | | +-------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +-------------------------------------------------------------------+ | Class of relevant security: | Long | Short | | | | | |-------------------------------------+--------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (2) Derivatives (other than | | | | | | options) | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | Total | | | | | | | | | | | +-------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short | Number of securities | Price per unit | | name, | (Note 6) | (Note 7) | (Note 5) | | e.g. CFD | | | | |----------+------------+--------------------------+----------------| | | | | | | CFD | LONG | 402,861 | 1078.4312 | | CFD | LONG | 850,000 | 1078.7500 | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 20th June 2007 | |--------------------------------------------------+----------------| | Contact name | James Feast | |--------------------------------------------------+----------------| | Telephone number | 0207 469 1901 | |--------------------------------------------------+----------------| | If a connected EFM, name of offeree/offeror with | | | which connected | | |--------------------------------------------------+----------------| | If a connected EFM, state nature of connection | | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

In continuation of the recent acquisitions made by Promens hf. the Board of Directors of Promens hf. has approved a new organisational structure for the company which will be effective as of July 1st 2007. The main objectives of the organisational changes are to integrate all the underlying businesses, increase efficiency and establish a strong base for further growth and development of the company. The main change in the organisational structure concerns the Polimoon Group, which since being acquired in December 2006 has been run as an independent company within Promens, but will now be operated as an integrated part of the Promens Group. The Board of Directors of Promens hf. and Arne Vraalsen, President and CEO of Polimoon, have reached an agreement according to which he will leave his current position as a CEO of Polimoon as of June 30th, although he will continue to work for Promens as a consultant until the end of 2007. According to the new organisational structure Promens will be divided into three business units, being Packaging, Rotational Moulding and Components. Special emphasis will be put on Procurement and Productivity & Quality which will be run as support units within the Group. Promens' head office will continue to be in Iceland, but a corporate service centre will be established in Oslo, Norway, responsible for financial management, IT, procurement and productivity & quality. The new executive team of Promens' consists of the following: Ragnhildur Geirsdóttir, who became the President and CEO of Promens in January 2006, will continue to lead the Group. Adrian Platt who has been the CFO of Polimoon since 2000 has been appointed the Chief Financial Officer of Promens. Jón Sigurðsson who has been the CFO at Promens since its establishment in 2005, has been appointed Senior Vice President of Procurement. Thor Audun Saga has been appointed Senior Vice President of Productivity & Quality. He has held a similar position in Polimoon since 2006. Aart Fortanier has been appointed Senior Vice President of Rotational Moulding. He has been heading Promens' rotational moulding in Europe since Promens acquired Bonar Plastics in 2005. Erik Feijen has been appointed Senior Vice President of Components. He has held the same position in Polimoon since 2002. Jeroen Hooft has been appointed Senior Vice President Packaging. He has managed the packaging operation for Polimoon in Continental Europe since 2002. "Promens has during the last two years been one of the fastest, if not the fastest growing plastics conversion company in the world, and we plan to further grow the company. With these organisational changes in place, we have the structure and the management team to lead the company into the next era and further grow and develop the company." says Ragnhildur Geirsdóttir, President and CEO of Promens. Further information about the management is in the following attachment About Promens: Promens is a leading global plastics manufacturer operating over 60 manufacturing facilities in Europe, North America, Asia and Africa. The company manufactures a wide range of products, including consumer-, chemical-, pharmaceutical- and food packaging, as well as plastic components for the automotive, heavy machinery and electronic industries. Promens' factories utilise most of the production methods used by the plastics industry, such as injection moulding, blow moulding and thermoforming, as well as being the world's largest rotational moulder. Promens revenue in 2007 is projected to be in the range of EUR 710 million, and the total number of employees is approximately 5,800. The main shareholders of Promens hf. are the investment company Atorka Group hf. and Landsbanki. About Atorka Group: Atorka Group is a progressive investment company that is listed on the OMX Nordic Exchange in Iceland and is included in the ICEX-15 index. Atorka invests in companies on global growth markets ans supports growth both internal and external. In its investments, Atorka emphasises companies characterised by solid operations and strong cash flow, strong management, promising conditions for internal and external growth, and opportunities for value enhancement. For further information, contact Ragnhildur Geirsdóttir, President and CEO of Promens, at +354 580 5550, rgeirsdottir@promens.is www.promens.com.


 

Pöyry has been awarded contracts for new railway lines in Algeria and Finland. The total value of the assignments is EUR 3.5 million. ANESRIF, the infrastructure company of the Algerian railway company SNTF has awarded Pöyry a contract concerning the new railway line between El Bayadh and Mecheria in Algeria. The assignment is for the overall design of the 100 km long rail track which connects the El Bayadh region with the Algerian railway network. The value of the contract is EUR 2.4 million. The Algerian Government has recently launched a large long-term investment programme up to 2025 to expand and electrify the rail network including high-speed lines. This project is one of the first steps in this programme. The overall design comprises the railway construction including the electrical equipment and all engineering works. The services shall be completed within 12 months. The Finnish Rail Administration has commissioned Pöyry to prepare a plan for a new urban railway serving the Helsinki metropolitan area. The plan will be prepared in cooperation with other consulting companies. Pöyry's share of the services amounts to EUR 1.1 million. The plan shall be prepared by March 2008. The new railway line will connect the Martinlaakso line with the main line via the Helsinki-Vantaa airport. The length of the line is 18 km, of which more than 8 km in a tunnel under the airport area. Seven new stations are planned for the line. Together with the Kerava and Leppävaara urban lines and the Martinlaakso line it will constitute an integrated urban railway loop. Trains will run at 10-minute intervals during peak periods. The shortest travelling time from Helsinki to the airport will be some 30 minutes. Pöyry is a global consulting and engineering firm focusing on the energy, forest industry and infrastructure & environment sectors. Pöyry's net sales in 2006 amounted to about EUR 620 million and it employs 6400 experts. PÖYRY PLC Satu Perälampi Vice President, Corporate Communications and Investor Relations Additional information by: Project in Algeria: Johann Schmieder, Managing Director, Pöyry Infra GmbH, Germany Tel. +49 7621 93 00 45 Project in Finland: Kari Fagerholm, Manager, Railway and Geo-technical Department, Pöyry Infra Oy, Finland tel. 010 33 26449 www.poyry.com DISTRIBUTION: Major media


 

Zug, Switzerland - June 20, 2007 Converium informs of likely date of Extraordinary General Meeting following successful SCOR offer Converium announces that it is planning to hold an Extraordinary General Meeting on August 16, 2007 in accordance with the Transaction Agreement between Converium and SCOR dated May 10 which stipulates that such a meeting be held as soon as possible after the Offer has been declared successful. At this meeting, it is planned that the current Board of Directors will resign and a new Board be elected. In addition, in accordance with the Transaction Agreement, Inga Beale, Chief Executive Officer, and Paolo De Martin, Chief Financial Officer, will step down from their respective positions on this date. Converium, its Board of Directors as well as its CEO and CFO have agreed to provide their best efforts in supporting the transfer of the managerial control to SCOR. The meeting will take place at the Kongresshaus in Zurich at 2pm CET. As a prerequisite to be authorized to attend Converium's Extraordinary General Meeting as a shareholder and to be entitled to vote, Converium shares must be registered in the share register (SAG SIS Aktienregister AG, Olten, Switzerland) by August 13, 2007. Enquiries Beat W. Werder Marco Circelli Head of Public Relations Head of Investor Relations beat.werder@converium.com marco.circelli@converium.com Phone: +41 44 639 90 22 Phone: +41 44 639 91 31 Fax: +41 44 639 70 22 Fax: +41 44 639 71 31 Dr. Kai-Uwe Schanz Inken Ehrich Chief Communication & Corporate Investor Relations Specialist Development Officer inken.ehrich@converium.com kai-uwe.schanz@converium.com Phone: +41 44 639 90 94 Phone: +41 44 639 90 35 Fax: +41 44 639 70 94 Fax: +41 44 639 70 35 About Converium Converium is an independent international multi-line reinsurer known for its innovation, professionalism and service. Today Converium employs about 500 people in 15 offices around the globe and is organized into three business segments: Standard Property & Casualty Reinsurance, Specialty Lines and Life & Health Reinsurance. Converium has an "A-" ("strong") financial strength rating (outlook stable) from Standard & Poor's and a "B++" financial strength rating (outlook positive) from A.M. Best Company. Important Disclaimers This document contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. It contains forward-looking statements and information relating to the Company's financial condition, results of operations, business, strategy and plans, based on currently available information. These statements are often, but not always, made through the use of words or phrases such as 'seek to', 'expects', 'aims' 'should continue', 'believes', 'anticipates', 'estimates' and 'intends'. The specific forward-looking statements cover, among other matters, the Company's strategy and management objectives, our growth prospects and our ability to ensure a smooth transition of our business with that of SCOR. Such statements are inherently subject to certain risks and uncertainties. Actual future results and trends could differ materially from those set forth in such statements due to various factors. Such factors include whether we are able to secure an upgrade of our financial strength ratings; our ability to refinance our outstanding indebtedness and increase our use of hybrid capital; uncertainties of assumptions used in our reserving process; risk associated with implementing our business strategies and our capital improvement measures; cyclicality of the reinsurance industry; the occurrence of natural and man-made catastrophic events with a frequency or severity exceeding our estimates; acts of terrorism and acts of war; changes in economic conditions, including interest and currency rate conditions that could affect our investment portfolio; actions of competitors, including industry consolidation and development of competing financial products; a decrease in the level of demand for our reinsurance or increased competition in our industries or markets; our ability to expand into emerging markets; our ability to enter into strategic investment partnerships; a loss of our key employees or executive officers without suitable replacements being recruited within a suitable period of time; our ability to address material weaknesses we have identified in our internal control environment; political risks in the countries in which we operate or in which we reinsure risks; the passage of additional legislation or the promulgation of new regulation in a jurisdiction in which we or our clients operate or where our subsidiaries are organized; the effect on us and the insurance industry as a result of the investigations being carried out by the US Securities and Exchange Commission, New York's Attorney General and other governmental authorities; our ability to regain past customers following any rating upgrades and the resolution of the investigations being carried out by the US Securities and Exchange Commission, New York's Attorney General and other governmental authorities; changes in our investment results due to the changed composition of our invested assets or changes in our investment policy; failure of our retrocessional reinsurers to honor their obligations or changes in the credit worthiness of our reinsurers; our failure to prevail in any current or future arbitration or litigation; and extraordinary events affecting our clients, such as bankruptcies and liquidations, and other risks and uncertainties, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission (including, but not limited to, our Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission) and the SWX Swiss Exchange. The Company does not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.


 

20 June 2007 - Aker Kvaerner has signed a contract for delivery of equipment and modifications to Aker Floating Production's SMART 1 Floating Production Storage Offloading (FPSO) vessel. This new contract is an amendment to a contract awarded in November 2006 for both SMART 1 and 2 vessels. The total contract value for Aker Kvaerner related to SMART 1 is now approximately NOK 610 million, representing an increase of NOK 430 million since November 2006. The scope of work which will be undertaken by the Aker Kvaerner subsidiary Aker Kvaerner Process Systems includes delivery of two separation modules, one utility module and two skids for the flare system. "We are proud to have been awarded this important contract. The award confirms our position and ambitions for technology deliveries to the global FPSO market" says Mads Andersen, Executive Vice President in Aker Kvaerner. "Our first FPSO will be installed on the MD-6 field offshore India. We are pleased to have Aker Kvaerner onboard contributing to our delivery to Reliance Industries Ltd of India" says Svein Olsen, President & CEO of Aker Floating Production. The modules will be fabricated in Dubai and installed on the FPSO in Singapore. The delivery from Aker Kvaerner is expected in third quarter of 2007. Engineering, procurement and fabrication follow-up is carried out by Aker Kvaerner's Process Systems office in Oslo. ENDS For further information, please contact: Media: Siw Anett Enerud, Communications Manager, Aker Kvaerner Products & Technologies. Tel.: +47 95 19 34 15 Investor relations: Lasse Torkildsen, VP Investor Relations, Aker Kvaerner. Tel: +47 67 51 30 39 Suppliers: For further information about sourcing and potential subcontracts for this project, please contact Richard Reynolds, vice president global supply chain. Tel.: +44 1224 424868 Career opportunities: Visit http://www.akerkvaerner.com/Internet/CareerCentre AKER KVÆRNER ASA, through its subsidiaries and affiliates ("Aker Kvaerner"), is a leading global provider of engineering and construction services, technology products and integrated solutions. The business within Aker Kvaerner comprises several industries, including Oil & Gas, Refining & Chemicals, Mining & Metals and Power Generation. The Aker Kvaerner group is organised in a number of separate legal entities. Aker Kvaerner is used as the common brand/trademark for most of these entities. The parent company in the group is Aker Kværner ASA. Aker Kvaerner has aggregated annual revenues of approximately NOK 50 billion and employs approximately 23 000 people in about 30 countries. Aker Kvaerner is part of Aker (www.akerasa.com), a group of premier companies with a focus on energy, maritime and marine-resources industries. The Aker companies share a common set of values and long traditions of industrial innovation. As an industrial owner with a 40.1 per cent holding in Aker Kvaerner, Aker ASA takes an active role in the development of its holdings. Aker Kvaerner Process Systems is a global supplier of selected advanced process equipment and modules for treatment of well stream, oil, gas, produced water and solids for the upstream oil and gas industry. The product lines are mainly based on own proprietary/novel technology within, wellstream separation, heavy crude treatment, gas conditioning, MEG reclamation and regeneration, sulphate removal, VOC recovery, sand management systems and produced water treatment. This press release may include forward-looking information or statements and is subject to our disclaimer, see our web-pages www.akerkvaerner.com


 
Hitt og þetta
20. júní 2007

AGM Statement

20 June 2007 Providence Resources P.l.c. ("Providence" or "the Company") Annual General Meeting At Providence's Annual General Meeting held this morning in Dublin, shareholders were up-dated on the Company's activities and on its future plans, the highlights of which include: * Providence will commence appraisal drilling on its Hook Head Project in the Celtic Sea later this summer; * Providence has agreed to acquire the majority of the producing Singleton field, onshore UK, thereby improving the Company's future production cash flow; * The High Island A-268 Gas Project in the Gulf of Mexico is on schedule for start-up in production in August; * The next stage of the AJE Project in Nigeria is anticipated to be announced in the coming months, including plans for future drilling (subject to rig); * Providence, together with its partners, ExxonMobil and Sosina, was awarded 15 new blocks in the Goban Spur, offshore Ireland, further demonstrating the attractiveness of the exploration potential of the Atlantic Margin; and * Providence has enhanced its financial resources with a recent ¤25.7 million placing of shares. This, together with the previously announced ¤50 million revolving credit facility with Macquarie Bank, ensures that that the Company has the necessary financial resources to execute its corporate objectives; All resolutions proposed for consideration at today's AGM were approved by shareholders. Addressing shareholders, Dr. Brian Hillery, Chairman of Providence, said: "This has been a productive year for Providence. The Company continues to pursue a portfolio strategy focusing on international development and exploration. I am particularly pleased with the prospect of the imminent drilling programme at Hook Head, which marks a major milestone for Providence. I believe Providence is now extremely well placed to develop, and ultimately, capitalise on its extensive asset portfolio." Contacts: Providence Resources Plc Tel: +353 1 6675740 Tony O'Reilly Jnr. Chief Executive Powerscourt Tel: +44 (0)207 250 1446 Rory Godson/Victoria Brough Murray Consultants Tel: +353 1 498 0300 Pauline McAlester Notes to Editors Providence Resources Plc is an independent oil and gas exploration company listed on the AIM market in London and on Dublin's IEX market. The Company was founded in 1997, but with roots going back to 1981 when it predecessor company, Atlantic Resources Plc was formed by a group of investors led by Sir Anthony O'Reilly. Providence's active oil and gas portfolio includes interests in Ireland (offshore), the United Kingdom (onshore and offshore), the United States (offshore) and West Africa (offshore Nigeria). Providence's portfolio is balanced between production, appraisal and exploration assets, as well as being diversified geographically. Comprehensive information on Providence and its oil and gas portfolio, including the AIM Admission document and Annual Reports are available from Providence's website at www.providenceresources.com ---END OF MESSAGE---


 

Carl Zeiss Meditec AG: 7,5000th IOLMaster® sold Newly-developed software allows a wider range of applications - including in Asia and Latin America Jena, June 20th, 2007 - Carl Zeiss Meditec AG plans to further enhance its sales successes with newly-developed software for the IOLMaster®, a system to aid diagnosis of the ophthalmic disease of cataracts. "To date the IOLMaster, with its optical method for measuring the eye, is the only device of its type in the world and is successfully established in the market - this is evidenced impressively by the 7,500 systems we have already sold", says Ulrich Krauss, President and CEO of Carl Zeiss Meditec AG. "The latest generation of devices now allows ophthalmologists to provide individualized treatment to even more patients." In Germany, three out of four eye surgeons are already using the device. With the delivery of the 7,500th device to an ophthalmologist in Malaysia, the globally active company has demonstrated its leading role in providing innovative product solutions for ophthalmology. With cataracts, the lens of the eye clouds up over a period of many years, potentially causing blindness. This disease can be healed by removing the misted lens and inserting an artificial intraocular lens (IOL). Carl Zeiss Meditec AG has revolutionized this diagnosis and treatment process: the IOLMaster® allows the eyes to be measured prior to the operation with no contact whatsoever, and the correct refraction power of the artificial lenses is calculated. The system has been further developed and now with optimised signal processing, patients suffering from very advanced clouding of the lens can now also be measured. Previously, it was not possible to calculate the strength of the lens at this advanced cataract stage. This means that patients in Asian and Latin American countries, for example, where ophthalmologists are used infrequently - and often belatedly - can now also be treated. These special needs, in combination with the improved features of the IOLMaster®, are opening new sales opportunities for Carl Zeiss Meditec AG. Brief profile Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world's leading medical technology companies. This market position is based on over 160 years of experience in optical innovation. The company has two primary areas of activity: In the field of ophthalmology Carl Zeiss Meditec offers integrated solutions for treating the four main eye diseases: vision defects (refraction), cataracts, glaucomas and retinal disorders. The company's system solutions are employed in all phases of the disease management, from diagnosis to treatment and aftercare. Carl Zeiss Meditec has always applied its technological expertise to product innovations. These innovations range from basic systems such as slit lamps and fundus cameras to standard setting diagnostic systems such as the Humphrey® Field Analyser, the Stratus OCT(TM) and the IOLMaster®, through to the surgical microscopes and innovative treatment systems in refractive laser surgery. The product portfolio in ophthalmic surgery is rounded off by intraocular lenses and consumables. In the field of neuro and ENT surgery, Carl Zeiss Meditec is the world's leading provider of surgical microscopes and microsurgical visualisation solutions for a very broad range of applications, such as tumor and vascular surgery in the head region and/or spinal surgery. The most recent example of our innovative performance in the area of microsurgery is the OPMI Pentero® visualisation system, which allows efficient and ergonomic patient treatment. Carl Zeiss Meditec will systematically expand its product range in this area and become a solution provider in neuro and ENT surgery as well. Carl Zeiss Meditec's medical technology portfolio is rounded off by visualisation systems for doctors in private practice and promising future technologies such as intraoperative radiation therapy, which allows the targeted treatment of breast cancer and brain cancer directly during surgery. An aging global population, rising expectations of doctors and patients, together with innovative treatment methods in medical technology are expected to promote market growth in the long term. Carl Zeiss Meditec holds an optimum position for future developments in the health sector. The company focuses its solution portfolio on the three medical challenges with a significant social and economic impact: loss of mobility, vision and cognitive abilities. The goal is to deliver technologies and application-oriented solutions that allow doctors to improve the quality of life of their patients and to further improve the efficiency of diagnosis and treatment. Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in Germany (Carl Zeiss Surgical GmbH and Carl Zeiss Meditec Vertriebsgesellschaft mbH), the USA (Carl Zeiss Meditec, Inc., Dublin California), in Japan (Carl Zeiss Meditec Co., Ltd., Tokyo), Spain (Carl Zeiss Meditec Iberia S.A., Madrid) and France (Ioltech SAS, La Rochelle, and Carl Zeiss Meditec France SAS, Le Pecq). Thirty-five percent of the Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss, one of the world's leading international groups engaged in the optical and opto-electronics industry. Contact Kerstin Nössig/Public Relations Jens Brajer/Director Investor Relations Göschwitzer Straße 51-52 Göschwitzer Straße 51-52 07745 Jena 07745 Jena Phone: +49 (0) 36 41 - 2 20 - 3 35 Telefax: +49 (0) 36 41 - 2 20 - 2 82 Phone: +49 (0) 36 41 - 2 20 - 1 05 Fax: +49 (0) 36 41 - 2 20 - 1 17 E-Mail:k.noessig@meditec.zeiss.com Web: http://www.meditec.zeiss.com E-Mail: investors@meditec.zeiss.com Web: http://www.meditec.zeiss.com --- End of Message --- Carl Zeiss Meditec AG Goeschwitzer Strasse 51-52 Jena Germany WKN: 531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share, TecDAX; Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse, Geregelter Markt in Frankfurter Wertpapierbörse;


 

Refer to the stock exchange notice on the 06 June 2007 attached the summons and agenda for the Annual General Meeting in Petrojack ASA. The Annual General Meeting has been completed and the items nos. 1 - 6 and 10 on the agenda were approved. The items nos. 7 - 9 did not obtain the qualified numbers of votes and thus were dejected. Bergen/Oslo, 20 June 2007.


 

Jarvis Securities plc ("Jarvis" or "the Company") Transaction in Own Shares The Company announces that between 13 and 20 June 2007 it purchased 25,500 Ordinary Shares at an average price of 193p per share to hold in Treasury. The Company now has in issue 11,200,000 Ordinary Shares with 200,000 pending cancellation. The Company will continue to purchase its own shares for Treasury when appropriate, and in accordance with the authority granted by its Members. Jarvis Securities plc Mathew Edmett Tel: 0870 224 1111 Daniel Stewart & Company plc Stewart Dick Tel: 0207 776 6550 ---END OF MESSAGE---


 

Wärtsilä Corporation, Press Release 20 June 2007 Wärtsilä was awarded a contract in May 2007 from JB Entech Co Ltd, South Korea, to deliver engineering and equipment for a 25.3 MWe combined heat and power plant (CHP) for the Cheong Soo community in Cheon Ahn City. This is Wärtsilä's first CHP project in South Korea under the CES (Community Energy System) concept, which is based on South Korean government legislation to encourage decentralized energy production. The CES aims to supply heat and electricity from independent heat and power production facilities to residential, commercial, business, and hospital buildings and facilities that are concentrated in a specific area. Wärtsilä will deliver the equipment in two phases. The first phase requires two Wärtsilä 34SG gas-engined generating sets. In the second phase, Wärtsilä will deliver a third identical generating set, raising the total electrical output to 25 MWe and the thermal output to 21 MWth. Waste heat recovery from these engines will provide thermal energy for district heating and cooling. The first phase of the plant is due to be operational in the second half of 2009, and the second phase around mid 2012. For additional information, please contact Ms Eeva Kainulainen, VP Corporate Communications, tel. +358 10 709 5235. Wärtsilä in brief: Wärtsilä enhances the business of its customers by providing them with complete lifecycle power solutions. When creating better and environmentally compatible technologies, Wärtsilä focuses on the marine and energy markets with products and solutions as well as services. Through innovative products and services, Wärtsilä sets out to be the most valued business partner of all its customers. This is achieved by the dedication of more than 14,000 professionals manning 130 Wärtsilä locations in close to 70 countries around the world. www.wartsila.com


 

Education company Jönsson & Lepp chooses Mandator as training partner in Gothenburg. The collaboration creates a training offering that combines extensive IT expertise with solid teaching experience and know-how. Teaming Mandator with Jönsson & Lepp makes for an exceptionally strong player when it comes to Microsoft products. For Jönsson & Lepp the collaboration brings to the table a reliable partner with key expertise in advanced IT solutions. For Mandator the collaboration entails improved teaching support for the company's customers. Mandator bases its solutions on the early adoption of advanced technology. If customers are to manage such solutions, they must have the necessary knowledge, and access to Jönsson & Lepp's infrastructure is a definite advantage. "This partnership is an important part of our offering," says Helen Fredin, head of Mandator's operations in Gothenburg. "Aside from the factual knowledge and experience that the courses will provide, many of them will be held on our premises. The physical proximity means that we not only offer our customers traditional education, but also the opportunity to meet with our consultants and discuss actual practical applications." Mandator and Jönsson & Lepp are among Microsoft's foremost partners in Sweden and both hold the highest partner level. Microsoft products comprise an area where Mandator employs the latest technology and collaboration with Jönsson & Lepp will provide an additional boost. The collaboration between Mandator and Jönsson & Lepp will begin in the autumn of 2007. For more information, please contact: Helen Fredin, Business Unit Manager, Mandator Gothenburg, tel. +46 705 56 06 63 helen.fredin@mandator.com Anders Velander, Head of Sales, Mandator, tel. +46 70 521 63 43 anders.velander@mandator.com About Mandator Mandator is an IT consultancy that increases customers' efficiency and competitive edge based on a combination of IT expertise and business know-how. Mandator's prioritised sectors are industry, telecom and the public sector. Clients include Agria, Electrolux, Ericsson, Estonian Ministry of Economic Affairs, FMV (Swedish Defence Materiel Administration), GE, Gunnebo, Husqvarna, IBM, Lantmäteriet (Swedish National Land Survey), NCC, Swedish municipalities, Sandvik, SJ/Linkon, Sony Ericsson, Symbian, Tekniska Verken i Linköping, Tele2, Volvo Car, Volvo Group and Vägverket (Swedish National Road Administration). Mandator is listed on Stockholmsbörsen, the Stockholm Stock Exchange, and has more than 500 employees in five countries. Read more about Mandator at www.mandator.com. About Jönsson & Lepp Jönsson & Lepp is a leader in education for system developers, IT technicians and computer users. Our education concept focuses on giving the customer the market's best education results. We believe in providing the right learning conditions, such as pedagogically adept course tutors with practical experience, solution-oriented education and first-rate teaching materials. Jönsson & Lepp is a certified Microsoft partner for learning solutions. The company was founded in 1990 and is represented in Stockholm, Gothenburg and Malmö. Courses are held throughout the country. For more information, visit www.jonssonlepp.se.


 
Hitt og þetta
20. júní 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |----------------------------------------------+--------------------| | Company dealt in | Domestic & General | | | Group Plc | |----------------------------------------------+--------------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |----------------------------------------------+--------------------| | Date of dealing | 19th June 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price paid | | securities | (Note 3) | (Note 3) | | purchased | | | |--------------------------+--------------------+-------------------| | 80 | 1,265.25p | 1,265.25p | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |-------------------------+--------------------+--------------------| | 0 | | | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +-------------------------------------------------------------------+ | Date of disclosure | 20th June 2007 | |----------------------------------------+--------------------------| | Contact name | Seema Soni | |----------------------------------------+--------------------------| | Telephone number | 0207 992 1565 | |----------------------------------------+--------------------------| | Name of offeree/offeror with which | Domestic & General Group | | connected | Plc | |----------------------------------------+--------------------------| | Nature of connection (Note 6) | Connected Advisor | +-------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

LBi International AB ("LBi"), the leading international full service digital agency network will from 1 July 2007 be presented in the Mid Cap on the OMX Nordic Exchange Stockholm. LBi has a current market capitalization of EUR 356,783,104 (SEK 3 272 189 843). LBi CEO Robert Pickering states: "We continue to be optimistic and confident that 2007 will generate strong revenue and profit improvement. We started out 2006 with the intention to merge the two leading digital marketing and communications companies in Europe, Framfab and LB Icon. We have completed our combination and we are now positioned to compete on the world stage with any other international agency. Our company is still in its infancy but we have come a long way. " Nordic companies with a market value between 150 million and 1 billion euro are contained within the Mid Cap segment on the OMX Nordic Exchange. The segments are revised every six months, on 1 January and 1 July, based on the weighted average price for May and November. For further information please contact: Robert Pickering, CEO, LBI International AB +31 20 460 45 00, robert.pickering@lbi.com Eva Ottosson, Group Communications Manager, LBI International AB +46 709 41 21 40, eva.ottosson@lbi.com About LBi: LBi is the leading international full service digital agency network, servicing clients with marketing and technology solutions. The Company employs approx. 1,400 professionals located primarily in the major European and American business centers, such as Amsterdam, Berlin, Brussels, Copenhagen, London, Madrid, Milan, Mumbai, Munich, New York and Stockholm. Through interdisciplinary teams, LBi creates innovative multi-channel solutions for its national and international corporate clients by uniquely combining strategy development and creative design with specific industry expertise and latest digital technology. LBi was formed by the merger of LB Icon and Framfab in August 2006 and is listed on Euronext in Amsterdam as well as on the OMX Nordic Midcap segment in Stockholm (symbol: LBI).


 

20 June 2007 PayPoint plc - AGM ANNOUNCEMENT PayPoint plc announces that the Annual General Meeting will be held on the 4th July 2007 at 12pm at JPMorgan Cazenove at 20 Moorgate, London, EC2R 6DA. - ends - Enquiries PayPoint plc Susan Court 01707 600316 Finsbury Don Hunter 020 7251 3801 ---END OF MESSAGE---


 

Munich, 20 June 2007: FEP Ethiopia PLC, Ethiopia, a fully owned subsidiary of Flora EcoPower Holding AG, Germany, signed a land lease agreement with Oromia State and a collaboration agreement with the peasant Associations (Community Farming), 26 associations in total for all Fedis and Midega Region. The land lease agreement secures the company 8,000 hectares of government land for castor cultivation for 45 years, 15 hectares for building of oil mill factory, residence and other facilities and 2 hectares for residence. Clemente Signoroni, CEO of Flora EcoPower Holding: "The closing of the agreement is a huge success for our plans. After months of negotiations we now immediately can start to plant castor. We also successfully negotiated options to lease additional land in the district area. We provide work for 2,500 workers from the beginning and also help the people by building a medical care Center, providing fresh water delivered by trucks and transferring agricultural know how. Additionally we are very cautious not to disturb the wild life and the restricted elephant areas. For Flora EcoPower this mandatory concept has strong priority. Social aspects and the efforts to increase children's education and health are one of our company key targets. The agreement with the Oromia government also includes some wild land areas, however, we have refused to start any exploration there and we are expecting to receive different land to be developed. Furthermore in the area we are working with local villagers we left large areas uncultivated to be used by wild animal as seasonal corridors. All this matters are daily supervised and carefully managed by a committee established with the Oromia State experts." Alon Hovev, CEO of FEP Ethiopia PLC: "At the lease agreement closing ceremony the commissioner of Oromia State, regional and local administration authorities, heads and chairmen of several associations and many farmers presented the project to the national press. The collaboration agreement is the frame for the community farming in the district of Fedis and Midega, which count 42,000 house-holds. Oromia state is the largest state in Ethiopia and represents approx. 45 percent in the land's population and we are very happy that we now can start the planting castor and produce castor oil. More than 3,000 farmers who feed house holds of approx. 18,000 people work for Flora EcoPower on a community farming basis. They all grow castor under a contract with Flora EcoPower. This project will increase yearly house hold income by the factor of four compared to the current situation." ++ End of press release ++ About Flora EcoPower Holding Flora EcoPower Holding AG is headquartered in Munich, Germany and conducts deals in Ethiopia and Israel. The company is a spin-off from the highly successful 43-year-old Hovev Group, which has large scale agricultural operations across the globe. Flora EcoPower's vision is to create an end-to-end bio-energy supply chain. In addition, the company offers consultancy services for bio-diesel projects. About Castor The castor bean plant is a native of tropical Africa cultivated in several varieties for the oil found in its leaves and for its bold foliage. The plant is very robust and may grow 6 to 15 feet (2-5 meters) in one season with full sunlight, heat and adequate moisture. Castor seed is the source of castor oil. The seeds contain between 40% and 60% oil that is rich in triglycerides. Among vegetable oils, castor oil is distinguished by its high content (over 85%) of ricinoleic acid. No other vegetable oil contains so high a proportion of fatty hydroxyacids. Castor oils unsaturated bond, high molecular weight (298), low melting point (5ºC) and very low solidification point (-12ºC to -18ºC) make it industrially useful, most of all for the highest and most stable viscosity of any vegetable oil. --- End of Message --- Flora EcoPower Holding AG Kanalstr. 17 München Germany WKN: A0HHE3; ISIN: DE000A0HHE38; Listed: Freiverkehr in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen;


 

Espoo, Finland and London, UK - Nokia and Vodafone have launched a new website designed to help share ideas on how to use mobile communications for social and environmental benefits. The site, www.shareideas.org, was created in direct response to NGO calls for better tools and information to help them use mobile services more effectively in their work. Although initially created with support from Nokia and Vodafone, the site will be developed by a wide range of individuals and organizations interested in using mobile technology for social change. The wiki format means people can edit, update or comment on case studies and stories on the site, and add their own from wherever they are around the world. Case studies are grouped into six key areas - civic engagement, economic empowerment, education, environment, health and safety, and humanitarian relief projects - topics chosen after consultation with many NGOs. Stories already shared on the site include how the development of an SMS alert system has made it possible for one organization to mobilize hundreds of volunteers to carry out emergency clean up efforts in the event of an oil spill in the Baltic Sea. Other examples include how mobile games have been created in Africa and India to educate the public about HIV/AIDS and prevention measures, and how teachers in remote areas in the Philippines are receiving training and state of the art learning materials through a simple SMS message. Tips and advice to help NGOs use mobile devices to help manage their work and communication between their teams or their supporters are also available on the site. Ndidi Nwuneli, Founder and CEO of LEAP Africa, a Nigerian NGO dedicated to nurturing a new generation of African leaders, said, "The positive contribution mobile technology can make to societies is without doubt, but to realise its full potential we need to share our experiences and learnings more effectively. The partnership between Nokia and Vodafone has created something which is simple and practical to use, and will give us access to information which will help make a real difference to people's lives." About Nokia Nokia is a world leader in mobile communications, driving the growth and sustainability of the broader mobility industry. Nokia connects people to each other and the information that matters to them with easy-to-use and innovative products like mobile phones, devices and solutions for imaging, games, media and businesses. Nokia provides equipment, solutions and services for network operators and corporations. Media Enquiries: Nokia Communications Tel. +358 7180 34900 E-mail: press.office@nokia.com www.nokia.com Vodafone Caroline Dewing Tel: +44 7919 444546 E-mail: Caroline.dewing@vodafone.com www.vodafone.com --- End of Message --- NOKIA P.O. Box 226<br>FIN-00045 NOKIA GROUP Espoo WKN: 870737; ISIN: FI0009000681; Index: DJ STOXX Large 200, DJ STOXX 50; Listed: Nordic list (Large Cap) in THE HELSINKI STOCK EXCHANGE;


 

20 June 2007 Lehman Brothers Private Equity, a unit of Lehman Brothers Inc. (together "Lehman Brothers"), today announces the launch of a Global Offering (the "IPO") of shares in a closed-ended investment company to be created to grant investors access to its private equity fund-of-funds investment strategy through the equity market for the first time. Lehman Brothers Private Equity Partners Limited ("LBPE" or the "Company") intends to seek a listing on Euronext Amsterdam N.V.'s Eurolist by Euronext ("Euronext"). LBPE will issue a single class of US dollar denominated shares at $10 per share. Conditional dealings are expected to commence on 18 July 2007 and unconditional dealings on 25 July 2007. The offering has been structured to align the interests of Lehman Brothers with those of investors. Lehman Brothers will bear all IPO costs and furthermore, has undertaken to subscribe for $100 million of LBPE shares in the IPO, which will be subject to a 3 year lock-up. The entire expected gross IPO proceeds of approximately $500 million will be committed to a diversified portfolio of private equity fund investments selected by Lehman Brothers Private Fund Investments Group ("LBPFIG" or the "Investment Manager") and alongside leading sponsors in certain direct private equity investments. LBPE offers investors exposure to Lehman Brothers' private equity platform and has been specifically designed to provide exposure to a private equity fund-of-funds investment strategy in the form of listed, tradable shares with liquidity on Euronext. Lehman Brothers International (Europe) is Sole Global Coordinator. Joint Bookrunners are Lehman Brothers International (Europe), Hoare Govett Limited and UBS Investment Bank. LBPE Investment Highlights: +-------------------------------------------------------------------+ | * | LBPE enables investors to participate in the long-term | | | returns generated by the Investment Manager's private | | | equity fund-of-funds strategy, via tradable shares with | | | liquidity on Euronext. | |------+------------------------------------------------------------| | * | LBPFIG manages $6.5bn in commitments - it has 40 | | | investment professionals, 110 administration and finance | | | personnel and an investment committee of 10 members that | | | have over 170 years of private equity experience between | | | them. | |------+------------------------------------------------------------| | * | Since inception in 1987, the Investment Manager has | | | achieved an Internal Rate of Return ("IRR") of 18.1%, net | | | of fees and expenses. | |------+------------------------------------------------------------| | * | The Investment Manager intends to make investments that | | | are diversified across private equity asset class, | | | geography, industry, vintage year and sponsor. | |------+------------------------------------------------------------| | * | LBPE expects to acquire a portfolio of private equity | | | assets for an aggregate purchase price of approximately | | | $237.8 million, and assume related unfunded commitments | | | aggregating approximately $365.4 million1. | |------+------------------------------------------------------------| | * | Capital structure designed to minimise cash drag, | | | utilising a pre-arranged credit facility to support a | | | prudent over-commitment strategy intended to allow LBPE to | | | maintain full investment. | |------+------------------------------------------------------------| | * | Lehman Brothers will subscribe to $100 million of LBPE | | | shares in the IPO. | |------+------------------------------------------------------------| | * | Lehman Brothers will bear the underwriting, placement fees | | | and other expenses associated with the IPO to ensure 100% | | | of gross proceeds are available for investment. | |------+------------------------------------------------------------| | * | Management fees will be charged on invested capital only; | | | there will be no fees on cash or unfunded commitments. | |------+------------------------------------------------------------| | * | LBPE has the option to buy back up to 14.99% of issued | | | share capital, financed through a combination of | | | distributions and, to the extent permitted, the credit | | | facility. | +-------------------------------------------------------------------+ Joe Malick, Managing Director, Lehman Brothers Private Equity, commented: "We are delighted to offer investors around the world access to our successful private equity platform via the equity markets for the first time." "We have structured the offering with investors in mind, not least because Lehman Brothers will be the largest single investor. Furthermore, we are fully committed to following best practice investor communications, including monthly reports, full quarterly performance disclosure, and audited annual reports." For further information, please contact: Lehman Brothers +44 20 7102 3424 Jeremy Apfel Financial Dynamics +44 20 7269 7200 Rob Bailhache Charles Gorman Nick Henderson About Lehman Brothers Private Equity Lehman Brothers' Private Equity business, started in 1984, has assets under management of approximately $19 billion and consists of 16 different fund strategies across six asset classes: merchant banking, venture capital, real estate, fund-of-funds, credit and infrastructure. About Lehman Brothers Lehman Brothers, an innovator in global finance, serves the financial needs of corporations, governments and municipalities, institutional clients, and high net worth individuals worldwide. Founded in 1850, Lehman Brothers maintains leadership positions in equity and fixed income sales, trading and research, investment banking, private investment management, asset management and private equity. The Firm is headquartered in New York, with regional headquarters in London and Tokyo, and operates in a network of offices around the world. For further information about Lehman Brothers' services, products and recruitment opportunities, visit www.lehman.com. 1) The purchase price for the Initial Investments will be their aggregate net asset value as of December 31, 2006 plus the amount of drawdowns on the related unfunded commitments, minus distributions in respect of such assets, plus an interest factor. Estimates regarding the allocation of unfunded commitments are based on the Investment Manager's proprietary analyses. DISCLAIMER This announcement is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. This announcement is for marketing purposes and is not a prospectus and, if the transaction proceeds, investors should not purchase or subscribe for any securities referred to in this announcement except on the basis of information in the prospectus to be published by the proposed issuer in due course in connection with the admission of the shares in the capital of the proposed issuer to listing on Euronext Amsterdam N.V.'s Eurolist by Euronext and to trading on the regulated market of Euronext Amsterdam N.V. (the "Prospectus"). Subject to the transaction proceeding, copies of the Prospectus will, following publication, be available at no cost from the joint bookrunners and from the proposed issuer's registered office. In the United Kingdom, this announcement is directed only at persons (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the ''Order'') or who fall within Article 49(2)(a) to (d) of the Order, or (ii) to whom it may otherwise lawfully be communicated (all such persons being referred to as ''relevant persons''). This announcement must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available, in the United Kingdom, only to relevant person and will be engaged in only with such persons. The proposed issuer will not be subject to (a) the license requirement under the Financial Supervision Act (Wet op het financieel toezicht) and (b) the supervision of the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten). Hoare Govett Limited, Lehman Brothers International (Europe) and UBS Limited (collectively, the "Banks") are acting for the Company and no-one else in connection with the global offering and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in relation to the global offering, this announcement or any other matter. The Banks make no representation or warranty, expressed or implied, as to the accuracy or completeness of the information contained in this announcement, and nothing in this announcement is, or shall be relied upon as, a promise or representation by the Banks. In connection with the global offering, LBPE intends to appoint a stabilising manager (the "Stabilising Manager") who (or persons acting on behalf of the Stabilising Manager) may, to the extent permitted by applicable law, over-allot shares up to a maximum of 10% of the total number of shares comprised in the global offering and effect transactions that stabilize or maintain the market price of the shares at levels above those which might otherwise prevail in the open market of Euronext Amsterdam N.V. Such transactions may commence on or after the date of the commencement of trading on Euronext Amsterdam N.V. and will end no later than 30 days thereafter. Such transactions may be effected on Euronext Amsterdam N.V., in the over-the-counter market or otherwise. There is no assurance that such stabilization will be undertaken and, if it is undertaken, it may be discontinued at any time. Application will be made for consent under the Control of Borrowing (Bailiwick of Guernsey) Ordinances 1959 (as amended) for the raising of funds by the issue of shares. It must be specifically understood that neither the Guernsey Financial Services Commission nor the States Policy Council takes any responsibility for the financial soundness of the Company or for the correctness of any of the statements made or opinions expressed with regard to it. The press release can also be downloaded from the following link:


 

Cambridge, UK, 20th June 2007 - CeNeS Pharmaceuticals plc (AIM: CEN), the Cambridge based biopharmaceutical company today announces new data on its short-acting sedative, CNS 7056. These preclinical data show that CNS induces deep sedation, has a rapid onset of action and rapid offset of action with predictable effects over a wide range of doses. On the basis of this successful outcome, the compound will be developed for the indications of induction and maintenance of anaesthesia in addition to sedation for day-case procedures. CeNeS also announces that the first full academic paper on CNS 7056 will be published in the July issue of the leading journal 'Anesthesiology'. The paper is one of a small number highlighted in the introductory section of this issue. Additional indications Following the successful completion of studies at the University of Adelaide and under a material transfer agreement with an International Pharmaceutical company, CeNeS will develop CNS 7056 for the induction and maintenance of anaesthesia in addition to the existing development for sedation during day-case procedures. These latest pre-clinical studies show that CNS 7056 has the desirable features for an anaesthetic drug of inducing deep sedation rapidly and controllably, with predictable effects over a wide range of doses and a rapid recovery. Academic publication CeNeS is pleased to note that the first full academic paper on CNS 7056 will be published in the July issue of the leading international Journal 'Anesthesiology' and has been selected as a featured article for the section 'this month in Anesthesiology'. Neil Clark, Chief Executive of CeNeS commented: "CNS 7056 shows an excellent profile in preclinical studies. Development for the additional indications of the induction and maintenance of anaesthesia means that the market potential is significantly larger. We believe that the peak sales opportunity for this compound is now doubled to £400m. We are looking forward to filing an IND for this compound in the next few months and commencing Phase I clinical trials. CNS 7056 exemplifies CeNeS' strategy of focussing on low-risk programmes that provide early and simple proof of concept in clinical trials. Indeed, an important feature of this development programme is that we will be able to generate proof of concept data on sedation/anaesthesia in Phase I volunteer studies rather than having to wait for Phase II patient studies as is the case for most drug development programmes." For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466 JM Finn Geoff Nash Tel: +44(0) 207 628 9688 Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113 About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com About CNS 7056 A series of short-acting sedatives were assigned to CeNeS from GlaxoSmithKline (GSK) in November 2003. Building on the experience gained with the short-acting opiate, remifentanil, these compounds were developed by GSK to improve upon the widely-used sedative, midazolam. The lead compound, CNS 7056, is an ester that is rapidly hydrolysed in the body by esterases to an inactive metabolite. An attractive potential advantage offered by this mechanism of deactivation is a more predictable onset and offset profile compared to that seen with midazolam. Pre-clinical studies reveal that CNS 7056 has a significantly shorter duration of action than midazolam. The lack of reliance on a cytochrome P450 system for metabolism also means less scope for drug-drug interactions than midazolam. CNS 7056 is currently in pre-clinical development. CeNeS aims to file an IND application with the FDA in 2007. The press release can be downloaded from the following link: --- End of Message --- CeNeS Pharmaceuticals Plc WKN: 913665; ISIN: GB0002070505; Listed: Freiverkehr in Börse Berlin Bremen, Freiverkehr in Frankfurter Wertpapierbörse;


 

Ericsson (NASDAQ: ERIC) has been awarded two hosting agreements with Indian operator Bharat Sanchar Nigam Ltd (BSNL), one of the largest public sector companies in India. The agreements are for downloads and ringback tones. These contracts focus on entertainment and personalization services. Under one contract, Ericsson is responsible for providing a content service that allows BSNL to tailor the ultimate customer experience. A next-generation portal that includes a variety of mobile content and applications will be used, giving subscribers the chance to order any type of mobile content - ringtones, games, pictures, video clips and software applications - via web, WAP or SMS. The second agreement is for hosted ringback tones, one of the most popular and highest revenue-generating mobile data services available today. Ringback tones are tunes or other sound bites that replace the standard tone callers hear as they wait for their calls to be answered. The service is based on Ericsson's Personalized Greeting Service. Ericsson is responsible for end-to-end systems integration as well as hosting and day-to-day management of both services. Hans Vestberg, Executive Vice President and Head of Global Services, Ericsson, says: "BSNL is a key customer to Ericsson and we are proud to be chosen for these two hosting contracts. Since hosting was launched in 2004 Ericsson has announced more than 70 contracts. We feel positive that BSNL's subscribers will enjoy these multimedia services we are supporting them with." Hosting services are part of Ericsson's overall content package that also includes offerings for music, video and downloads. Managed Services Hosting is a good business model for operators wanting to provide value-added services easily and cost efficiently to their subscribers. It also brings shorter time-to-market, an important factor for these kinds of services. Ericsson is shaping the future of Mobile and Broadband Internet communications through its continuous technology leadership. Providing innovative solutions in more than 140 countries, Ericsson is helping to create the most powerful communication companies in the world. Read more at http://www.ericsson.com FOR FURTHER INFORMATION, PLEASE CONTACT Ericsson Media Relations Phone: +46 8 7196992 E-mail: press.relations@ericsson.com About Ericsson's Managed Services offering Ericsson has the telecom industry's most comprehensive offering of managed services, ranging from designing, building, operating and managing day-to-day operations of a customer's network, to hosting service applications and enablers, as well as providing network coverage and capacity on demand. As the undisputed leader in managed services, Ericsson has officially announced more than 100 contracts for managed services with operators since 2002. In all current contracts for managed services, excluding hosting, Ericsson is managing networks that together serve more than 120 million subscribers worldwide.


 

Ericsson (NASDAQ:ERIC) has been selected by Malaysia's leading mobile operator, Maxis Communications Berhad (Maxis), to expand and upgrade its WCDMA/HSPA network enabling the operator to provide wireless residential broadband services to major cities and towns on mainland Malaysia. Under the agreement, Ericsson will supply, integrate and deploy radio access network equipment and deliver radio optimization services. The contract includes Ericsson's latest HSPA software, enabling speeds of up to 14.4Mbps in the downlink and up to 1.4Mbps in the uplink, allowing Maxis to enhance its broadband service quality and speed. Implementation has commenced and is scheduled to be completed by the end of the year. End users in areas that were previously without broadband access will be able to experience high-speed internet connections allowing seamless downloads of audio, video and large files. Jon Eddy, Chief Operating Officer at Maxis, says: "We are aiming to expand our broadband footprint through this high-quality network while also supporting the government's national broadband plan. Maxis broadband is now widely available in Klang Valley, Penang and Johor Bahru. By extending our broadband services to more areas, we can address the shortage of residential broadband access while making broadband affordable and reliable. Ericsson is a strong partner in helping us to realize these ambitions, including our aim to become a major broadband player in the country." Krishna Kumar, President of Ericsson Malaysia, says: "Ericsson is proud to support Maxis and believes that the HSPA network providing wireless residential broadband will play a significant role in meeting broadband access needs in Malaysia. HSPA provides the fastest and most cost-effective solution for operators that want to offer broadband services and will deliver end users an enhanced experience with competitive pricing." Ericsson is shaping the future of Mobile and Broadband Internet communications through its continuous technology leadership. Providing innovative solutions in more than 140 countries, Ericsson is helping to create the most powerful communication companies in the world. Read more at www.ericsson.com FOR FURTHER INFORMATION, PLEASE CONTACT Ericsson Media Relations Phone: +4687196992 E-mail: press.relations@ericsson.com About Maxis Group The Maxis Group is the region's emerging mobile telecommunications Group serving nearly 14 million customers as of end March 2007. It has operations in Malaysia, India through subsidiary, Aircel Limited, and Indonesia through PT Natrindo Telepon Seluler. The Group has a 5,000 strong workforce and its vision is to be a 'Regional Communications Leader of Choice' by delivering service excellence and innovative solutions that bring people together. For more information, please visit www.maxis.com.my


 

SINGAPORE -- (MARKET WIRE) -- June 19, 2007 -- The Open Mobile Alliance (OMA), an international specifications setting body, announces the public availability of its Mobile Broadcast (BCAST) Version 1.0 Candidate Enabler Release. The specification is an open global standard for interactive mobile TV as well as on-demand video services, and is adaptable to any IP-based mobile content delivery technology. Currently, OMA's BCAST 1.0 can be adapted to broadcast systems like DVB-H as well as cellular systems like 3GPP MBMS, 3GPP2 BCMCS and mobile unicast streaming systems. Over 35 companies have actively contributed to OMA's new specification, setting the global market requirements of the end result. "The regulatory, cultural and network environments for TV are very complex around the world," says Jari Alvinen, Chairman of the Board, OMA. "Release of this specification demonstrates the effectiveness of OMA efforts in the introduction of globally interoperable mobile TV services. The OMA BCAST Enabler opens the door for all potential players in the Mobile TV Value chain to compete and differentiate their products and services." "The OMA BCAST specification suite accommodates several bearer network technologies and supports multiple business models," says Sungoh Hwang, Chairman of the OMA BCAST Working Group. "The specification equally caters to deployments driven by broadcasters as well as those driven by operators. Users can now have both interactive and simple broadcast mobile TV, buffered infotainment content on-demand, and any of the many new services that are currently being developed in the market." OMA BCAST 1.0 Candidate Enabler Release Features -- Highly functional Service Guide, allowing flexible deployments -- Service and Content Protection using OMA DRM 2.0 or 3GPP/3GPP2 Smartcard -- Distribution Solution for both real-time and non-real-time media content -- Service Interactivity enabling active user involvement with services -- Network agnostic for both IP-based broadcast and cellular bearers About the OMA Release Program To date, OMA has published 51 Enabler Releases. The OMA continuously operates an interoperability program to validate Enabler specifications, as well as the implementations of member products and services. Using a clear working process, the Enabler Release Program is designed to deliver two key milestones for each enabler: A Candidate Enabler Release (CER) delivers an approved set of open technical specifications that can be implemented in products and solutions, and then tested for interoperability. An Approved Enabler Release (AER) represents Candidate Enabler Releases that have gone through the Interoperability Program (IOP) of OMA. The IOP tests interoperability between different member company's implementations -- either within the OMA or through other means. For more information, visit http://www.openmobilealliance.org/release_program/index.html. About the Open Mobile Alliance (OMA) The Open Mobile Alliance (OMA) delivers open specifications for creating interoperable services that work across countries, operators, fixed and mobile terminals. Driven by users' needs and the expanding market for data services, the member companies of the Open Mobile Alliance stimulate the adoption of new and enhanced information, communication and entertainment services. The Open Mobile Alliance includes contributors from all key elements of the wireless value chain, and contributes to the timely and efficient introduction of services and applications. The Open Mobile Alliance (OMA) name and logo are trademarks of Open Mobile Alliance Ltd. Other product and company names mentioned herein may be trademarks or trade names of their respective owners. Contact: Bobby Fraher OMA Communications +1.415.531.2680 bfraher@omaorg.org


 

VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- 06/19/07 -- Augusta Resource Corporation (TSX: AZC)(AMEX: AZC)(FRANKFURT: A5R) ("Augusta" or the "Company") reports it has closed the non-brokered private placement (the "Placement") of 10,719,827 common shares at C$3.50 per share for total gross proceeds of C$37,519,394 announced on June 14, 2007. The Placement was subscribed for by Sumitomo Corporation and Sumitomo Corporation of America ("Sumitomo") as to 7,600,000 common shares and two funds managed by US private investment firm Harbinger Capital Partners ("Harbinger") as to 3,119,827 common shares resulting in Sumitomo holding 8.7% interest in Augusta and Harbinger holding 19.9% (from 18.6%) in Augusta. Proceeds from the Placement will be used towards the advancement of the Rosemont Property and for general working capital purposes. ABOUT AUGUSTA RESOURCE CORPORATION - Augusta is a mineral exploration and development company responsibly advancing the Rosemont copper project in Southern Arizona. The Company's Rosemont property is located in Pima County, approximately 50 kilometers southeast of Tucson, Arizona, and contains a potentially world class open-pit copper/molybdenum/silver ("Cu/Mo/Ag") deposit. Augusta has a solid asset base, proven management team, and is committed to becoming a mid-tier copper producer within five years. The company is traded on the American Stock Exchange and the Toronto Stock Exchange under the symbol AZC, and on the Frankfurt Stock Exchange under the symbol A5R. ON BEHALF OF THE BOARD OF DIRECTORS Gil Clausen, President and CEO CAUTIONARY STATEMENT REGARDING FORWARD LOOKING INFORMATION Certain of the statements made and information contained herein and in the documents incorporated by reference may contain forward-looking statements or information within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward looking statements or information within the meaning of the Securities Act (Ontario). Forward-looking statements or information include statements regarding the expectations and beliefs of management. Forward looking statements or information include, but are not limited to, statements or information with respect to known or unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. Forward-looking statements or information are subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking statements or information, including, without limitation, risks and uncertainties relating to the Company's plans at its Rosemont Property and other mineral properties, the interpretation of drill results and the estimation of mineral resources and reserves, the geology, grade and continuity of mineral deposits, the possibility that future exploration, development or mining results will not be consistent with the Company's expectations, metal recoveries, accidents, equipment breakdowns, title matters, labor disputes or other unanticipated difficulties with or interruptions in production and operations, the potential for delays in exploration or development activities or the completion of feasibility studies, the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses, commodity price fluctuations, currency fluctuations, failure to obtain adequate financing on a timely basis, the effect of hedging activities, including margin limits and margin calls, regulatory restrictions, including environmental regulatory restrictions and liability, the speculative nature of mineral exploration, dilution, competition, loss of key employees, and other risks and uncertainties, including those described under "Risk Factors Relating to the Company's Business" in the Company's Annual Information Form dated March 1, 2007. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information. We do not expect to update forward-looking statements or information continually as conditions change, and you are referred to the full discussion of the Company's business contained in the Company's reports filed with the securities regulatory authorities in Canada and the United States. Contacts: Augusta Resource Corporation Gil Clausen President and CEO (303) 300-0136 (303) 300-0135 (FAX) Email: gclausen@augustaresource.com Augusta Resource Corporation Marlo Hamer-Jackson Investor Relations Manager (604) 687-1717 (604) 687-1715 (FAX) Email: mhamer-jackson@augustaresource.com Website: www.augustaresource.com


 

At the Annual General Meeting held in Zug on June 19, 2007, the shareholders of Private Equity Holding AG approved all proposals of the Board of Directors with an overwhelming majority. The Members of the Board, Messrs. Dr. Hans Baumgartner, Zurich, Dr. Hans Christoph Tanner, Horgen and Stuart D. Frankel, Baltimore/USA were re-elected for another one year term. The agenda items and the proposals of the Board of Directors as well as the presentation shown at the Annual General Meeting are published on the website of the company under www.peh.ch. *** Private Equity Holding AG (SWX: PEHN) offers investors the opportunity to invest, within a simple legal and tax optimized structure, in a broadly diversified and professionally managed private equity portfolio. For further information: Claudine Birbaum, Investor Relations, claudine.birbaum@peh.ch, phone +41 41 726 79 80. --- End of Message --- Private Equity Holding AG Innere Güterstrasse 4 Zug WKN: 906781; ISIN: CH0006089921; Index: IGSP; Listed: Investment Companies in SWX Swiss Exchange;


 

Ackermans & van Haaren (acting through its 74% subsidiary Sofinim) has reached an agreement with the family Patrick Maas and the management of Manuchar, led by Mr Philippe Huybrechs, for the acquisition of a 20%-stake in Manuchar. Sofinim has also an option to increase its participation to 30%. Manuchar, located in Antwerp, is a trader, distributor and a logistics player mainly active in chemicals, steel and wood. Over the past years Manuchar recorded a strong growth. In 2000, turnover amounted to ¤ 120 million with a result after taxes of ¤ 0.5 million. In 2006, consolidated turnover of Manuchar amounted to ¤ 469 million, on which Manuchar realised an EBITDA of ¤ 24 million and a result after taxes of ¤ 9 million. More specifically, Manuchar provides its customers with: * sourcing of products (mainly chemicals, steel and wood) through the world * organisation of logistics between producer and customer * financing of goods during transportation * further handling and repackaging of goods * distribution and marketing of these products through its local network. Manuchar offers this services through a wide local distribution and sourcing network which extends today to 25 countries in Latin America, Africa, the Middle East and larger parts of Asia, with own offices in: * Latin America: * South America: Brazil, Venezuela, Colombia, Ecuador, Peru, Bolivia, Chile and Argentina * Central America: Mexico, El Salvador, Honduras * Caribbean: Dominican Republic, Cuba * Africa: Nigeria, South Africa, Uganda * Asia: China, India, Thailand, the Philippines, Hong Kong * Europe: Belgium, Oekraïne, Russia Its wide network enables Manuchar to offer her clients a single point of contact for global sourcing and distribution of goods, across continents, down to more remote areas. In particular, in these remote areas, the combined offer of logistics and financing are the key to commercial success. Through the further development of its local presence in Asia and Africa Manuchar aims to offer her clients a wider logistic platform and to further diversify its services and products. With this transaction AvH concludes a long-term partnership with the family Maas and the management of Manuchar and wishes to support the group in the realisation of her ambitious development plans. Ackermans & van Haaren is a diversified group active in 4 key sectors: dredging, environmental and construction services (DEME, one of the largest dredging companies in the world - Algemene Aannemingen Van Laere, a leading contractor in Belgium), Real Estate and related services (Leasinvest Real Estate, a listed real-estate investment trust with real estate assets of approximately ¤ 450 million - Extensa, an important land and real estate developer focused on Belgium and Luxemburg), private banking (Bank Delen, one of the largest independent private asset managers in Belgium - Bank J.Van Breda & C°, niche bank for entrepreneurs and liberal professions) and private equity (Sofinim, one of the largest private equity providers in Belgium, and GIB). The group concentrates on a limited number of strategic participations with an important potential for growth. Market capitalisation of AvH is over ¤ 2.4 billion. As of March 2nd 2007, the AvH share has been included in the reference index BEL20 of Euronext Brussels. All press releases issued by AvH and its most important group companies as well as the 'Investor Presentation' can also be consulted on the AvH website: www.avh.be. For further information please contact: Luc Bertrand Philippe Huybrechs CEO - Chairman of the Executive Committee Managing Director Ackermans & van Haaren NV Manuchar NV Tel. +32 (0)3 231 87 70 Tel. +32 (0)3 640 93 00 e-mail : dirsec@avh.be e-mail: philippe.huybrechs@manuchar.com website: www.avh.be website: www.manuchar.com Matthias De Raeymaeker Investment Manager Sofinim NV Tel. +32 (0)3 897 92 30 e-mail : m.deraeymaeker@sofinim.be


 

Jena, 19th June 2007; the Management Board of CyBio AG, Jena, (German Stock Exchange: General Standard, ISIN-Number DE0005412308) today passed a resolution, with the approval of the Supervisory Board, to increase the company's share capital for cash by 600.000 new bearer shares under utilization of the authorized capital. A subscription right is granted to the shareholders. According to the resolved subscription ratio of 8:1, one new CyBio share may be subscribed for eight old shares at a subscription price of 4.00 EUR. A trading in subscription rights is excluded. The subscription period is expected to commence on 25th June 2007 and end on 9th of July 2007. Shareholders unsubscribed shares will be placed with institutional investors for a subscription price of 4.00 EUR. The subscription will lead to proceeds of approximately 2.40 Mio. EUR. The influx of funds will strengthen CyBio's equity base and provide the necessary flexibility to soundly finance the planned internal and external growth in the field of automation and the innovative new generation of instruments. In the upcoming periods CyBio will focus its R & D activities on a new modular liquid handling system for the pharmaceutical industry. The business year 2007 continues to develop within CyBio's expectations. In comparison to last year CyBio is confident to achieve a significant increase in the mid-year turnover. The interim report will be available from 14th of August 2007 at www.cybio-ag.com Contact: CyBio AG Franziska Haase-Metz Göschwitzer Str. 40 07745 Jena Phone +49 3641.351 401 Fax +49 3641.351 409 E-Mail: irpr@cybio-ag.com --- End of Message --- CyBio AG Göschwitzer Straße 40 Jena WKN: 541230; ISIN: DE0005412308; Index: CDAX; Listed: General Standard in Frankfurter Wertpapierbörse, Geregelter Markt in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover;


 

Swiss researcher Bern Bodenmiller today won the first prize in the DSM Science & Technology Awards (South) 2007. An international judging committee, chaired by Dr Manfred Eggersdorfer, R&D Director at DSM Nutritional Products, selected Bernd Bodenmiller, who will obtain his doctorate from the Swiss Federal Institute of Technology (ETH) Zurich in November 2007 for his PhD thesis entitled 'Quantitative Analysis of Protein Phosphorylation on a Proteome-Wide Scale: Technology Development, Validation and Applications'. Bernd Bodenmiller has succeeded in developing and validating a novel technology in proteomics research to enrich, identify and quantify phosphopeptides on a system-wide scale. So far this has been a tremendous challenge due to low abundance and high complexity of phosphoproteins. He has demonstrated the power of this technology by successful applications in two relevant biological models. His research has already resulted in several publications in high-ranking journals. Bernd Bodenmiller was presented with an award trophy and a certificate by Mr Stephan Tanda, member of DSM's Managing Board. As the winner of the first prize he will also receive a cash prize of EUR 7,500. The winner of the second prize, Eveline Trachsel, also of the Swiss Federal Institute of Technology (ETH) Zurich (Switzerland), will receive a cash prize of EUR 5,000. The winner of the third prize, Thomas Hofer of the Leopold-Franzens University Innsbruck (Austria), will receive a cash prize of EUR 2,500. The other nine finalists will each receive a cash prize of EUR 1,250. The DSM Science & Technology Awards form part of the DSM Innovation Awards Program sponsored by the DSM Innovation Center. They are granted for outstanding PhD research by doctoral students from Switzerland, which is the home base of DSM Nutritional Products, and the neighboring regions of Austria, Northeastern France and Southern Germany. The awards presentation event was held at Park Hotel Vitznau in Vitznau (Switzerland). Speaking on the occasion, Mr Tanda said: 'Recognizing the work of outside specialists forms part of our Open Innovation approach. We hope that the introduction of the DSM Science & Technology Awards at our Swiss base and in the neighboring regions will be a great success. And that the awards will encourage PhD research scientists to undertake pioneering research to help shape tomorrow's world.' Report of the judging committee In its report about the winner of the first prize, Bernd Bodenmiller, the judging committee said it was impressed by the successful integration of several techniques, such as chemical, biological, mass spectrometric and computational approaches, which is unique and world-leading: 'The judging committee expects that the outcome of the research will prove useful in the elucidation of intracellular signalling pathways involved in the development of severe diseases and hence provide the basis for the development of appropriate prevention strategies. This may also open-up opportunities for new nutritional concepts to improve human health.' The judging committee commended the high quality of the work of all the other finalists. The winners of the first, second and third prizes Bernd Bodenmiller conducted his research at the Institute of Molecular Systems Biology at the Swiss Federal Institute of Technology Zurich (Switzerland), under the supervision of Prof. Dr. Rudolf Aebersold. Title of PhD thesis: 'Quantitative Analysis of Protein Phosphorylation on a Proteome-Wide Scale: Technology Development, Validation and Applications'. Eveline TRACHSEL conducted her research at the Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH) Zurich (Switzerland), under the supervision of Prof. Dr. Dario Neri. Title of PhD thesis: 'Antibody-based Vascular Targeting for the Treatment of Chronic Inflammation'. Thomas HOFER conducted his research at the Department of Theoretical Chemistry, Leopold-Franzens University Innsbruck (Austria), under the supervision of Prof. Dr. Dr. Bernd M. Rode. Title of PhD thesis: 'Development and Application of Advanced QM/MM MD Methodologies'. Other winners The other nine prize-winners are: Elena ALEKSANDROVA Institute of Physical Chemistry, University of Stuttgart (Germany) Matthias BECHTOLD Swiss Federal Institute of Technology (ETH) Zurich (Switzerland) Wolfgang BICKER Department of Analytical Food Chemistry, University of Vienna (Austria) Christine CARAPITO Louis Pasteur University of Strasbourg (France) François DEBAENE Chemistry Department, ISIS, Louis Pasteur University of Strasbourg (France) Alexis KLEIN INSERM U 866, IFR Santé-STIC, Medicine School, Burgundy University Dijon (France) Peter LIPOWSKY Max Planck Institute for Metals Research, Stuttgart (Germany) Ulrich PLUTOWSKI Institute for Organic Chemistry, University of Karlsruhe (Germany) Florian RUDROFF Institute of Applied Synthetic Chemistry, Vienna University of Technology (Austria) Two parallel awards schemes DSM launched the Science & Technology Awards twenty-two years ago. Until 2006, the awards were open to doctoral students from the Netherlands, Belgium and the German state of Nordrhein-Westfalen (DSM Science & Technology Awards - North). In view of the high reputation and popularity the awards had gained in academic circles, DSM this year introduced a parallel contest for PhD researchers from universities in Switzerland, Austria, Northeastern France and Southern Germany (DSM Science & Technology Awards - South). Encouraging pioneering research DSM performs a great deal of its R&D work in close collaboration with universities. Through its Science & Technology Awards DSM wants to encourage young research scientists to undertake creative, pioneering research. This is important because this kind of research often provides the basis for the development of new, knowledge-intensive industrial processes and innovative products. DSM DSM is active worldwide in nutritional and pharma ingredients, performance materials and industrial chemicals. The company develops, produces and sells innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM's strategy, named Vision 2010 - Building on Strengths, focuses on accelerating profitable and innovative growth of the company's specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over ¤8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with locations in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at www.dsm.com. For further information: DSM Innovation Center (NL) DSM Nutritional Products (CH) Vikas Sonak Christine Stamm R&D Communications Manager Communications Manager Tel. +31 (0)46 4763771 Tel: +41 (0)61 6887714 E-mail vikas.sonak@dsm.com E-mail: christine.stamm@dsm.com Internet: Internet: www.dsm-researchawards.com www.dsmnutritionalproducts.com


 

LUGANO, SWITZERLAND -- (MARKET WIRE) -- June 19, 2007 -- www.RichOrBeautiful.com has just announced the launch of their innovative website that promises to break new ground in the realm of dating. Amidst stiff competition this site claims to have honed in on a unique selling point that will get members to sit up and take note. Potential clients can now log on to their aesthetically designed website for full details on membership and services. The site has a protected member area, FAQs section, 'top rated' and 'featured' listings and other user-friendly sections. The target market is obvious from its name. It's a dating site for rich or beautiful people. No ambiguity there. If the 'or' is replaced with an 'and' people will still get membership provided they meet the eligibility criteria. Talking about eligibility, this site caters to a niche client base which includes the rich or the beautiful or both. Its members include those looking for a serious relationship and yet want to think 'out of the box.' Thus, at this website they can meet like-minded members, chat online and view their profiles and date. www.RichOrBeautiful.com has taken this unique approach to bring together a network of rich and beautiful people all under one big e-roof. So how does this really work? The site approves clients under the 'rich' category if their earnings are more than $200,000 a year. As beauty cannot be quantified, existing members vote on the beauty factor to approve the membership of a prospective member. If the votes are in favor, the client is given free membership to join the group. The site does not allow membership to those who do not fulfill the eligibility criteria. However, the public can still buy books from their bookstore. The management of www.RichOrBeautiful.com has big plans for the coming year. They anticipate a large number of signups from both marketing efforts and word-of-mouth. The site is all set to take this industry by storm. Their novel concept is catching on at such a tremendous speed that the site believes it will have to make their member approvals even more stringent. For rich and beautiful singles looking for an ideal relationship, this site offers an opportunity to meet 'that special someone.' www.RichOrBeautiful.com is all set to give other dating sites a run for their money. About www.RichOrBeautiful.com This is a revolutionary site that offers dating services for rich or/and beautiful people. They have captured this niche market segment by enforcing an eligibility criterion with regard to membership. Servicing an elite clientele of millionaires, CEOs, doctors, lawyers, models, actors, etc., they provide a perfect platform for singles to interact on a personal level. Contact: RichOrBeautiful.com seo@richorbeautiful.com


 

STOCKHOLM, 19 June 2007 - Racon Holdings AB ("Milestone"), a Swedish subsidiary of Milestone ehf., announced on 26 April 2007 a cash tender offer to the holders of shares and warrants in Invik & Co. AB (publ) ("Invik") (the "Offer"). In a press release of 13 June 2007 Milestone extended the acceptance period for the Offer until 29 June 2007. By the end of the initial acceptance period, on 15 June 2007, the Offer has been accepted by holders of 801,658 Class A shares and 7,978,771 Class B shares in Invik, representing in the aggregate 17.1% of the voting rights and 28.3% of the share capital in Invik. The Offer has also been accepted by holders of 160,000 warrants. Milestone has on 26 April 2007, immediately prior to the announcement of the Offer, entered into agreements with Investment AB Kinnevik (publ), Emesco AB and certain other sellers regarding direct and indirect purchases of 5,700,774 Class A shares and 2,387,520 Class B shares in Invik representing in the aggregate 63.1% of the voting rights and 25.9% of the share capital in Invik. These shares, together with the shares tendered during the initial acceptance period of the Offer represents 80.2% of the voting rights and 54.2% of the share capital in Invik. Necessary approvals from relevant authorities in Sweden and Luxembourg have been obtained. Necessary approval from the relevant authority in the Netherlands has, however, not yet been obtained but Milestone expects to receive such approval within short. For holders of shares and warrants that have accepted the Offer during the initial acceptance period which expired on 15 June 2007, settlement will be commenced as soon as possible after regulatory approval from the Netherlands has been obtained. Settlement in respect of the extended acceptance period will commence on or about 6 July 2007. The offer document and an English translation thereof is available at www.milestone.is, www.bearstearns.com/invikoffer and www.mangold.se. Racon Holdings AB The Board of Directors For further information, please contact: Milestone ehf. Guðmundur Ólason, CEO Tel: +354 414 1800 Mangold Fondkommission AB Peter Fredriksson Tel: 08 503 015 56 Mobil: 070 268 94 63


 

This is a press release of Stork N.V. pursuant to the provisions of Section 9b, subsection 1 and subsection 2 (c) of the Dutch Securities Trade Supervision Decree 1995 (Besluit toezicht effectenverkeer, 1995). This is not a public announcement that a public offer is to be made. Not for release, distribution or publication, in whole or in part, in the United States of America, Australia, Japan or Canada. Naarden, 19 June 2007 Stork announces interest from Private Equity group Stork announces that the company is in discussions with Candover, a leading European private equity group, which may lead to an offer for all the outstanding shares of Stork. If such discussions do lead to an offer, it will be in the form of cash, at an indicative price of ¤ 47 per share, subject to due diligence. Candover has expressed a serious interest in the potential of Stork's underlying businesses and has indicated a commitment to continue the current strategy of growing the businesses through autonomous growth and acquisitions. The discussions are taking place with the consent and support of the full Supervisory Board, including the three additional members who were appointed by the Enterprise Chamber in January 2007. Stork shareholders Centaurus and Paulson have been informed of this possible offer. There can be no assurance that a formal offer will be made. Further announcements will be made when appropriate and in any case an update will be given no later than August 1st, 2007. Press information: Stork N.V., Dick Kors, tel.: +31 (0)35 - 695 75 75 Disclaimer This release does not constitute or form part of an offer to buy or subscribe for any securities by anyone in any jurisdiction. Nowhere outside the Netherlands any action is taken (nor will any action be taken) to make a public offer possible in any jurisdiction where such action would be required. This press release is also published in Dutch. This English version will prevail over the Dutch version.


 

PARIS, FRANCE -- (MARKET WIRE) -- June 19, 2007 -- New advanced composites components have entered service on Bombardier Aerospace's Next Generation regional jets, following Bombardier's 8m pounds sterling investment in the development of its advanced composites capabilities in Belfast. The composite flaps, vanes and ailerons for the Bombardier CRJ700 and CRJ900 NextGen aircraft are being produced in a new 20,000 square feet dedicated facility in Bombardier's plant in Dunmurry, west Belfast, using an innovative Resin Transfer Moulding (RTM) technology. The RTM composite wing components are being fitted to Northwest Airlines' CRJ900 NextGen regional jets, one of which is currently on display in Bombardier's static area at the Paris Air Show. Northwest's first CRJ900 NextGen entered service in early June. The application of the RTM components will become standard on all CRJ700 NextGen and CRJ900 NextGen aircraft, including the new CRJ1000. An example of the RTM flap and other composites technology are also on exhibit in Bombardier's pavilion at the Air Show. The RTM process allows for the manufacture of components in a much more integrated and efficient way than the traditional composites process, and requires fewer parts. For example, the total number of parts needed to assemble the wing components has fallen by almost 80 per cent for the aileron and 95 per cent for the flap and the vane. Benefits to airlines include reduced inspection and maintenance costs, as advanced composite structures do not suffer corrosion like metal. RTM also offers the potential for reduced weight and improved aerodynamics, which contribute to fuel efficiency and environmental benefits. Commenting on the investment in its composites capabilities, Michael Ryan, Vice-President and General Manager, Bombardier Aerospace, Belfast, said: "Bombardier has over 30 years' experience in composites, and this investment helps to reinforce our position as a centre of excellence in this field. We are investing in the next generation of composite technologies, in particular resin transfer infusion technologies such as RTM, to ensure Bombardier is at the forefront of the application of carbon fibre reinforced structures, which are playing an increasing role in new aircraft design. "Following five years of strategic research, it is particularly gratifying to see these world-class technologies being applied and entering service on the latest Bombardier aircraft, and we look forward to further developing these for future aircraft." About Bombardier A world-leading manufacturer of innovative transportation solutions, from regional aircraft and business jets to rail transportation equipment, Bombardier Inc. is a global corporation headquartered in Canada. Its revenues for the fiscal year ended Jan. 31, 2007, were $14.8 billion US and its shares are traded on the Toronto Stock Exchange (BBD). News and information are available at www.bombardier.com. Bombardier, CRJ700, CRJ900, CRJ1000 and NextGen are trademarks of Bombardier Inc or it subsidiaries. Notes to editors The 8m pounds sterling investment by Bombardier in developing the new RTM composites capabilities has been supported by Regional Development Agency, Invest Northern Ireland, which provided a 1.5m pounds sterling grant towards the total cost of the investment. Bombardier Aerospace, Belfast has a composite manufacturing portfolio of over 30 components covering all aspects of airframe structures including flaps, nacelles, rudders, fairings, and landing gear doors. Bombardier is continuing to develop its composites capabilities through technology development activities such as UK and European research programmes TANGO (wing spars); ALCAS (integrally stiffened wing covers); Integrated Wing (composite primary structure) and SILENCER (nacelle acoustic intake liner development). Contacts: Bombardier Aerospace, Belfast Alec McRitchie Communications & Public Affairs +44 (0)28 9073 3514 Bombardier Paris Chalet Helen Gregory Communications & Public Affairs +33 1 49 92 01 00


 

- For the second time running, GENEART is one of the 50 most dynamic Bavarian companies. - Since 2000, annual sales have grown on average by above 70%. - Furthermore GENEART is one of the few profitable life science companies in Germany. - GENEART expects to keep up its unbroken growth dynamics in 2007. Regensburg / Munich, June 19, 2007. GENEART AG is the recipient of the "BAYERNS BEST 50 / BAVARIA'S BEST 50" award for the second time running. The Bavarian Ministry of State honors GENEART for being one of the 50 fastest-growing companies in Bavaria. As one of the few profitable biotechnology companies in Germany, the Regensburg based specialist for synthetic genes and for synthetic biology was able to convince the jury of Ernst & Young with an average annual sales growth rate above 70% since the year 2000 and the growing staff of now more than 120 employees. Last night, Bavaria's Minister of Economic Affairs Erwin Huber honored the 50 most dynamic Bavarian enterprises. The award was established six years ago and goes to companies, which have demonstrated strong growth with increases in sales and personnel in recent years. With its extraordinary sustained growth dynamics in recent years GENEART is one of Bavaria's model enterprises. The company has entered the synthetic gene market in 2000 and has since become the global market leader in this field. On average, the annual sales have increased in this time by more than 70%. In 2006, sales have grown by 72 % to EUR 7.8M. The operating result (EBIT) for this period were EUR 1.0M. GENEART was able to continue the growth trend in the first quarter 2007 with an increase in total revenues to EUR 3.1M. This is a 68% increase over the same period in the prior year. In the first quarter, the operating result (EBIT) increased to EUR 0.4M and the earnings before taxes grew to EUR 0.5M. The IPO in 2006 provided GENEART with sufficient funds to sustain the profitable growth and to strengthen its leadership position in the global markets. "Our technology leadership in the gene synthesis field and the largest production capacities will enable us to continue taking full advantage of the dynamic development in the global synthetic biology market. Meanwhile, our first rate technology "made in Bavaria" has become an indispensable tool in the development of innovative therapeutics and vaccines for the pharmaceutical industry. The technology also helps to improve industrial enzymes in the industrial biotechnology. The highly qualified work force in the Regensburg region provide a good setting to further improve our competitive position in the market", comments Professor Dr. Ralf Wagner, CEO of the GENEART AG at the festive award ceremony. Photographs of the prize winner award ceremony will be available beginning Tuesday, June 19, 2007. For further inquiries please contact: Bernd Merkl Frank Ostermair GENEART AG Haubrok Investor Relations GmbH Josef-Engert-Str. 11 Maximilianstr. 45 D-93053 Regensburg 80538 Munich Tel.: +49-(0)941-942 76 - 38 Tel: +49-(0)89-461347-10 Fax: +49-(0)941-942 76 - 75 Fax: +49-(0)89-461347-29 ir@geneart.com f.ostermair@haubrok.de www.geneart.com Legal Information This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results. Background Information About GENEART AG In 2000, GENEART entered the gene synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the synthetic biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. Our production and service spectrum spans a wide range, from the production of synthetic genes according to DIN EN ISO 9001-2000, to the creation of gene libraries in the combinatorial biology, to the development and production of DNA-based biologically active substances. The GENEART AG in Regensburg (Germany) and the subsidiary GENEART Inc. in Toronto (Canada) employ more than 120 people. Since May 2006, GENEART is listed on the German Stock Exchange. BAYERNS BEST 50 The BAYERNS BEST 50 award will be granted for the sixth time on June 18, 2007. Tonight, the Bavarian Minister Erwin Huber honors, the 50 most dynamic companies that have shown unusually strong growth for the last few years and saw higher-than-average increases in both sales and job creation with a ceremony in the Kaisersaal of the residence in Munich. The award ceremony should send the right signals and at the same time also encourage both start-up entrepreneurs and medium-sized businesses in Bavaria. Evaluation for BAYERNS BEST 50 was performed by the audit firm Ernst & Young AG in 2007, and ranking was according to the Birch Index, with the main criteria being growth in both revenue and job creation. For information, go to www.bb50.de.


 

Dynamic optical transport features, Layer 2 Ethernet functionality, increased speed and extended reach highlight new FSP 3000 release 8 Mahwah, New Jersey, USA and Martinsried/Munich, Germany. June 19, 2007. ADVA Optical Networking today announced the latest release of its flagship optical platform, the Fiber Service Platform (FSP) 3000 release 8. The new release gives service providers and enterprises more flexibility in delivering new services, as well as a greater ability to scale their networks. The intelligent integration of Optical+Ethernet technologies provides a scalable foundation for next-generation networks, which is packet-friendly and easy to use. The product is being released at NXTcomm 2007 in Chicago and is on display in ADVA Optical Networking's booth #4875. The release 8 of the FSP 3000 includes many new features, including those enabling: * Ease of use - Dynamic optical transport features enable faster service provisioning and platform interoperability. * A Generalized Multiprotocol Label Switching (GMPLS) control plane allows improved path setup, including path computation, resource reservation and provisioning of the expanded Reconfigurable Optical Add/Drop Multiplexer (ROADM) portfolio. * Conformation to Optical Transport Hierarchy (OTH), as specified in ITU G.709, enables seamless interoperability to other industry platforms. * To further simplify the administration and logistics, expanded multi-service transponder options are being introduced to allow network operators to offer Ethernet, storage and legacy Synchronous Optical Network (SONET)/Synchronous Digital Hierarchy (SDH) services from a single muxponder card. * Scalability - Wavelength switching, faster speeds and longer distances enable service providers to increase capacity and simplify their network topologies, reducing network cost and complexity. * Service providers can choose from a portfolio of ROADMs, including the eROADM® and a multi-degree ROADM, which allow for wavelength switching and provide maximum optical provisioning flexibility, as well as maximum impairment tolerance. * 40Gbit/s linespeed capability is fully integrated with 1x40G and 4x10G transponder options for an Optical Transport Unit (OTU)-3 network port supporting high-end applications such as core router interconnect. * New variable gain amplifiers and reach-optimized, noise-tolerant optical interfaces support distances of up to 2,000km, enabling longer un-regenerated reach, automated power balancing and more cost-effective amplifier placement. * Lowest cost per service - An Optical+Ethernet approach supports all upcoming Ethernet service offerings with advanced standards-compliant Ethernet service provisioning and OAM features, enabling triple- and quadruple play residential services, as well as E-LAN and E-Line-based business services over Wavelength Division Multiplexing (WDM). * Gigabit-Ethernet aggregation and multiplexing reduces the cost per bit by reducing the number of interfaces. * Gigabit-Ethernet-optimized add/drop multiplexer cards and integrated Layer 2 aggregation and switching functionality deliver flexibility and control, providing increased functionality within traffic streams. "ADVA Optical Networking continues to expand its product benefits for customers building transport networks from the customer premise to the metro access, metro core and regional arenas," stated Ian Redpath, senior analyst of Ovum-RHK. "The addition of more carrier-class features to expand the applications while improving service management and provisioning creates a compelling advantage of simplicity. ADVA Optical Networking continues its tradition of bringing new features to market right when the market is ready for them, enabling them to hold their top 2 position in EMEA and now capture the top 2 position in North America in the metro WDM segment for 1Q07." "Our customer base continues to demand leading features that help them build networks to drive successful businesses," explained Brian P. McCann, ADVA Optical Networking's chief marketing and strategy officer. "This new FSP 3000 release is a clear indicator of ADVA Optical Networking's commitment to Optical+Ethernet-based solutions that deliver more scalability in the optical layer while increasing intelligence into the access layer, where Ethernet continues to be the protocol of choice." To view more about the FSP 3000, visit: http://www.advaoptical.com/default.aspx?id=102. # # # ABOUT ADVA OPTICAL NETWORKING ADVA Optical Networking (FSE: ADV) is at the forefront of providing Optical+Ethernet solutions that advance next-generation networks for data, storage, voice and video services. Our company's strength comes from passionate and dedicated employees, all sharing a common vision: a fast, customized response to customers' ever-changing needs. Our innovative Fiber Service Platform (FSP) and strong customer focus provide carriers and enterprises the ability to scale their networks and deliver intelligent, competitive new services. ADVA Optical Networking's solutions have been deployed at more than 200 carriers and 10,000 enterprises around the world. For further information about ADVA Optical Networking: www.advaoptical.com. PUBLISHED BY: ADVA AG Optical Networking, Martinsried/Munich and Meiningen, Germany ADVA Optical Networking Inc., Mahwah, New Jersey, USA ADVA Optical Networking Corp., Tokyo, Japan www.advaoptical.com FOR PRESS: Christine Keck t +1 201 258 8293 (U.S.) t +44 1904 699 358 (Europe) t +81 3 5408 5891 (Asia) public-relations@advaoptical.com FOR INVESTORS: Wolfgang Guessgen t +1 201 258 8300 (U.S.) t +49 89 89 0665 940 (Europe) t +81 3 5408 5891 (Asia) investor-relations@advaoptical.com


 

Reference is made to the press release sent 18 June 2007, regarding a contemplated bond issue. The Board of Directors and the management of Awilco Offshore are pleased to see that the bond issue was significantly oversubscribed. Due to the strong interest, the loan amount has been increased to NOK 500 million. Main terms: Amount NOK 500 million Coupon 3m NIBOR + 2.25 % p.a. Maturity July 2010 The senior unsecured bond is subject to finalization of loan documentation and completed settlement which is expected to be 6 July 2007. Pareto Securities ASA is acting as arranger for the bond loan. Oslo, 19 June 2007 For further information, please contact: Henrik Fougner, Managing Director Telephone +47 22 01 43 00 Awilco Offshore has invested in eight jack-up drilling rigs (of which six are under construction), three semi submersible drilling rigs under construction and two accommodation units in operation. The company also holds one option for the construction of one further semi submersible drilling rig.


 

SAN DIEGO, CA -- (MARKET WIRE) -- June 19, 2007 -- ESRI International User Conference -- MetaCarta®, Inc., the leading provider of geographic search and referencing solutions, today announced two new geographic data modules (GDMs) that identify, disambiguate, and resolve Arabic and Spanish geographic references found in documents. For the first time, Spanish and Arabic documents can be made "location-aware" making that information available to be geographically categorized, visualized and mined. The new GDMs enable MetaCarta GeoTagger to automatically identify the language and character set of each document and assign latitude and longitude coordinates and country code tags to each place name in the document. Customers in the public sector, media and publishing, and the energy industry can now discover, visualize, and act on important location-based information in English, Arabic and Spanish. "Location is becoming more important to all global businesses as well as to the intelligence community," said David Sonnen, consultant at IDC for Spatial Information Management Research. "Location information isn't always stored in databases but is found on the Internet, social media, and in other repositories. Global situations require that organizations be able to identify that data regardless of language." MetaCarta GDMs are knowledge bases used by MetaCarta GeoTagger that enable the product to identify and disambiguate geographic references, and assign latitude and longitude coordinates. GDMs contain natural language processing (NLP) logic to recognize the jargons and data types that represent geographic entities, disambiguate names and establish geo-confidence. GeoTagger is a product that parses documents and identifies geographic references within the content. The geographic references are assigned latitude and longitude coordinates and country code tags in an XML file, which may be used as metadata and for processing by third-party systems. "While 85% of all unstructured content has some geographic reference, a huge amount of content is NOT in English," said Claudine Bianchi, Vice President of Marketing for MetaCarta. "It's imperative that certain organizations be able to identify and understand the geographic references in content, no matter what language the content has been created in. Arabic and Spanish are just the first languages we intend to support." MetaCarta will be showcasing the new capabilities at ESRI International User Conference, BOOTH #915 at the San Diego Convention Center; San Diego, CA from Tuesday, June 19, 2007 - Thursday, June 21, 2007. About MetaCarta MetaCarta, Inc. is the leading provider of geographic search and referencing solutions. MetaCarta products make data and unstructured content "location-aware" making that information geographically relevant. Using a map interface, these innovative solutions make it possible for customers to discover, visualize, and act on important location-based information. Founded by a team of MIT researchers in 2001, MetaCarta is privately held, with US headquarters in Cambridge, Massachusetts and offices in Vienna, Virginia and Houston, Texas and resellers worldwide. For more information, please visit www.metacarta.com MetaCarta Resource Center. MetaCarta is a trademark of MetaCarta, Incorporated. All other product or corporate references may be trademarks or registered trademarks of their respective companies. Contact: Lisa Allocca Red Javelin Communications, Inc. 978-470-2227 lisa@redjavelin.com


 

The board of directors of Aftonbladet has today decided upon a cost reduction program for the print newspaper Aftonbladet of approx. SEK 50 million in 2007 and an additional approx. SEK 40 million in 2008. The cost reductions are related to the current cost level. Staff reductions as a consequence of earlier retirements are one of the means of the cost reduction program. In relation to the cost reduction program, the board of directors of Aftonbladet has accepted a restructuring charge of approx. SEK 50 million, which primarily will be booked in Q3 2007. Contact persons: CFO of Schibsted, Trond Berger tel.: +47 91 68 66 95 CEO of Aftonbladet, Carl Gyllfors tel.: +46 706 762 107 Oslo, June 19, 2007 SCHIBSTED ASA --- End of Message --- Schibsted Apotekergt 10, Pb 1178 Sentrum Oslo Norway ISIN: NO0003028904; ;


 

Silverstone Continues to Expand Mineralized Zones at the Copala Silver-Gold Project, Sinaloa State, Mexico VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- June 19, 2007 -- Silverstone Resources Corp. ("Silverstone") (TSX VENTURE: SST) is pleased to report results from 14 additional drill holes (1355m HQ core drilling) from the company's ongoing Phase IIA drilling on the Copala Project. Copala is located 60km ENE of the city of Mazatlan, Sinaloa State, Mexico. All of the drill holes were targeted on mineralization in the Clemens and El Muerto zones on the Animas Refugio vein. A summary of the results from Holes SC-07-72 through SC-07-86 is presented in the following table. HIGHLIGHTS (True Widths) - SC-07-72: 11.33m grading 1.65g/t gold and 288g/t silver - SC-07-73: 7.75m grading 1.86g/t gold and 227g/t silver - SC-07-74: 6.23m grading 1.60g/t gold and 189g/t silver - SC-07-75: 5.31m grading 1.69g/t gold and 204g/t silver - SC-07-83: 3.24m grading 2.31g/t gold and 259g/t silver Table 1 -------------------------------------------------------------------------- Inter- True Hole No. From To val Width(i) Au (g/t) Ag (g/t) -------------------------------------------------------------------------- SC-07-72 22.50 39.75 17.25 11.33 1.65 288 -------------------------------------------------------------------------- SC-07-73 86.50 95.50 9.00 7.75 1.86 227 -------------------------------------------------------------------------- SC-07-74 107.00 116.25 9.25 6.23 1.60 189 -------------------------------------------------------------------------- SC-07-75 40.75 46.25 5.50 5.31 1.69 204 -------------------------------------------------------------------------- SC-07-76 56.00 62.25 6.25 4.80 2.11 226 -------------------------------------------------------------------------- SC-07-77 0.00 0.00 no significant intersection -------------------------------------------------------------------------- SC-07-78 48.00 52.00 4.00 1.94 1.65 110 -------------------------------------------------------------------------- SC-07-79 0.00 0.00 no significant intersection -------------------------------------------------------------------------- SC-07-81 69.75 72.50 2.75 2.22 0.55 98 -------------------------------------------------------------------------- SC-07-82 97.50 101.00 3.50 2.74 0.90 198 -------------------------------------------------------------------------- SC-07-83 117.25 123.00 5.75 3.24 2.31 259 -------------------------------------------------------------------------- SC-07-84 95.00 99.25 4.25 2.29 1.58 296 -------------------------------------------------------------------------- SC-07-85 104.50 112.75 8.25 6.40 1.09 208 -------------------------------------------------------------------------- SC-07-86 120.25 123.25 3.00 2.62 1.06 200 -------------------------------------------------------------------------- - (i)True widths are estimated by correcting for the strike and dip of the vein and the bearing and inclination of the drill hole. - Holes SC-07-77 and SC-07-79 were anomalous and all cut the Animas- Refugio vein near the surface. - Hole SC-07-80 is being re-assayed and the results are expected next month. - Drill hole location maps are found on Silverstone's website at www.silverstonecorp.com. These data show that the silver-gold mineralization in both the Clemens and El Muerto zones is open along strike and down dip. There is excellent potential for both underground and open pit development on this vein. Silverstone management is very enthused over the drilling results to date and has committed to the following work: - Continued drilling of mineralization on the Animas-Refugio vein with the addition of a second drill rig. - Preliminary metallurgical testing of mineralization from the Clemens and El Muerto zones. - Completion of a third party mineral resource estimate by the 4th quarter of 2007. - Continued exploration and drilling of other silver-gold mineralized veins at Copala. The Animas-Refugio vein has a strike length greater than 2.4km within mining claims controlled by Silverstone. Within this strike length, there are four zones that have historic workings. Prior to drilling the Clemens zone, Silverstone drill tested the San Carlos, El Muerto and Clavo San Francisco zones. To date, Silverstone has drilled 91 holes totaling 9,042m at Copala. Previous results were presented in news releases dated October 11, 2006 and March 6, 2007. Samples were assayed by ALS Chemex in Vancouver. Blank, standard and duplicate pulp samples have also been assayed by ALS Chemex and duplicate core samples have been sent to SGS Lakefield in Toronto, Ontario. The results for these QA/QC samples have been acceptable in the mineralized intervals and additional QA/QC analyses are in progress. Hugh Willson, Vice President of Exploration for Silverstone and a qualified person under NI 43-101, has reviewed the contents of this news release and supervised the Copala Project for Silverstone since its inception. ABOUT SILVERSTONE Silverstone is a growth oriented silver mining company with 100% of its revenue from silver production. Silverstone expects to have 2007 silver sales of approximately 1.0 million ounces and increasing to 3 million ounces by late 2009. More information is available online at: www.silverstonecorp.com. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. The TSX Venture Exchange has neither approved or disapproved of the contents herein. Contacts: Silverstone Resources Corp. Chris Tomanik (604) 637-8151 (604) 688-2180 (FAX) Email: ctomanik@silverstonecorp.com Website: www.silverstonecorp.com SOURCE: Silverstone Resources Corp.


 

In addition to the six newbuildings announced in the press release dated 2 May 2007 Camillo Eitzen & Co ASA has signed agreements for long term time charter with purchase option for additional four 58-60,000 dwt Supramax Bulkcarrier newbuildings. The vessels will be delivered from Japanese ship yards during 2011-2012. Long term coverage of about 30 years total duration has been secured for these four vessels. Including the above mentioned contracts, Camillo Eitzen & Co ASA has 13 newbuildings including owned as well as tonnage controlled vis-à-vis long term charter with purchase options, for delivery during the period 2008 - 2012. In total 78 years of coverage are secured for the newbuilding vessels including two Contract of Affreightment recently entered into which run up to 2013. On 14 June 2007 Camillo Eitzen & Co ASA took delivery of the newbuilding " SIBULK INITIATOR ", a 56,000 tdw Supramax Bulk Carrier from Mitsui Tamano Shipyard on long term Time Charter with Purchase Option from Japanese Owners. Axel C. Eitzen Chief Executive Officer Tel: +47 67 11 98 00 --- End of Message --- Camillo Eitzen & Co ASA P.O. Box 216 Norway ISIN: NO0010227036; ;


 

FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | AXA Investment Managers UK | | | Limited/AXA Framlington | | | Investment Management Limited | |-----------------------------------+-------------------------------| | Company dealt in | Taylor Woodrow | |-----------------------------------+-------------------------------| | Class of relevant security to | Ordinary shares | | which the dealings being | | | disclosed relate (Note 2) | | |-----------------------------------+-------------------------------| | Date of dealing | 18/06/07 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------------------------------+ | | Long | Short | | | | | |---------------+--------------------------+------------------------------------------------| | |Number |Number | | | (%) | (%) | |---------------+--------------------------+------------------------------------------------| |(1) Relevant |8,828,522(1.52%) | | |securities | | | | | | | |---------------+--------------------------+------------------------------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+--------------------------+------------------------------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+--------------------------+------------------------------------------------| |Total |8,828,522(1.52%) | | | | | | +-------------------------------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +--------------------------------------------------------------------------+ |Class of | Long | Short | |relevant | | | |security: | | | | | | | |---------------+----------------------------+-----------------------------| | |Number |Number | | | (%) | (%) | |---------------+----------------------------+-----------------------------| |(1) Relevant | | | |securities | | | | | | | |---------------+----------------------------+-----------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+----------------------------+-----------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+----------------------------+-----------------------------| |Total | | | | | | | +--------------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | Sell | 151,687 | 4.20p | | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short (Note | Number of securities | Price per | | name, | 6) | (Note 7) | unit (Note | | e.g. CFD | | | 5) | |----------+------------------+------------------------+------------| | | | | | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 19/06/2007 | |---------------------------------------------------+---------------| | Contact name | Maria Mauro | |---------------------------------------------------+---------------| | Telephone number | 0207 003 2812 | |---------------------------------------------------+---------------| | If a connected EFM, name of offeree/offeror with | N/A | | which connected | | |---------------------------------------------------+---------------| | If a connected EFM, state nature of connection | N/A | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 
Hitt og þetta
19. júní 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |----------------------------------------------+--------------------| | Company dealt in | Domestic & General | | | Group Plc | |----------------------------------------------+--------------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |----------------------------------------------+--------------------| | Date of dealing | 18th June 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price | | securities | (Note 3) | paid | | purchased | | (Note 3) | |---------------------------+--------------------+------------------| | 0 | | | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |------------------------+--------------------+---------------------| | 1,636 | 1,232p | 1,275.50p | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +-------------------------------------------------------------------+ | Date of disclosure | 19th June 2007 | |----------------------------------------+--------------------------| | Contact name | Seema Soni | |----------------------------------------+--------------------------| | Telephone number | 0207 992 1565 | |----------------------------------------+--------------------------| | Name of offeree/offeror with which | Domestic & General Group | | connected | Plc | |----------------------------------------+--------------------------| | Nature of connection (Note 6) | Connected Advisor | +-------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

Hakon Invest has signed an agreement to acquire a 50% stake in the online retailer inkClub, which sells ink cartridges on the Internet. Hakon Invest's investment amounts to SEK 428 M. inkClub is a pure-play online retailer that sells ink cartridges and other printer consumables via the Internet. The company, which was founded by entrepreneur Lennart Nyberg in 2000, has seen rapid growth and posted a profit since the start. inkClub currently have some 1 million active costumers in 14 European countries and in 2006 reported sales of SEK 344 M and an operating profit of SEK 41 M. This places inkClub among the leading global players in online sales of ink cartridges. Claes-Göran Sylvén, President of Hakon Invest: "Lennart Nyberg, with initially very modest resources, has succeeded in building up a highly successful and professional business in just a few years. The Internet is an attractive sales channel and we see good potential for expansion for inkClub." Online shopping is becoming an increasingly important retail sales channel. The investment in inkClub means that Hakon Invest is raising its exposure towards this growing segment while broadening its retail trading expertise at the same time. With a strong financial position inkClub is well equipped for continued growth. inkClub's success has been recognized with a number of awards in recent years, including an Export Hermes and World Class diploma last year from the Stockholm Chamber of Commerce for the most successful export company. In 2005, the newspaper Dagens Industri chose inkClub's founder Lennart Nyberg as Businessman of the Year. Lennart Nyberg, founder of inkClub: "With Hakon Invest we are acquiring a professional owner with a thorough knowledge of retailing. We see major opportunities to further develop InkClub and capture a larger market share in partnership with Hakon Invest. The ink cartridge is a perfect product for the Internet." Hakon Invest's investment in inkClub will be made through acquisition of existing shares for SEK 428 M in cash. Hakon Invest will thus acquire 50% of the capital and voting rights in inkClub. Following the sale, the principal owner Lennart Nyberg and his family will still own 45% of the shares with other shareholders owing 5%. The deal is subject to the usual terms and conditions and approval from the authorities. The deal and acquisition analysis are planned to be completed during the third quarter of 2007. For further information, please contact: Hakon Invest, President & CEO Claes-Göran Sylvén tel +46 8 55 33 99 64 Hakon Invest, IR Manager Pernilla Linger tel +46 8 55 33 99 55 inkClub, founder Lennart Nyberg tel +46 708 24 39 11 inkClub, President & CEO Fredrik Brandt tel +46 708 24 39 21 Hakon Invest, which is listed on the Nordic Exchange Large Cap, conducts active and long-term investment operations in retail-oriented companies in the Nordic region. Hakon Invest owns 40% of ICA AB, the Nordic region's leading retail company with focus on food. In addition have holdings in Forma Publishing Group, Kjell & Company, Hemma and Cervera. Further information about Hakon Invest is available at www.hakoninvest.se.


 

TietoEnator Corporation Press Release 19 June 2007 at 12.00 am EET TietoEnator and If P&C Insurance have agreed on the renewal of If's end user services agreement covering all Nordic countries as well as If's offices outside the Nordic area, excluding the Baltic countries. This renewal strengthens TietoEnator's partnership with If. The original outsourcing contract was signed on March 18, 2005 and is effective until January 31, 2008. The contract is now renewed and prolonged until May 31, 2010. TietoEnator's total order value increases with about 18 million euros. Agreement for If's server operation service signed also on March 2005 is valid until 31 January 2011. End user service is an integration service for all If's services as it includes service desk services for 8.700 end users. The contract covers also a rollout of a new standardised workstation client for all users. For more information please contact: Sakari Lehtola, Executive Vice President, TietoEnator Processing & Network, tel. +358 400 445 769 Leo Höykinpuro, Vice President, TietoEnator Processing & Network, tel. +358 400 445 596 Caroline Uliana, Press Officer, If P&C Insurance, tel. +46 70 628 2363 TIETOENATOR CORPORATION DISTRIBUTION Principal media TietoEnator is among the leading architects in building a more efficient information society and one of the largest IT services providers in Europe. TietoEnator specializes in consulting, developing and hosting its customers' business operations in the digital economy. The Group's services are based on a combination of deep industry-specific expertise and the latest information technology. TietoEnator has about 16 000 experts in close to 30 countries. www.tietoenator.com If P&C Insurance is the leading Nordic P&C insurance company, with about 3.8 million customers in the Nordic and Baltic countries. If earned premiums of SEK 38 billion in 2003 and employed 6800 people.


 

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ** Guernsey, 19 June 2007 - Volta Finance Limited has published its May monthly report. The full report is attached to this release and is available on Volta Finance Limited's financial website (www.voltafinance.com). As of 31 May 2007, Volta Finance Limited's Gross Asset Value stood at ¤9.91, up ¤0.03 from 30 April 2007. Gross Asset Value +---------------------------------------------------------+ | | At 31.05.07 | At 30.04.07 | |-----------------------------+-------------+-------------| | Gross Asset Value (GAV - ¤) | 297,387,237 | 296,433,896 | |-----------------------------+-------------+-------------| | GAV per Share (¤) | 9.91 | 9.88 | +---------------------------------------------------------+ Asset Breakdown by Primary Target Asset Class +---------------------------------------+ | Asset class | At 31.05.07 | |-------------------------+-------------| | Corporate Credits | 26.6% | |-------------------------+-------------| | CDOs | 16.0% | |-------------------------+-------------| | Asset Backed Securities | 18.5% | |-------------------------+-------------| | Leveraged Loans (TRS) | 24.9% | |-------------------------+-------------| | Cash | 14.0% | +---------------------------------------+ (Full monthly report in attachment or on www.voltafinance.com) ** ABOUT VOLTA FINANCE LIMITED Volta Finance Limited is incorporated in Guernsey under the Companies (Guernsey) Laws, 1994 to 1996 (as amended) and listed on Euronext Amsterdam. Its investment objectives are to preserve capital and to provide a stable stream of income to its shareholders through dividends. For this purpose, it pursues a multi-asset investment strategy targeting various underlying assets. Volta Finance's basic approach to its underlying assets is through vehicles and arrangements that provide leveraged exposure. The exposure to those underlying assets is gained through direct and indirect investment in five principal asset classes: corporate credits, CDOs, ABS, leveraged loans, and infrastructure assets. Volta Finance has appointed AXA Investment Managers Paris, an investment management company with a division specialised in structured credit, for the investment management of all its assets. ABOUT AXA INVESTMENT MANAGERS AXA Investment Managers (AXA IM) is a multi-expert asset management company within the AXA Group, a global leader in financial protection and wealth management. AXA IM is one of the largest European-based asset managers with ¤550 billion in assets under management as of the end of March 2007. AXA IM employs approximately 2,800 people around the world and operates out of 19 countries. CONTACTS Company Secretary Mourant Guernsey Limited volta.finance@mourant.com +44 (0) 1481 715601 Porfolio Administrator Deutsche Bank voltaadmin@list.db.com For the Investment Manager AXA Investment Managers Paris Julien Laplante julien.laplante@axa-im.com +33 (0) 1 44 45 94 92 ** This press release is for information only and does not constitute an invitation or inducement to acquire shares in Volta Finance. Its circulation may be prohibited in certain jurisdictions and no recipient may circulate copies of this document in breach of such limitations or restrictions. This press release is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). Volta Finance has not registered, and does not intend to register, any portion of any offering of its securities in the United States or to conduct a public offering of any securities in the United States. ** This document is being distributed by Volta Finance Limited in the United Kingdom only to investment professionals falling within article 19(5) of the Financial Services and Market Act 2000 (Financial Promotion) Order 2005 (the "Order") or high net worth companies and other persons to whom it may lawfully be communicated, falling within article 49(2)(A) to (E) of the Order ("Relevant persons"). The shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire the shares will be engaged only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Past performance cannot be relied on as a guide to future performance. **


 

Ericsson (NASDAQ:ERIC) and its wholly-owned subsidiary Redback Networks today announced they had won a series of new international deals in the past 90 days, spanning Brazil, China, Hungary, Lebanon, Romania, Spain, Turkey and a mobile operator in the UK. The contracts highlight Ericsson's strong global sales reach and its commitment to giving customers easy access to broadband over wireline and wireless infrastructures. Björn Olsson, executive vice president and deputy head of Networks, Ericsson, says: "These joint wins represent a great start. They underscore the value of the Redback acquisition, and will help carriers accelerate their network upgrades for broadband video and mobile broadband. "Ericsson and Redback are at the center of one of the fastest-growing router markets, and have the opportunity to upgrade up to 2 billion wireline and wireless users to full service broadband by 2012." Among the new deals are: contracts to deliver triple-play services for Jiangsu Telecom, a unit of China Telecom; and providing broadband services for enterprise and end users for Lebanese carrier Sodetel. Fifteen of the top 20 telephone companies worldwide use Redback's SmartEdge routers to deliver a combination of IP-based data, voice and video services to more than 50 million broadband subscribers. Ericsson is shaping the future of Mobile and Broadband Internet communications through its continuous technology leadership. Providing innovative solutions in more than 140 countries, Ericsson is helping to create the most powerful communication companies in the world. Read more at www.ericsson.com FOR FURTHER INFORMATION, PLEASE CONTACT Ericsson Media Relations Phone: +46 8 719 6992 E-mail: press.relations@ericsson.com


 

FORM 8.1/8.3 IRISH TAKEOVER PANEL Lodge with the Irish Stock Exchange (Company Announcements Office) (which will publicise) and the Panel. Date of disclosure: 19/06/2007 DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) and 8.3 OF THE IRISH TAKEOVER PANEL ACT 1997, (TAKEOVER) RULES, 1997 Date of dealing: 18/06/2007 Dealing in: Aerlingus (1) Class of securities (e.g. ordinary shares): Ordinary (2) Amount bought Amount sold Price per unit 150,000 2.66 (3) Resultant total of the same class owned or 19,983,989 controlled: (and percentage of class): 3.78% (4) Party making disclosure: Bank of Ireland Asset Management Compliance (5) Either (a) Name of purchaser/ vendor: (Note 1) Or (b) If dealing for discretionary Bank of Ireland client(s), name of fund management Asset Management organisation: Ltd. (6) Reason for disclosure (Note 2) (a) (i) offeror or associate of offeror (Note 3) No (ii) offeree or associate of offeree No Specify which category or categories of associate ((a) to (l) page 3 /4): If category (l), explain: (b) Rule 8.3 (i.e. disclosure because of ownership or control of Yes 1% or more of the class of relevant securities dealt in): Signed, for and on behalf of the party named in (4) above: (Also print name of signatory): Sharon Tracey Telephone and extension number: 01-6378000 Ext. 8117 Note 1. Specify owner, not nominee or vehicle company. If relevant, also identify controller of owner, e.g., where an owner normally acts on instructions of a controller. Note 2. Disclosure might be made for more than one reason; if so, state all reasons. Note 3. Specify which offeror if there is more than one. Note 4. When an arrangement exists with any offeror, with the offeree company or with an associate of any offeror or of the offeree company in relation to relevant securities, details of such arrangement must be disclosed, as required by Rule 8.7. Note 5. It may be necessary, particularly when disclosing derivative transactions, to append a sheet to this disclosure form so that all relevant information can be given. Note 6. In the case of an average price bargain, each underlying trade should be disclosed. Note 7. Unless otherwise stated, references to Rules are to Rules in Part B of the Rules. For full details of disclosure requirements, see Rule 8. If in doubt, consult the Panel. ---END OF MESSAGE---


 

Ericsson boosts capacity for delivering IPTV Ericsson (NASDAQ:ERIC) today announced an upgrade to its high-performance Gigabit Passive Optical Network (GPON) system, the EDA 1500, an important part of the company's broadband offering. The upgraded version of EDA 1500 can now switch bandwidth up to 320Gbps for commercial and residential next-generation multimedia services. Fiber optic technology and fiber-to-the-home (FTTH) deployments are becoming an increasingly important part of access networks capable of delivering cutting-edge services such as IPTV and other IP-based multimedia services. GPON is the leading fiber access standard and became an important part of Ericsson's broadband offering with the acquisition of industry leader Entrisphere in February 2007. Service providers can make their networks future-proof with the enhanced EDA 1500. The increased capacity enables the move from multi-casted (one-to-many) to uni-casted (one-to-one) broadband connections. This enables individual end users to experience their own high-speed services such as video-on-demand and time-shifting TV streams. Once the system and switch interfaces are installed, future capacity upgrades simply require new software and service cards. Ericsson's GPON solution is already in service in North America and has been deployed by leading telecom carriers around the globe. In related news, Ericsson will provide equipment for AT&T's planned deployment of Gigabit Passive Optical Network (GPON) in "new build" areas as part of its overall U-verse network strategy. Björn Olsson, Executive Vice President and deputy head of Business Unit Networks at Ericsson says: "Ericsson's innovative GPON solutions help service providers increase efficiency and generate additional revenue because they deliver individualized content to end users across the same network that delivers business services such as high-speed internet or VoIP." With this upgrade, the EDA 1500 now includes the fastest GPON switch on the market with 320 Gbps of switch capacity. It also provides for the most uplink bandwidth toward the network with its G28 card that includes two 10 Gigabit Ethernet interfaces and eight 1 Gigabit Ethernet interfaces on one card. New software also provides 1:64 split ratio on the fiber and Dynamic Bandwidth Allocation (DBA) along with a suite of IP features including Quality of Service (QoS), security and other upgrades designed to enable carriers to deliver new services cost-effectively. EDA 1500 will be demonstrated at NXTcomm in Chicago, June 19-21, 2007. The demonstration will showcase IPTV and triple-play services running on the service platform. Note to editors: AT&T's press release about GPON contract: www.att.com/gen/press-room?pid=4800&cdvn=news&newsarticleid=23962 Ericsson is shaping the future of Mobile and Broadband Internet communications through its continuous technology leadership. Providing innovative solutions in more than 140 countries, Ericsson is helping to create the most powerful communication companies in the world. Read more at www.ericsson.com FOR FURTHER INFORMATION, PLEASE CONTACT Ericsson Media Relations Phone: +46 8 719 69 92 E-mail: press.relations@ericsson.com


 

Ericsson (NASDAQ: ERIC) has been selected by Indian operator Spice Telecom to provide push e-mail and personal information management services via its hosted enterprise solution. The push e-mail solution provides users with easy-to-use secure, real-time access to e-mail and personal information via a wide variety of mobile devices. It enables quick and easy access to e-mails, contacts and calendar functions while on the move. E-mails are delivered wirelessly in real-time and all activities, such as writing, deleting or sending messages, are instantaneously reflected in the subscriber's account. Installation and maintenance of the e-mail solution are designed to be as simple and straightforward as possible, offering low total cost of ownership. Under the agreement, Ericsson will provide hosting, systems integration and day-to-day management of the service. Mr Prakash Nanani, CEO, Spice Telecom, says: "Spice believes in launching cutting edge mobile applications and Spice Push mail service is another such service. We are proud to offer push e-mail to our customers, enabling them to have full control over their e-mail, whether in the office or on the move. This service will enable the consumer to access an e-mail solution that is useful, fast, secure, simple and cost-efficient. What is more is that customers don't need to have any particular handset, as the service is not handset dependent, and shall work on most handsets that support GPRS. We expect this to help Spice to broad base the reach of email service to the masses." Mats Granryd, President, Ericsson India, says: "Operators are increasingly positioning mobile push e-mail solutions beyond the professional segment, moving into the mass-consumer domain. Hosting is a proven business model that meets operators' growing needs to quickly and cost-efficiently launch new multimedia services for both business segment and the consumer." Ericsson is shaping the future of Mobile and Broadband Internet communications through its continuous technology leadership. Providing innovative solutions in more than 140 countries, Ericsson is helping to create the most powerful communication companies in the world. Read more at http://www.ericsson.com FOR FURTHER INFORMATION, PLEASE CONTACT Ericsson Media Relations Phone: +46 8 719 6992 E-mail: press.relations@ericsson.com About Spice Telecom Spice Telecom, the brand name of Spice Communications Limited is presently operating Cellular Phone Services in the states of Punjab and Karnataka in India. Spice has over 3 Million customers, as on 31st May 2007, and is considered as one of the best service providers of mobile telephony in India. Spice brand is positioned as a youthful & vibrant brand, and has many firsts to its credit, such as: Background Music & Incoming Call Block. Spice Telecom has been promoted by Modi Wellvest Private Limited. Telekom Malaysia Berhad (TM) has 49% stake in Spice Communications Limited (Spice) through TMI India Limited, a wholly-owned subsidiary of TM's international investment holding company TM International Sdn Bhd (TMI). The remaining 51% is with Modi Wellvest Private Limited, the promoter company. Spice Communications Ltd is proposing to make a public issue of securities and has filed a Draft Red Herring Prospectus with SEBI. The DRHP is available on SEBI website, www.sebi.gov.in as well as the BRLM's website, www.enam.com. For more information on Telekom Malaysia, please visit www.tm.com.my For more information on Spice visit www.spiceindia.com About Ericsson's Managed Services offering Ericsson has the telecom industry's most comprehensive offering for managed services, ranging from designing, building, operating and managing day-to-day operations of a customer's network, to hosting service applications and enablers, as well as providing network coverage and capacity on demand. As the undisputed leader in managed services, Ericsson has officially announced more than 100 contracts for managed services with operators worldwide since 2002. In all current contracts for managed services, excluding hosting, Ericsson is managing networks that together serve more than 120 million subscribers.


 

TOMRA's second quarter 2007 results will be released on Thursday 12 July 2007. The written material will be available from 16:35 CET at www.tomra.com (under the investor relations section), www.oslobors.no, www.huginonline.com and at Høyres Hus, Stortingsgaten 20 (6th floor), Oslo. President & CEO Amund Skarholt will present the results at 16:45 CET. The presentation will be held in English and take place at Høyres Hus, Stortingsgaten 20 (6th floor), Oslo. A live broadcast of the presentation will be available on www.tomra.com and www.oslobors.no/webcast. A recorded version of the presentation will also be available after the broadcast has concluded. Asker, 19 June 2007 Tomra Systems ASA


 

Users Test on Flights Between U.S., Europe and the Caribbean OTTAWA and PARIS, June 19, 2007 (PRIME NEWSWIRE) -- OTTAWA and PARIS, June 19, 2007 (PRIME NEWSWIRE) -- EMS SATCOM, a division of EMS Technologies, Inc. (Nasdaq:ELMG), announced today at the Paris Air Show, that a Fortune 100 corporate aircraft has been performing in-flight trials of EMS SATCOM's eNfusion(tm) SwiftBroadband communications system since early 2007 on flights between cities in the United States, Europe and the Caribbean. As of today, passengers on two BBJ aircraft will have performed advanced tests of the Early Entry SwiftBroadband service for a total flight time of more than 300 hours. Even in these early days of the service, EMS SATCOM's flight-test team reports that the system is supporting 10 simultaneous users surfing the web, using e-mail services, and performing file transfers, with an average speed of 200-300 kbps. The systems being used for testing the Early Entry SwiftBroadband services include EMS SATCOM's eNfusion CNX(r) Cabin Gateway family of networking equipment, an AMT-50 High-gain Antenna and radome, and an HSD-400 High-Speed Data Terminal. "These successful trials affirm what EMS SATCOM and Inmarsat have been projecting as the solution for in-flight high-speed Internet connectivity is now almost a reality," says John Broughton, EMS SATCOM vice president of Product Development. "There is still work to do through the rest of this year, including testing with the upgraded ground network, but we are satisfied with the performance of the system so far." Jean Menard, EMS SATCOM vice president of Commercial Sales, noted, "I have been extremely proud of the team that has collaborated closely to prove the capabilities of this new service. We have been working with our customers and partners to ensure that the promise of SwiftBroadband is realized in business, air transport and military platforms." The early success of EMS SATCOM's SwiftBroadband trials is a demonstration of its continuing leadership in providing robust Inmarsat-based equipment. The alpha and beta trials that will follow this July and August with other global operators are the next steps in the progression to the scheduled launch of commercially-available SwiftBroadband services, later this year. "Over the last years we have seen the demand for in-flight connectivity drastically increase and today 23 of the top 25 Fortune 500 companies are using Inmarsat on their aircraft," says Lars Ringertz, Head of Aero Marketing at Inmarsat. "SwiftBroadband is the key to further penetration of this market and these flight trials show that Inmarsat and its partners are on track for the commercial service introduction of the service later this year." About EMS Technologies, Inc. EMS Technologies, Inc. (Nasdaq:ELMG) is a wireless and satellite communication solutions leader, serving aeronautical, defense, maritime, commercial space and supply chain markets. Through its LXE, EMS SATCOM, and Defense & Space Systems divisions, EMS keeps people, systems and data connected, wherever they are -- on the ground, in the warehouse, in the air, or in space. The company is headquartered in Atlanta, employs approximately 1,000 people worldwide and operates major manufacturing facilities in Atlanta and Ottawa, Canada. EMS SATCOM specializes in the design and development of satellite-based terminals and antennas for the aeronautical, ground-mobile, maritime and emergency management markets. A leading supplier of Swift64 high-speed data communications equipment, its eNfusion Broadband(tm) product line enables voice, e-mail, videoconferencing and Internet capabilities on a broad variety of aircraft under its own brand and those of the three major avionics manufactures. Its tracking and messaging systems business delivers crucial capabilities to force tracking systems, as well as to the transport industry and a variety of service vehicles. A pioneer in Search and Rescue solutions, EMS SATCOM also provides leading-edge software and hardware that has helped save tens-of-thousands of lives around the globe. Based in Ottawa, Canada, and a division of EMS Technologies, Inc., it employs approximately 300 people in development and sales offices in Ottawa, the U.K., the United States and Europe. Visit www.emssatcom.com for more information. For more information, visit EMS on the World Wide Web at www.ems-t.com. NOTE TO EDITORS: EMS SATCOM is exhibiting at the Paris Airshow, Booth Hall 3/E7/1. Product images: http://www.ems-t.com/press/satcom/ParisAS2007 CONTACT: EMS SATCOM Kate Murchison, Senior Manager, Communications +1 613 727 6277 X1415 Mobile: +1 613 286 5235 murchison.k@emssatcom.com


 

BALTIMORE, June 19, 2007 (PRIME NEWSWIRE) -- Northrop Grumman Corporation (NYSE:NOC) has taken delivery of the first 10 sets of auxiliary power supply modules for the F-35 Lightning II aircraft radar system. Produced by Brookx Company B.V. of Zoetermeer, the Netherlands, the modules are part of the power system for the F-35's radar array, which is being developed and produced by Northrop Grumman. "We've selected the best-value suppliers to join us in this unprecedented global effort to develop the F-35, and Brookx demonstrates that excellence in delivery, quality, cost and other value-added services," said Karen Campbell, program director of F-35 Lightning II radar for Northrop Grumman. As a principal member of the Lockheed Martin-led F-35 global industry team, Northrop Grumman plays a critical role in the development and production of the weapons system. The company's contributions include: producing and integrating a major section of the aircraft's structure; producing key avionics and communications subsystems; developing mission systems and mission planning software and pilot and maintenance training systems; and developing logistic support hardware and software. The team also includes BAE Systems. Northrop Grumman Corporation is a $30 billion global defense and technology company whose 120,000 employees provide innovative systems, products, and solutions in information and services, electronics, aerospace and shipbuilding to government and commercial customers worldwide. CONTACT: Katie Lamb-Heinz Northrop Grumman Electronic Systems Paris Air Show + 1 (847) 815-0755 katie.lamb@ngc.com Alleace Gibbs Northrop Grumman Electronic Systems + 1 (410) 765-1294 alleace.gibbs@ngc.com


 

Barry Callebaut, Cadbury Schweppes expand outsourcing cooperation: Barry Callebaut announces increased co-operation with Cadbury Schweppes * Barry Callebaut AG announces that it has signed a Memorandum of Understanding with Cadbury Schweppes for supply to its production sites in Poland, thereby doubling its annual deliveries to around 30,000 metric tonnes * Barry Callebaut confirmed as the outsourcing partner of choice in the chocolate industry Contacts for investors and financial analysts: for the media: Daniela Altenpohl, Head of Investor Gaby Tschofen, VP Corporate Relations Communications Barry Callebaut AG Barry Callebaut AG Phone: +41 43 204 04 23 Phone: +41 43 204 04 60 daniela_altenpohl@barry-callebaut.com gaby_tschofen@barry-callebaut.com The news release can be downloaded from the following link: --- End of Message --- Barry Callebaut AG P.O. Box Zurich Switzerland WKN: 914661; ISIN: CH0009002962; Index: SMCI, SPI, SPIEX; Listed: Main Market in SWX Swiss Exchange;


 

ING announced today that it has reached an agreement with OYAK to acquire Oyak Bank for an amount of USD 2.673 billion (EUR 2.0 billion against the exchange rate of 15 June, 2007). Under the terms of the agreement ING will acquire 100 per cent of the shares in Oyak Bank for a cash consideration of USD 2.673 billion which will be financed entirely from existing internal resources. The transaction is expected to result in a decrease in the Tier 1 ratio of ING Bank NV of approximately 50 basis points. The proposed purchase will have no impact on the ongoing share buy-back programme. Michel Tilmant, Chairman of the executive board of ING Group said, "Oyak Bank is a high quality bank with a strong position in the rapidly growing Turkish market. The acquisition is in-line with our strategy of supporting the strong organic growth of the group with suitable add-on acquisitions and will provide ING with a solid banking platform with significant further growth potential. It also provides the opportunity to distribute wealth management products in the future as the market further grows." Founded in 1984, Oyak Bank is a professional and well managed, top ten bank in the Turkish market with 5581 employees and a market share of approximately 3%. It offers a full range of banking services with a focus on retail banking. The bank has 1.2 million active retail customers and 10,000 SME customers. In total it has 360 branches throughout Turkey, with a good representation in all major cities. In 2006 it made pre tax profits of YTL 165 million and at the year end it had total assets of YTL 11.8 billion and its book value was YTL 988 million. Based on the consideration, the transaction will result in a Price/Book multiple of 3.26 of shareholder's equity as at 31 March 2007, a Price/Earnings multiple of 26.6 times the 2006 normalised earnings and is expected to be accretive to ING's EPS as of 2008. Eli Leenaars, Executive Board member responsible for ING's global retail banking activities said: "Given our experience in Poland and Romania this is an exciting opportunity to enter another major fast growing market. Oyak Bank is a strong bank with an excellent management team. By further leveraging ING's retail banking expertise, especially in internet banking, marketing and risk management in combination with Oyak Bank's strong distribution and knowledge of the market, we are in a good position to rapidly expand our position in Turkey." ING expects to increase Oyak Bank's market share over the next five years as it assists Oyak Bank in executing its growth strategy by improving its internet banking and marketing capabilities and risk management function. Oyak Bank will be integrated in the retail banking business line of ING Group and will be re-branded under the ING brand within the first year after the closing of the transaction. ING expects to close the transaction in the second half of 2007. The acquisition is subject to approval of the relevant authorities. +-----------------------------------------------+ | Press enquiries: ING Group | | Nanne Bos, +31 20 541 6516, nanne.bos@ing.com | +-----------------------------------------------+ ING Group will organise a media conference call on the Oyak Bank acquisition today at 09.00 am CET and an analyst conference call at 10.00 am CET. Both conference calls will be hosted by Michel Tilmant and Eli Leenaars. To join the call in the listen-only mode, please dial the telephone number below 10 minutes in advance of the conference call: * From the Netherlands: +31 20 794 8500 * From the United Kingdom: +44 20 7190 1537 ING is a global financial institution of Dutch origin offering banking, insurance and asset management to over 60 million private, corporate and institutional clients in over 50 countries. With a diverse workforce of about 120,000 people, ING comprises a broad spectrum of prominent companies that increasingly serve their clients under the ING brand.


 

VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- June 18, 2007 -- On June 15, 2007, BCM Resources Corporation (TSX VENTURE: B) announced results of 0.189% Mo. over 17.34 meters. Actual high grade results are 0.152% over 17.34 meters. This discrepancy was due to a sample interval error discovered during a final review of a due diligence database compiled at the request of third parties interested in the Shan Molybdenum Property. This interval was from Hole 27 which terminated in high-grade mineralization in what appears to be a pre-mineralized fault zone. The company is currently drilling two new holes at depth to determine the true extent of the zone and whether it is a mineralized fault zone or rubble from a mineralized zone cut off by a post-mineral fault. Qualified Person Daryl Hanson, P.Eng., a Qualified Person as defined in NI 43-01, has reviewed the technical content of the drill program. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. Contacts: BCM Resources Corporation Dale McClanaghan President & CEO (604) 646-0144 Website: www.bcmresources.com SOURCE: BCM Resources Corporation


 

VICTORIA, British Columbia, June 18, 2007 - Maple Seal Homes Ltd. "MSH" http://www.maplesealhomes.com the wholly owned Canadian subsidiary of Maisonette International Enterprises Ltd. "the Company" (PINKSHEETS:MAEN) http:// www.maisonetteworld.com is pleased to announce that following its press release dated April 16th 2007 it has received an official regulatory go ahead to export its 16,000 Sq.Ft. of commercial space from Canada. The 16,000 Sq.Ft. order is an inquiry from its partner in France for a potential commercial building construction using its panelized building technique manufactured by its manufacturing partner in Coble Hill, British Columbia, Canada. The commercial building is to be the headquarters for a solar panel manufacturer and the architect wanted to use environmental friendly materials such as the ones produced by Maple Seal Homes's manufacturing partner in British Columbia, Canada. This order is to be one of many eco-friendly orders to be shipped to Europe, complying with the European Union's push towards green building and sustainable building methods in the housing sector as well as the commercial building industry. Maple Seal Homes has received several inquiries from France lately and it is working hard to close several deals for the year 2007. This approval proves that MSH can produce Eco-Friendly housing at affordable pricing for export to the EU, underlining Canada's long history of environmental responsibility and green, sustainable building push in the construction industry. About Maisonette International Enterprises Ltd. Maisonette International Enterprises Ltd. is a publicly held holding company incorporated in Nevada, USA. Its primary asset is a 100% wholly owned Canadian company called Maple Seal Homes Ltd. (www.maplesealhomes.com) with its primary activity being the sale and distribution of panelized prefabricated housing and building materials for the general public and professionals. Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors affecting the Company's operations, markets, products and prices and other factors discussed in the Company's various filings with the Securities and Exchange Commission. There may be other factors not mentioned above that may cause actual results to differ materially from any forward-looking information. Inquiry Contact: Maple Seal Homes Ltd. sales@maplesealhomes.com www.maplesealhomes.com


 

Munich, 18 June 2007 - The technology group The Linde Group has acquired the majority of the shares in the state-owned Algerian industrial and medical gases company ENGI (Entreprise Nationale de Gaz Industriels). Terms of the transaction were not disclosed. ENGI, which has 10 production sites and employs about 700 people, is the leading gases company in Algeria and achieved sales of around 32 million euro in the 2006 financial year. "This transaction will enable us to act as the leading and full range supplier of industrial and medical gases in the fast growing Algerian market", explained Dr Aldo Belloni, member of the Executive Board of Linde AG. "Together with our sub-saharan operations, this new acquisition further strengthens Linde's position on the African continent." Algeria is the second largest market for industrial gases in North Africa after Egypt. The market volume of the region is worth a total of 200 million euro. Annual market growth is expected to be at a rate of around 15 percent. The Linde Group is a world-leading industrial gases, medical gases and engineering company with around 49,000 employees working in around 70 countries worldwide. Following the acquisition of The BOC Group plc, the company has gases and engineering sales of around 12 billion euro per annum. The strategy of The Linde Group is geared towards earnings-based growth and focuses on the expansion of its international business with forward-looking products and services. For more information, please see The Linde Group online at http://www.linde.com Further information: Press Uwe Wolfinger Telephone: +49.89.35757-1320 Investor Relations Thomas Eisenlohr Telephone: +49.89.35757-1330


 

(Amended Rule 8.3 Disclosure: Hanson Plc.) FORM 8.3 AMENDMENT TO DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the Takeover Code) 1. KEY INFORMATION Name of person dealing (Note 1) Pendragon Capital LLP Company dealt in Hanson Plc Class of relevant security to which the 10p Ordinary dealings being disclosed relate (Note 2) Date of dealing Jun 14th 2007 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) Long Short Number (%) Number (%) (1) Relevant securities (2) Derivatives (other than options) 7,985,078 1.12% (3) Options and agreements to purchase/sell Total 7,985,078 1.12% (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) Class of relevant security: Long Short Number (%) Number (%) (1) Relevant (2) Derivatives (other than options) (3) Options and agreements to purchase/sell Total (c) Rights to subscribe (Note 3) Class of relevant security: Details 3. DEALINGS (Note 4) (a) Purchases and sales Purchase/sale Number of securities Price per unit (Note 5) (b) Derivatives transactions (other than options) Product name, Long/short (Note Number of securities Price per unit e.g. CFD 6) (Note 7) (Note 5) CFD Long 1,000,000 1077.84p c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product Writing, Number of Exercise Type, Expiry Option money name,e.g. selling, securities price e.g. date paid/received call purchasing, to which American, per unit option varying the option European (Note 5) etc. relates etc. (Note 7) (ii) Exercising Product name, e.g. call Number of securities Exercise price per unit option (Note 5) (d) Other dealings (including new securities) (Note 4) Nature of transaction (Note Details Pr